7633940	Chemical	Gene	D006221	6261	False	9	What is [PHARMGKB] between @ChemicalSrc$ halothane @/ChemicalSrc$ and @GeneTgt$ skeletal muscle ryanodine receptor @/GeneTgt$ ? [SEP] C1840-T mutation in the human @GeneTgt$ skeletal muscle ryanodine receptor @/GeneTgt$ gene : frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response . In swine , a point mutation in the ryanodine receptor gene can account for all cases of malignant hyperthermia ( MH ) . The frequency of a corresponding mutation in humans ( C1840-T ) and its relationship to the in vitro contracture profile is unknown . We screened 192 patients from 28 unrelated northern German families for the C1840-T mutation in the human ryanodine receptor gene and tested for MH susceptibility using the in vitro contracture test ( IVCT ) according to the European MH Protocol . In our patients 106 revealed MH susceptible ( MHS ) , 56 MH nonsusceptible and 30 MH equivocal status following IVCT . In each family one or two individuals had developed clinical signs of MH or a MH crisis . All of these patients were classified MHS . The C1840-T mutation was found in 2 of 28 families ( 7.1 % ) . All eight individuals of the two families characterized by this mutation revealed MHS status following IVCT . The thresholds for @ChemicalSrc$ halothane- @/ChemicalSrc$ and caffeine-induced contractures as well as the contracture profiles following cumulative ( 0.4 - 10.0 mumol/l every 3 min ) and bolus ( 10 mumol/l ) administration of ryanodine were found to be similar in MHS patients with and without the C1840-T mutation . In conclusion , the C1840-T mutation in the human ryanodine receptor gene is a rare abnormality in MHS families . Similar contracture profiles in the presence and absence of this mutation might imply no major functional role with respect to the contracture response . At present , molecular genetic analysis can not replace IVCT to discover MH susceptibility in humans .	2 18 11 11 11 11|5 11|5 11|5 11|5 11 11|5 2 2 18 17 17 17 13 18 21 21 18 21 24 21 29 29 26 26 24 18 33 44 44 37 37 44 42 42 42 42 37 44 44 47 47 44 50 50 47 52 50 52 44 56 76 60 60 60 56 62 60 64 62 64 62 68 76 74 74 74 71 74 68 76 76 76 79 79 81 79 87 87 87 87 87 81 91 91 91 81 97 97 97 97 97 91 79 79 102 102 99 102 108 108 105 108 103 110 108 110 117 112 117 117 117 108 79 121 121 123 121 123 125 123 127 125 127 125 132 132 125 132 135 136 137 132 139 132 123 144 144 144 147 144 144 149 149 149 151 149 153 151 153 157 157 153 149 164 162 162 159 164 164 164 164 169 169 171 171 171 176 175 175 176 171 179 179 176 179 171 183 184 193 188 188 188 184 188 192 192 189 193 195 193 197 195 193 200 234 202 206|201 206 206|201 202 202 200 206 207 207 212 212 206 230 230 219 218 218 219 214 222 222 219 222 219 219 228 228 225 228 212 232 230 234 234 237 237 234 240 240 237 246 241 241 246 246 240 234 250 264 264 254 254 264 260 260 260 260 260 254 264 264 264 264 267 267 264 264 271 271 281 274 274 271 274 274 279 279 274 281 281 285 285 285 281 287 281 291 291 291 287 281 294 301 301 298 298 301 301 301 301 301 304 301 306 304 308 306 301	Association
11849656	Chemical	Gene	D000077583	185	True	0	What is [PHARMGKB] between @ChemicalSrc$ quinapril @/ChemicalSrc$ and @GeneTgt$ AT1R @/GeneTgt$ ? [SEP] Influence of angiotensinogen M253 T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention . We studied the relation between renin-angiotensin system ( RAS ) related gene polymorphisms , such as angiotensin converting enzyme ( ACE ) insertion/deletion ( I/D ) , angiotensinogen ( AGT ) M253 T and @GeneTgt$ angiotensin II type 1 receptor @/GeneTgt$ ( @GeneTgt$ AT1R @/GeneTgt$ ) A1166C , and the effect of @ChemicalSrc$ quinapril @/ChemicalSrc$ , an ACE inhibitor with high tissue-binding affinity , on preventing restenosis after percutaneous coronary intervention ( PCI ) . A total of 253 patients successfully treated for coronary artery disease were randomly assigned to @ChemicalSrc$ quinapril @/ChemicalSrc$ or control . Of the 215 patients who completed the follow-up , we determined gene polymorphisms in 204 patients with 241 lesions who provided blood samples for genotype determination . In the control , the ACE D homozygotes showed a smaller minimal lumen diameter ( MLD ) at follow-up ( P=0.063 ) . The other two genotypes of AGT and @GeneTgt$ AT1R @/GeneTgt$ did not affect restenosis after PCI . According to @ChemicalSrc$ quinapril @/ChemicalSrc$ treatment , the AGT T homozygotes significantly showed a beneficial effect of @ChemicalSrc$ quinapril @/ChemicalSrc$ on MLD ( P=0.013 ) and late lumen loss ( P=0.013 ) . The ACE I homozygotes also exhibited beneficial effects of @ChemicalSrc$ quinapril @/ChemicalSrc$ on larger MLD ( P=0.065 ) . The @GeneTgt$ AT1R @/GeneTgt$ genotype did not influence the @ChemicalSrc$ quinapril @/ChemicalSrc$ effect . In conclusion , the AGT T homozygotes might benefit from effects of @ChemicalSrc$ quinapril @/ChemicalSrc$ on preventing restenosis after PCI .	1 7 7 7 7 7 1 7 13 13 13 13 7 15 13 19 19 19 1 1 22 22 24 22 27 27 31 29 27 29 33 33 24 33 43 35 43 39 43 41 43 41 65 45 43 45 43 53 50 53 53 53 43 43 54|55|62 54|55|62 54|55|62 54|55|62 54|55|62 62|55 54|55|62 62 56|43 43 56|43 62 33 33 22 69 22 71 69|64 69 69|64 71 76 76 71 80 80 78 76 71 83 69 83 88 88 88 83 90 88 90 22 97 109 100 100 97 102 100 106 106 106 102 109 109 109 111 109|110 109 109|110 111 111 109 120 120 120 127 122 120 124 122 127 127 127 129 127 132 132 129 135 135 132 137 129 139 137 142 142 139 127 146 146 152 152 151 151 151 152 152 157 157 157 157 152 159 157 159 162 152 164 162 164 152 170 170 170 178 172 170 172 172|173 172 172|173 178 178 178 178 181 178 178 188 184 185|188 188 185|188 195 195 193 193 193 195 195 195 198 198 195 200 198 198 198 203 198 205 203 205 203 210 210 203 212 210 212 195 220 220 220 222 222 222 224 222 226 224|225 224 224|225 230 230 224 232 230 232 222 239 236|239 239 236|239 242 242 242 242 246 246|242 246 246|242 242 242 251 258 258 256 256 256 258 258 258 260 258 262 260|261 260 260|261 265 258 265 268 265 258	Association
12124989	Chemical	Gene	D006221	6261	True	0	What is [PHARMGKB] between @ChemicalSrc$ halothane @/ChemicalSrc$ and @GeneTgt$ RYR1 @/GeneTgt$ ? [SEP] @GeneTgt$ RYR1 @/GeneTgt$ mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes . Malignant hyperthermia ( MH ) and central core disease ( CCD ) are autosomal dominant disorders of skeletal muscle . Susceptibility to MH is only apparent after exposure to volatile anesthetics and/or depolarizing muscle relaxants . CCD patients present with diffuse muscular weakness but are also at risk of MH . Mutations in @GeneTgt$ RYR1 @/GeneTgt$ ( 19q13.1 ) , encoding a @GeneTgt$ skeletal muscle calcium release channel @/GeneTgt$ ( ryanodine receptor ) , account for the majority of MH and CCD cases . Fifteen @GeneTgt$ RYR1 @/GeneTgt$ N-terminal mutations are considered causative of MH susceptibility , five of which are also associated with CCD . In the first extensive UK population survey , eight of 15 mutations were detected in 85 out of 297 ( 29 % ) unrelated MH susceptible cases , with G2434R detected in 53 cases ( 18 % ) . Mutation type was shown to affect significantly MH phenotypes ( in vitro contracture test ( IVCT ) response to caffeine , @ChemicalSrc$ halothane @/ChemicalSrc$ , and ryanodine ) . @GeneTgt$ RYR1 @/GeneTgt$ mutations associated with both CCD and MH ( R163C , R2163H , R2435H ) had more severe caffeine and @ChemicalSrc$ halothane @/ChemicalSrc$ response phenotypes than those associated with MH alone . Mutations near the amino terminal ( R163C , G341R ) had a relatively greater effect on responses to caffeine than @ChemicalSrc$ halothane @/ChemicalSrc$ , with a significantly increased caffeine : @ChemicalSrc$ halothane @/ChemicalSrc$ tension ratio compared to G2434R of the central domain . All phenotypes were more severe in males than females , and were also affected by muscle specimen size and viability . Discordance between @GeneTgt$ RYR1 @/GeneTgt$ genotype and IVCT phenotype was observed in seven families ( nine individuals ) , with five false-positives and four false-negatives . This represents the most extensive study of MH patient clinical and genetic data to date and demonstrates that @GeneTgt$ RYR1 @/GeneTgt$ mutations involved in CCD are those associated with one end of the spectrum of MH IVCT phenotypes .	0|3 3 0|3 9 3 7 7 4 9 9 14 12 14 14 19 19 15 19 19 9 9 23 37 25 23 25 23 30 30 23 32 30 32 37 37 37 37 40 40 37 37 47 44 42 47 47 47 49 47 52 52 49 52 56 56 52 47 59 59 59 64 63 64 60 59 67 69 69 59 71 69 59 94 75 73|74 73 73|74 78 75 78 73 73 83 81|83 81|83 81|83 81|83 81|83 81|83 81|83 91 91 83 91 73 94 97 97 94 99 102 99 99 97 94 110 106|109 109 106|109 110 112 112 112 112 116 116 113 123 123 120 118 123 123 112 125 123 123 134 134 134 134 134 134 141 141 138 138 139 141 141 141 143 146 146 146 154 149 149 146 149 154 153 154 141 154 157 141 157 161 161 158 164 164 161 164 141 168 170 170 170 172 170 175 175 172 180 180 177 180 184 184 184 184 172 186 184 186 186|187 186 186|187 186 186 186 184 170 195|198 198 195|198 212 198 202 202 199 202 202 206 202 206 206 206 206 206 212 214 215 212 215 220|215 220 220|215 220 215 222 212 222 225 223 225 212 240 236 236 236 236 236 230 236 236 236 240 244 243 244 240 246 244 248 246 250 246|249 246 246|249 240 257 257 256 257 240 257 262|257 262 262|257 262 240 265 265 240 269 269 269 265 240 274 277 277 277 277 279 277 281 279 277 277 286 286 277 290 289 290 286 290 290 277 303 298 295|298 298 295|298 294 298 301 298 303 303 306 306 303 309 309 306 309 306 314 314 306 314 317 314 303 321 321 325 324 325 321 328 328 332 328 329 329 325 334 332 321 321 345 337|340 340 337|340 345 340 343 341 345 336 345 349 349 346 352 352 349 356 356 356 352 321	Association
12724618	Chemical	Gene	D013390	590	False	1	What is [PHARMGKB] between @ChemicalSrc$ succinylcholine @/ChemicalSrc$ and @GeneTgt$ BChE @/GeneTgt$ ? [SEP] Frequency of @GeneTgt$ butyrylcholinesterase @/GeneTgt$ gene mutations in individuals with abnormal inhibition numbers : an Italian-population study . OBJECTIVES : More than 30 genetic variants of serum @GeneTgt$ cholinesterase @/GeneTgt$ ( @GeneTgt$ butyrylcholinesterase @/GeneTgt$ , @GeneTgt$ BChE @/GeneTgt$ ) have been described . Some of them ( the atypical and the fluoride-resistant variants ) are well known because carriers are prone to develop prolonged apnea following the administration of the muscle relaxant @ChemicalSrc$ succinylcholine @/ChemicalSrc$ . Genotype characterization is therefore important in order to prevent such episodes . Genetic studies have so far focused on selected individuals or families rather than on the random population . METHODS : From a large group of healthy blood donors ( n = 2609 ) , we selected all the 58 individuals with low serum @GeneTgt$ cholinesterase @/GeneTgt$ activity : among them 28 subjects had abnormal dibucaine and fluoride inhibition numbers . Twenty-five mutations in the coding region of the human @GeneTgt$ cholinesterase @/GeneTgt$ gene were analyzed . RESULTS : All individuals with abnormal inhibition numbers were homozygotes or double heterozygotes in several mutations . Asp70Gly ( Atypical variant ) and Ala539Thr ( K variant ) were the most frequently observed amino acid substitutions . The majority of subjects with low @GeneTgt$ BChE @/GeneTgt$ activity but normal dibucaine and fluoride number presented only the K form . We analyzed 106 randomly chosen subjects for K and atypical variants . Carriers of these alleles were at risk of low @GeneTgt$ BChE @/GeneTgt$ activity ( OR = 9.55 , 95%CI , 5.61 - 16.26 and OR = 30.33 , 95%CI , 7.05 - 130.52 respectively ) . CONCLUSIONS : Data obtained from this study help to better define the etiology of low @GeneTgt$ BChE @/GeneTgt$ activity and the role of the rather common K allele . It is the first time that such a large population has been screened for so many mutations . @GeneTgt$ BChE @/GeneTgt$ is also implicated in detoxifying cocaine ; therefore genetic analysis could be useful in cases of cocaine toxicity in Italian subjects .	1 6 2|6 6 2|6 6 1 8 6 12 12 12 8 1 16 16 1 1 19 19 23 23 25 25 39 28 28 27|31 31 27|31 31 29|25 25 29|25 31 31 31 31 31 39 39 19 39 57 46 44 49 49 44 49 52 49 49 49 57 57 57 61 61 61 57 63 61 65 63 68 68 63 73 73 73 73 68|72 68 68|72 57 78 81 81 81 81 83 81 85 83 87 85 81 90 94 94 93 94 94 97 97 94 97 97 97 100 105 105 105 97 94 124 124 112 112 112 124 116 116 116 112 118 112 118 119 118 124 124 124 128 128 128 124 134 134 134 131|134 134 131|134 124 124 137 140 139 137 124 142 140 142 142 146 142 124 150 162 154 154 154 150 160 160 160 157|160 160 157|160 154 162 162 162 165 165 168 174 172 172 172 168 174 165 174 177 174 180 180 174 165 200 185 185 182 185 182 182 191 191 188 191 200 200 196 197 200 200 200 200 200 203 217 205 203 210 210 210|207 210 210|207 203 210 213 210 213 213 213 217 221 221 221 217 217 225 225 229 228 229 225 231 229 231 231 231 225 242 239 239 236 242 242 242 247 247 244|247 247 244|247 242 250 250 247 250 251 250 253 253 253 253 257 253 253 253 261 250 263 263 265 263 250 250 242 272 272 279 274 278 278 275 272 282 282 279 284 282 289 289 289|286 289 289|286 284 284 292 284 298 298 296 298 298 292 272 305 305 305 305 305 313 310 310 310 313 313 313 305 317 316 317 313 305 318|323 323 318|323 323 323 323 326 326 323 323 333 330 333 333 333 323 335 333 338 338 335 341 341 338 323	Association
15608561	Chemical	Gene	D011345	5465	True	0	What is [PHARMGKB] between @ChemicalSrc$ fenofibrate @/ChemicalSrc$ and @GeneTgt$ PPARA @/GeneTgt$ ? [SEP] Response to micronized @ChemicalSrc$ fenofibrate @/ChemicalSrc$ treatment is associated with the @GeneTgt$ peroxisome-proliferator-activated receptors alpha @/GeneTgt$ G/C intron7 polymorphism in subjects with type 2 diabetes . OBJECTIVE : The association between polymorphisms in candidate genes related to lipoprotein metabolism and the reduction in plasma triglyceride ( TG ) in response to @ChemicalSrc$ fenofibrate @/ChemicalSrc$ treatment was evaluated in subjects with type 2 diabetes treated with micronized @ChemicalSrc$ fenofibrate @/ChemicalSrc$ ( 200 mg/day ) for at least 3 years in the Diabetes Atherosclerosis Intervention Study . METHODS : The cholesteryl ester transfer protein Taq1B , LPL S447X , hepatic lipase -514 C--&gt;T , @GeneTgt$ peroxisome-proliferator-activated receptors alpha @/GeneTgt$ ( @GeneTgt$ PPARA @/GeneTgt$ ) L162V and G/C intron 7 polymorphisms and the apolipoprotein E2/E3/E4 alleles were genotyped using PCR and restriction enzyme digestion . Subjects were divided into high TG-responders ( with & gt ; 30 % TG relative reduction after treatment ) and low TG-responders . RESULTS : The frequency of the @GeneTgt$ PPARA @/GeneTgt$ intron 7 G/G genotype was higher in high TG-responders than in low TG-responders ( 85 % vs. 69 % , P & lt ; 0.05 ) . There was no significant difference between the percentage of high TG-responders and low TG-responders for any of the other genetic polymorphisms examined . In stepwise logistic regression , baseline TG and only the @GeneTgt$ PPARA @/GeneTgt$ intron 7 polymorphism among the others were selected in the model as significant predictors of TG-response ( odds ratio : 3.10 , 95 % CI : 1.28 - 7.52 , P = 0.012 for @GeneTgt$ PPARA @/GeneTgt$ polymorphism ) . With age , gender , body mass index , smoking status and HbA1c as additional factors , baseline TG ( P&lt ; 0.0001 ) , intron 7 ( P = 0.013 ) , body mass index ( P = 0.040 ) and LPL-S447X ( P = 0.084 ) were significant predictors of TG-response . CONCLUSION : These results indicate that elevated baseline TG levels and @GeneTgt$ PPARA @/GeneTgt$ gene intron 7 G/G genotype were associated with TG reduction & gt ; 30 % after @ChemicalSrc$ fenofibrate @/ChemicalSrc$ treatment in patients with type 2 diabetes .	8 6 6 3|6 6 3|6 1 8 8 11 11 8|9|11|17 8|9|11|17 8|9|11|17 8|17|11 8|9|11|17 17 17 11 19 17 23 23 23 19 8 27 27 30 56 32 30 35 35 32 35 39 39 36 39 42 56 45 45 42 47 45 47 50 42 54 51|54 54 51|54 50 56 27 58 56 62 62 62 58 62 66 66 63|64 63 63|64 70 70 66 70 74 74 75 76 63 82 82 80 82 82 63 56 123 123 93 93 93 93 93 123 123 96 123 96 99 96 99 103 101 101|102|103|111 101|102|103|111 101|102|103|111 101|103|111 101|102|103|111 108 111|104 111 111|104 111 96 111 114 116 116 96 96 121 121 121 96 123 123 123 124 125 128 129 125 123 135 135 135 138 138 135 140 148 140 140 140 145 148 148 148 138 150 148 148 148 154 148 135 156 156 159 169 167 167 167|161 167 167|161 167 167 167 159 169 156 172 172 169 176 176 176 169 179 179 176 179 182 179 182 182 184 184 179 179 179 169 193 193 196 196 193 199 199 196 202 202 199 199 205 199 207 205 212 212 212 212 207 212 193 218 218 218 234 234 221 234 221 229 229 224|229 229 224|229 229 229 221 232 232 229 234 234 237 237 234 240 240 234 242 240 245 245 240 251 251 247 250 251 245 251 255 255 251 258 258 234 258 263 263|259 263 263|259 258 258 234 269 318 318 318 271 275 275 271 275 278 275 278 278 283 283 278 283 286 283 283 290 290 283 290 283 283 293 297 297 293 297 297 283 303 303 283 306 306 303 306 306 303 303 313 313 310 313 313 318 318 318 320 318 318 326 326 325 326 326 341 331 331 331 341 331 332|336 336 332|336 336 339 339 339 331 341 326 344 344 341 344 344 341 349 341 353 353|349 353 353|349 349 355 353 359 359 359 355 326	Association
15634941	Chemical	Gene	D009543	1576	True	0	What is [PHARMGKB] between @ChemicalSrc$ nifedipine @/ChemicalSrc$ and @GeneTgt$ CYP3A @/GeneTgt$ ? [SEP] Recombinant @GeneTgt$ CYP3A4 @/GeneTgt$ * 17 is defective in metabolizing the hypertensive drug @ChemicalSrc$ nifedipine @/ChemicalSrc$ , and the @GeneTgt$ CYP3A4 @/GeneTgt$ * 17 allele may occur on the same chromosome as CYP3A5 * 3 , representing a new putative defective @GeneTgt$ CYP3A @/GeneTgt$ haplotype . Genetic variation in @GeneTgt$ CYP3A @/GeneTgt$ activity may influence the rate of the metabolism and elimination of @GeneTgt$ CYP3A @/GeneTgt$ substrates in humans . We previously reported four new @GeneTgt$ CYP3A4 @/GeneTgt$ coding variants in three different racial groups . In the present study , we examined metabolism of @ChemicalSrc$ nifedipine @/ChemicalSrc$ by the recombinant forms of these allelic variants . Metabolism of @ChemicalSrc$ nifedipine @/ChemicalSrc$ by the L293P ( @GeneTgt$ CYP3A4 @/GeneTgt$ * 18 ) , M445 T ( CYP3A4 * 3 ) , and P467S ( @GeneTgt$ CYP3A4 @/GeneTgt$ * 19 ) allelic variants was not significantly different from wild-type @GeneTgt$ CYP3A4 @/GeneTgt$ * 1 . However , F189S ( @GeneTgt$ CYP3A4 @/GeneTgt$ * 17 ) exhibited a & gt;99 % decrease in both V(max ) and CL(max ) of @ChemicalSrc$ nifedipine @/ChemicalSrc$ compared with @GeneTgt$ CYP3A4 @/GeneTgt$ * 1 . Of 72 racially diverse individuals , @GeneTgt$ CYP3A4 @/GeneTgt$ * 17 was identified in 1 of 24 Caucasian samples [ 1:5 Eastern European ( Adygei ethnic group ) ] . Genotyping of an extended set of 276 genomic DNAs of Caucasians ( 100 from the Coriell Repository and an additional 176 from the United States ) for @GeneTgt$ CYP3A4 @/GeneTgt$ * 17 detected no additional individuals containing the @GeneTgt$ CYP3A4 @/GeneTgt$ * 17 allele . However , additional genotyping of four more Adygei samples available from Coriell detected an additional individual carrying the @GeneTgt$ CYP3A4 @/GeneTgt$ * 17 allele . New specific polymerase chain reaction-restriction fragment length polymorphism genotyping procedures were developed for the major splice variant of CYP3A5 ( CYP3A5 * 3 ) and @GeneTgt$ CYP3A4 @/GeneTgt$ * 17 . Genotyping revealed that the two individuals carrying @GeneTgt$ CYP3A4 @/GeneTgt$ * 17 were either homozygous or heterozygous for the more frequent CYP3A5 * 3 allele , suggesting that the two alleles may exist on the same chromosome as a new putative @GeneTgt$ CYP3A @/GeneTgt$ poor metabolizer haplotype . We predict that individuals who are homozygous for defective alleles of both of these genes would metabolize @GeneTgt$ CYP3A @/GeneTgt$ substrates poorly . The new genetic tests will be useful in future clinical studies to investigate genotype/phenotype associations .	2 1|7 7 1|7 2 2 7 7 9 7 13 13 13 9|11 9 9|11 13 13 22 22|15 22 22|15 22 22 24 24 7 28 28 28 24 30 24 30 30 30 24 41 41 41 41 41|35 41 41|35 34 24 48 54 52 49|52 52 49|52 48 54 54 56 54 59 59 56 56 56 65 65|61 65 65|61 61 67 61 54 73 73 73 79 79 79|75 79 79|75 79 73 84 84 84 84 79 73 90 90 90 93 93 93 93 93 96 94|95 94 94|95 101 101 101 94 105 105 105 101 93 143 110 108|109 108 108|109 139 139 113 116 114 114 114 119 116 119 116 123 114 125 123 125 125 125 114 114 139 133 139|130 139 139|130 139 139 139 139 108 143 143 143 143 146 146 142|143 143 142|143 146 146 143 164 164 164 159 157|158 157 157|158 159 159 159 164 169 165 168 165 164 172 172 169 172 169 169 175 178 176|169 169 176|169 182 182 179|164 164 179|164 182 182 164 191 194 193 194 201 194 194|195 194 194|195 196 196 201 201 203 207 205 207 207 201 215 215 211 215 215 215 215 207 215 207 201 251 224 224 224 220 228 228 228 224 230 228 230 230 236 236 236 232 230 240 240 230 244 244 244 240 244 247 230|246 230 230|246 247 247 251 254 254 251 254 261 261|255 261 261|255 261 261 255 251 277 277 268 277 273 273 270 273 268 273 276 274 277 280 280 277 280 287 282|287 287 282|287 287 287 281 277 299 299 299 299 299 299 299 299 299 301 301 301 306 306 306 306 301 310 310 310 306 310 310 310 306 314|306 306 314|306 315 315 301 322 322 334 326 326 334 326 327 327 327 328 328 334 334 322 334 334 344 341 340 341 344 344 344 334 322 322 352 350 350 352 352 346 356 356 356 352 365 365 365 365 365|359 365 365|359 365 365 352 322 370 370 385 385 375 375 372 378 378 375 380 378 383 383 380 385 370 385|388 388 385|388 385 385 370 395 395 395 398 398 398 398 402 402 402 398 404 398 406 404 398	Association
17286537	Chemical	Gene	D008727	8836	True	0	What is [PHARMGKB] between @ChemicalSrc$ MTX @/ChemicalSrc$ and @GeneTgt$ GGH @/GeneTgt$ ? [SEP] Exploratory analysis of four polymorphisms in human @GeneTgt$ GGH @/GeneTgt$ and FPGS genes and their effect in @ChemicalSrc$ methotrexate-treated @/ChemicalSrc$ rheumatoid arthritis patients . The enzyme folylpoly-gamma-glutamase synthethase ( FPGS ) plays an important role in the intracellular polyglutamation of the disease-modifying antirheumatic drug @ChemicalSrc$ methotrexate @/ChemicalSrc$ ( @ChemicalSrc$ MTX @/ChemicalSrc$ ) and the length of the polyglutamated @ChemicalSrc$ MTX @/ChemicalSrc$ product correlates with the time that @ChemicalSrc$ MTX @/ChemicalSrc$ resides in the cell . The glutamates are released from @ChemicalSrc$ MTX @/ChemicalSrc$ by activity of the enzyme @GeneTgt$ gamma-glutamyl-hydrolase @/GeneTgt$ ( @GeneTgt$ GGH @/GeneTgt$ ) , thereby allowing the efflux of @ChemicalSrc$ MTX @/ChemicalSrc$ . @GeneTgt$ GGH @/GeneTgt$ 452C&gt;T has been associated with decreased catalytic activity and higher accumulation of long-chain MTX-polyglutamate . However , single nucleotide polymorphisms ( SNPs ) in FPGS and @GeneTgt$ GGH @/GeneTgt$ genes have not yet been explored for association with @ChemicalSrc$ MTX @/ChemicalSrc$ efficacy or toxicity . We selected for SNPs with frequencies higher than 10 % or , in case of FPGS 114G&gt;A , causing an amino acid change with no known frequencies . In this study , frequencies of two SNPs in FPGS ( 1994A&gt;G and 114G&gt;A , rs10106 and rs10760502 , respectively ) and @GeneTgt$ GGH @/GeneTgt$ genes ( 452C&gt;T and 16T&gt;C , rs11545078 and rs1800909 , respectively ) , were determined using a newly developed method in rheumatoid arthritis patients ( n = 352 ) and in a group of healthy controls ( n = 360 ) . Next , the SNPs were associated with response to @ChemicalSrc$ MTX @/ChemicalSrc$ in rheumatoid arthritis patients treated with @ChemicalSrc$ MTX @/ChemicalSrc$ monotherapy . In rheumatoid arthritis patients , allele frequencies of FPGS 1994A&gt;G were 0.534 ( A ) and 0.466 ( G ) , and for FPGS 114G&gt;A 0.714 ( G ) and 0.286 ( A ) . Allele frequencies of @GeneTgt$ GGH @/GeneTgt$ 16T&gt;C were 0.737 ( T ) and 0.263 ( C ) and for @GeneTgt$ GGH @/GeneTgt$ 452C&gt;T 0.912 ( C ) and 0.088 ( T ) . No significant differences in allele frequencies between rheumatoid arthritis patients and healthy controls were found . In addition , the SNPs were not associated with good clinical response to @ChemicalSrc$ MTX @/ChemicalSrc$ . Only patients with the @GeneTgt$ GGH @/GeneTgt$ 16C-allele and one or no copies of the @GeneTgt$ GGH @/GeneTgt$ 452C-16 T haplotype were associated with good clinical improvement at 3 months upon treatment with @ChemicalSrc$ MTX @/ChemicalSrc$ . No associations with efficacy at 6 months and @ChemicalSrc$ MTX-induced @/ChemicalSrc$ toxicity were found . Therefore we conclude that despite the positive association of the @GeneTgt$ GGH @/GeneTgt$ 16C-allele and one or no copies of the @GeneTgt$ GGH @/GeneTgt$ 452C-16 T haplotype with good clinical improvement at 3 months upon treatment with @ChemicalSrc$ MTX @/ChemicalSrc$ , the tested SNPs in @GeneTgt$ GGH @/GeneTgt$ and FPGS genes are suggested not to be clinically important for @ChemicalSrc$ MTX @/ChemicalSrc$ treatment outcome .	2 2 5 5 2 8 8 5|7 5 5|7 8 8 8 5 15 5 21 21|15 21 21|15 21 21 15 2 28 28 28 32 30 28 30 32 35 35 32 39 39 39 32 45 45 45 45 45 44|39 39 44|39 48 45|46 45 45|46 48 39 53 60 59 59 59 59|54 59 59|54 53 32 63 63 60 67 67|61 67 67|61 63 70 70 67 60 77 79 79 79 81 79|80 79 79|80 84 79 88 88 88 84|86 84 84|86 91 88 88 88 91 79 96 79 98 96 100 96|98 98 96|98 79 106|109 109 106|109 112 112 112 112 116 116 116 112 116 119 116 122 122 119 112 143 143 129 129 143 131 129 131 134 129 134 134|135 134 134|135 134 143 143 143 143 143 145 143 149 149|145 149 149|145 145 149 149 143 156 156 158 156 160 158 160 163 164 161 156 156 168 156 170 168 170 156 156 177 177 177 173 181 181 181 177 156 185 185 221 221 221 190 190 187 192 187 194 192 194 194 194 194 198 198 194 194 194 192 207|204 207 207|204 192 209 207 209 209 209 209 209 209 209 209 209 187 221 221 221 226 225 226 222 230 230 230 226 232 233 230 233 233 230 239 239 230 242 242 239 244 245 226 245 245 221 255 255 253 255 255 255 257 255 259 257|258 257 257|258 264 264 264 257 264 269 265|269 269 265|269 265 255 276 276 276 284 284 279 284 281 279 281 284 284 286 284 286 286 286 291 286 291 286 286 298 298 298 286 300 298 300 298 298 305 298 305 284 309 315 313 310|313 313 310|313 309 315 315 317 315 317 315 315 322 315 322 315 326 315|324 315 315|324 326 328 331 328 331 328 328 336 326 336 315 343 343 355 346 346 343 350 350 350 346 350 353 350 355 355 355 358 364 364 361 364 364 364 364 368 368 368 364 370 368|369 368 368|369 364 375 394 378 378 377|380 380 377|380 375 380 385 382 382 380 392 392 392|386 392 392|386 392 392 385 394 394 398 398 398 394 401 401 398 403 394 405 402|403 403 402|403 394 412 423 414 412 417 417 414 414 418|421 421 418|421 414 423 423 423 428 428 428 474 433 433 433 474 438 438 435|438 438 435|438 433 438 443 440 440 438 450 450 450|444 450 450|444 450 450 443 454 454 454 443 457 457 454 459 443 461 458|459 459 458|459 474 466 466 474 468 466|464 466 466|464 468 468 468 474 428 479 479 479 479 474 484 484|476 484 484|476 484 479 428	Association
17457342	Chemical	Gene	D002945	4036	True	0	What is [PHARMGKB] between @ChemicalSrc$ cisplatin @/ChemicalSrc$ and @GeneTgt$ megalin @/GeneTgt$ ? [SEP] @GeneTgt$ Megalin @/GeneTgt$ genetic polymorphisms and individual sensitivity to the ototoxic effect of @ChemicalSrc$ cisplatin @/ChemicalSrc$ . Ototoxicity and nephrotoxicity are dose-limiting side effects of @ChemicalSrc$ cisplatin @/ChemicalSrc$ . @GeneTgt$ Megalin @/GeneTgt$ , a member of the low-density lipoprotein receptor family , is highly expressed in renal proximal tubular cells and marginal cells of the stria vascularis of the inner ear - tissues , which accumulate high levels of platinum-DNA adducts . On the assumption that the mechanisms of @ChemicalSrc$ cisplatin-induced @/ChemicalSrc$ nephro- and ototoxicity involve @GeneTgt$ megalin @/GeneTgt$ we analyzed the incidence of the non-synonymous single nucleotide polymorphisms ( SNP ) rs2075252 and rs4668123 in 25 patients who developed a distinct hearing loss during @ChemicalSrc$ cisplatin @/ChemicalSrc$ therapy and in 25 patients without hearing impairment after @ChemicalSrc$ cisplatin @/ChemicalSrc$ therapy . We found no association between cisplatin-induced ototoxicity and any allele of rs4668123 but observed a higher frequency of the A-allele of rs2075252 in the group with hearing impairment than in the group with normal hearing after cisplatin therapy ( 0.32 versus 0.14 ) ( chi(2)=5.83 , P&lt;0.02 ; odds ratio : 3.45 ; 95 % confidence interval : 1.11 - 11.2 ) indicating that SNPs at the @GeneTgt$ megalin @/GeneTgt$ gene might impact the individual susceptibility against cisplatin-induced ototoxicity .	0|4 4 0|4 4 4 4 7 4 11 11 11 7 13 11 11 11 4 24 18 18 24 24 24 24 26 25|24 24 25|24 24 29|44 44 29|44 30 34 30 40 40 40 40 40 34 30 44 44 44 49 49 49 49 44 49 52 49 56 56 56 49 62 62 62 62 62 56 62 65 62 67 65 70 70 67 44 75 75 89 85 78 85 82 82|79 82 82|79 78 82 82 75 84|85 85 84|85 89 89 91 89 97 97 97 97 97 101 99 101 101 91 101 101 106 106 91 108 106 112 112 112 108 116 116|111 116 116|111 108 116 120 120 116 122 108 122 127 121|127 127 121|127 122 89 134 134 136 134 139 139 136 139 142 139 144 142 134 134 149 149 146 152 152 149 154 152 157 157 149 159 149 159 164 164 164 159 167 167 164 170 170 167 179 179 172 172 174 177 172 179 170 134 182 134 182 189 184 187 189 189 182 189 193 193 189 193 134 204 204 202 202 199|202 202 199|202 197 204 195 207 207 204 210 210 207 134	Association
18245543	Chemical	Gene	D000077289	1588	True	0	What is [PHARMGKB] between @ChemicalSrc$ letrozole @/ChemicalSrc$ and @GeneTgt$ CYP19 @/GeneTgt$ ? [SEP] A single-nucleotide polymorphism in the @GeneTgt$ aromatase @/GeneTgt$ gene is associated with the efficacy of the @GeneTgt$ aromatase @/GeneTgt$ inhibitor @ChemicalSrc$ letrozole @/ChemicalSrc$ in advanced breast carcinoma . PURPOSE : To evaluate the efficacy of treatment with the @GeneTgt$ aromatase @/GeneTgt$ inhibitor @ChemicalSrc$ letrozole @/ChemicalSrc$ in breast cancer patients segregated with respect to DNA polymorphisms of the @GeneTgt$ aromatase @/GeneTgt$ gene @GeneTgt$ CYP19 @/GeneTgt$ . PATIENTS AND METHODS : Postmenopausal patients ( n = 67 ) with hormone receptor-positive metastatic breast cancer were treated with the @GeneTgt$ aromatase @/GeneTgt$ inhibitor @ChemicalSrc$ letrozole @/ChemicalSrc$ . PCR allelic discrimination was used to examine three single-nucleotide polymorphisms ( SNP ) in DNA obtained from breast carcinoma tissue . Two SNPs analyzed ( rs10046 and rs4646 ) were located in the 3 ' untranslated region and one ( rs727479 ) was in the intron of the @GeneTgt$ aromatase @/GeneTgt$ @GeneTgt$ CYP19 @/GeneTgt$ gene . The primary end point of treatment efficacy was time to progression ( TTP ) . RESULTS : Median age was 62 years and median number of metastatic sites was 2 . Observed allelic SNP frequencies were rs10046 , 71 % ; rs4646 , 46 % ; and rs727479 , 63 % . Of the 67 patients , 65 were evaluable for efficacy . Median TTP was 12.1 months . We observed no relationship between TTP and the rs10046 or rs727479 variants . In contrast , we found that TTP was significantly improved in patients with the rs4646 variant , compared with the wild-type gene ( 17.2 versus 6.4 months ; P = 0.02 ) . CONCLUSION : In patients with hormone receptor-positive metastatic breast cancer treated with the @GeneTgt$ aromatase @/GeneTgt$ inhibitor @ChemicalSrc$ letrozole @/ChemicalSrc$ , the presence of a SNP in the 3 ' untranslated region of the @GeneTgt$ CYP19 @/GeneTgt$ @GeneTgt$ aromatase @/GeneTgt$ gene is associated with improved treatment efficacy . Testing for the @GeneTgt$ CYP19 @/GeneTgt$ rs4646 SNP as a predictive tool for breast cancer patients on antiaromatase therapy deserves prospective evaluation .	3 3 10 8 8 8|5 8 8|5 3 10 10 13 13 10 19 19 18|14 18 18|14 19 16|13 13 16|13 24 24 24 13 10 48 29 32 29 34 32 36 34 42 42 38|41 41 38|41 42 36|40 36 36|40 47 47 47 36 48 50 48 53 53 50 58 58 53|58 58 53|58 59 55|48 48 55|48 48 66 66 66 66 71 84 73 71 73 74 73 82 79 82 82 82 71 84 66 90 90 89|86 89 89|86 90 84|88 84 84|88 84 97 97 99 99 99 101 99 104 104 101 106 104 106 109 104 109 114 114 114 110 99 117 118 118 120 118 120 120 120 125 118 131 131 131 131 131 125 131 131 135 133 135 140 140 140 125 147 147 147|142 147 147|142 147|143 147 147|143 140 118 154 154 154 159 157 157 154 159 159 161 159 163 161 163 159 180 166 169 172 172 172 166 172 175 172 178 178 175 180 180 180 185 185 185 187 187 187 187 190 187 187 187 192 195 192 192 192 192 198 201 198 187 206 206 206 210 210 210 210 210 212 210 210 215 218 218 218 218 218 221 221 223 221 225 223 225 228 225 228 228 228 221 234 237 237 237 237 242 242 242 242 237 244 242 248 248 248 244 242 242 254 254 254 250 259 259 256 256 254 262 262 237 262 262 237 266 266 269 304 275 272 275 275 275 269 269 282 282 281|278 281 281|278 282 276|280 276 276|280 304 286 304 289 289 286 295 295 295 295 295 286 302 302 302|295 302 302|295 302|296 302 302|296 295 304 266 308 308 308 304 266 332 320 320 316|320 320 316|320 320 314 324 324 324 314 328 328 328 324 331 331 328 332 334 332 332	Association
18780301	Chemical	Gene	D000077265	590	True	0	What is [PHARMGKB] between @ChemicalSrc$ Donepezil @/ChemicalSrc$ and @GeneTgt$ cholinesterase @/GeneTgt$ ? [SEP] Variability of AChE , @GeneTgt$ BChE @/GeneTgt$ , and ChAT genes in the late-onset form of Alzheimer 's disease and relationships with response to treatment with @ChemicalSrc$ Donepezil @/ChemicalSrc$ and Rivastigmine . Several factors are believed to give rise to the late onset sporadic form of Alzheimer 's disease ( LOAD ) . We have studied the variation at the genes of three enzymes of the cholinergic system : acetylcholinesterase , butyrylcholinesterase , and choline acetyltransferase . The single nucleotide polymorphisms ( SNPs ) examined were : AChE rs2571598 , @GeneTgt$ BChE @/GeneTgt$ rs1355534 , @GeneTgt$ BChE @/GeneTgt$ rs1803274 , and ChAT rs2177369 . The sample for the case-control study was 471 LOAD patients aged 60 years or older , and 254 subjects with no neurodegenerative disorders as the control group . A significant difference in the genotype distribution between patients and controls was observed only for ChAT rs2177369 , showing that the G/G genotype was to be considered a risk factor with respect to the G/A + A/A genotypes ( odds ratio = 1.56 ; 95 % Confidence Interval = 1.10 - 2.22 ; P = 0.01 ) . Though indicating a significant association with AD onset , our results are far from definitive since contrast with the ones reported by other authors in a previous case-control study , and call for further investigations . Among patients , 171 took part in an observational study concerning the possible role of the genetic composition on the efficacy of treatment with @ChemicalSrc$ Donepezil @/ChemicalSrc$ and Rivastigmine . We related the SNPs of the above cited genes with cognitive status measured by MMSE . Carrying an allele or a genotype of these SNPs does not seem to play a relevant role in the response to treatment with the two @GeneTgt$ cholinesterase @/GeneTgt$ inhibitors , though some significant results were found associated with the AChE A/A genotype that had the best response when treated with Rivastigmine .	1 3 1 3 3|4 3 3|4 3 3 3 3 14 14 14 1 18 18 18 14 14 14 22 20 24 22 26 24 24 24 26 26 1 34 36 36 36 38 36 38 43 43 43 45 45 38 49 49 49 45 51 49 51 36 56 56 56 58 56 61 61 58 64 64 61 68 68 68 64 56 56 70 70 70 70 76 70 56 81 81 81 89 83 81 83 81 89 89 89 89 89 93|90 93 93|90 89 93 93|97 97 93|97 93 93 93 101 93 89 106 114 110 110 110 106 114 114 114 114 114 117 119 117 114 119 119 123 114 127 127 127 123 131 131 131 114 114 135 135 145 139 139 139 135 141 139 141 141 145 145 149 149 149 145 145 145 159 155 155 159 159 159 159 151 162 162 159 164 162 167 167 164 167 170 167 173 173 174 162 174 174 178 180 180 159 180 184 184 181 180 187 180 187 180 145 192 203 195 195 192 198 198 195 203 201 203 203 203 205 203 207 203 210 210 207 210 214 214 211 219 219 219 219 211 203 203 203 225 225 222 203 228 231 231 231 231 231 236 236 236 231 240 240 240 236 244 244 244 240 247 247 240 249 247 251 250|249 249 250|249 251 251 231 258 258 260 258 265 265 265 265 260 268 268 265 268 271 269 258 284 275 273 275 278 275 281 281 278 284 284 284 286 284 289 289 286 292 292 286 294 292 300 300 300 297|300 300 297|300 294 284 307 305 305 307 307 284 307 313 313 313 313 308 315 313 318 318 315 320 315 322 320 284	Association
18780301	Chemical	Gene	D000068836	43	True	0	What is [PHARMGKB] between @ChemicalSrc$ Rivastigmine @/ChemicalSrc$ and @GeneTgt$ AChE @/GeneTgt$ ? [SEP] Variability of @GeneTgt$ AChE @/GeneTgt$ , BChE , and ChAT genes in the late-onset form of Alzheimer 's disease and relationships with response to treatment with Donepezil and @ChemicalSrc$ Rivastigmine @/ChemicalSrc$ . Several factors are believed to give rise to the late onset sporadic form of Alzheimer 's disease ( LOAD ) . We have studied the variation at the genes of three enzymes of the cholinergic system : acetylcholinesterase , butyrylcholinesterase , and choline acetyltransferase . The single nucleotide polymorphisms ( SNPs ) examined were : @GeneTgt$ AChE @/GeneTgt$ rs2571598 , BChE rs1355534 , BChE rs1803274 , and ChAT rs2177369 . The sample for the case-control study was 471 LOAD patients aged 60 years or older , and 254 subjects with no neurodegenerative disorders as the control group . A significant difference in the genotype distribution between patients and controls was observed only for ChAT rs2177369 , showing that the G/G genotype was to be considered a risk factor with respect to the G/A + A/A genotypes ( odds ratio = 1.56 ; 95 % Confidence Interval = 1.10 - 2.22 ; P = 0.01 ) . Though indicating a significant association with AD onset , our results are far from definitive since contrast with the ones reported by other authors in a previous case-control study , and call for further investigations . Among patients , 171 took part in an observational study concerning the possible role of the genetic composition on the efficacy of treatment with Donepezil and @ChemicalSrc$ Rivastigmine @/ChemicalSrc$ . We related the SNPs of the above cited genes with cognitive status measured by MMSE . Carrying an allele or a genotype of these SNPs does not seem to play a relevant role in the response to treatment with the two cholinesterase inhibitors , though some significant results were found associated with the @GeneTgt$ AChE @/GeneTgt$ A/A genotype that had the best response when treated with @ChemicalSrc$ Rivastigmine @/ChemicalSrc$ .	1 3 1|2 1 1|2 3 3 3 3 3 3 14 14 14 1 18 18 18 14 14 14 22 20 24 22 26 24 26 26 26 26 1 34 36 36 36 38 36 38 43 43 43 45 45 38 49 49 49 45 51 49 51 36 56 56 56 58 56 61 61 58 64 64 61 68 68 68 64 56 56 70 70 70 70 76 70 56 81 81 81 90 83 81 83 81 90 90 87|90 90 87|90 90 90 93 90 93 96 93 93 93 100 93 90 104 112 108 108 108 104 112 112 112 112 112 115 117 115 112 117 117 121 112 125 125 125 121 129 129 129 112 112 133 133 143 137 137 137 133 139 137 139 139 143 143 147 147 147 143 143 143 157 153 153 157 157 157 157 149 160 160 157 162 160 165 165 162 165 168 165 171 171 172 160 172 172 176 178 178 157 178 182 182 179 178 185 178 185 178 143 190 201 193 193 190 196 196 193 201 199 201 201 201 203 201 205 201 208 208 205 208 212 212 209 217 217 217 217 209 201 201 201 223 223 220 201 226 229 229 229 229 229 234 234 234 229 238 238 238 234 242 242 242 238 245 245 238 247 245 249 247 249 249|250 249 249|250 229 256 256 258 256 263 263 263 263 258 266 266 263 266 269 267 256 282 273 271 273 276 273 279 279 276 282 282 282 284 282 287 287 284 290 290 284 292 290 297 297 297 297 292 282 304 302 302 304 304 282 304 311 311 311|307 311 311|307 311 305 313 311 316 316 313 318 313 320 318 318 318 282	Association
18780301	Chemical	Gene	D000068836	1103	True	0	What is [PHARMGKB] between @ChemicalSrc$ Rivastigmine @/ChemicalSrc$ and @GeneTgt$ ChAT @/GeneTgt$ ? [SEP] Variability of AChE , BChE , and @GeneTgt$ ChAT @/GeneTgt$ genes in the late-onset form of Alzheimer 's disease and relationships with response to treatment with Donepezil and @ChemicalSrc$ Rivastigmine @/ChemicalSrc$ . Several factors are believed to give rise to the late onset sporadic form of Alzheimer 's disease ( LOAD ) . We have studied the variation at the genes of three enzymes of the cholinergic system : acetylcholinesterase , butyrylcholinesterase , and choline acetyltransferase . The single nucleotide polymorphisms ( SNPs ) examined were : AChE rs2571598 , BChE rs1355534 , BChE rs1803274 , and @GeneTgt$ ChAT @/GeneTgt$ rs2177369 . The sample for the case-control study was 471 LOAD patients aged 60 years or older , and 254 subjects with no neurodegenerative disorders as the control group . A significant difference in the genotype distribution between patients and controls was observed only for @GeneTgt$ ChAT @/GeneTgt$ rs2177369 , showing that the G/G genotype was to be considered a risk factor with respect to the G/A + A/A genotypes ( odds ratio = 1.56 ; 95 % Confidence Interval = 1.10 - 2.22 ; P = 0.01 ) . Though indicating a significant association with AD onset , our results are far from definitive since contrast with the ones reported by other authors in a previous case-control study , and call for further investigations . Among patients , 171 took part in an observational study concerning the possible role of the genetic composition on the efficacy of treatment with Donepezil and @ChemicalSrc$ Rivastigmine @/ChemicalSrc$ . We related the SNPs of the above cited genes with cognitive status measured by MMSE . Carrying an allele or a genotype of these SNPs does not seem to play a relevant role in the response to treatment with the two cholinesterase inhibitors , though some significant results were found associated with the AChE A/A genotype that had the best response when treated with @ChemicalSrc$ Rivastigmine @/ChemicalSrc$ .	1 3 1 3 3 3 3 3|7 3 3|7 3 14 14 14 1 18 18 18 14 14 14 22 20 24 22 26 24 26 26 26 26 1 34 36 36 36 38 36 38 43 43 43 45 45 38 49 49 49 45 51 49 51 36 56 56 56 58 56 61 61 58 64 64 61 68 68 68 64 56 56 70 70 70 70 76 70 56 81 81 81 89 83 81 83 81 89 89 89 89 89 92 89 92 95 92 92 92 97|100 100 97|100 92 89 104 112 108 108 108 104 112 112 112 112 112 115 117 115 112 117 117 121 112 125 125 125 121 129 129 129 112 112 133 133 143 137 137 137 133 139 137 139 139 143 143 148 148 148|145 148 148|145 143 143 143 158 154 154 158 158 158 158 150 161 161 158 163 161 166 166 163 166 169 166 172 172 173 161 173 173 177 179 179 158 179 183 183 180 179 186 179 186 179 143 192 203 195 195 192 198 198 195 203 201 203 203 203 205 203 207 203 210 210 207 210 214 214 211 219 219 219 219 211 203 203 203 225 225 222 203 228 231 231 231 231 231 236 236 236 231 240 240 240 236 244 244 244 240 247 247 240 249 247 251 249 251 251|252 251 251|252 231 258 258 260 258 265 265 265 265 260 268 268 265 268 271 269 258 284 275 273 275 278 275 281 281 278 284 284 284 286 284 289 289 286 292 292 286 294 292 299 299 299 299 294 284 306 304 304 306 306 284 306 312 312 312 312 307 314 312 317 317 314 319 314 321 320|319 319 320|319 284	Association
18780301	Chemical	Gene	D000077265	1103	True	0	What is [PHARMGKB] between @ChemicalSrc$ Donepezil @/ChemicalSrc$ and @GeneTgt$ ChAT @/GeneTgt$ ? [SEP] Variability of AChE , BChE , and @GeneTgt$ ChAT @/GeneTgt$ genes in the late-onset form of Alzheimer 's disease and relationships with response to treatment with @ChemicalSrc$ Donepezil @/ChemicalSrc$ and Rivastigmine . Several factors are believed to give rise to the late onset sporadic form of Alzheimer 's disease ( LOAD ) . We have studied the variation at the genes of three enzymes of the cholinergic system : acetylcholinesterase , butyrylcholinesterase , and choline acetyltransferase . The single nucleotide polymorphisms ( SNPs ) examined were : AChE rs2571598 , BChE rs1355534 , BChE rs1803274 , and @GeneTgt$ ChAT @/GeneTgt$ rs2177369 . The sample for the case-control study was 471 LOAD patients aged 60 years or older , and 254 subjects with no neurodegenerative disorders as the control group . A significant difference in the genotype distribution between patients and controls was observed only for @GeneTgt$ ChAT @/GeneTgt$ rs2177369 , showing that the G/G genotype was to be considered a risk factor with respect to the G/A + A/A genotypes ( odds ratio = 1.56 ; 95 % Confidence Interval = 1.10 - 2.22 ; P = 0.01 ) . Though indicating a significant association with AD onset , our results are far from definitive since contrast with the ones reported by other authors in a previous case-control study , and call for further investigations . Among patients , 171 took part in an observational study concerning the possible role of the genetic composition on the efficacy of treatment with @ChemicalSrc$ Donepezil @/ChemicalSrc$ and Rivastigmine . We related the SNPs of the above cited genes with cognitive status measured by MMSE . Carrying an allele or a genotype of these SNPs does not seem to play a relevant role in the response to treatment with the two cholinesterase inhibitors , though some significant results were found associated with the AChE A/A genotype that had the best response when treated with Rivastigmine .	1 3 1 3 3 3 3 3|7 3 3|7 3 14 14 14 1 18 18 18 14 14 14 22 20 24 22 26 24 24 24 26 26 1 34 36 36 36 38 36 38 43 43 43 45 45 38 49 49 49 45 51 49 51 36 56 56 56 58 56 61 61 58 64 64 61 68 68 68 64 56 56 70 70 70 70 76 70 56 81 81 81 89 83 81 83 81 89 89 89 89 89 92 89 92 95 92 92 92 97|100 100 97|100 92 89 104 112 108 108 108 104 112 112 112 112 112 115 117 115 112 117 117 121 112 125 125 125 121 129 129 129 112 112 133 133 143 137 137 137 133 139 137 139 139 143 143 148 148 148|145 148 148|145 143 143 143 158 154 154 158 158 158 158 150 161 161 158 163 161 166 166 163 166 169 166 172 172 173 161 173 173 177 179 179 158 179 183 183 180 179 186 179 186 179 143 192 203 195 195 192 198 198 195 203 201 203 203 203 205 203 207 203 210 210 207 210 214 214 211 219 219 219 219 211 203 203 203 225 225 222 203 228 231 231 231 231 231 236 236 236 231 240 240 240 236 244 244 244 240 247 247 240 249 247 251 250|249 249 250|249 251 251 231 258 258 260 258 265 265 265 265 260 268 268 265 268 271 269 258 284 275 273 275 278 275 281 281 278 284 284 284 286 284 289 289 286 292 292 286 294 292 299 299 299 299 294 284 306 304 304 306 306 284 306 312 312 312 312 307 314 312 317 317 314 319 314 321 319 284	Association
18780301	Chemical	Gene	D000077265	43	True	0	What is [PHARMGKB] between @ChemicalSrc$ Donepezil @/ChemicalSrc$ and @GeneTgt$ AChE @/GeneTgt$ ? [SEP] Variability of @GeneTgt$ AChE @/GeneTgt$ , BChE , and ChAT genes in the late-onset form of Alzheimer 's disease and relationships with response to treatment with @ChemicalSrc$ Donepezil @/ChemicalSrc$ and Rivastigmine . Several factors are believed to give rise to the late onset sporadic form of Alzheimer 's disease ( LOAD ) . We have studied the variation at the genes of three enzymes of the cholinergic system : acetylcholinesterase , butyrylcholinesterase , and choline acetyltransferase . The single nucleotide polymorphisms ( SNPs ) examined were : @GeneTgt$ AChE @/GeneTgt$ rs2571598 , BChE rs1355534 , BChE rs1803274 , and ChAT rs2177369 . The sample for the case-control study was 471 LOAD patients aged 60 years or older , and 254 subjects with no neurodegenerative disorders as the control group . A significant difference in the genotype distribution between patients and controls was observed only for ChAT rs2177369 , showing that the G/G genotype was to be considered a risk factor with respect to the G/A + A/A genotypes ( odds ratio = 1.56 ; 95 % Confidence Interval = 1.10 - 2.22 ; P = 0.01 ) . Though indicating a significant association with AD onset , our results are far from definitive since contrast with the ones reported by other authors in a previous case-control study , and call for further investigations . Among patients , 171 took part in an observational study concerning the possible role of the genetic composition on the efficacy of treatment with @ChemicalSrc$ Donepezil @/ChemicalSrc$ and Rivastigmine . We related the SNPs of the above cited genes with cognitive status measured by MMSE . Carrying an allele or a genotype of these SNPs does not seem to play a relevant role in the response to treatment with the two cholinesterase inhibitors , though some significant results were found associated with the @GeneTgt$ AChE @/GeneTgt$ A/A genotype that had the best response when treated with Rivastigmine .	1 3 1|2 1 1|2 3 3 3 3 3 3 14 14 14 1 18 18 18 14 14 14 22 20 24 22 26 24 24 24 26 26 1 34 36 36 36 38 36 38 43 43 43 45 45 38 49 49 49 45 51 49 51 36 56 56 56 58 56 61 61 58 64 64 61 68 68 68 64 56 56 70 70 70 70 76 70 56 81 81 81 90 83 81 83 81 90 90 87|90 90 87|90 90 90 93 90 93 96 93 93 93 100 93 90 104 112 108 108 108 104 112 112 112 112 112 115 117 115 112 117 117 121 112 125 125 125 121 129 129 129 112 112 133 133 143 137 137 137 133 139 137 139 139 143 143 147 147 147 143 143 143 157 153 153 157 157 157 157 149 160 160 157 162 160 165 165 162 165 168 165 171 171 172 160 172 172 176 178 178 157 178 182 182 179 178 185 178 185 178 143 190 201 193 193 190 196 196 193 201 199 201 201 201 203 201 205 201 208 208 205 208 212 212 209 217 217 217 217 209 201 201 201 223 223 220 201 226 229 229 229 229 229 234 234 234 229 238 238 238 234 242 242 242 238 245 245 238 247 245 249 248|247 247 248|247 249 249 229 256 256 258 256 263 263 263 263 258 266 266 263 266 269 267 256 282 273 271 273 276 273 279 279 276 282 282 282 284 282 287 287 284 290 290 284 292 290 297 297 297 297 292 282 304 302 302 304 304 282 304 311 311 311|307 311 311|307 311 305 313 311 316 316 313 318 313 320 318 282	Association
18780301	Chemical	Gene	D000068836	590	True	0	What is [PHARMGKB] between @ChemicalSrc$ Rivastigmine @/ChemicalSrc$ and @GeneTgt$ cholinesterase @/GeneTgt$ ? [SEP] Variability of AChE , @GeneTgt$ BChE @/GeneTgt$ , and ChAT genes in the late-onset form of Alzheimer 's disease and relationships with response to treatment with Donepezil and @ChemicalSrc$ Rivastigmine @/ChemicalSrc$ . Several factors are believed to give rise to the late onset sporadic form of Alzheimer 's disease ( LOAD ) . We have studied the variation at the genes of three enzymes of the cholinergic system : acetylcholinesterase , butyrylcholinesterase , and choline acetyltransferase . The single nucleotide polymorphisms ( SNPs ) examined were : AChE rs2571598 , @GeneTgt$ BChE @/GeneTgt$ rs1355534 , @GeneTgt$ BChE @/GeneTgt$ rs1803274 , and ChAT rs2177369 . The sample for the case-control study was 471 LOAD patients aged 60 years or older , and 254 subjects with no neurodegenerative disorders as the control group . A significant difference in the genotype distribution between patients and controls was observed only for ChAT rs2177369 , showing that the G/G genotype was to be considered a risk factor with respect to the G/A + A/A genotypes ( odds ratio = 1.56 ; 95 % Confidence Interval = 1.10 - 2.22 ; P = 0.01 ) . Though indicating a significant association with AD onset , our results are far from definitive since contrast with the ones reported by other authors in a previous case-control study , and call for further investigations . Among patients , 171 took part in an observational study concerning the possible role of the genetic composition on the efficacy of treatment with Donepezil and @ChemicalSrc$ Rivastigmine @/ChemicalSrc$ . We related the SNPs of the above cited genes with cognitive status measured by MMSE . Carrying an allele or a genotype of these SNPs does not seem to play a relevant role in the response to treatment with the two @GeneTgt$ cholinesterase @/GeneTgt$ inhibitors , though some significant results were found associated with the AChE A/A genotype that had the best response when treated with @ChemicalSrc$ Rivastigmine @/ChemicalSrc$ .	1 3 1 3 3|4 3 3|4 3 3 3 3 14 14 14 1 18 18 18 14 14 14 22 20 24 22 26 24 26 26 26 26 1 34 36 36 36 38 36 38 43 43 43 45 45 38 49 49 49 45 51 49 51 36 56 56 56 58 56 61 61 58 64 64 61 68 68 68 64 56 56 70 70 70 70 76 70 56 81 81 81 89 83 81 83 81 89 89 89 89 89 93|90 93 93|90 89 93 93|97 97 93|97 93 93 93 101 93 89 106 114 110 110 110 106 114 114 114 114 114 117 119 117 114 119 119 123 114 127 127 127 123 131 131 131 114 114 135 135 145 139 139 139 135 141 139 141 141 145 145 149 149 149 145 145 145 159 155 155 159 159 159 159 151 162 162 159 164 162 167 167 164 167 170 167 173 173 174 162 174 174 178 180 180 159 180 184 184 181 180 187 180 187 180 145 192 203 195 195 192 198 198 195 203 201 203 203 203 205 203 207 203 210 210 207 210 214 214 211 219 219 219 219 211 203 203 203 225 225 222 203 228 231 231 231 231 231 236 236 236 231 240 240 240 236 244 244 244 240 247 247 240 249 247 251 249 251 251|252 251 251|252 231 258 258 260 258 265 265 265 265 260 268 268 265 268 271 269 258 284 275 273 275 278 275 281 281 278 284 284 284 286 284 289 289 286 292 292 286 294 292 300 300 300 297|300 300 297|300 294 284 307 305 305 307 307 284 307 313 313 313 313 308 315 313 318 318 315 320 315 322 320 320 320 284	Association
19201048	Chemical	Gene	D000077156	1956	True	0	What is [PHARMGKB] between @ChemicalSrc$ Gefitinib @/ChemicalSrc$ and @GeneTgt$ EGFR @/GeneTgt$ ? [SEP] Polymorphisms of @GeneTgt$ EGFR @/GeneTgt$ predict clinical outcome in advanced non-small-cell lung cancer patients treated with @ChemicalSrc$ Gefitinib @/ChemicalSrc$ . PURPOSE : Genetic variations in @GeneTgt$ EGFR @/GeneTgt$ may alter protein function and therefore the therapeutic efficacy of @GeneTgt$ epidermal growth factor receptor @/GeneTgt$ inhibitors . This study investigated the association between polymorphisms in @GeneTgt$ EGFR @/GeneTgt$ and clinical outcome in patients with advanced non-small-cell lung cancer ( NSCLC ) treated with @ChemicalSrc$ Gefitinib @/ChemicalSrc$ . METHODS : A whole gene-based tag-SNP approach was used to determine the candidate SNPs in @GeneTgt$ EGFR @/GeneTgt$ . Four tag SNPs , one CA simple sequence repeat ( CA-SSR ) in intron 1 , one coding region SNP ( R521 K ) , and SNPs identified by resequencing in the tyrosine kinase domain of @GeneTgt$ EGFR @/GeneTgt$ were selected to analyze their association with therapeutic outcome and survival in 84 advanced NSCLC patients treated with @ChemicalSrc$ Gefitinib @/ChemicalSrc$ . Progression-free and overall survivals were computed by Cox model adjusted for clinical factors . RESULTS : We identified two @GeneTgt$ EGFR @/GeneTgt$ polymorphisms , rs2293347 ( D994D ) and CA-SSR in intron 1 , associated with clinical outcome of @ChemicalSrc$ Gefitinib @/ChemicalSrc$ therapy . The response rate for the rs2293347GG or shorter CA repeat genotype was significantly higher than that for the rs2293347GA or AA or longer CA repeat genotype ( 71.2 % versus 37.5 % , P=0.0043 and 88.5 % versus 48.3 % , P=0.0005 ) . The rs2293347GG genotype was also associated with longer progression-free survival compared with the rs2293347GA or AA genotype ( 11 months versus 3 months , P=0.0018 ) . A combination of rs2293347GG and shorter CA repeat genotypes had more pronounced clinical benefit . CONCLUSION : The D994D and CA-SSR polymorphisms in @GeneTgt$ EGFR @/GeneTgt$ are potential predictors for clinical outcome in advanced NSCLC patients treated with @ChemicalSrc$ Gefitinib @/ChemicalSrc$ .	5 3 1|2 1 1|2 5 7 5 13 13 13 13 13 7 13 16 14 14 14 5 21 21 24 29 26 24|25 24 24|25 29 21 31 29 29 36 36 36 21 43 36|43 36|43 36|43 36|43 43 36|43 36 21 48 49 49 51 49 53 51 55 54|53 53 54|53 55 59 53 61 59 66 66 66 66 61 68 66 68 66 72 70 70 70 49 85 85 83 83 83 83 85 85 85 87 85 90 90 87 92 90|91 90 90|91 85 98 98 135 98 104 104 104 104 135 106 104 106 109 104 109 109 115 115 115 109 118 118 115 118 104 104 104 122 125 123 130 130 130 130 125 132 130|131 130 130|131 135 135 137 135 139 137 142 142 139 142 142 149 149 149 149 142 149 152 150 150 150 135 162 157 157 157 162 162 165 165 162 165 169 169 166 162 171 171 174 171 178 178|175 178 178|175 174 178 178 182 180 182 180 180 187 185 187 178 178 193 193 190 197 197|193 197 197|193 193 171 203 203 214 206 206 203 206 206 211 211 206 214 214 214 216 214 219 219 216 219 219 219 219 226 226 219 229 229 219 229 232 229 232 229 219 237 219 237 240 237 237 237 219 214 247 247 250 250 250 250 254 254 252 250 250 258 258 255 258 258 258 264 264 261 264 267 264 258 258 258 250 273 281 275 273 275 280 280 280 275 281 283 285 285 281 281 287 299 293 293 290 290 299 295 294|293 293 294|293 299 299 287 302 302 299 306 306 306 302 306 309 307 307 307 287	Association
19362955	Chemical	Gene	D010984	2067	True	0	What is [PHARMGKB] between @ChemicalSrc$ platinum @/ChemicalSrc$ and @GeneTgt$ ERCC1 @/GeneTgt$ ? [SEP] DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer . BACKGROUND : Genetic polymorphisms of genes involved in DNA repair and glutathione metabolic pathways may affect patients ' response to @ChemicalSrc$ platinum-based @/ChemicalSrc$ chemotherapy . We retrospectively assessed whether single nucleotide polymorphisms ( SNP ) of DNA-repair genes @GeneTgt$ ERCC1 @/GeneTgt$ , XPD , XRCC1 and glutathione S-transferase genes GSTP1 , GSTT1 and GSTM1 predict overall survival ( OS ) , response and toxicity in 119 non-small-cell lung cancer ( NSCLC ) patients treated with @ChemicalSrc$ platinum-based @/ChemicalSrc$ regimens as first- or second-line chemotherapy . PATIENTS AND METHODS : Patients ' genotypes were determined by PCR-RFLP and sequencing approaches . RESULTS : @GeneTgt$ ERCC1 @/GeneTgt$ ( Asn118Asn ) genotype was significantly associated with response to treatment . Patients with either one or two C alleles ( C/C , C/T ) at Asn118Asn were more likely to respond to @ChemicalSrc$ platinum-based @/ChemicalSrc$ chemotherapy compared with those without the C allele ( Odds ratio , 0.10 ; 95 % CI , 0.013 - 0.828 ; P = .033 , by binary logistic regression ) . There was a significant association between the @GeneTgt$ ERCC1 @/GeneTgt$ C8092A polymorphism and OS ( P = .009 , by log-rank test ) , with median survival times of 9.8 ( C/C ) and 14.1 ( C/A or A/A ) months , respectively , suggesting that any copies of the A allele were associated with an improved outcome . Cox 's multivariate analysis suggested that the joint effect of @GeneTgt$ ERCC1 @/GeneTgt$ polymorphic variants ( C8092A and N118N ) ( 0 vs. 2 , hazard ratio 2.5 ; 95 % CI , 1.26 - 4.96 ; P = .009 ) as well as the XRCC1 N399Q polymorphism ( AA vs. GA/GG , hazard ratio 3.1 ; 95 % CI , 1.4 - 6.8 ; P = .005 ) were independent prognostic factors for OS in advanced NSCLC patients treated with platinum-based chemotherapy . CONCLUSION : These findings support the notion that assessment of genetic variations of @GeneTgt$ ERCC1 @/GeneTgt$ and XRCC1 could facilitate therapeutic decisions for individualized therapy in advanced NSCLC .	4 4 4 5 5 8 8 5 13 13 13 13 8 5 15 15 18 30 20 18 20 24 24 21 24 28 28 24 30 15 33 31 30 37 34|37 37 34|37 33 30 42 42 42 68 46 46 68 48 46 48 52 52 46 52 52 52 53 53 53 53 53 61 62 53 62 63 63 63 63 42 70 68 72 70 72 70 70 75 75 86 86 86 82 86 84 86 86 75 86 91 87|91 91 87|91 87 96 96 93 93 87 42 100 100 100 100 106 104 108 108 100 110 108 110 110 110 108 115 115 122|116 122 122|116 122 122 122 125 125 125 115 127 125 129 127 115 149 135 135 132 135 135 139 135 141 139 141 141 141 146 132 149 149 149 151 149 155 155|152 155 155|152 151 149 158 156 162 162 162 158 165 165 158 165 165 165 170 171 165 171 165 175 165 165 178 165 178 165 184 184 184 156 149 149 189 189 192 192 189 198 198 198|194 198 198|194 198 192 198 198 202 200 202 203 202 208 208 192 208 189 214 214 214 189 216 218 218 214 218 214 214 223 221 223 223 227 214 189 189 189 189 240 234 240 238 238 238 234 240 231 244 244 244 240 189 250 247 250 251 251 318 255 255 318 260 256|260 260 256|260 260 255 262 260 262 262 262 267 262 267 267 267 272 262 272 262 276 277 262 281 281 281 262 284 284 262 284 284 262 287 287 293 293 293 262 295 293 295 295 295 300 295 300 295 304 305 260 305 309 309 305 312 312 255 312 312 318 318 318 251 320 318 324 324 324 320 324 328 328 325 251 331 335 334 335 331 337 335 349 349 342 342 339 344 342|343 342 342|343 344 344 349 337 351 349 354 354 351 357 357 354 331	Association
19444285	Chemical	Gene	D009543	154	True	0	What is [PHARMGKB] between @ChemicalSrc$ nifedipine @/ChemicalSrc$ and @GeneTgt$ beta2-adrenoceptor @/GeneTgt$ ? [SEP] Arg347Cys polymorphism of alpha1A-adrenoceptor gene is associated with blood pressure response to @ChemicalSrc$ nifedipine @/ChemicalSrc$ GITS in Chinese hypertensive patients . Our objectives were to evaluate whether polymorphisms in the alpha1A- and @GeneTgt$ beta2-adrenoceptor @/GeneTgt$ genes influence blood pressure response to @ChemicalSrc$ nifedipine @/ChemicalSrc$ gastrointestinal therapeutic system ( GITS ) . Hypertensive patients received daily treatment with an oral dosage of 30 mg @ChemicalSrc$ nifedipine @/ChemicalSrc$ GITS for 16 days . Genotypes of the Arg347Cys polymorphism in the alpha1A-adrenoceptor gene and the Arg16Gly and Gln27Glu polymorphisms in the @GeneTgt$ beta2-adrenoceptor @/GeneTgt$ gene were determined by TaqMan single-nucleotide polymorphism genotyping assay . The sixteenth-day steady-state plasma concentration of @ChemicalSrc$ nifedipine @/ChemicalSrc$ was measured using HPLC with UV detection . Multivariate linear regression was performed in a total of 447 patients to evaluate the effects of these polymorphisms on blood pressure response to @ChemicalSrc$ nifedipine @/ChemicalSrc$ GITS . Patients carrying the Cys347 allele of the alpha1A-adrenoceptor gene had a greater systolic blood pressure reduction than did those carrying two Arg347 alleles of the alpha1A-adrenoceptor gene ( 32.5+/-14.0 versus 27.3+/-15.5 mm Hg , respectively , P=0.006 ) . However , diastolic blood pressure reduction was not associated with the Arg347Cys polymorphism in the alpha1A-adrenoceptor gene . In addition , no significant associations were observed between blood pressure reduction and two polymorphisms in the @GeneTgt$ beta2-adrenoceptor @/GeneTgt$ gene . Our data suggest that the Arg347Cys polymorphism in the alpha1A-adrenoceptor gene may be used to predict blood pressure response to @ChemicalSrc$ nifedipine @/ChemicalSrc$ GITS in Chinese hypertensive patients .	2 7 5 5 2 7 7 11 11 11 7 15 12|15 15 12|15 11 19 19 19 11 7 23 26 26 26 26 36 36 31 31 28 31 31|32 31 31|32 31 26 39 39 36 45 45|39 45 45|39 45 45 39 47 45 47 26 53 54 54 56 54 60 60 60 54 66 63 66 63|66 66 63|66 60 69 69 54 54 93 76 76 76 72 80 80 80 72 80 83 80 83 83 83 91 91 88|91 91 88|91 80 93 93 99 99 99 99 99 93 93 106 106 106 106 111 108 106|107 106 106|107 111 111 111 112 116 116 112 111 121 121 123 123 123 126 126 123 129 129 126 131 123 133 131 136 136 133 140 140 140 133 144 144|141 144 144|141 140 123 156 147 151 151 148 155 155 155 151 156 162 162 162 162 162 156 164 162 164 165 169 169 166 173 173 173 169 179 179 175 175 175 173 179 183 183 179 179 156 194 194 191 191 191 194 194 194 194 198 198 198 194 202 202 202 198 194 205 211 211 209 209 211 211 211 215 215 215 211 215 218 215 223 223 220|223 223 220|223 215 211 227 228 228 239 232 232 239 236 236 236 232 239 239 228 241 239 244 244 241 248 245|248 248 245|248 244 252 252 252 244 228	Association
19444285	Chemical	Gene	D009543	148	True	0	What is [PHARMGKB] between @ChemicalSrc$ nifedipine @/ChemicalSrc$ and @GeneTgt$ alpha1A-adrenoceptor @/GeneTgt$ ? [SEP] Arg347Cys polymorphism of @GeneTgt$ alpha1A-adrenoceptor @/GeneTgt$ gene is associated with blood pressure response to @ChemicalSrc$ nifedipine @/ChemicalSrc$ GITS in Chinese hypertensive patients . Our objectives were to evaluate whether polymorphisms in the alpha1A- and beta2-adrenoceptor genes influence blood pressure response to @ChemicalSrc$ nifedipine @/ChemicalSrc$ gastrointestinal therapeutic system ( GITS ) . Hypertensive patients received daily treatment with an oral dosage of 30 mg @ChemicalSrc$ nifedipine @/ChemicalSrc$ GITS for 16 days . Genotypes of the Arg347Cys polymorphism in the @GeneTgt$ alpha1A-adrenoceptor @/GeneTgt$ gene and the Arg16Gly and Gln27Glu polymorphisms in the beta2-adrenoceptor gene were determined by TaqMan single-nucleotide polymorphism genotyping assay . The sixteenth-day steady-state plasma concentration of @ChemicalSrc$ nifedipine @/ChemicalSrc$ was measured using HPLC with UV detection . Multivariate linear regression was performed in a total of 447 patients to evaluate the effects of these polymorphisms on blood pressure response to @ChemicalSrc$ nifedipine @/ChemicalSrc$ GITS . Patients carrying the Cys347 allele of the @GeneTgt$ alpha1A-adrenoceptor @/GeneTgt$ gene had a greater systolic blood pressure reduction than did those carrying two Arg347 alleles of the @GeneTgt$ alpha1A-adrenoceptor @/GeneTgt$ gene ( 32.5+/-14.0 versus 27.3+/-15.5 mm Hg , respectively , P=0.006 ) . However , diastolic blood pressure reduction was not associated with the Arg347Cys polymorphism in the @GeneTgt$ alpha1A-adrenoceptor @/GeneTgt$ gene . In addition , no significant associations were observed between blood pressure reduction and two polymorphisms in the beta2-adrenoceptor gene . Our data suggest that the Arg347Cys polymorphism in the @GeneTgt$ alpha1A-adrenoceptor @/GeneTgt$ gene may be used to predict blood pressure response to @ChemicalSrc$ nifedipine @/ChemicalSrc$ GITS in Chinese hypertensive patients .	2 8 6 3|6 6 3|6 2 8 8 12 12 12 8 16 16|12 16 16|12 12 20 20 20 12 8 25 28 28 28 28 37 37 33 33 30 33 33 33 28 40 40 37 46 41|46 46 41|46 46 46 40 48 46 48 28 53 54 54 56 54 60 60 60 54 66 63 66 63|66 66 63|66 60 69 69 54 54 93 76 76 76 72 81 81 81|78 81 81|78 72 81 84 81 84 84 84 91 91 91 81 93 93 99 99 99 99 99 93 93 106 106 106 106 111 108 106|107 106 106|107 111 111 111 112 116 116 112 111 121 121 123 123 123 126 126 123 129 129 126 131 123 133 131 136 136 133 140 140 140 133 144 144|141 144 144|141 140 123 157 147 151 151 148 156 156 156|153 156 156|153 151 157 163 163 163 163 163 157 165 163 165 166 170 170 167 175 175 171|175 175 171|175 170 181 181 177 177 177 175 181 185 185 181 181 157 198 198 195 195 195 198 198 198 198 202 202 202 198 207 207 207|204 207 207|204 202 198 211 217 217 215 215 217 217 217 221 221 221 217 221 224 221 228 228 228 221 217 231 232 232 244 236 236 244 241 241 238|241 241 238|241 236 244 244 232 246 244 249 249 246 253 253|249 253 253|249 249 257 257 257 249 232	Association
19747927	Chemical	Gene	D008694	3350	True	0	What is [PHARMGKB] between @ChemicalSrc$ METH @/ChemicalSrc$ and @GeneTgt$ HTR1A @/GeneTgt$ ? [SEP] Serotonin 1A receptor gene is associated with Japanese @ChemicalSrc$ methamphetamine-induced @/ChemicalSrc$ psychosis patients . BACKGROUND : Several investigations have reported associations the @GeneTgt$ serotonin 1A ( 5-HT1A ) receptor @/GeneTgt$ to schizophrenia and psychotic disorders , making @GeneTgt$ 5-HT1A receptor @/GeneTgt$ gene ( @GeneTgt$ HTR1A @/GeneTgt$ ) an adequate candidate gene for the pathophysiology of schizophrenia and @ChemicalSrc$ methamphetamine @/ChemicalSrc$ @ChemicalSrc$ (METH)-induced @/ChemicalSrc$ psychosis . Huang and colleagues reported that rs6295 in @GeneTgt$ HTR1A @/GeneTgt$ was associated with schizophrenia . The symptoms of @ChemicalSrc$ methamphetamine @/ChemicalSrc$ @ChemicalSrc$ (METH)-induced @/ChemicalSrc$ psychosis are similar to those of paranoid type schizophrenia . It may indicate that @ChemicalSrc$ METH-induced @/ChemicalSrc$ psychosis and schizophrenia have common susceptibility genes . In support of this hypothesis , we reported that the V-act murine thymoma viral oncogene homologue 1 ( AKT1 ) gene was associated with @ChemicalSrc$ METH-induced @/ChemicalSrc$ psychosis and schizophrenia in the Japanese population . Furthermore , we conducted an analysis of the association of @GeneTgt$ HTR1A @/GeneTgt$ with @ChemicalSrc$ METH-induced @/ChemicalSrc$ psychosis . METHOD : Using one functional SNP ( rs6295 ) and one tagging SNP ( rs878567 ) , we conducted a genetic association analysis of case-control samples ( 197 METH-induced psychosis patients and 337 controls ) in the Japanese population . The age and sex of the control subjects did not differ from those of the @ChemicalSrc$ methamphetamine @/ChemicalSrc$ dependence patients . RESULTS : Rs878567 was associated with @ChemicalSrc$ METH-induced @/ChemicalSrc$ psychosis patients in the allele/genotype-wise analysis . Moreover , this significance remained after Bonferroni correction . In addition , we detected an association between rs6295 and rs878567 in @GeneTgt$ HTR1A @/GeneTgt$ and @ChemicalSrc$ METH-induced @/ChemicalSrc$ psychosis patients in the haplotype-wise analysis . Although we detected an association between rs6295 and @ChemicalSrc$ METH-induced @/ChemicalSrc$ psychosis patients , this significance disappeared after Bonferroni correction . CONCLUSION : @GeneTgt$ HTR1A @/GeneTgt$ may play an important role in the pathophysiology of @ChemicalSrc$ METH-induced @/ChemicalSrc$ psychosis in the Japanese population . However , because we did not perform a mutation scan of @GeneTgt$ HTR1A @/GeneTgt$ , a replication study using a larger sample may be required for conclusive results .	4 4 4 6 6 6 12 12 8|12 12 8|12 12 6 6 20 20 18 20 20 20 20 23 22|23|21 22|23|21 22|23|21 22|23|21 22|23|21 22|23|21 23|21 22|23|21 31 21 31 31 31 20 20 30|40 30|40 40 30|40 48 42 40|33 40 40|33 42 48 48 48 36 51 51 48 53 51 53 57|45 57 57|45 46|59 59 46|59 53 20 69 66 66 69 76 76 73 71|72 71 71|72 76 69 78 76 69 82 90 88 83|86 86 83|86 88|84 88 88|84 82 90 90 92 90 96 96 96 92 90 102 102 102 109 103|106 106 103|106 109 106 106 102 112 112 109 102 116 122 119 119 116 122 122 122 137 135 135 135 135 135 130 135 135 133 135 135 137 137 122 141 138|141 141 138|141 137 141 141 147 147 147 141 122 153 153 153 153 155 153 158 158 155 160 158|159 158 158|159 165 165|161 165 165|161 158 153 187 169 169 174 174 171 176 174 176 174 181 181 174 183 181 183 187 187 187 191 191 191 187 194 194 191 199 199 199 199 194 199 202 199 202 207 207 207 199 187 210 219 210 210 216 216 216 210 219 219 219 221 219 227 227 227|223 227 227|223 227 221 219 230 230 234 234 230 239 239|235 239 239|235 239 234 243 243 243 234 230 250 250 249 250 250 253 253 250 250 256 259 259 259 259 261 259 263 261 263 263 267 263|266 263 263|266 263 273|268 273 273|268 273 263 277 277 277 261 259 283 283 296 285 283 287 285 287 288|287 287 288|287 292 287 296 295 296 296 299 299 296 296 307 307 303|307 307 303|307 307 307 310 310 307 313 313 307 317 317|313 317 317|313 313 321 321 321 313 307 348 348 331 331 331 331 348 334 334 331 336 334|335 334 334|335 336 341 341 336 341 345 345 342 348 348 348 351 351 348 348	Association
19842932	Chemical	Gene	D061466	1244	True	0	What is [PHARMGKB] between @ChemicalSrc$ LPV @/ChemicalSrc$ and @GeneTgt$ ABCC2 @/GeneTgt$ ? [SEP] Association between @GeneTgt$ ABCC2 @/GeneTgt$ polymorphism and @ChemicalSrc$ lopinavir @/ChemicalSrc$ accumulation in peripheral blood mononuclear cells of HIV-infected patients . AIM : @ChemicalSrc$ Lopinavir @/ChemicalSrc$ ( @ChemicalSrc$ LPV @/ChemicalSrc$ ) is a potent protease inhibitor used in combination with low doses of ritonavir in the treatment of HIV-infected patients . @ChemicalSrc$ LPV @/ChemicalSrc$ pharmacokinetics is characterized by a large interindividual variability requiring the use of therapeutic drug monitoring in different clinical situations . While the sources of this variability are still unknown , several genetic polymorphisms in biotransformation enzymes or transporter proteins involved in the metabolism and/or the distribution of LPV appear as good candidates . Therefore , the aim of the present study was to investigate the influence of selected genetic polymorphisms on @ChemicalSrc$ LPV @/ChemicalSrc$ trough plasma concentrations ( [LPV](Cmin ) ) , @ChemicalSrc$ LPV @/ChemicalSrc$ concentrations in peripheral blood mononuclear cells ( [LPV](CC ) ) and the @ChemicalSrc$ LPV @/ChemicalSrc$ accumulation ratio ( [LPV](CC):[LPV](Cmin ) ) . MATERIALS & amp ; METHODS : A total of 53 patients receiving Kaletra((R ) ) ( Abbott Laboratories , IL , USA ) ( LPV+ritonavir ) were genotyped for 14 different polymorphisms in biotransformation enzymes and transporter proteins . [LPV](Cmin ) , [LPV](CC ) and [LPV](CC):[LPV](Cmin ) were compared according to the patient 's genotypes . RESULTS & amp ; CONCLUSION : The 4544G&gt;A (rs8187710)polymorphism in @GeneTgt$ ABCC2 @/GeneTgt$ was associated with a higher accumulation of @ChemicalSrc$ LPV @/ChemicalSrc$ in peripheral blood mononuclear cells of HIV-treated patients . As already observed in previous studies , ABCB1 or CYP3A5 polymorphisms had no impact on [LPV](Cmin ) and we did not detect any influence of these polymorphisms on [LPV](CC ) and its accumulation in mononuclear cells . In conclusion , this pilot study suggests , for the first time , that the 4544G&gt;A polymorphism in @GeneTgt$ ABCC2 @/GeneTgt$ could explain a significant part of the interindividual variability in LPV pharmacokinetics . Further investigations are needed to confirm this association and to explore its real pharmacodynamic impact .	1 5 2|5 5 2|5 1 5 9|5 9 9|5 5 14 14 14 14 9 17 17 14 1 21 21 22|33 33 22|33 26 23|24 23 23|24 26 33 33 33 33 21 33 36 34 39 39 36 41 39 44 44 34 47 47 44 21 50|53 53 50|53 55 55 55 60 60 60 60 55 60 63 61 67 67 67 63 71 71 71 63 55 82 76 82 79 79 76 82 82 102 102 86 86 102 89 89 86 89 92 89 92 96 96 93 96 99 96 101 99 102 105 105 102 102 115 115 110 115 114 114 114 110 115 117 115 119 117 123 123 123 119 129 124|129 129 124|129 129 129 119 131 129 131 131 117 133|137 137 133|137 117 142 142 142 142 137 144 142 144 144 142 152 146|152 152 146|152 152 142 154 152 154 154 115 161 161 161 161 161 161 168 161 171 171 168 171 172 173 161 178 178 188 178 178 180 180 185 185 178 178 188 161 192 192 192 188 195 195 192 195 198 195 161 209 203 203 200 203 203 203 203 209 209 215 210 213 215 213 209 209 230 217 217 217 217 221 225 225 230 227 225|226 225 225|226 230 230 234 234 234 230 236 234 234 234 242 242 242 242 234 245 245 242 230 251 251 260 254 254 251 254 260 256 256 256 260 262 260 264 262 260 260 270 270 270 260 272 270 275 275 272 277 275 270 260 281 260 284 284 281 260 287 292 292 291 291 292 292 292 297 297 297 292 292 307 302 302 307 304 302|303 302 302|303 307 292 310 310 307 314 314 314 310 317 317 314 292 321 323 323 323 325 323 327 325 325 330 325 334 334 332 330 323	Association
20732371	Chemical	Gene	D003024	887	True	0	What is [PHARMGKB] between @ChemicalSrc$ clozapine @/ChemicalSrc$ and @GeneTgt$ CCKB receptor @/GeneTgt$ ? [SEP] Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients . Cholecystokinin ( CCK ) gene and its receptors play an important role in several biological processes including satiety signaling . Administration of exogenous or endogenously secreted CCK leads to decreased food intake in both rats and humans . Similarly , in rats pretreated with intraperitoneal CCK , antagonists of the CCKA receptor prevent decrease in food intake . The @GeneTgt$ CCKB receptor @/GeneTgt$ plays an important role in anxiety and gastric acid secretion . We investigated the role of polymorphisms in the CCK gene ( 2 SNPs ) and its receptors CCKA ( 4 SNPs ) and @GeneTgt$ CCKB @/GeneTgt$ ( 4SNPs , 1 microsatellite , CTn ) in antipsychotic induced weight gain ( n=215 ) . Weight change ( % ) from baseline was compared across genotypic groups using analysis of covariance . In the European ancestry patients treated with @ChemicalSrc$ clozapine @/ChemicalSrc$ or olanzapine a trend of association was observed with the SNP rs2929183 ( p=0.10 ) in @GeneTgt$ CCKBR @/GeneTgt$ gene . Carriers of the genotype AA ( 3.23%+-4.8 ) gained less weight than the AG and GG genotypes ( 6.50%+-6.5 ; p=0.035 ) . A similar trend was observed for the CTn repeat , where carriers of the LL genotype gained less weight ( 3.73%+-5.41 ) than the S allele carrying genotypes ( 6.29%+-6.2 , p=0.05 ) . In the subjects of African ancestry we observed similar marginal association although with the opposite allele . However , none of these observations would survive corrections for multiple testing . None of the other polymorphisms in either CCK or CCKA receptor genes was associated with weight change ( % ) . In conclusion , @GeneTgt$ CCKB receptor @/GeneTgt$ gene may play a role in antipsychotic induced weight gain . However , these observations need to be replicated in a larger and independent sample set .	2 15 4 2 7 7 4 4 10 4 12 15 15 15 15 18 18 15 15 24 24 24 24 28 24 27 24 28 31 31 28 35 35 35 28 38 38 35 28 47 42 46 42 42 42 40 47 51 51 51 47 54 54 51 54 54 47 72 72 61 72 61 65 65 62 72 72 71 71 71 67 72 72 76 76 73 72 79 78|79|82 78|79|82 79|82 78|79|82 82 85 85 82 87 82 87 91 91 87 82 95 95 97 95 99 97 103 103 103 97 106 106 103 106 103 110 103 110 114 114 111 114 111 111|116 111 111|116 120 117 120 123 120 125 123 120 128 131 131 131 103 133 103 133 95 138 145 140 138 140 143 138 145 145 148 148 145 145 149 152 150 145 158 158 158 158 170 158 161 159|160 159 159|160 161 161 166 158 168 166 170 170 174 174 174 170 176 174 176 181 177|181 181 177|181 176 170 193 189 189 189 185 191 189 191 193 195 193 198 198 201 198 198 195 203 201 203 203 203 193 210 210 212 212 212 216 216 216 212 216 224 224 223 223 223 219 216 226 224 228 226 228 233 233 233 226 233 234 237 226 237 237 237 212 244 244 249 247 247 244 249 249 252 252 249 257 257 257 257 252 249 266 266 266 264 264 261 266 266 266 270 270 267 266 285 276 276 276 272 279 279 276 279 279 283 285 285 285 288 288 285 290 288 290 285 294 301 301 295|299 295|299 299 295|299 301 301 301 303 301 308 308 308 308 303 301 315 315 314 315 315 318 318 315 324 324 324 321 321 318 324 315	Association
20732371	Chemical	Gene	D000077152	887	True	0	What is [PHARMGKB] between @ChemicalSrc$ olanzapine @/ChemicalSrc$ and @GeneTgt$ CCKB receptor @/GeneTgt$ ? [SEP] Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients . Cholecystokinin ( CCK ) gene and its receptors play an important role in several biological processes including satiety signaling . Administration of exogenous or endogenously secreted CCK leads to decreased food intake in both rats and humans . Similarly , in rats pretreated with intraperitoneal CCK , antagonists of the CCKA receptor prevent decrease in food intake . The @GeneTgt$ CCKB receptor @/GeneTgt$ plays an important role in anxiety and gastric acid secretion . We investigated the role of polymorphisms in the CCK gene ( 2 SNPs ) and its receptors CCKA ( 4 SNPs ) and @GeneTgt$ CCKB @/GeneTgt$ ( 4SNPs , 1 microsatellite , CTn ) in antipsychotic induced weight gain ( n=215 ) . Weight change ( % ) from baseline was compared across genotypic groups using analysis of covariance . In the European ancestry patients treated with clozapine or @ChemicalSrc$ olanzapine @/ChemicalSrc$ a trend of association was observed with the SNP rs2929183 ( p=0.10 ) in @GeneTgt$ CCKBR @/GeneTgt$ gene . Carriers of the genotype AA ( 3.23%+-4.8 ) gained less weight than the AG and GG genotypes ( 6.50%+-6.5 ; p=0.035 ) . A similar trend was observed for the CTn repeat , where carriers of the LL genotype gained less weight ( 3.73%+-5.41 ) than the S allele carrying genotypes ( 6.29%+-6.2 , p=0.05 ) . In the subjects of African ancestry we observed similar marginal association although with the opposite allele . However , none of these observations would survive corrections for multiple testing . None of the other polymorphisms in either CCK or CCKA receptor genes was associated with weight change ( % ) . In conclusion , @GeneTgt$ CCKB receptor @/GeneTgt$ gene may play a role in antipsychotic induced weight gain . However , these observations need to be replicated in a larger and independent sample set .	2 15 4 2 7 7 4 4 10 4 12 15 15 15 15 18 18 15 15 24 24 24 24 28 24 27 24 28 31 31 28 35 35 35 28 38 38 35 28 47 42 46 42 42 42 40 47 51 51 51 47 54 54 51 54 54 47 72 72 61 72 61 65 65 62 72 72 71 71 71 67 72 72 76 76 73 72 79 78|79|82 78|79|82 79|82 78|79|82 82 85 85 82 87 82 87 91 91 87 82 95 95 97 95 99 97 103 103 103 97 106 106 103 106 103 110 103 110 114 114 111 114 111 111|116 111 111|116 120 117 120 123 120 125 123 120 128 131 131 131 103 133 103 133 95 138 145 140 138 140 143 138 145 145 148 148 145 145 149 152 150 145 158 158 158 158 170 158 161 159 161 161|162 161 161|162 166 158 168 166 170 170 174 174 174 170 176 174 176 181 177|181 181 177|181 176 170 193 189 189 189 185 191 189 191 193 195 193 198 198 201 198 198 195 203 201 203 203 203 193 210 210 212 212 212 216 216 216 212 216 224 224 223 223 223 219 216 226 224 228 226 228 233 233 233 226 233 234 237 226 237 237 237 212 244 244 249 247 247 244 249 249 252 252 249 257 257 257 257 252 249 266 266 266 264 264 261 266 266 266 270 270 267 266 285 276 276 276 272 279 279 276 279 279 283 285 285 285 288 288 285 290 288 290 285 294 301 301 295|299 295|299 299 295|299 301 301 301 303 301 308 308 308 308 303 301 315 315 314 315 315 318 318 315 324 324 324 321 321 318 324 315	Association
20809084	Chemical	Gene	C072379	169026	True	0	What is [PHARMGKB] between @ChemicalSrc$ repaglinide @/ChemicalSrc$ and @GeneTgt$ SLC30A8 @/GeneTgt$ ? [SEP] Association analysis of @GeneTgt$ SLC30A8 @/GeneTgt$ rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and @ChemicalSrc$ repaglinide @/ChemicalSrc$ response in Chinese patients . OBJECTIVE : Genome-wide association studies ( GWASs ) identified that @GeneTgt$ SLC30A8 @/GeneTgt$ genetic polymorphism was a risk of type 2 diabetes mellitus ( T2DM ) in several populations . This study aimed to investigate whether the @GeneTgt$ SLC30A8 @/GeneTgt$ rs13266634 and rs16889462 polymorphisms were associated with T2DM susceptibility and @ChemicalSrc$ repaglinide @/ChemicalSrc$ therapeutic efficacy in Chinese T2DM patients . METHODS : We conducted a case-control study of 443 T2DM patients and 229 healthy volunteers to identify @GeneTgt$ SLC30A8 @/GeneTgt$ rs13266634 and rs16889462 genotypes by polymerase chain reaction-restriction fragment length polymorphism ( PCR-RFLP ) assay . Forty-eight patients were randomly selected and underwent an 8-week @ChemicalSrc$ repaglinide @/ChemicalSrc$ treatment ( 3 mg/d ) . Fasting plasma glucose ( FPG ) , postprandial plasma glucose ( PPG ) , glycated hemoglobin ( HbAlc ) , fasting serum insulin ( FINS ) , postprandial serum insulin ( PINS ) , homeostasis model assessment for insulin resistance ( HOMA-IR ) , serum triglyceride , total cholesterol ( TC ) , low-density lipoprotein-cholesterol ( LDL-c ) and high-density lipoprotein-cholesterol ( HDL-c ) were determined before and after @ChemicalSrc$ repaglinide @/ChemicalSrc$ treatment . RESULTS : @GeneTgt$ SLC30A8 @/GeneTgt$ rs13266634 risk C allele frequency was higher in T2DM patients than in healthy controls ( P & lt ; 0.05 ) . There was a better @ChemicalSrc$ repaglinide @/ChemicalSrc$ response on FINS ( P & lt ; 0.05 ) and PINS ( P & lt ; 0.01 ) in patients with rs13266634 CT+TT genotypes compared with CC genotype carriers . Patients with rs16889462 GA genotype showed an enhanced @ChemicalSrc$ repaglinide @/ChemicalSrc$ efficacy on FPG ( P & lt ; 0.01 ) , PPG ( P & lt ; 0.01 ) and HbAlc ( P & lt ; 0.05 ) compared with GG genotype individuals . CONCLUSIONS : @GeneTgt$ SLC30A8 @/GeneTgt$ rs13266634 and rs16889462 polymorphisms were associated with @ChemicalSrc$ repaglinide @/ChemicalSrc$ therapeutic efficacy in Chinese T2DM patients .	2 2 6 3|6 6 3|6 2 6 6 6 14 14 14 14 2 14 18|14 18 18|14 14 21 21 14 2 25 25 29 29 33 31 29 31 25 41 34|38 38 34|38 38 41 41 41 33 46 46 46 46 41 48 46 48 52 52 41 25 56 57 57 59 57 69 64 64|61 64 64|61 69 64 64 69 69 59 72 72 69 72 72|76 76 72|76 77 72 81 81 81 72 57 88 88 88 88 91 91 88 95 95 95 91 95 99 99 95 101 88 101|104 104 101|104 101 104 104 104 118 111 111 118 118 114 112 116 118 116 101 88 122 125 125 125 125 125 125 132 132 129|132 132 129|132 127 135 135 132 135 125 141 141 175 143 141 143 141 148 148 141 150 148 150 141 154 141 156 154 156 141 161 161 141 163 161 163 141 168 168 141 170 168 170 141 175 175 204 178 178 175 180 178 180 178 184 178 178 187 178 189 187 189 187 193 187 195 193 195 193 199 187 201 199 201 204 204 210 205 210 210|207 210 210|207 204 204 213 213 221|214 221 221|214 221 221 221 221 223 223 213 226 226 223 230 230 230 223 232 230 232 232 232 232 232 213 241 241 246 246 243|246 246 243|246 241 248 246 250 248 250 250 250 250 254 250 250 259 257 259 259 263 241 263 266 263 270 270 270 266 263 275 275 275 271 241 283 282 282 282 278 283 288 288 285|288 288 285|288 283 290 288 292 290 292 292 296 292 296 292 292 301 299 301 301 305 301 305 301 301 310 308 310 310 310 283 314 283 320 319 320 316 283 323 323 324|327 327 324|327 332 327 327 332 332 323 337 332|337 337 332|337 334 332 341 341 341 337 323	Association
20837989	Chemical	Gene	D003630	8574	True	0	What is [PHARMGKB] between @ChemicalSrc$ DAUN @/ChemicalSrc$ and @GeneTgt$ AKR7A2 @/GeneTgt$ ? [SEP] Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of @ChemicalSrc$ daunorubicin @/ChemicalSrc$ and doxorubicin . Doxorubicin ( DOX ) and @ChemicalSrc$ daunorubicin @/ChemicalSrc$ ( @ChemicalSrc$ DAUN @/ChemicalSrc$ ) are effective anticancer drugs ; however , considerable interpatient variability exists in their pharmacokinetics . This may be caused by altered metabolism by nonsynonymous single-nucleotide polymorphisms ( ns-SNPs ) in genes encoding aldo-keto reductases ( AKRs ) and carbonyl reductases . This study examined the effect of 27 ns-SNPs , in eight human genes , on the in vitro metabolism of both drugs to their major metabolites , doxorubicinol and daunorubicinol . Kinetic assays measured metabolite levels by high-performance liquid chromatography separation with fluorescence detection using purified , histidine-tagged , human wild-type , and variant enzymes . Maximal rate of activity ( V(max ) ) , substrate affinity ( K(m ) ) , turnover rate ( k(cat ) ) , and catalytic efficiency ( k(cat)/K(m ) ) were determined . With DAUN as substrate , variants for three genes exhibited significant differences in these parameters compared with their wild-type counterparts : the A106 T , R170C , and P180S variants significantly reduced metabolism compared with the AKR1C3 wild-type ( V(max ) , 23 - 47 % decrease ; k(cat ) , 22 - 47 % ; k(cat)/K(m ) , 38 - 44 % ) ; the L311V variant of AKR1C4 significantly decreased V(max ) ( 47 % lower ) and k(cat ) and k(cat)/K(m ) ( both 43 % lower ) ; and the A142 T variant of @GeneTgt$ AKR7A2 @/GeneTgt$ significantly affected all kinetic parameters ( V(max ) and k(cat ) , 61 % decrease ; K(m ) , 156 % increase ; k(cat)/K(m ) , 85 % decrease ) . With DOX , the R170C and P180S variants of AKR1C3 showed significantly reduced V(max ) ( 41 - 44 % decrease ) , k(cat ) ( 39 - 45 % ) , and k(cat)/K(m ) ( 52 - 69 % ) , whereas the A142 T variant significantly altered all kinetic parameters for @GeneTgt$ AKR7A2 @/GeneTgt$ ( V(max ) , 41 % decrease ; k(cat ) , 44 % decrease ; K(m ) , 47 % increase ; k(cat)/K(m ) , 60 % decrease ) . These findings suggest that ns-SNPs in human AKR1C3 , AKR1C4 , and @GeneTgt$ AKR7A2 @/GeneTgt$ significantly decrease the in vitro metabolism of DOX and @ChemicalSrc$ DAUN @/ChemicalSrc$ .	2 2 2 7 7 7 3 12 12 12 10 3 14 12|13 12 12|13 14 14 2 34 22 20 22 20 20|24 20 20|24 28 25|26 25 25|26 28 34 33 34 34 34 41 41 40 40 41 34 44 44 41 41 51 51 51 51 54 54 51 58 58 58 54 60 58 60 63 58 63 66 64 68 66 68 66 72 66 51 75 76 76 78 76 81 81 78 81 86 86 86 78 86 92 92 92 90 86 95 95 92 99 99 99 92 99 99 101 101 76 106 107 107 109 107 114 114 114 114 107 117 117 114 117 128 119 119 119 124 119 119 119 119 118 107 131 161 133 131 135 133 135 135 133 140 133 142 140 142 142 140 147 140 149 147 149 131 131 131 155 131 157 155 157 155 161 161 161 164 172 166 164 166 172 171 171 168 172 174 172 177 177 174 182 182 182 182 172 172 186 186 194 186 186 186 186 192 194 194 172 194 194 200 200 200 196 202 200 202 209 209 207 205 205 200 172 172 211 172 216 216 217 172 217 217 219 217 224 224 225 217 172 172 230 230 234 232 230 234 172 234 235 240 239 240 235 240 235 235 243 234 234 246 252 251 251 252 234 252 234 172 259 259 259 264 261 259|260 259 259|260 264 172 267 267 264 269 267 269 267 267 267 264 277 277 264 277 277 279 277 283 284 277 264 264 286 264 290 291 264 264 172 296 305 305 299 305 299 299 299 304 302 305 307 308 305 308 315 314 313 311 315 308 315 308 308 318 324 323 323 324 308 324 308 308 308 328 334 334 333 331 308 334 305 305 341 341 341 343 343 305 346 346 343 348 346|347 346 346|347 351 348 351 348 355 356 343 343 343 358 343 362 363 343 343 343 365 343 369 370 343 343 343 372 343 376 377 343 343 305 382 383 383 396 396 388 388 385 388 388 388 388 388|392 388 388|392 396 383 400 400 398 396 402 400 402 402 402 402 383	Association
20837989	Chemical	Gene	D004317	8574	True	0	What is [PHARMGKB] between @ChemicalSrc$ DOX @/ChemicalSrc$ and @GeneTgt$ AKR7A2 @/GeneTgt$ ? [SEP] Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and @ChemicalSrc$ doxorubicin @/ChemicalSrc$ . @ChemicalSrc$ Doxorubicin @/ChemicalSrc$ ( @ChemicalSrc$ DOX @/ChemicalSrc$ ) and daunorubicin ( DAUN ) are effective anticancer drugs ; however , considerable interpatient variability exists in their pharmacokinetics . This may be caused by altered metabolism by nonsynonymous single-nucleotide polymorphisms ( ns-SNPs ) in genes encoding aldo-keto reductases ( AKRs ) and carbonyl reductases . This study examined the effect of 27 ns-SNPs , in eight human genes , on the in vitro metabolism of both drugs to their major metabolites , doxorubicinol and daunorubicinol . Kinetic assays measured metabolite levels by high-performance liquid chromatography separation with fluorescence detection using purified , histidine-tagged , human wild-type , and variant enzymes . Maximal rate of activity ( V(max ) ) , substrate affinity ( K(m ) ) , turnover rate ( k(cat ) ) , and catalytic efficiency ( k(cat)/K(m ) ) were determined . With DAUN as substrate , variants for three genes exhibited significant differences in these parameters compared with their wild-type counterparts : the A106 T , R170C , and P180S variants significantly reduced metabolism compared with the AKR1C3 wild-type ( V(max ) , 23 - 47 % decrease ; k(cat ) , 22 - 47 % ; k(cat)/K(m ) , 38 - 44 % ) ; the L311V variant of AKR1C4 significantly decreased V(max ) ( 47 % lower ) and k(cat ) and k(cat)/K(m ) ( both 43 % lower ) ; and the A142 T variant of @GeneTgt$ AKR7A2 @/GeneTgt$ significantly affected all kinetic parameters ( V(max ) and k(cat ) , 61 % decrease ; K(m ) , 156 % increase ; k(cat)/K(m ) , 85 % decrease ) . With @ChemicalSrc$ DOX @/ChemicalSrc$ , the R170C and P180S variants of AKR1C3 showed significantly reduced V(max ) ( 41 - 44 % decrease ) , k(cat ) ( 39 - 45 % ) , and k(cat)/K(m ) ( 52 - 69 % ) , whereas the A142 T variant significantly altered all kinetic parameters for @GeneTgt$ AKR7A2 @/GeneTgt$ ( V(max ) , 41 % decrease ; k(cat ) , 44 % decrease ; K(m ) , 47 % increase ; k(cat)/K(m ) , 60 % decrease ) . These findings suggest that ns-SNPs in human AKR1C3 , AKR1C4 , and @GeneTgt$ AKR7A2 @/GeneTgt$ significantly decrease the in vitro metabolism of @ChemicalSrc$ DOX @/ChemicalSrc$ and DAUN .	2 2 2 7 7 7 3 12 12 12 10 3 14 12 14 14|15 14 14|15 2 19|34 34 19|34 23 20|21 20 20|21 23 20 20 29 27 29 34 33 34 34 34 41 41 40 40 41 34 44 44 41 41 51 51 51 51 54 54 51 58 58 58 54 60 58 60 63 58 63 66 64 68 66 68 66 72 66 51 75 76 76 78 76 81 81 78 81 86 86 86 78 86 92 92 92 90 86 95 95 92 99 99 99 92 99 99 101 101 76 106 107 107 109 107 114 114 114 114 107 117 117 114 117 128 119 119 119 124 119 119 119 119 118 107 131 161 133 131 135 133 135 135 133 140 133 142 140 142 142 140 147 140 149 147 149 131 131 131 155 131 157 155 157 155 161 161 161 164 172 166 164 166 172 171 171 168 172 174 172 177 177 174 182 182 182 182 172 172 186 186 194 186 186 186 186 192 194 194 172 194 194 200 200 200 196 202 200 202 209 209 207 205 205 200 172 172 211 172 216 216 217 172 217 217 219 217 224 224 225 217 172 172 230 230 234 232 230 234 172 234 235 240 239 240 235 240 235 235 243 234 234 246 252 251 251 252 234 252 234 172 259 259 259 264 261 259|260 259 259|260 264 172 267 267 264 269 267 269 267 267 267 264 277 277 264 277 277 279 277 283 284 277 264 264 286 264 290 291 264 264 172 296 295|306 306 295|306 306 300 306 300 300 300 305 303 306 308 309 306 309 316 315 314 312 316 309 316 309 309 319 325 324 324 325 309 325 309 309 309 329 335 335 334 332 309 335 306 306 342 342 342 344 344 306 347 347 344 349 347 347 347 352 349 352 349 356 357 344 344 344 359 344 363 364 344 344 344 366 344 370 371 344 344 344 373 344 377 378 344 344 306 384 385 385 398 398 390 390 387 390 390 390 390 390|394 390 390|394 398 385 402 402 400 398 404 402 402 402 404 404 385	Association
20837989	Chemical	Gene	D004317	8644	True	0	What is [PHARMGKB] between @ChemicalSrc$ DOX @/ChemicalSrc$ and @GeneTgt$ AKR1C3 @/GeneTgt$ ? [SEP] Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and @ChemicalSrc$ doxorubicin @/ChemicalSrc$ . @ChemicalSrc$ Doxorubicin @/ChemicalSrc$ ( @ChemicalSrc$ DOX @/ChemicalSrc$ ) and daunorubicin ( DAUN ) are effective anticancer drugs ; however , considerable interpatient variability exists in their pharmacokinetics . This may be caused by altered metabolism by nonsynonymous single-nucleotide polymorphisms ( ns-SNPs ) in genes encoding aldo-keto reductases ( AKRs ) and carbonyl reductases . This study examined the effect of 27 ns-SNPs , in eight human genes , on the in vitro metabolism of both drugs to their major metabolites , doxorubicinol and daunorubicinol . Kinetic assays measured metabolite levels by high-performance liquid chromatography separation with fluorescence detection using purified , histidine-tagged , human wild-type , and variant enzymes . Maximal rate of activity ( V(max ) ) , substrate affinity ( K(m ) ) , turnover rate ( k(cat ) ) , and catalytic efficiency ( k(cat)/K(m ) ) were determined . With DAUN as substrate , variants for three genes exhibited significant differences in these parameters compared with their wild-type counterparts : the A106 T , R170C , and P180S variants significantly reduced metabolism compared with the @GeneTgt$ AKR1C3 @/GeneTgt$ wild-type ( V(max ) , 23 - 47 % decrease ; k(cat ) , 22 - 47 % ; k(cat)/K(m ) , 38 - 44 % ) ; the L311V variant of AKR1C4 significantly decreased V(max ) ( 47 % lower ) and k(cat ) and k(cat)/K(m ) ( both 43 % lower ) ; and the A142 T variant of AKR7A2 significantly affected all kinetic parameters ( V(max ) and k(cat ) , 61 % decrease ; K(m ) , 156 % increase ; k(cat)/K(m ) , 85 % decrease ) . With @ChemicalSrc$ DOX @/ChemicalSrc$ , the R170C and P180S variants of @GeneTgt$ AKR1C3 @/GeneTgt$ showed significantly reduced V(max ) ( 41 - 44 % decrease ) , k(cat ) ( 39 - 45 % ) , and k(cat)/K(m ) ( 52 - 69 % ) , whereas the A142 T variant significantly altered all kinetic parameters for AKR7A2 ( V(max ) , 41 % decrease ; k(cat ) , 44 % decrease ; K(m ) , 47 % increase ; k(cat)/K(m ) , 60 % decrease ) . These findings suggest that ns-SNPs in human @GeneTgt$ AKR1C3 @/GeneTgt$ , AKR1C4 , and AKR7A2 significantly decrease the in vitro metabolism of @ChemicalSrc$ DOX @/ChemicalSrc$ and DAUN .	2 2 2 7 7 7 3 12 12 12 10 3 14 12 14 14|15 14 14|15 2 19|34 34 19|34 23 20|21 20 20|21 23 20 20 29 27 29 34 33 34 34 34 41 41 40 40 41 34 44 44 41 41 51 51 51 51 54 54 51 58 58 58 54 60 58 60 63 58 63 66 64 68 66 68 66 72 66 51 75 76 76 78 76 81 81 78 81 86 86 86 78 86 92 92 92 90 86 95 95 92 99 99 99 92 99 99 101 101 76 106 107 107 109 107 114 114 114 114 107 117 117 114 117 128 119 119 119 124 119 119 119 119 118 107 131 161 133 131 135 133 135 135 133 140 133 142 140 142 142 140 147 140 149 147 149 131 131 131 155 131 157 155 157 155 161 161 161 164 172 166 164 166 172 171 171 168 172 174 172 177 177 174 182 182 182 182 172 172 186 186 194 186 186 186 186 192 194 194 172 194 194 201 201 198|201 201 198|201 196 203 201 203 210 210 208 206 206 201 172 172 212 172 217 217 218 172 218 218 220 218 225 225 226 218 172 172 231 231 235 233 231 235 172 235 236 241 240 241 236 241 236 236 244 235 235 247 253 252 252 253 235 253 235 172 260 260 260 264 262 260 264 172 267 267 264 269 267 269 267 267 267 264 277 277 264 277 277 279 277 283 284 277 264 264 286 264 290 291 264 264 172 296 295|307 307 295|307 307 300 307 300 300 300 305 303 303 303 307 309 310 307 310 317 316 315 313 317 310 317 310 310 320 326 325 325 326 310 326 310 310 310 330 336 336 335 333 310 336 307 307 343 343 343 345 345 307 348 348 345 350 348 352 350 352 350 356 357 345 345 345 359 345 363 364 345 345 345 366 345 370 371 345 345 345 373 345 377 378 345 345 307 384 385 385 398 398 390 390 387|389 387 387|389 390 390 390 390 390 398 385 402 402 400 398 404 402 402 402 404 404 385	Association
20837989	Chemical	Gene	D003630	8644	True	0	What is [PHARMGKB] between @ChemicalSrc$ DAUN @/ChemicalSrc$ and @GeneTgt$ AKR1C3 @/GeneTgt$ ? [SEP] Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of @ChemicalSrc$ daunorubicin @/ChemicalSrc$ and doxorubicin . Doxorubicin ( DOX ) and @ChemicalSrc$ daunorubicin @/ChemicalSrc$ ( @ChemicalSrc$ DAUN @/ChemicalSrc$ ) are effective anticancer drugs ; however , considerable interpatient variability exists in their pharmacokinetics . This may be caused by altered metabolism by nonsynonymous single-nucleotide polymorphisms ( ns-SNPs ) in genes encoding aldo-keto reductases ( AKRs ) and carbonyl reductases . This study examined the effect of 27 ns-SNPs , in eight human genes , on the in vitro metabolism of both drugs to their major metabolites , doxorubicinol and daunorubicinol . Kinetic assays measured metabolite levels by high-performance liquid chromatography separation with fluorescence detection using purified , histidine-tagged , human wild-type , and variant enzymes . Maximal rate of activity ( V(max ) ) , substrate affinity ( K(m ) ) , turnover rate ( k(cat ) ) , and catalytic efficiency ( k(cat)/K(m ) ) were determined . With DAUN as substrate , variants for three genes exhibited significant differences in these parameters compared with their wild-type counterparts : the A106 T , R170C , and P180S variants significantly reduced metabolism compared with the @GeneTgt$ AKR1C3 @/GeneTgt$ wild-type ( V(max ) , 23 - 47 % decrease ; k(cat ) , 22 - 47 % ; k(cat)/K(m ) , 38 - 44 % ) ; the L311V variant of AKR1C4 significantly decreased V(max ) ( 47 % lower ) and k(cat ) and k(cat)/K(m ) ( both 43 % lower ) ; and the A142 T variant of AKR7A2 significantly affected all kinetic parameters ( V(max ) and k(cat ) , 61 % decrease ; K(m ) , 156 % increase ; k(cat)/K(m ) , 85 % decrease ) . With DOX , the R170C and P180S variants of @GeneTgt$ AKR1C3 @/GeneTgt$ showed significantly reduced V(max ) ( 41 - 44 % decrease ) , k(cat ) ( 39 - 45 % ) , and k(cat)/K(m ) ( 52 - 69 % ) , whereas the A142 T variant significantly altered all kinetic parameters for AKR7A2 ( V(max ) , 41 % decrease ; k(cat ) , 44 % decrease ; K(m ) , 47 % increase ; k(cat)/K(m ) , 60 % decrease ) . These findings suggest that ns-SNPs in human @GeneTgt$ AKR1C3 @/GeneTgt$ , AKR1C4 , and AKR7A2 significantly decrease the in vitro metabolism of DOX and @ChemicalSrc$ DAUN @/ChemicalSrc$ .	2 2 2 7 7 7 3 12 12 12 10 3 14 12|13 12 12|13 14 14 2 34 22 20 22 20 20|24 20 20|24 28 25|26 25 25|26 28 34 33 34 34 34 41 41 40 40 41 34 44 44 41 41 51 51 51 51 54 54 51 58 58 58 54 60 58 60 63 58 63 66 64 68 66 68 66 72 66 51 75 76 76 78 76 81 81 78 81 86 86 86 78 86 92 92 92 90 86 95 95 92 99 99 99 92 99 99 101 101 76 106 107 107 109 107 114 114 114 114 107 117 117 114 117 128 119 119 119 124 119 119 119 119 118 107 131 161 133 131 135 133 135 135 133 140 133 142 140 142 142 140 147 140 149 147 149 131 131 131 155 131 157 155 157 155 161 161 161 164 172 166 164 166 172 171 171 168 172 174 172 177 177 174 182 182 182 182 172 172 186 186 194 186 186 186 186 192 194 194 172 194 194 201 201 198|201 201 198|201 196 203 201 203 210 210 208 206 206 201 172 172 212 172 217 217 218 172 218 218 220 218 225 225 226 218 172 172 231 231 235 233 231 235 172 235 236 241 240 241 236 241 236 236 244 235 235 247 253 252 252 253 235 253 235 172 260 260 260 264 262 260 264 172 267 267 264 269 267 269 267 267 267 264 277 277 264 277 277 279 277 283 284 277 264 264 286 264 290 291 264 264 172 296 306 306 299 306 299 299 299 304 302|303 302 302|303 306 308 309 306 309 316 315 314 312 316 309 316 309 309 319 325 324 324 325 309 325 309 309 309 329 335 335 334 332 309 335 306 306 342 342 342 344 344 306 347 347 344 349 347 351 349 351 349 355 356 344 344 344 358 344 362 363 344 344 344 365 344 369 370 344 344 344 372 344 376 377 344 344 306 382 383 383 396 396 388 388 385|387 385 385|387 388 388 388 388 388 396 383 400 400 398 396 402 400 402 402 402 402 383	Association
20837989	Chemical	Gene	D003630	1109	True	0	What is [PHARMGKB] between @ChemicalSrc$ DAUN @/ChemicalSrc$ and @GeneTgt$ AKR1C4 @/GeneTgt$ ? [SEP] Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of @ChemicalSrc$ daunorubicin @/ChemicalSrc$ and doxorubicin . Doxorubicin ( DOX ) and @ChemicalSrc$ daunorubicin @/ChemicalSrc$ ( @ChemicalSrc$ DAUN @/ChemicalSrc$ ) are effective anticancer drugs ; however , considerable interpatient variability exists in their pharmacokinetics . This may be caused by altered metabolism by nonsynonymous single-nucleotide polymorphisms ( ns-SNPs ) in genes encoding aldo-keto reductases ( AKRs ) and carbonyl reductases . This study examined the effect of 27 ns-SNPs , in eight human genes , on the in vitro metabolism of both drugs to their major metabolites , doxorubicinol and daunorubicinol . Kinetic assays measured metabolite levels by high-performance liquid chromatography separation with fluorescence detection using purified , histidine-tagged , human wild-type , and variant enzymes . Maximal rate of activity ( V(max ) ) , substrate affinity ( K(m ) ) , turnover rate ( k(cat ) ) , and catalytic efficiency ( k(cat)/K(m ) ) were determined . With DAUN as substrate , variants for three genes exhibited significant differences in these parameters compared with their wild-type counterparts : the A106 T , R170C , and P180S variants significantly reduced metabolism compared with the AKR1C3 wild-type ( V(max ) , 23 - 47 % decrease ; k(cat ) , 22 - 47 % ; k(cat)/K(m ) , 38 - 44 % ) ; the L311V variant of @GeneTgt$ AKR1C4 @/GeneTgt$ significantly decreased V(max ) ( 47 % lower ) and k(cat ) and k(cat)/K(m ) ( both 43 % lower ) ; and the A142 T variant of AKR7A2 significantly affected all kinetic parameters ( V(max ) and k(cat ) , 61 % decrease ; K(m ) , 156 % increase ; k(cat)/K(m ) , 85 % decrease ) . With DOX , the R170C and P180S variants of AKR1C3 showed significantly reduced V(max ) ( 41 - 44 % decrease ) , k(cat ) ( 39 - 45 % ) , and k(cat)/K(m ) ( 52 - 69 % ) , whereas the A142 T variant significantly altered all kinetic parameters for AKR7A2 ( V(max ) , 41 % decrease ; k(cat ) , 44 % decrease ; K(m ) , 47 % increase ; k(cat)/K(m ) , 60 % decrease ) . These findings suggest that ns-SNPs in human AKR1C3 , @GeneTgt$ AKR1C4 @/GeneTgt$ , and AKR7A2 significantly decrease the in vitro metabolism of DOX and @ChemicalSrc$ DAUN @/ChemicalSrc$ .	2 2 2 7 7 7 3 12 12 12 10 3 14 12|13 12 12|13 14 14 2 34 22 20 22 20 20|24 20 20|24 28 25|26 25 25|26 28 34 33 34 34 34 41 41 40 40 41 34 44 44 41 41 51 51 51 51 54 54 51 58 58 58 54 60 58 60 63 58 63 66 64 68 66 68 66 72 66 51 75 76 76 78 76 81 81 78 81 86 86 86 78 86 92 92 92 90 86 95 95 92 99 99 99 92 99 99 101 101 76 106 107 107 109 107 114 114 114 114 107 117 117 114 117 128 119 119 119 124 119 119 119 119 118 107 131 161 133 131 135 133 135 135 133 140 133 142 140 142 142 140 147 140 149 147 149 131 131 131 155 131 157 155 157 155 161 161 161 164 172 166 164 166 172 171 171 168 172 174 172 177 177 174 182 182 182 182 172 172 186 186 194 186 186 186 186 192 194 194 172 194 194 200 200 200 196 202 200 202 209 209 207 205 205 200 172 172 211 172 216 216 217 172 217 217 219 217 224 224 225 217 172 172 230 230 235 232 230|231 230 230|231 235 172 235 236 241 240 241 236 241 236 236 244 235 235 247 253 252 252 253 235 253 235 172 260 260 260 264 262 260 264 172 267 267 264 269 267 269 267 267 267 264 277 277 264 277 277 279 277 283 284 277 264 264 286 264 290 291 264 264 172 296 305 305 299 305 299 299 299 304 302 305 307 308 305 308 315 314 313 311 315 308 315 308 308 318 324 323 323 324 308 324 308 308 308 328 334 334 333 331 308 334 305 305 341 341 341 343 343 305 346 346 343 348 346 350 348 350 348 354 355 343 343 343 357 343 361 362 343 343 343 364 343 368 369 343 343 343 371 343 375 376 343 343 305 380 381 381 394 394 386 386 383 386 386|387 386 386|387 386 386 386 394 381 398 398 396 394 400 398 400 400 400 400 381	Association
20837989	Chemical	Gene	D004317	1109	True	0	What is [PHARMGKB] between @ChemicalSrc$ DOX @/ChemicalSrc$ and @GeneTgt$ AKR1C4 @/GeneTgt$ ? [SEP] Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and @ChemicalSrc$ doxorubicin @/ChemicalSrc$ . @ChemicalSrc$ Doxorubicin @/ChemicalSrc$ ( @ChemicalSrc$ DOX @/ChemicalSrc$ ) and daunorubicin ( DAUN ) are effective anticancer drugs ; however , considerable interpatient variability exists in their pharmacokinetics . This may be caused by altered metabolism by nonsynonymous single-nucleotide polymorphisms ( ns-SNPs ) in genes encoding aldo-keto reductases ( AKRs ) and carbonyl reductases . This study examined the effect of 27 ns-SNPs , in eight human genes , on the in vitro metabolism of both drugs to their major metabolites , doxorubicinol and daunorubicinol . Kinetic assays measured metabolite levels by high-performance liquid chromatography separation with fluorescence detection using purified , histidine-tagged , human wild-type , and variant enzymes . Maximal rate of activity ( V(max ) ) , substrate affinity ( K(m ) ) , turnover rate ( k(cat ) ) , and catalytic efficiency ( k(cat)/K(m ) ) were determined . With DAUN as substrate , variants for three genes exhibited significant differences in these parameters compared with their wild-type counterparts : the A106 T , R170C , and P180S variants significantly reduced metabolism compared with the AKR1C3 wild-type ( V(max ) , 23 - 47 % decrease ; k(cat ) , 22 - 47 % ; k(cat)/K(m ) , 38 - 44 % ) ; the L311V variant of @GeneTgt$ AKR1C4 @/GeneTgt$ significantly decreased V(max ) ( 47 % lower ) and k(cat ) and k(cat)/K(m ) ( both 43 % lower ) ; and the A142 T variant of AKR7A2 significantly affected all kinetic parameters ( V(max ) and k(cat ) , 61 % decrease ; K(m ) , 156 % increase ; k(cat)/K(m ) , 85 % decrease ) . With @ChemicalSrc$ DOX @/ChemicalSrc$ , the R170C and P180S variants of AKR1C3 showed significantly reduced V(max ) ( 41 - 44 % decrease ) , k(cat ) ( 39 - 45 % ) , and k(cat)/K(m ) ( 52 - 69 % ) , whereas the A142 T variant significantly altered all kinetic parameters for AKR7A2 ( V(max ) , 41 % decrease ; k(cat ) , 44 % decrease ; K(m ) , 47 % increase ; k(cat)/K(m ) , 60 % decrease ) . These findings suggest that ns-SNPs in human AKR1C3 , @GeneTgt$ AKR1C4 @/GeneTgt$ , and AKR7A2 significantly decrease the in vitro metabolism of @ChemicalSrc$ DOX @/ChemicalSrc$ and DAUN .	2 2 2 7 7 7 3 12 12 12 10 3 14 12 14 14|15 14 14|15 2 19|34 34 19|34 23 20|21 20 20|21 23 20 20 29 27 29 34 33 34 34 34 41 41 40 40 41 34 44 44 41 41 51 51 51 51 54 54 51 58 58 58 54 60 58 60 63 58 63 66 64 68 66 68 66 72 66 51 75 76 76 78 76 81 81 78 81 86 86 86 78 86 92 92 92 90 86 95 95 92 99 99 99 92 99 99 101 101 76 106 107 107 109 107 114 114 114 114 107 117 117 114 117 128 119 119 119 124 119 119 119 119 118 107 131 161 133 131 135 133 135 135 133 140 133 142 140 142 142 140 147 140 149 147 149 131 131 131 155 131 157 155 157 155 161 161 161 164 172 166 164 166 172 171 171 168 172 174 172 177 177 174 182 182 182 182 172 172 186 186 194 186 186 186 186 192 194 194 172 194 194 200 200 200 196 202 200 202 209 209 207 205 205 200 172 172 211 172 216 216 217 172 217 217 219 217 224 224 225 217 172 172 230 230 235 232 230|231 230 230|231 235 172 235 236 241 240 241 236 241 236 236 244 235 235 247 253 252 252 253 235 253 235 172 260 260 260 264 262 260 264 172 267 267 264 269 267 269 267 267 267 264 277 277 264 277 277 279 277 283 284 277 264 264 286 264 290 291 264 264 172 296 295|306 306 295|306 306 300 306 300 300 300 305 303 306 308 309 306 309 316 315 314 312 316 309 316 309 309 319 325 324 324 325 309 325 309 309 309 329 335 335 334 332 309 335 306 306 342 342 342 344 344 306 347 347 344 349 347 351 349 351 349 355 356 344 344 344 358 344 362 363 344 344 344 365 344 369 370 344 344 344 372 344 376 377 344 344 306 382 383 383 396 396 388 388 385 388 388|389 388 388|389 388 388 388 396 383 400 400 398 396 402 400 400 400 402 402 383	None-PHARMGKB
20859245	Chemical	Gene	D006220	9152	True	0	What is [PHARMGKB] between @ChemicalSrc$ haloperidol @/ChemicalSrc$ and @GeneTgt$ SLC6A5 @/GeneTgt$ ? [SEP] Glutamatergic gene variants impact the clinical profile of efficacy and side effects of @ChemicalSrc$ haloperidol @/ChemicalSrc$ . BACKGROUND : The glutamatergic system may be relevant to the pathophysiology of psychosis and to the effects of antipsychotic treatments . OBJECTIVES : We investigated a set of 62 SNPs located in genes coding for subunits of glutamatergic receptors ( GAD1 , GRIA1 , GRIA3 , GRIA4 , GRID2 , GRIK1 , GRIK2 , GRIK3 , GRIK4 , GRIN2B , GRM1 and GRM4 ) , and the transporter of glycine ( @GeneTgt$ SLC6A5 @/GeneTgt$ ) , as modulators of the effects of @ChemicalSrc$ haloperidol @/ChemicalSrc$ . METHODS AND RESULTS : We studied a sample of 101 acutely ill psychotic patients . We then validated our result in two independent samples from Slovenia ( n=71 and n=118 ) of schizophrenic patients treated with antipsychotics . We both investigated the antipsychotic effect ( Positive and Negative Syndrome Scale ) and motor side effect ( Extrapyramidal Symptom Rating Scale ) at baseline and days 3 , 7 , 14 , 21 and 28 . @GeneTgt$ SLC6A5 @/GeneTgt$ variant ( rs2298826 ) was found to be associated with a rapid rise of motor side effects at the beginning of the treatment ( repeated measures of analysis of variance , P=0.0002 ) , followed by a subsequent adaptation , probably dependent on @ChemicalSrc$ haloperidol @/ChemicalSrc$ doses down titration . A specific effect was noted for dyskinetic symptoms . Haplotype analysis strengthened the relevance of @GeneTgt$ SLC6A5 @/GeneTgt$ : the C-A-C haplotype ( rs1443548 , rs883377 , rs1945771 ) was found to be associated with higher Extrapyramidal symptom rating scale scores ( overall P=0.01 , haplotype P=0.000001 ) . We successfully replicated this finding in the two independent samples from Slovenia . CONCLUSION : This result further stresses the relevance of the glutamatergic system in modulating the effects of @ChemicalSrc$ haloperidol @/ChemicalSrc$ treatment , especially with regards to motor side effects .	3 3 4 4 7 7 4 9 7 9 9 9 14 12|13 12 12|13 4 18 18 22 22 25 25 25 18 28 28 25 30 28 28 34 34 28 37 37 34 25 42 42 42 42 44 42 47 47 44 47 50 48 50 53 51 56 56 53 58 56 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 56 44 85 44 87 85 89 87|88 87 87|88 89 85 94 44 97 97 94 99 97 97 97 42 109 104 104 109 109 109 111 109 117 117 115 116 117 111 109 121 121 121 123 121 127 127 127 123 129 127 131 129 131 131 131 137 137 129 137 140 138 121 144 142 144 147 147 144 149 147 149 149 153 149 153 149 157 158 149 163 163 163 163 149 163 166 149 166 166 168 149 149 149 149 149 149 149 149 144 178|181 181 178|181 186 183 181 183 186 186 189 189 186 193 193 193 189 197 197 197 193 200 200 193 203 203 206 206 206 200 208 206 210 208 212 210 212 193 193 219 219 219 215 219 222 219 226 226|222 226 226|222 222 228 222 186 234 234 236 236 236 239 239 236 236 242 243 243 245 243 247 245|246 245 245|246 247 252 252 261 254 252 254 254 254 254 254 261 243 264 264 261 271 271 271 271 270 271 264 274 274 271 274 277 274 274 243 283 283 283 285 283 290 290 290 290 285 292 290 283 283 294 297 283 299 297 301 299 305 305 305 301 307 301 309 307 313 313|310 313 313|310 309 299 317 317 299 321 321 321 317 283	Association
20887379	Chemical	Gene	D018119	7124	False	1	What is [PHARMGKB] between @ChemicalSrc$ stavudine @/ChemicalSrc$ and @GeneTgt$ TNF @/GeneTgt$ ? [SEP] @GeneTgt$ Tumour necrosis factor @/GeneTgt$ haplotypes associated with sensory neuropathy in Asian and Caucasian human immunodeficiency virus patients . In human immunodeficiency virus ( HIV ) patients , neuropathy is a common adverse side effect to some antiretroviral treatments , particularly @ChemicalSrc$ stavudine @/ChemicalSrc$ . As @ChemicalSrc$ stavudine @/ChemicalSrc$ is cheap , it is widely used in Asia and Africa . We showed that increasing age and height moderately predict the development of neuropathy . This was improved by the inclusion of @GeneTgt$ tumour necrosis factor @/GeneTgt$ @GeneTgt$ (TNF)-1031 @/GeneTgt$ ( rs1799964 ) . To investigate this association , Malay ( n = 64 ) , Chinese ( n = 74 ) and Caucasian patients ( n = 37 ) exposed to @ChemicalSrc$ stavudine @/ChemicalSrc$ were screened for neuropathy . DNA samples were genotyped for polymorphisms in the central major histocompatibility complex ( MHC ) near @GeneTgt$ TNF @/GeneTgt$ , and haplotypes were derived . The haplotype group FVa6,7,8 ( incorporating @GeneTgt$ TNF-1031 @/GeneTgt$ ) was found to be associated with neuropathy in Chinese patients in bivariate analyses ( P = 0.03 ) , and in Malays and Chinese in a multivariate analysis correcting for age and height ( P = 0.02 , P = 0.03 , respectively ) . This trend was also confirmed in Caucasians .	0|5 0|5 0|5 5 0|5 5 5 9 9 6 17 17 11 11 17 17 17 9 5 27 27 23 27 25 27 25 35 35 35 35 35 35 35 35 35 39 39 39 35 39 42 39|41 39 39|41 35 50 46|50 50 46|50 50 55 55 55 55 55 55 57 55 57 57 55 63 63 70 66 70 66 66 70 63 72 70 74 72 63 78 78 78 81 81 78 87 87|82 87|82 87|82 87 87|82 83|81 81 83|81 90 87 90 78 96 126 98 96 126 126 102 100 102 103 102 100 100 109 107 109 110 110 109 115 109 117 115 117 118 117 115 123 121|122 121 121|122 126 126 128 126 126 132 134 134 134 136 134 144 144 144 144 142 144 144 136 144 147 146|144 144 146|144 144 144 144 153 134 134 158 158 159 166 161 159 161 161 161 161 166 166 169 169 166 171 169 174 174 171 177 177 169 180 180 177 180 180 177 177 186 177 186 186 192 192 192 169 192 195 193 195 195 199 200 195 200 204 204 200 204 204 204 166 166 212 215 215 215 215 217 215 215	Association
20938465	Chemical	Gene	D003561	5243	False	4	What is [PHARMGKB] between @ChemicalSrc$ cytarabine @/ChemicalSrc$ and @GeneTgt$ ABCB1 @/GeneTgt$ ? [SEP] Association of @GeneTgt$ ABCB1 @/GeneTgt$ polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype . Overexpression of the multi-drug transporter @GeneTgt$ P-glycoprotein @/GeneTgt$ , encoded by the @GeneTgt$ ABCB1 @/GeneTgt$ gene , is a clinically relevant problem in acute myeloid leukemia ( AML ) . Polymorphisms in @GeneTgt$ ABCB1 @/GeneTgt$ might contribute to cancer risk and therapeutic response . We therefore investigated the influence of polymorphisms G1199A , C1236 T , G2677T/A and C3435 T on cancer susceptibility , in vitro cytotoxicity and overall survival in 100 de novo AML patients with normal karyotype . Patients with 1236C/C or 2677G/G genotypes showed poorer survival than patients with other genotypes ( P=0.03 and P=0.02 , respectively ) . Both these genotypes were significant factors for survival in multivariate analysis , along with age , NPM1 and FLT3 mutation status . In vitro cytotoxicity studies demonstrated that leukemic cells from 1236T/T and 2677T/T patients were significantly more susceptible to mitoxantrone ( P=0.02 ) , and tended to be more susceptible to etoposide and daunorubicin ( P=0.07 - 0.09 ) , but not to @ChemicalSrc$ cytarabine @/ChemicalSrc$ . No significant difference in allele frequencies was found between patients and healthy volunteers ( n=400 ) .	1 5 2|5 5 2|5 1 7 1 7 11 9 7 17 17 13 17 17 7 20 20 17 1 42 28 28 28 28 23|27 23 23|27 28 28 36 36 32|36 36 32|36 31 23 42 42 41 42 42 46 46 46 42 48 46 48 42 58 55 53|54 53 53|54 58 58 60 61 58 61 61 61 58 69 69 69 71 69 73 71 73 74 77 74 74 74 74 74 74 85 85 71 85 89 87 85 89 92 89 98 98 98 95 98 89 101 101 98 69 109 105 103 105 105 105 109 111 109 113 111 116 116 113 118 116 118 118 118 118 118 109 127 127 130 130 130 130 132 130 135 135 132 130 139 139 130 130 130 141 141 145 130 130 150 147 150 151 151 163 154 163 156 154 156 156 156 163 163 163 151 165 163 167 165 167 151 151 151 175 175 175 171 177 175 177 177 183 183 183 179 183 177 187 189 189 188|177 177 188|177 151 195 195 200 198 198 195 200 200 202 200 202 205 202 207 205 207 200	Association
20938465	Chemical	Gene	D008942	5243	False	4	What is [PHARMGKB] between @ChemicalSrc$ mitoxantrone @/ChemicalSrc$ and @GeneTgt$ ABCB1 @/GeneTgt$ ? [SEP] Association of @GeneTgt$ ABCB1 @/GeneTgt$ polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype . Overexpression of the multi-drug transporter @GeneTgt$ P-glycoprotein @/GeneTgt$ , encoded by the @GeneTgt$ ABCB1 @/GeneTgt$ gene , is a clinically relevant problem in acute myeloid leukemia ( AML ) . Polymorphisms in @GeneTgt$ ABCB1 @/GeneTgt$ might contribute to cancer risk and therapeutic response . We therefore investigated the influence of polymorphisms G1199A , C1236 T , G2677T/A and C3435 T on cancer susceptibility , in vitro cytotoxicity and overall survival in 100 de novo AML patients with normal karyotype . Patients with 1236C/C or 2677G/G genotypes showed poorer survival than patients with other genotypes ( P=0.03 and P=0.02 , respectively ) . Both these genotypes were significant factors for survival in multivariate analysis , along with age , NPM1 and FLT3 mutation status . In vitro cytotoxicity studies demonstrated that leukemic cells from 1236T/T and 2677T/T patients were significantly more susceptible to @ChemicalSrc$ mitoxantrone @/ChemicalSrc$ ( P=0.02 ) , and tended to be more susceptible to etoposide and daunorubicin ( P=0.07 - 0.09 ) , but not to cytarabine . No significant difference in allele frequencies was found between patients and healthy volunteers ( n=400 ) .	1 5 2|5 5 2|5 1 7 1 7 11 9 7 17 17 13 17 17 7 20 20 17 1 42 28 28 28 28 23|27 23 23|27 28 28 36 36 32|36 36 32|36 31 23 42 42 41 42 42 46 46 46 42 48 46 48 42 58 55 53|54 53 53|54 58 58 60 61 58 61 61 61 58 69 69 69 71 69 73 71 73 74 77 74 74 74 74 74 74 85 85 71 85 89 87 85 89 92 89 98 98 98 95 98 89 101 101 98 69 109 105 103 105 105 105 109 111 109 113 111 116 116 113 118 116 118 118 118 118 118 109 127 127 130 130 130 130 132 130 135 135 132 130 139 139 130 130 130 141 141 145 130 130 150 147 150 151 151 163 154 163 156 154 156 156 156 163 163 163 151 165 163|164 163 163|164 168 165 168 151 151 151 176 176 176 172 178 176 178 178 184 184 184 180 184 178 188 190 190 178 151 195 195 200 198 198 195 200 200 202 200 202 205 202 207 205 207 200	Association
21052022	Chemical	Gene	D004110	23327	True	0	What is [PHARMGKB] between @ChemicalSrc$ diltiazem @/ChemicalSrc$ and @GeneTgt$ NEDD4L @/GeneTgt$ ? [SEP] A functional variant of the @GeneTgt$ NEDD4L @/GeneTgt$ gene is associated with beneficial treatment response with beta-blockers and diuretics in hypertensive patients . OBJECTIVE : The capability of the protein @GeneTgt$ NEDD4L @/GeneTgt$ to reduce renal tubular expression of epithelial Na+ channel ( ENaC ) is influenced by a functional rs4149601 G A @GeneTgt$ NEDD4L @/GeneTgt$ polymorphism . As diuretics and beta-blockers inhibit renal sodium reabsorption and renin release , respectively , we hypothesized that the beta-blocker or diuretic-induced blood pressure reduction and prevention of cardiovascular disease would be greater in patients with the highest ENaC expression ( rs4149601 G-allele ) , whereas there would be no such genetically mediated differences in treatment efficacy among patients treated with the vasodilator @ChemicalSrc$ diltiazem @/ChemicalSrc$ . METHODS : We related rs4149601 status to 6-month blood pressure reduction and risk of cardiovascular events in 5152 hypertensive patients ( DBP & gt;= 100 mmHg ) from the Nordic @ChemicalSrc$ Diltiazem @/ChemicalSrc$ Study ( NORDIL ) randomized to either beta-blocker and/or diuretic-based treatment or @ChemicalSrc$ diltiazem-based @/ChemicalSrc$ treatment . RESULTS : In patients on beta-blocker or diuretic monotherapy , carriers of the G-allele had greater SBP reduction ( 19.5 + - 16.8 vs. 15.0 + - 19.3 mmHg , P & lt ; 0.001 ) and DBP reduction ( 15.4 + - 8.3vs . 14.1 + - 8.4 mmHg , P = 0.02 ) and during 4.5 years of follow-up among patients randomized to beta-blockers and/or diuretics , carriers of the G-allele had greater protection from cardiovascular events [ relative risk ( RR ) = 0.52 , 95 % confidence interval ( CI ) = 0.36 - 0.74 , P & lt ; 0.001 ] as compared to AA homozygotes . Within the @ChemicalSrc$ diltiazem @/ChemicalSrc$ group , there was no difference in blood pressure reduction or risk of cardiovascular events according to genotype . CONCLUSION : The functional @GeneTgt$ NEDD4L @/GeneTgt$ rs4149601 polymorphism influences the efficacy of beta-blocker and/or diuretic-based antihypertensive treatment both in terms of blood pressure reduction and cardiovascular disease protection , whereas @ChemicalSrc$ diltiazem-based @/ChemicalSrc$ antihypertensive treatment efficacy is not influenced by this @GeneTgt$ NEDD4L @/GeneTgt$ polymorphism .	3 3 10 8 8 8|5 8 8|5 3 10 10 14 14 14 10 16 14 16 16 21 21 16 10 24 24 27 46 31 31 31 27|30 27 27|30 34 27 37 37 34 41 41 41 37 43 41 43 46 24 55 55 55 55 55 55 55|51 55 55|51 46 46 60 63 60 60 63 66 66 63 66 69 66 63 63 74 74 63 90 77 90 77 77 82 82 77 82 82 87 87 84 90 90 74 92 90 97 97 97 97 92 100 100 97 100 74 106 106 106 74 111 111 110 111 106 114 114 111 116 114 116 121 121 121 117|120 117 117|120 74 128 128 128 128 130 128 135 135 135 135 130 135 135 140 140 137 144 144 144 140 146 144 146 146 150 146 146 157 157 157 157|154 157 157|154 144 159 157 159 144 164 164 161 164 164 164 167 167|171 171 167|171 167 128 175 175 178 189 180 178 180 180 180 189 189 188 188 185 175 192 192 189 203 203 194 197 194 197 194 199 202 199 189 203 203 205 205 209 203 209 189 213 189 224 224 215 218 215 215 224 220 223 220 213 227 227 224 227 227 189 233 233 248 235 233 237 235 237 240 238 240 240 248 248 247 247 244 189 250 248 253 253 250 260 256 260 258 256 258 248 260 261 266 266 266 260 268 266 268 266 273 273 270 270 270 275 275 279 260 279 282 189 285 285 282 175 291 291 288|291 291 288|291 294 294 294 294 296 294 300 300 300 296 300 300 305 305 302 308 306 296 294 311 319 318 318 318|314 318 318|314 318 319 311 321 319 323 321 323 327 327 323 319 330 319 334 334 334 330 334 338 338 334 319 348 345|339 345 345|339 345 345 348 348 348 319 353 353 353|348 353 353|348 348 311	Association
21094359	Chemical	Gene	D000068718	1401	True	0	What is [PHARMGKB] between @ChemicalSrc$ rosuvastatin @/ChemicalSrc$ and @GeneTgt$ CRP @/GeneTgt$ ? [SEP] Effect of central obesity , low high-density lipoprotein cholesterol and @GeneTgt$ C-reactive protein @/GeneTgt$ polymorphisms on @GeneTgt$ C-reactive protein @/GeneTgt$ levels during treatment with @ChemicalSrc$ Rosuvastatin @/ChemicalSrc$ ( 10 mg Daily ) . Plasma levels of high-sensitivity @GeneTgt$ C-reactive protein @/GeneTgt$ ( hsCRP ) are an important predictor of cardiovascular disease , and achievement of lower targets of hsCRP with @ChemicalSrc$ rosuvastatin @/ChemicalSrc$ treatment was associated with improved cardiovascular outcomes . The aim of this study was to examine whether hsCRP levels were related to genetic variants and traditional cardiovascular risk factors in Chinese patients treated with @ChemicalSrc$ rosuvastatin @/ChemicalSrc$ 10 mg/day . The relations were analyzed between on-treatment plasma hsCRP concentrations and cardiovascular risk factors and 14 single-nucleotide polymorphisms in @GeneTgt$ CRP @/GeneTgt$ and other candidate genes . In 281 patients with a median plasma hsCRP level of 0.81 mg/L ( interquartile range 0.46 to 1.86 ) , higher hsCRP levels were significantly associated with female gender , greater waist circumference ( WC ) , having diabetes , higher triglycerides , and lower high-density lipoprotein ( HDL ) cholesterol . Three single-nucleotide polymorphisms ( rs1205 , 3872G&gt;A and rs2808630 , 5237A&gt;G in @GeneTgt$ CRP @/GeneTgt$ and rs1169288 , I27L in HNF1A ) were independently associated with hsCRP levels before and after adjustment for other variables . WC and the @GeneTgt$ CRP @/GeneTgt$ rs1205 polymorphism showed the strongest relations with hsCRP , and in multiple regression analysis , gender , WC , diabetes , triglycerides , HDL cholesterol , and the 3 genetic variants explained 35.5 % of the variance in hsCRP levels . The 2 @GeneTgt$ CRP @/GeneTgt$ polymorphisms , female gender , higher WC , and lower HDL cholesterol were associated with risk for having @GeneTgt$ CRP @/GeneTgt$ concentrations & gt;= 1 mg/L. In conclusion , central obesity , low HDL cholesterol , and @GeneTgt$ CRP @/GeneTgt$ polymorphisms are major determinants of higher hsCRP levels in Chinese patients receiving treatment with @ChemicalSrc$ rosuvastatin @/ChemicalSrc$ .	1 4 4 1 1 9 9 9 1 9 10|14 10|14 14 10|14 9 19 19|13 19|13 19 19|13 9 21 9 23 18|21 21 18|21 27 27 28 23 21 1 35 47 38 38 35|37|38 35|37|38 35|38 35|37|38 42 38 42 47 47 47 47 50 50 47 50 50 64 56 56 53 58 56 62 57|62 62 57|62 53 64 47 68 68 68 64 47 73 77 76 76 73 77 79 77 84 82 84 84 79 87 87 84 87 92 92 92 87 95 95 87 95 98 96|97 96 96|97 101 84 77 105 107 107 107 112 112 112 112 107 112 116 116 112 116 120 120 116 122 120|121 120 120|121 122 127 127 122 107 132 132 155 138 138 138 138 138 132 141 141 138 144 144 141 147 147 144 144 141 152 152 155 155 155 155 158 158 155 158 162 162 158 164 162 164 162 158 167 168 171 168 171 168 176 176 180 178 180 180 168 155 184 184 205 186 184 186 186 186 186 186 186 194 193|186 186 193|186 186 186 186 186 201 199 186 205 205 205 208 208 205 212 209 209 205 215 215 212 205 225 218 224 220|224 224 220|224 224 218 225 228 228 225 230 228 225 225 236 236 236 225 236 236 238 238 240 240 238 238 238 247 238 238 236 253 253 253 254 225 256 254 259 259 256 262 262 259 225 269 269 266|269 269 266|269 282 269 272 269 272 275 272 275 275 280 280 269 282 282 284 282 286 284 289|285 289 289|285 286 289 293 293 289 295 293 284 298 284 298 302 302 298 284 282 307|302 307 307|302 310 310 310 282 314 314 314 310 317 317 314 317 318 321 317|319 319 317|319 282	Association
21094359	Chemical	Gene	D000068718	6927	False	2	What is [PHARMGKB] between @ChemicalSrc$ rosuvastatin @/ChemicalSrc$ and @GeneTgt$ HNF1A @/GeneTgt$ ? [SEP] Effect of central obesity , low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with @ChemicalSrc$ Rosuvastatin @/ChemicalSrc$ ( 10 mg Daily ) . Plasma levels of high-sensitivity C-reactive protein ( hsCRP ) are an important predictor of cardiovascular disease , and achievement of lower targets of hsCRP with @ChemicalSrc$ rosuvastatin @/ChemicalSrc$ treatment was associated with improved cardiovascular outcomes . The aim of this study was to examine whether hsCRP levels were related to genetic variants and traditional cardiovascular risk factors in Chinese patients treated with @ChemicalSrc$ rosuvastatin @/ChemicalSrc$ 10 mg/day . The relations were analyzed between on-treatment plasma hsCRP concentrations and cardiovascular risk factors and 14 single-nucleotide polymorphisms in CRP and other candidate genes . In 281 patients with a median plasma hsCRP level of 0.81 mg/L ( interquartile range 0.46 to 1.86 ) , higher hsCRP levels were significantly associated with female gender , greater waist circumference ( WC ) , having diabetes , higher triglycerides , and lower high-density lipoprotein ( HDL ) cholesterol . Three single-nucleotide polymorphisms ( rs1205 , 3872G&gt;A and rs2808630 , 5237A&gt;G in CRP and rs1169288 , I27L in @GeneTgt$ HNF1A @/GeneTgt$ ) were independently associated with hsCRP levels before and after adjustment for other variables . WC and the CRP rs1205 polymorphism showed the strongest relations with hsCRP , and in multiple regression analysis , gender , WC , diabetes , triglycerides , HDL cholesterol , and the 3 genetic variants explained 35.5 % of the variance in hsCRP levels . The 2 CRP polymorphisms , female gender , higher WC , and lower HDL cholesterol were associated with risk for having CRP concentrations & gt;= 1 mg/L. In conclusion , central obesity , low HDL cholesterol , and CRP polymorphisms are major determinants of higher hsCRP levels in Chinese patients receiving treatment with @ChemicalSrc$ rosuvastatin @/ChemicalSrc$ .	1 4 4 1 1 9 9 9 1 9 13 13 9 17 17 17 9 19 9 21 19|20 19 19|20 25 25 26 21 19 1 31 42 35 35 35 31 37 35 37 42 42 42 42 45 45 42 45 45 59 51 51 48 53 51 57 54|57 57 54|57 48 59 42 63 63 63 59 42 67 71 70 70 67 71 73 71 78 76 78 78 73 81 81 78 81 86 86 86 81 89 89 81 89 92 90|91 90 90|91 95 78 71 99 101 101 101 106 106 106 106 101 106 110 110 106 110 114 114 110 116 114 116 120 120 116 101 124 124 147 130 130 130 130 130 124 133 133 130 136 136 133 139 139 136 136 133 144 144 147 147 147 147 150 150 147 150 154 154 150 156 154 156 154 150 159 160 163 160 163 160 168 168 172 170 172 172 160 147 176 176 197 178 176 178 178 178 178 178 178 186 178 178 178 178 178 192 190|191 190 190|191 178 197 197 197 200 200 197 204 201 201 197 207 207 204 197 216 210 215 215 215 210 216 219 219 216 221 219 216 216 227 227 227 216 227 227 229 229 231 231 229 229 229 238 229 229 227 244 244 244 245 216 247 245 250 250 247 253 253 250 216 258 258 258 271 258 261 258 261 264 261 264 264 269 269 258 271 271 273 271 275 273 277 275 277 281 281 277 283 281 273 286 273 286 290 290 286 273 271 294 297 297 297 271 301 301 301 297 304 304 301 304 305 308 306|307 306 306|307 271	Association
21435719	Chemical	Gene	D013792	2067	False	1	What is [PHARMGKB] between @ChemicalSrc$ thalidomide @/ChemicalSrc$ and @GeneTgt$ ERCC1 @/GeneTgt$ ? [SEP] Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with @ChemicalSrc$ thalidomide @/ChemicalSrc$ . Single nucleotide polymorphisms ( SNPs ) in 12 genes involving multidrug resistance , drug metabolic pathways , DNA repair systems and cytokines were examined in 28 patients with relapsed/refractory multiple myeloma ( MM ) treated with single agent @ChemicalSrc$ thalidomide @/ChemicalSrc$ and the results were correlated with response , toxicity and overall survival ( OS ) . The response rate was higher in patients with SNPs in @GeneTgt$ ERCC1 @/GeneTgt$ ( rs735482 ) ( p=0.006 ) , ERCC5 ( rs17655 ) ( p=0.04 ) or XRCC5 ( rs1051685 ) ( p=0.013 ) . Longer OS was associated with the SNP in @GeneTgt$ ERCC1 @/GeneTgt$ ( rs735482 ) ( p=0.005 ) and XRCC5 ( rs1051685 ) ( p=0.02 ) . Finally , polymorphism in GSTT1 ( rs4630 ) was associated with a lower frequency of @ChemicalSrc$ thalidomide-induced @/ChemicalSrc$ peripheral neuropathy ( p=0.04 ) .	8 3 1 3 3 7 3 8 11 11 8 13 8 13 13 18 18 13 18 21 19|20 19 19|20 8 27 27 48 29 27 29 33 33 27 33 36 34 36 39 40 36 27 44 44 27 44 44 48 48 51 51 48 55 55 55 51 57 55 57 55 62 62 63 59|62 59 59|62 48 67 69 69 48 71 69 71 71 71 76 71 78 76 78 48 84 84 86 86 86 88 86 90 88 95 91|95 95 91|95 95 90 95 98 95 98 95 106 103 106 106 106 95 106 95 95 111 109 111 114 90 86 86 119 121 121 121 124 124 121 126 125|132 132 125|132 129 132 129 132 124 132 124 124 137 135 137 140 135 140 121 153 153 153 148 146 150 148 150 153 153 157 157 157 153 162 162|158 162 162|158 162 157 164 162 164 153	Association
21435719	Chemical	Gene	D013792	2952	True	0	What is [PHARMGKB] between @ChemicalSrc$ thalidomide @/ChemicalSrc$ and @GeneTgt$ GSTT1 @/GeneTgt$ ? [SEP] Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with @ChemicalSrc$ thalidomide @/ChemicalSrc$ . Single nucleotide polymorphisms ( SNPs ) in 12 genes involving multidrug resistance , drug metabolic pathways , DNA repair systems and cytokines were examined in 28 patients with relapsed/refractory multiple myeloma ( MM ) treated with single agent @ChemicalSrc$ thalidomide @/ChemicalSrc$ and the results were correlated with response , toxicity and overall survival ( OS ) . The response rate was higher in patients with SNPs in ERCC1 ( rs735482 ) ( p=0.006 ) , ERCC5 ( rs17655 ) ( p=0.04 ) or XRCC5 ( rs1051685 ) ( p=0.013 ) . Longer OS was associated with the SNP in ERCC1 ( rs735482 ) ( p=0.005 ) and XRCC5 ( rs1051685 ) ( p=0.02 ) . Finally , polymorphism in @GeneTgt$ GSTT1 @/GeneTgt$ ( rs4630 ) was associated with a lower frequency of @ChemicalSrc$ thalidomide-induced @/ChemicalSrc$ peripheral neuropathy ( p=0.04 ) .	8 3 1 3 3 7 3 8 11 11 8 13 8 13 13 18 18 13 18 21 19|20 19 19|20 8 27 27 48 29 27 29 33 33 27 33 36 34 36 39 40 36 27 44 44 27 44 44 48 48 51 51 48 55 55 55 51 57 55 57 55 62 62 63 59|62 59 59|62 48 67 69 69 48 71 69 71 71 71 76 71 78 76 78 48 84 84 86 86 86 88 86 90 88 94 94 94 90 94 97 94 97 94 105 102 105 105 105 94 105 94 94 110 108 110 113 90 86 86 117 119 119 119 122 122 119 124 129 126 129 126 129 122 129 122 122 134 132 134 137 132 137 119 150 150 150 144 142|143 142 142|143 147 144 147 150 150 154 154 154 150 159 159|154 159 159|154 159 154 161 159 161 150	Association
21435719	Chemical	Gene	D013792	7520	False	1	What is [PHARMGKB] between @ChemicalSrc$ thalidomide @/ChemicalSrc$ and @GeneTgt$ XRCC5 @/GeneTgt$ ? [SEP] Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with @ChemicalSrc$ thalidomide @/ChemicalSrc$ . Single nucleotide polymorphisms ( SNPs ) in 12 genes involving multidrug resistance , drug metabolic pathways , DNA repair systems and cytokines were examined in 28 patients with relapsed/refractory multiple myeloma ( MM ) treated with single agent @ChemicalSrc$ thalidomide @/ChemicalSrc$ and the results were correlated with response , toxicity and overall survival ( OS ) . The response rate was higher in patients with SNPs in ERCC1 ( rs735482 ) ( p=0.006 ) , ERCC5 ( rs17655 ) ( p=0.04 ) or @GeneTgt$ XRCC5 @/GeneTgt$ ( rs1051685 ) ( p=0.013 ) . Longer OS was associated with the SNP in ERCC1 ( rs735482 ) ( p=0.005 ) and @GeneTgt$ XRCC5 @/GeneTgt$ ( rs1051685 ) ( p=0.02 ) . Finally , polymorphism in GSTT1 ( rs4630 ) was associated with a lower frequency of @ChemicalSrc$ thalidomide-induced @/ChemicalSrc$ peripheral neuropathy ( p=0.04 ) .	8 3 1 3 3 7 3 8 11 11 8 13 8 13 13 18 18 13 18 21 19|20 19 19|20 8 27 27 48 29 27 29 33 33 27 33 36 34 36 39 40 36 27 44 44 27 44 44 48 48 51 51 48 55 55 55 51 57 55 57 55 62 62 63 59|62 59 59|62 48 67 69 69 48 71 69 71 71 71 76 71 78 76 78 48 84 84 86 86 86 88 86 90 88 94 94 94 90 94 97 94 97 94 105 102 105 105 105 94 105 94 107|94 94 107|94 111 108 111 114 90 86 86 119 121 121 121 124 124 121 126 131 128 131 128 131 124 131 124 133|124 124 133|124 137 134 137 140 134 140 121 153 153 153 148 146 150 148 150 153 153 157 157 157 153 162 162|158 162 162|158 162 157 164 162 164 153	Association
21993426	Chemical	Gene	D012254	3434	False	3	What is [PHARMGKB] between @ChemicalSrc$ ribavirin @/ChemicalSrc$ and @GeneTgt$ IFIT1 @/GeneTgt$ ? [SEP] Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C. Chronic hepatitis C ( CHC ) is a worldwide health problem that is highly related to liver fibrosis , cirrhosis , and hepatocellular carcinoma . The achievement of response to the current standard of care-pegylated interferon plus @ChemicalSrc$ ribavirin-has @/ChemicalSrc$ recently been described to be associated with single-nucleotide polymorphisms ( SNPs ) near the IL-28B gene . Additionally , baseline expression levels of genes involved in interferon (IFN)-stimulated genes ( ISGs ) have been found to be related to treatment outcome . In the present study , 285 patients were genotyped for 63 SNPs within genes of the IFN signaling pathway ( IPGs ) and ISGs . Two ISG polymorphisms-OASL rs12819210 ( odds ratio (OR)=2.1 , P=0.03 ) and @GeneTgt$ IFIT1 @/GeneTgt$ rs304478 ( OR=2.5 , P=0.01)-were found to be independent predictive factors of sustained virological response ( SVR ) after adjusting for other clinical covariates . Furthermore , the predictive value of IL-28B SNP was notably improved by simultaneous genotyping of rs12819210 and rs304478 , particularly in patients with the worst prognosis ( viral genotype 1 , area under the curve (AUC)=0.74 ) . In conclusion , ISG SNPs could constitute a valuable tool for individualizing CHC therapy .	2 2 5 5 2 2 2 11 11 11 2 13 11 16 16 13 20 20 20 16 23 23 31 25 23 25 31 31 31 31 31 35 35 35 31 38 38 35 38 38 40 38 44 38 31 47 62 49 47 53 53 53 47 56 56 53 56 47|57 47 47|57 62 62 62 65 65 62 68 68 65 70 68 70 75 75 75 68 62 95 95 82 82 95 84 82 84 89 89 89 85 91 89 91 95 95 95 98 98 95 101 101 98 95 106 106 106 111 111 109 111 111 111 114 114 111 116 114 121 121 121 121 116 123 121 123 121 121 111 131 131 131 131 134 134 131 134 134 134 137 134 139|142 142 139|142 134 144 142 144 144 134 152 152 152 152 147 156 156 156 152 158 156 158 161 131 165 165 165 161 131 178 178 172 172 178 175 175 172 178 178 178 181 181 178 183 181 183 183 183 189 189 181 193 193 193 189 196 196 193 196 196 196 203 203 203 199 196 178 207 212 212 210 212 212 212 215 215 212 217 215 219 217 212	Association
22180457	Chemical	Gene	D013629	83938	True	0	What is [PHARMGKB] between @ChemicalSrc$ tamoxifen @/ChemicalSrc$ and @GeneTgt$ C10orf11 @/GeneTgt$ ? [SEP] A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant @ChemicalSrc$ tamoxifen @/ChemicalSrc$ therapy for breast cancer patients in Japanese . Although many association studies of polymorphisms in candidate genes with the clinical outcomes of breast cancer patients receiving adjuvant @ChemicalSrc$ tamoxifen @/ChemicalSrc$ therapy have been reported , genetic factors determining individual response to @ChemicalSrc$ tamoxifen @/ChemicalSrc$ are not fully understood . To identify genetic polymorphisms associated with clinical outcomes of patients with @ChemicalSrc$ tamoxifen @/ChemicalSrc$ treatment , we conducted a genome-wide association study ( GWAS ) . We studied 462 Japanese patients with hormone receptor-positive , invasive breast cancer receiving adjuvant @ChemicalSrc$ tamoxifen @/ChemicalSrc$ therapy . Of them , 240 patients were analyzed by genome-wide genotyping using the Illumina Human610-Quad BeadChips , and two independent sets of 105 and 117 cases were used for replication studies . In the GWAS , we detected significant associations with recurrence-free survival at 15 single-nucleotide polymorphisms ( SNPs ) on nine chromosomal loci ( 1p31 , 1q41 , 5q33 , 7p11 , 10q22 , 12q13 , 13q22 , 18q12 and 19p13 ) that satisfied a genome-wide significant threshold ( log-rank P= 2.87 x 10(-9)-9.41 x 10(-8 ) ) . Among them , rs10509373 in @GeneTgt$ C10orf11 @/GeneTgt$ gene on 10q22 was significantly associated with recurrence-free survival in the replication study ( log-rank P= 2.02 x 10(-4 ) ) and a combined analysis indicated a strong association of this SNP with recurrence-free survival in breast cancer patients treated with @ChemicalSrc$ tamoxifen @/ChemicalSrc$ ( log-rank P= 1.26 x 10(-10 ) ) . Hazard ratio per C allele of rs10509373 was 4.51 [ 95 % confidence interval ( CI ) , 2.72 - 7.51 ; P= 6.29 x 10(-9 ) ] . In a combined analysis of rs10509373 genotype with previously identified genetic makers , CYP2D6 and ABCC2 , the number of risk alleles of these three genes had cumulative effects on recurrence-free survival among 345 patients receiving @ChemicalSrc$ tamoxifen @/ChemicalSrc$ monotherapy ( log-rank P= 2.28 x 10(-12 ) ) . In conclusion , we identified a novel locus associated with recurrence-free survival in Japanese breast cancer patients receiving adjuvant @ChemicalSrc$ tamoxifen @/ChemicalSrc$ therapy .	4 4 4 5 5 5 8 6 6 12 12 9 17 17 17|14 17 17|14 12 21 21 21 17 23 21 5 50 29 29 50 31 29 34 34 31 38 38 38 34 42 42 42 38 42 47 44|47 47 44|47 43 50 50 63 63 53 63 53 56 54 58 56 56 56 63 63 63 63 63 68 68 70 68 70 74 74 71 76 74 80 77|80 80 77|80 76 83 83 68 87 87 87 83 89 87 89 83 94 94 97 97 94 104 100 104 100 100 104 97 104 109 109|106 109 109|106 105 94 113 118 118 116 118 118 118 121 121 118 121 124 122 126 122 126 126 131 131 122 136 136 133 133 131 138 118 141 141 138 118 145 145 148 148 148 148 150 148 153 153 150 157 157 157 153 159 157 159 164 164 164 150 166 164 166 166 166 166 170 166 166 166 166 166 166 166 166 166 166 166 166 185 164 189 189 189 185 192 192 189 197 193 193 193 192 192 164 148 202 213 213 213 208 208|205 208 208|205 204 210 208 213 213 213 216 216 213 220 220 220 216 223 223 213 226 224 223 226 223 213 232 232 233 213 236 236 233 239 239 236 242 242 236 246 246 246 242 246 249 247 247 247 253 253 236 256 254 253 253 236 233 263 270 266 266 263 268 266 270 275 275 273 275 275 275 277 275 277 275 275 282 280 275 275 287 285 284 284 275 275 294 294 294 317 297 297 294 302 300 302 302 297 302 302 304 304 302 309 302 312 312 309 316 316 316 312 317 319 317 322 322 319 325 325 322 325 326|329 329 326|329 326 332 332 329 335 333 332 335 332 317 341 344 344 344 344 347 347 344 347 351 351 348 356 356 356 356 351 356 361 358|361 361 358|361 357 344	Association
22525200	Chemical	Gene	D004110	113026	False	1	What is [PHARMGKB] between @ChemicalSrc$ diltiazem @/ChemicalSrc$ and @GeneTgt$ PLCD3 @/GeneTgt$ ? [SEP] Pharmacogenetic implications for eight common blood pressure-associated single-nucleotide polymorphisms . OBJECTIVE : We aimed to test whether eight common recently identified single-nucleotide polymorphisms ( SNPs ) , strongly associated with blood pressure ( BP ) in the population , also have impact on the degree of BP reduction by antihypertensive agents with different mechanisms . METHODS : In 3863 Swedish hypertensive patients , we related number of unfavorable alleles of each SNP ( i.e. alleles associated with higher baseline BP ) to the magnitude of BP reduction during 6 months of monotherapy with either a beta-blocker , a thiazide diuretic or @ChemicalSrc$ diltiazem @/ChemicalSrc$ . RESULTS : For six SNPs ( rs16998073 , rs1378942 , rs3184504 , rs1530440 , rs16948048 , rs17367504 ) no pharmacogenetic interactions were suggested , whereas two SNPs showed nominal evidence of association with treatment response : @GeneTgt$ PLCD3-rs12946454 @/GeneTgt$ associated with more SBP ( beta = 1.53 mmHg per unfavorable allele ; P = 0.010 ) and DBP ( beta = 0.73 mmHg per unfavorable allele ; P = 0.014 ) reduction in patients treated with diltiazem , in contrast to those treated with beta-blockers or diuretics wherein no treatment response association was found . CYP17A1-rs11191548 associated with less DBP reduction ( beta = -1.26 mmHg per unfavorable allele ; P = 0.018 ) in patients treated with beta-blockers or diuretics , whereas there was no treatment response association in @ChemicalSrc$ diltiazem-treated @/ChemicalSrc$ patients . However , if accounting for multiple testing , the significant associations for rs12946454 and rs11191548 were attenuated . CONCLUSION : For a majority of these , eight recently identified BP-associated SNPs , there are probably no important pharmacogenetic interactions for BP reduction with use of beta-blockers , diuretics or @ChemicalSrc$ diltiazem @/ChemicalSrc$ . Whether the nominally significant associations for rs12946454 and rs11191548 are true signals and could be of possible clinical relevance for deciding treatment of polygenic essential hypertension should be further tested .	2 2 9 9 9 7 9 9 2 2 41 11 14 11 16 14 21 21 18 21 16 23 21 25 23 25 16 29 16 32 32 29 34 32 34 38 38 32 41 41 41 41 45 45 42 48 48 45 51 51 45 54 54 45 41 56 65 62 62 62 62 65 65 65 66 56 69 69 66 72 72 69 75 75 66 75 80 80 80 76 80 84 84 76 87 87 84 90 90 84 92 90 96 96 96 84 96 100 100 96 100 100|101 100 100|101 66 106 106 110 110 128 112 110 112 112 112 112 112 112 112 112 112 112 122 126 126 128 128 106 128 133 132 133 128 135 133 137 135 140 140 137 106 141|144 144 141|144 106 147 147 176 149 176 149 152 150 155 155 152 158 158 149 158 158 149 164 164 149 164 167 165 170 170 167 173 173 149 173 173 144 178 176 178 181 179 144 184 144 186 184 186 189 187 189 189 198 196 196 196 198 198 144 106 202 202 206 206 206 202 208 206 208 211 209 214 214 211 217 217 208 217 217 221 206 221 224 222 224 224 202 230 230 202 234 234 234 230 238 235|238 238 235|238 234 202 257 257 244 257 247 247 244 257 251 251 257 253 251 253 253 257 257 257 259 259 263 263 269 265 263 269 269 269 274 271 269 274 274 259 274 279 279 279 274 282 282 279 284 282 286 284 286 286 288 288|289 288 288|289 259 305 298 297 298 305 300 298 300 300 305 305 323 305 312 312 312 312 312 305 314 312 314 319 319 319 315 323 323 323 323 323	Association
22725663	Chemical	Gene	C011550	5243	True	0	What is [PHARMGKB] between @ChemicalSrc$ talinolol @/ChemicalSrc$ and @GeneTgt$ ABCB1 @/GeneTgt$ ? [SEP] Effects of curcumin on the pharmacokinetics of @ChemicalSrc$ talinolol @/ChemicalSrc$ in human with @GeneTgt$ ABCB1 @/GeneTgt$ polymorphism . This study was to investigate the effect of concomitantly administered curcumin on the pharmacokinetics of @ChemicalSrc$ talinolol @/ChemicalSrc$ and association with @GeneTgt$ ABCB1 @/GeneTgt$ C3435 T genetic polymorphism . A two-phase , randomized , single-blind , crossover study was carried out in 18 healthy male volunteers with different genotypes of @GeneTgt$ ABCB1 @/GeneTgt$ , including C3435C ( CC , n = 6 ) , C3435 T ( CT , n = 6 ) and T3435 T ( TT , n = 6 ) . The pharmacokinetics of @ChemicalSrc$ talinolol @/ChemicalSrc$ were measured after co-administration of placebo or 1000 mg curcumin capsules once daily for 14 days . The AUC(0 - 48 h ) and AUC(0- ) of @ChemicalSrc$ talinolol @/ChemicalSrc$ were increased by 67.0 % ( 95 % CI : 1.09~2.25 ; p = 0.002 ) and 80.8 % ( 95 % CI : 0.92~2.69 ; p = 0.005 ) respectively with curcumin co-administration . The C(max ) of @ChemicalSrc$ talinolol @/ChemicalSrc$ was significantly higher after curcumin administration as compared with placebo ( p = 0.029).The CL/F of @ChemicalSrc$ talinolol @/ChemicalSrc$ was decreased by 25.9 % ( p = 0.005 ) during the curcumin-treated phase . No significant change in t(max ) and t(1/2 ) of @ChemicalSrc$ talinolol @/ChemicalSrc$ were observed between the placebo- and curcumin-treated phases . AUC(0 - 48 ) , AUC(0- ) , C(max ) of @ChemicalSrc$ talinolol @/ChemicalSrc$ were extensively increased and CL(oral)/F decreased in TT subjects . Co-administration of curcumin significantly increased the plasma concentration of @ChemicalSrc$ talinolol @/ChemicalSrc$ in healthy volunteers . The effect of curcumin on @ChemicalSrc$ talinolol @/ChemicalSrc$ was associated with @GeneTgt$ ABCB1 @/GeneTgt$ genotypes ( C3435 T ) .	1 3 1 6 6 1 8 6|7 6 6|7 11 8 15 11|15 15 11|15 11 1 20 21 21 23 21 25 23 29 28 29 25 32 32 25 34 32|33 32 32|33 34 34 44 44|37 44 44|37 44 44 44 37 21 49 58 49 49 51 49 58 56 58 58 58 58 64 64 64 64 58 67 67 58 69 67|68 67 67|68 69 73 75 75 67 75 78 75 78 75 67 83 88 85 88 88 88 58 88 88 58 93 58 95 93 98 98 95 98 98 58 104 109 106 104|105 104 104|105 109 109 111 109 113 111 113 116 118 118 113 120 111 123 123 111 109 130 130 129 127 139 130 130 130 133 136 135|130 130 135|130 139 139 142 142 139 146 145 146 139 146 151 151 151 146 151 151 146 156 146 160 159 160 156 160 165 165 165 160 165 165 139 171 171 139 139 175 182 175 178 175|177 175 175|177 182 182 182 185 185 182 187 182 189 187 192 192 189 194 192 196 194 194 194 199 182 202 202 199 205 205 202 205 205 211 211 211 199 182 217 217 228 219 217 217 217 217 222 225 224|217 217 224|217 228 228 231 231 228 231 231 231 228 252 239 237 239 237 237 237 237 237 245 248 237|247 237 237|247 252 252 252 252 255 252 258 258 255 252 265 263 261 265 265 268 268 265 270 268|269 268 268|269 274 274 268 265 278 285 280 278 282 278|281 278 278|281 285 285 289 285|289 289 285|289 285 292 292 289 292 285	Association
22947179	Chemical	Gene	D016642	6531	True	0	What is [PHARMGKB] between @ChemicalSrc$ bupropion @/ChemicalSrc$ and @GeneTgt$ dopamine transporter @/GeneTgt$ ? [SEP] Analysis of 34 candidate genes in @ChemicalSrc$ bupropion @/ChemicalSrc$ and placebo remission . There is considerable variability in the rate of response and remission following treatment with antidepressant drugs or placebo in depression patients . No pharmacogenetic studies of @ChemicalSrc$ bupropion @/ChemicalSrc$ response have been done . We investigated 532 tagging single nucleotide polymorphisms ( SNPs ) in 34 candidate genes for association with remission and response to either @ChemicalSrc$ bupropion @/ChemicalSrc$ ( n=319 ) or placebo ( n=257 ) in patients with major depressive disorder . Analyses were performed using conditional logistic regression . Significant association ( gene-wide correction ) was observed for remission following treatment with @ChemicalSrc$ bupropion @/ChemicalSrc$ for a SNP within the serotonin receptor 2A gene ( HTR2A rs2770296 , p(corrected)=0.02 ) . Response to @ChemicalSrc$ bupropion @/ChemicalSrc$ treatment was significantly associated with a SNP in the @GeneTgt$ dopamine transporter @/GeneTgt$ gene ( rs6347 , p(corrected)=0.013 ) . Among the patients who received placebo , marginal association for remission was observed between a SNP in HTR2A ( rs2296972 , p(corrected)=0.055 ) as well as in the serotonin transporter gene ( 5-HTT or SLC6A4 rs4251417 , p(corrected)=0.050 ) . Placebo response was associated with SNPs in the glucocorticoid receptor gene ( NR3C1 ; rs1048261 , p(corrected)=0.040 ) and monoamine oxidase A gene ( MAOA ; rs6609257 , p corrected=0.046 ) . Although the above observations were significant after gene-wide corrections , none of these would be significant after a more conservative study-wide correction for multiple tests . These results suggest a possible role for HTR2A in remission to @ChemicalSrc$ bupropion @/ChemicalSrc$ treatment . In accordance with @ChemicalSrc$ bupropion @/ChemicalSrc$ pharmacology , @GeneTgt$ dopamine transporter @/GeneTgt$ may play a role in response . The MAOA gene may be involved in placebo response .	1 5 5 5 1 7 5|6 5 5|6 7 11 7 1 15 15 17 15 20 20 17 22 20 22 22 26 20 29 29 26 29 17 34 34 31 15 38 38 45 42 39|42 42 39|42 38 45 45 45 45 49 49 54 54 54 54 49 56 54 56 61 61 61 54 63 61 65 63 65 65 70 70 67|69 67 67|69 73 70 73 70 70 78 70 78 81 70 85 85 85 81 49 90 90 90 90 94 94 91 90 97 103 100 100 97 100 103 103 105 103 107 105 109 107|108 107 107|108 113 113 109 119 119 119 119 119 109 121 122 119 122 119 103 103 135 132 129|132 132 129|132 128 135 135 135 138 138 135 144 144 144|139 144|139 144 144|139 138 146 148 146 144 144 135 155 155 165 157 155 161 158 161 157 163 161 165 165 168 168 165 170 168 172 170 172 172 172 168 176 176 183 183 183 183 168 185 183 185 185 185 185 185 185 165 194 196 196 196 198 196 203 203 203 203 198 205 203 205 205 207 207 207 205 215 215 215 205 217 215 217 217 222 222 203 222 196 230 228 228 230 230 240 233 233 230 240 240 237 235 240 240 240 246 246 244 246 246 240 249 249 246 240 252 253 253 256 256 253 258 256 260 256 264 261|264 264 261|264 260 253 268 278 272 269|272 272 269|272 268 278 274|278|272 274|278|272 274|278 274|278|272 278 278 280 278 282 278 278 288 288 291 291 291 291 294 294 291 291	Association
22947179	Chemical	Gene	D016642	3356	True	0	What is [PHARMGKB] between @ChemicalSrc$ bupropion @/ChemicalSrc$ and @GeneTgt$ HTR2A @/GeneTgt$ ? [SEP] Analysis of 34 candidate genes in @ChemicalSrc$ bupropion @/ChemicalSrc$ and placebo remission . There is considerable variability in the rate of response and remission following treatment with antidepressant drugs or placebo in depression patients . No pharmacogenetic studies of @ChemicalSrc$ bupropion @/ChemicalSrc$ response have been done . We investigated 532 tagging single nucleotide polymorphisms ( SNPs ) in 34 candidate genes for association with remission and response to either @ChemicalSrc$ bupropion @/ChemicalSrc$ ( n=319 ) or placebo ( n=257 ) in patients with major depressive disorder . Analyses were performed using conditional logistic regression . Significant association ( gene-wide correction ) was observed for remission following treatment with @ChemicalSrc$ bupropion @/ChemicalSrc$ for a SNP within the serotonin receptor 2A gene ( @GeneTgt$ HTR2A @/GeneTgt$ rs2770296 , p(corrected)=0.02 ) . Response to @ChemicalSrc$ bupropion @/ChemicalSrc$ treatment was significantly associated with a SNP in the dopamine transporter gene ( rs6347 , p(corrected)=0.013 ) . Among the patients who received placebo , marginal association for remission was observed between a SNP in @GeneTgt$ HTR2A @/GeneTgt$ ( rs2296972 , p(corrected)=0.055 ) as well as in the serotonin transporter gene ( 5-HTT or SLC6A4 rs4251417 , p(corrected)=0.050 ) . Placebo response was associated with SNPs in the glucocorticoid receptor gene ( NR3C1 ; rs1048261 , p(corrected)=0.040 ) and monoamine oxidase A gene ( MAOA ; rs6609257 , p corrected=0.046 ) . Although the above observations were significant after gene-wide corrections , none of these would be significant after a more conservative study-wide correction for multiple tests . These results suggest a possible role for @GeneTgt$ HTR2A @/GeneTgt$ in remission to @ChemicalSrc$ bupropion @/ChemicalSrc$ treatment . In accordance with @ChemicalSrc$ bupropion @/ChemicalSrc$ pharmacology , dopamine transporter may play a role in response . The MAOA gene may be involved in placebo response .	1 5 5 5 1 7 5|6 5 5|6 7 11 7 1 15 15 17 15 20 20 17 22 20 22 22 26 20 29 29 26 29 17 34 34 31 15 38 38 45 42 39|42 42 39|42 38 45 45 45 45 49 49 54 54 54 54 49 56 54 56 61 61 61 54 63 61 65 63 65 65 70 70 67|69 67 67|69 73 70 73 70 70 78 70 78 81 70 85 85 85 81 49 90 90 90 90 94 94 91 90 97 103 100 100 97 100 103 103 105 103 107 105 109 107|108 107 107|108 113 113 109 119 119 119 119 119 109 121 119|123 123 119|123 119 123 119 103 103 137 134 131|134 134 131|134 130 137 137 137 140 140 137 145 145 145 145 140 147 149 147 145 145 137 155 155 165 157 155 161 158 161 157 163 161 165 165 168 168 165 170 168|169 168 168|169 173 170 173 173 173 168 177 177 184 184 184 184 168 186 184 186 186 186 186 186 186 165 196 198 198 198 200 198 205 205 205 205 200 207 205 207 207 209 209 209 207 217 217 217 207 219 217 219 219 224 224 205 224 198 232 230 230 232 232 242 235 235 232 242 242 239 237 242 242 242 248 248 246 248 248 242 251 251 248 242 254 255 255 258 258 255 260 258|259 258 258|259 263 258 267 263|267 267 263|267 263 255 272 281 276 273|276 276 273|276 272 281 279 281 281 281 283 281 285 281 281 290 290 293 293 293 293 296 296 293 293	Association
23230131	Chemical	Gene	C056507	1633	True	0	What is [PHARMGKB] between @ChemicalSrc$ dFdC @/ChemicalSrc$ and @GeneTgt$ DCK @/GeneTgt$ ? [SEP] Pharmacogenomics of @ChemicalSrc$ gemcitabine @/ChemicalSrc$ metabolism : functional analysis of genetic variants in cytidine deaminase and @GeneTgt$ deoxycytidine kinase @/GeneTgt$ . @ChemicalSrc$ Gemcitabine @/ChemicalSrc$ ( @ChemicalSrc$ dFdC @/ChemicalSrc$ , @ChemicalSrc$ 2',2'-difluorodeoxycytidine @/ChemicalSrc$ ) is metabolized by cytidine deaminase ( CDA ) and @GeneTgt$ deoxycytidine kinase @/GeneTgt$ ( @GeneTgt$ DCK @/GeneTgt$ ) , but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear . Wild-type enzymes and variants of CDA ( Lys27Gln and Ala70Thr ) and @GeneTgt$ DCK @/GeneTgt$ ( Ile24Val , Ala119Gly , and Pro122Ser ) were expressed in and purified from Escherichia coli , and enzyme kinetic parameters were estimated for cytarabine ( Ara-C ) , @ChemicalSrc$ dFdC @/ChemicalSrc$ , and its metabolite 2',2'-difluorodeoxyuridine ( dFdU ) as substrates . All three CDA proteins showed similar K(m ) and V(max ) for Ara-C and @ChemicalSrc$ dFdC @/ChemicalSrc$ deamination , except for CDA70Thr , which had a 2.5-fold lower K(m ) and 6-fold lower V(max ) for Ara-C deamination . All four @GeneTgt$ DCK @/GeneTgt$ proteins yielded comparable metabolic activity for Ara-C and @ChemicalSrc$ dFdC @/ChemicalSrc$ monophosphorylation , except for DCK24Val , which demonstrated an approximately 2-fold increase ( P & lt ; 0.05 ) in the intrinsic clearance of @ChemicalSrc$ dFdC @/ChemicalSrc$ monophosphorylation due to a 40 % decrease in K(m ) ( P & lt ; 0.05 ) . @GeneTgt$ DCK @/GeneTgt$ did not significantly contribute to dFdU monophosphorylation . In conclusion , the Lys27Gln substitution does not significantly modulate CDA activity toward @ChemicalSrc$ dFdC @/ChemicalSrc$ , and therefore would not contribute to interindividual variability in response to @ChemicalSrc$ gemcitabine @/ChemicalSrc$ . The higher in vitro catalytic efficiency of DCK24Val toward @ChemicalSrc$ dFdC @/ChemicalSrc$ monophosphorylation may be relevant to @ChemicalSrc$ dFdC @/ChemicalSrc$ clinical response . The substrate-dependent alterations in activities of CDA70Thr and DCK24Val in vitro were observed for the first time , and demonstrate that the in vivo consequences of these genetic variations should not be extrapolated from one substrate of these enzymes to another .	1 5 2|5 5 2|5 1 1 8 1 11 11 8 14 14 11 14 16|14 16|14 16|14 16|14 1 21|32 32 21|32 25 22|23 22 22|23 25 25 25 25 25 32 32 35 35 32 37 35 37 35 40|35|36 40|35|36 40|35 40|35|36 44 38|40 40 38|40 44 32 32 50 70 53 53 50 56 56 53 59 59 50 62 62 59 62 62 62 68 68 65 70 32 70 78 100 78 78 82 80 84 82 84 84 84 82 88|82 82 88|82 92 80 92 92 92 92 92 92 100 100 100 100 100 106 106 103 100 100 111 111 113 113 100 115 113 117 115 117 115 118|115 115 118|115 115 115 125 126 115 128 126 128 131 115 113 138 138 138 139 139 141 139 141 141 141 144 147 141 147 147|148 147 147|148 147 141 155 155 141 155 158 155 162 161 162 158 162 158 166 167 155 167 171 171 167 139 178 178 175|178 178 175|178 179 179 182 182 179 184 182 184 184 184 184 184 179 179 192 190 192 195 192 199 198 199 195 201 199 201 201 201 201 201 210 210 210 195 214 214|209 214 214|209 210 220 215 220 219 220 195 222 220 222 225 222 225 225 225 225 225 179 234|240 240 234|240 240 240 240 240 243 243 240 240 247 255 255 251 251 255 255 255 255 255 257 255 259 257|258 257 257|258 255 255 266 266 266 255 269 269 266 271 266 273 271 271 271 255 283 283 283 280 283 292 285 283 289 286|289 289 286|289 283 292 292 292 297 297|292 297 297|292 297 292 292 303 303 313 305 303 307 305 307 307 311 303 313 313 317 317 317 313 313 313 313 333 325 325 323 333 329 329 329 325 333 333 333 320 336 336 333 339 339 336 341 336 313	Association
23230131	Chemical	Gene	C056507	978	True	0	What is [PHARMGKB] between @ChemicalSrc$ dFdC @/ChemicalSrc$ and @GeneTgt$ CDA @/GeneTgt$ ? [SEP] Pharmacogenomics of @ChemicalSrc$ gemcitabine @/ChemicalSrc$ metabolism : functional analysis of genetic variants in @GeneTgt$ cytidine deaminase @/GeneTgt$ and deoxycytidine kinase . @ChemicalSrc$ Gemcitabine @/ChemicalSrc$ ( @ChemicalSrc$ dFdC @/ChemicalSrc$ , @ChemicalSrc$ 2',2'-difluorodeoxycytidine @/ChemicalSrc$ ) is metabolized by @GeneTgt$ cytidine deaminase @/GeneTgt$ ( @GeneTgt$ CDA @/GeneTgt$ ) and deoxycytidine kinase ( DCK ) , but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear . Wild-type enzymes and variants of @GeneTgt$ CDA @/GeneTgt$ ( Lys27Gln and Ala70Thr ) and DCK ( Ile24Val , Ala119Gly , and Pro122Ser ) were expressed in and purified from Escherichia coli , and enzyme kinetic parameters were estimated for cytarabine ( Ara-C ) , @ChemicalSrc$ dFdC @/ChemicalSrc$ , and its metabolite 2',2'-difluorodeoxyuridine ( dFdU ) as substrates . All three @GeneTgt$ CDA @/GeneTgt$ proteins showed similar K(m ) and V(max ) for Ara-C and @ChemicalSrc$ dFdC @/ChemicalSrc$ deamination , except for CDA70Thr , which had a 2.5-fold lower K(m ) and 6-fold lower V(max ) for Ara-C deamination . All four DCK proteins yielded comparable metabolic activity for Ara-C and @ChemicalSrc$ dFdC @/ChemicalSrc$ monophosphorylation , except for DCK24Val , which demonstrated an approximately 2-fold increase ( P & lt ; 0.05 ) in the intrinsic clearance of @ChemicalSrc$ dFdC @/ChemicalSrc$ monophosphorylation due to a 40 % decrease in K(m ) ( P & lt ; 0.05 ) . DCK did not significantly contribute to dFdU monophosphorylation . In conclusion , the Lys27Gln substitution does not significantly modulate @GeneTgt$ CDA @/GeneTgt$ activity toward @ChemicalSrc$ dFdC @/ChemicalSrc$ , and therefore would not contribute to interindividual variability in response to @ChemicalSrc$ gemcitabine @/ChemicalSrc$ . The higher in vitro catalytic efficiency of DCK24Val toward @ChemicalSrc$ dFdC @/ChemicalSrc$ monophosphorylation may be relevant to @ChemicalSrc$ dFdC @/ChemicalSrc$ clinical response . The substrate-dependent alterations in activities of CDA70Thr and DCK24Val in vitro were observed for the first time , and demonstrate that the in vivo consequences of these genetic variations should not be extrapolated from one substrate of these enzymes to another .	1 5 2|5 5 2|5 1 1 8 1 11 11 8 13 11|13 11|13 11|13 11|13 13 18 13 1 21|32 32 21|32 25 22|23 22 22|23 25 25 25 25 25 32 32 34 30|32|34 30|32|34 32|34 30|32|34 38 32|34 34 32|34 38 34 43 34 45 43 45 32 32 50 70 53 53 50 56 56 53 59 59 50 62 62 59 62 62 62 68 68 65 70 32 70 78 100 78 78 82 80|81 80 80|81 85 82 85 85 85 82 82 92 80 92 92 92 92 92 92 100 100 100 100 100 106 106 103 100 100 111 111 113 113 100 115 113 117 115 117 115 118|115 115 118|115 115 115 125 126 115 128 126 128 131 115 113 139 139 136|139 139 136|139 140 140 142 140 142 142 142 145 148 142 148 148 148 148 148 142 156 156 142 156 159 156 163 162 163 159 163 159 167 168 156 168 172 172 168 140 179 179 179 180 180 183 183 180 185 183 185 185|186 185 185|186 185 180 180 193 191 193 196 193 200 199 200 196 202 200 202 202 202 202 202 211 211 211 196 215 215|211 215 215|211 211 221 216 221 220 221 196 223 221 223 226 223 226 226 226 226 226 180 239 239 239 239 239 242 242 239 239 245 253 253 249 249 253 253 253 253 253 253|256 256 253|256 253 258 256 256 256 253 253 265 265 265 253 268 268 265 270 265 272 269|270 270 269|270 253 283 283 283 280 283 292 285 283 289 286|289 289 286|289 283 292 292 292 297 297|292 297 297|292 297 292 292 303 303 313 305 303 307 305 307 307 311 303 313 313 317 317 317 313 313 313 313 333 325 325 323 333 329 329 329 325 333 333 333 320 336 336 333 339 339 336 341 336 313	None-PHARMGKB
23230131	Chemical	Gene	D003561	978	True	0	What is [PHARMGKB] between @ChemicalSrc$ Ara-C @/ChemicalSrc$ and @GeneTgt$ CDA @/GeneTgt$ ? [SEP] Pharmacogenomics of gemcitabine metabolism : functional analysis of genetic variants in @GeneTgt$ cytidine deaminase @/GeneTgt$ and deoxycytidine kinase . Gemcitabine ( dFdC , 2',2'-difluorodeoxycytidine ) is metabolized by @GeneTgt$ cytidine deaminase @/GeneTgt$ ( @GeneTgt$ CDA @/GeneTgt$ ) and deoxycytidine kinase ( DCK ) , but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear . Wild-type enzymes and variants of @GeneTgt$ CDA @/GeneTgt$ ( Lys27Gln and Ala70Thr ) and DCK ( Ile24Val , Ala119Gly , and Pro122Ser ) were expressed in and purified from Escherichia coli , and enzyme kinetic parameters were estimated for @ChemicalSrc$ cytarabine @/ChemicalSrc$ ( @ChemicalSrc$ Ara-C @/ChemicalSrc$ ) , dFdC , and its metabolite 2',2'-difluorodeoxyuridine ( dFdU ) as substrates . All three @GeneTgt$ CDA @/GeneTgt$ proteins showed similar K(m ) and V(max ) for @ChemicalSrc$ Ara-C @/ChemicalSrc$ and dFdC deamination , except for CDA70Thr , which had a 2.5-fold lower K(m ) and 6-fold lower V(max ) for @ChemicalSrc$ Ara-C @/ChemicalSrc$ deamination . All four DCK proteins yielded comparable metabolic activity for @ChemicalSrc$ Ara-C @/ChemicalSrc$ and dFdC monophosphorylation , except for DCK24Val , which demonstrated an approximately 2-fold increase ( P & lt ; 0.05 ) in the intrinsic clearance of dFdC monophosphorylation due to a 40 % decrease in K(m ) ( P & lt ; 0.05 ) . DCK did not significantly contribute to dFdU monophosphorylation . In conclusion , the Lys27Gln substitution does not significantly modulate @GeneTgt$ CDA @/GeneTgt$ activity toward dFdC , and therefore would not contribute to interindividual variability in response to gemcitabine . The higher in vitro catalytic efficiency of DCK24Val toward dFdC monophosphorylation may be relevant to dFdC clinical response . The substrate-dependent alterations in activities of CDA70Thr and DCK24Val in vitro were observed for the first time , and demonstrate that the in vivo consequences of these genetic variations should not be extrapolated from one substrate of these enzymes to another .	1 4 4 1 1 7 1 10 10 7 12 10|11|12 10|11|12 10|12 10|11|12 12 17 12 1 27 22 20 22 22 22 27 27 29 27|28|29 27|28|29 27|29 27|28|29 33 29|30 29 29|30 33 29 38 29 40 38 40 27 27 45 65 48 48 45 51 51 48 54 54 45 57 57 54 57 57 57 63 63 60 65 27 65 70 92 70 70 74 72|73 72 72|73 77 74 77 77 77 74 74 84 72 84 84 84 84 84 84 92 92 92 92 92 98 98 95 92 92 103 103 105 105 92 107 105 105 105 110 107 107 107 110 107 107 107 107 118 119 107 121 119 121 124 107 105 133 133 130|133 133 130|133 134 134 136 134 136 136 136 139 142 136|140 136 136|140 142 142 142 136 150 150 136 150 153 150 157 156 157 153 157 153 161 162 150 162 167 162|167 167 162|167 162 134 175 175 175 176 176 179 179 176 181 179|180 179 179|180 181 181 181 176 176 189 187 189 192 189 196 195 196 192 198 196 198 198 198 198 198 207 207 207 192 210 210 207 216 211 216 215 216 192 218 216 218 221 218 221 221 221 221 221 176 233 233 233 233 233 236 236 233 233 239 247 247 243 243 247 247 247 247 247 247|250 250 247|250 247 252 250 247 247 258 258 258 247 261 261 258 263 258 265 263 247 273 273 273 270 273 281 275 273 278 278 273 281 281 281 285 285 285 281 281 289 289 299 291 289 293 291 293 293 297 289 299 299 303 303 303 299 299 299 299 319 311 311 309 319 315 315 315 311 319 319 319 306 322 322 319 325 325 322 327 322 299	Association
23230131	Chemical	Gene	D003561	1633	True	0	What is [PHARMGKB] between @ChemicalSrc$ Ara-C @/ChemicalSrc$ and @GeneTgt$ DCK @/GeneTgt$ ? [SEP] Pharmacogenomics of gemcitabine metabolism : functional analysis of genetic variants in cytidine deaminase and @GeneTgt$ deoxycytidine kinase @/GeneTgt$ . Gemcitabine ( dFdC , 2',2'-difluorodeoxycytidine ) is metabolized by cytidine deaminase ( CDA ) and @GeneTgt$ deoxycytidine kinase @/GeneTgt$ ( @GeneTgt$ DCK @/GeneTgt$ ) , but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear . Wild-type enzymes and variants of CDA ( Lys27Gln and Ala70Thr ) and @GeneTgt$ DCK @/GeneTgt$ ( Ile24Val , Ala119Gly , and Pro122Ser ) were expressed in and purified from Escherichia coli , and enzyme kinetic parameters were estimated for @ChemicalSrc$ cytarabine @/ChemicalSrc$ ( @ChemicalSrc$ Ara-C @/ChemicalSrc$ ) , dFdC , and its metabolite 2',2'-difluorodeoxyuridine ( dFdU ) as substrates . All three CDA proteins showed similar K(m ) and V(max ) for @ChemicalSrc$ Ara-C @/ChemicalSrc$ and dFdC deamination , except for CDA70Thr , which had a 2.5-fold lower K(m ) and 6-fold lower V(max ) for @ChemicalSrc$ Ara-C @/ChemicalSrc$ deamination . All four @GeneTgt$ DCK @/GeneTgt$ proteins yielded comparable metabolic activity for @ChemicalSrc$ Ara-C @/ChemicalSrc$ and dFdC monophosphorylation , except for DCK24Val , which demonstrated an approximately 2-fold increase ( P & lt ; 0.05 ) in the intrinsic clearance of dFdC monophosphorylation due to a 40 % decrease in K(m ) ( P & lt ; 0.05 ) . @GeneTgt$ DCK @/GeneTgt$ did not significantly contribute to dFdU monophosphorylation . In conclusion , the Lys27Gln substitution does not significantly modulate CDA activity toward dFdC , and therefore would not contribute to interindividual variability in response to gemcitabine . The higher in vitro catalytic efficiency of DCK24Val toward dFdC monophosphorylation may be relevant to dFdC clinical response . The substrate-dependent alterations in activities of CDA70Thr and DCK24Val in vitro were observed for the first time , and demonstrate that the in vivo consequences of these genetic variations should not be extrapolated from one substrate of these enzymes to another .	1 4 4 1 1 7 1 10 10 7 13 13 10 13 13|14|15 13|14|15 13|15 13|14|15 1 27 22 20 22 22 22 27 27 30 30 27 32 30 32 30 35|30|34 35|30|34 35|30 35|30|34 39 35|36 35 35|36 39 27 27 45 65 48 48 45 51 51 48 54 54 45 57 57 54 57 57 57 63 63 60 65 27 65 70 92 70 70 74 72 76 74 76 76 76 74 80|74 74 80|74 84 72 84 84 84 84 84 84 92 92 92 92 92 98 98 95 92 92 103 103 105 105 92 107 105 105 105 110 107 107 107 110 107 107 107 107 118 119 107 121 119 121 124 107 105 132 132 132 133 133 135 133 135 135 135 138 141 140|135 135 140|135 141 141 141 135 149 149 135 149 152 149 156 155 156 152 156 152 160 161 149 161 166 162|166 166 162|166 161 133 174 174 171|174 174 171|174 175 175 178 178 175 180 178 178 178 180 180 180 175 175 188 186 188 191 188 195 194 195 191 197 195 197 197 197 197 197 206 206 206 191 209 209 206 215 210 215 214 215 191 217 215 217 220 217 220 220 220 220 220 175 228|234 234 228|234 234 234 234 234 237 237 234 234 241 249 249 245 245 249 249 249 249 249 251 249 253 251 249 249 259 259 259 249 262 262 259 264 259 266 264 249 273 273 273 270 273 281 275 273 278 278 273 281 281 281 285 285 285 281 281 289 289 299 291 289 293 291 293 293 297 289 299 299 303 303 303 299 299 299 299 319 311 311 309 319 315 315 315 311 319 319 319 306 322 322 319 325 325 322 327 322 299	None-PHARMGKB
23327575	Chemical	Gene	D008874	1576	True	0	What is [PHARMGKB] between @ChemicalSrc$ MDZ @/ChemicalSrc$ and @GeneTgt$ CYP3A @/GeneTgt$ ? [SEP] @GeneTgt$ CYP3A4 @/GeneTgt$ intron 6 C&gt;T SNP ( @GeneTgt$ CYP3A4 @/GeneTgt$ * 22 ) encodes lower @GeneTgt$ CYP3A4 @/GeneTgt$ activity in cancer patients , as measured with probes @ChemicalSrc$ midazolam @/ChemicalSrc$ and erythromycin . AIM : The @GeneTgt$ CYP3A4 @/GeneTgt$ * 22 allele was recently reported to be associated with reduced @GeneTgt$ CYP3A4 @/GeneTgt$ activity . We investigated the impact of this allele on the metabolism of the @GeneTgt$ CYP3A-phenotyping @/GeneTgt$ probes , @ChemicalSrc$ midazolam @/ChemicalSrc$ ( @ChemicalSrc$ MDZ @/ChemicalSrc$ ) and erythromycin . PATIENTS & amp ; METHODS : Genomic DNA from 108 cancer patients receiving intravenous @ChemicalSrc$ MDZ @/ChemicalSrc$ and 45 undergoing the erythromycin breath test was analyzed for @GeneTgt$ CYP3A4 @/GeneTgt$ * 22 ( rs35599367 C&gt;T ) and CYP3A5 * 3 . RESULTS : The @ChemicalSrc$ MDZ @/ChemicalSrc$ metabolic ratio ( 1 -OH-MDZ : @ChemicalSrc$ MDZ @/ChemicalSrc$ ) was 20.7 % ( 95 % CI : -36.2 to -6.2 ) lower for @GeneTgt$ CYP3A4 @/GeneTgt$ * 22 carriers compared with @GeneTgt$ CYP3A4 @/GeneTgt$ * 1/*1 patients ( p = 0.01 ) . Combining @GeneTgt$ CYP3A4 @/GeneTgt$ * 22 and CYP3A5 * 3 genotypes showed a 38.7 % decrease ( 95 % CI : -50.0 to -27.4 ; p & lt ; 0.001 ) in 1 -OH-MDZ : MDZ for poor ( @GeneTgt$ CYP3A4 @/GeneTgt$ * 22-CYP3A5 * 3/*3 ) and 28.0 % ( 95 % CI : -33.3 to -22.6 ; p & lt ; 0.001 ) for intermediate ( @GeneTgt$ CYP3A4 @/GeneTgt$ * 1/*1-CYP3A5 * 3/*3 ) metabolizers , compared with extensive ( @GeneTgt$ CYP3A4 @/GeneTgt$ * 1/*1-CYP3A5 * 1 ) @GeneTgt$ CYP3A @/GeneTgt$ metabolizers . @GeneTgt$ CYP3A4 @/GeneTgt$ erythromycin N-demethylation activity was 40 % lower in @GeneTgt$ CYP3A4 @/GeneTgt$ * 22 carriers compared with @GeneTgt$ CYP3A4 @/GeneTgt$ * 1/*1 patients ( p = 0.032 ) . CONCLUSION : The @GeneTgt$ CYP3A4 @/GeneTgt$ * 22 allele is associated with decreased @GeneTgt$ CYP3A4-mediated @/GeneTgt$ metabolism , as verified by @GeneTgt$ CYP3A-phenotyping @/GeneTgt$ probes .	0|6 6 0|6 6 6 6 13 8 6 6 6 8 8 8 13 17 17|12 17 17|12 13 20 20 17 13 23 13 26 26 22|23 23 22|23 26 26 13 35 35 42 42|37 42 42|37 42 42 45 45 45 35 48 48 45 53 53 53|49 53 53|49 48 45 58 58 60 58 63 63 60 66 66 60 71 71 68|71 71 68|71 66 71 71 71 71 76 73 73 73 76 73 73 58 109 85 85 85 85 85 92 85 96 96 96 92 96 99 97|98 97 97|98 99 99 85 107 107 107 103 109 109 117 109|117 117 109|117 117 117 117 117 109 117 109 109 120 120 109 126 126 132 128|132 132 128|132 132 142 137 137 134 137 135|132 132 135|132 137 142 142 126 146 145 146 152 146 150 150 152 150 126 158 158|151 158 158|151 158 158 152 165 165 157|165 165 157|165 165 165 152 169 169 167 165 169 126 186 176|185 185 176|185 185 185 180 180 182 185 176 186 190 189 190 186 193 193 194 186 194 200 196 196 200 204 200 200 204 194 204 207 204 207 204 204 214 214 214 210|212 210 210|212 214 214 219 214 219 214 223 214 227 226 227 223 227 227 231 229 229 229 233 233 237 229 237 249 249 242 239|249 249 239|249 247 247 247 242 247 227 227 210 264 264 255 264|251 264 264|251 260 260 260 255 260 264|257 264 264|257 251 186 270|275 275 270|275 275 275 279 279 278 279 279 285 279|285 285 279|285 285 285 279 292 292 292|285 292 292|285 292 292 279 295 295 292 295 295 279 302 302 309 309|304 309 309|304 309 309 311 311 302 316 316 312|316 316 312|316 311 311 319 311 323 318|323 323 318|323 319 311	Association
23364847	Chemical	Gene	D000077152	23216	True	0	What is [PHARMGKB] between @ChemicalSrc$ olanzapine @/ChemicalSrc$ and @GeneTgt$ TBC1D1 @/GeneTgt$ ? [SEP] Exploratory study on association of genetic variation in @GeneTgt$ TBC1D1 @/GeneTgt$ with antipsychotic-induced weight gain . BACKGROUND : Previous studies have shown that antipsychotics with high propensity for antipsychotic-induced weight gain ( AIWG ) influence glucose transporter type 4 ( GLUT4 ) mediated glucose intake . Variation in the gene encoding @GeneTgt$ TBC1 domain family member 1 @/GeneTgt$ ( @GeneTgt$ TBC1D1 @/GeneTgt$ ) , a Rab-GTPase activating protein regulating GLUT4 trafficking , has been associated with obesity . Therefore , we investigated the impact of @GeneTgt$ TBC1D1 @/GeneTgt$ polymorphisms on AIWG . METHODS : We analyzed rs9852 and rs35859249 in @GeneTgt$ TBC1D1 @/GeneTgt$ in 195 schizophrenia subjects treated mostly with clozapine or @ChemicalSrc$ olanzapine @/ChemicalSrc$ for up to 14 weeks . Association was tested using analysis of variance and analysis of covariance with change ( % ) from baseline weight as the dependent variable . RESULTS : Analysis of covariance showed a non-significant trend for lower weight gain in carriers of the T-allele of rs9852 than in C-allele homozygotes ( p = 0.063 ) . This effect was more pronounced in the subgroup of patients treated with clozapine or @ChemicalSrc$ olanzapine @/ChemicalSrc$ ( p = 0.024 ) . For rs35859249 , no significant association with AIWG could be detected . CONCLUSIONS : This is the first study examining the association between @GeneTgt$ TBC1D1 @/GeneTgt$ and AIWG . The moderate association of rs9852 , located in the 3'UTR near a miRNA binding site , indicates an influence of @GeneTgt$ TBC1D1 @/GeneTgt$ on AIWG . Further investigations remain necessary to elucidate the role of this gene in AIWG .	2 2 4 2 7 7 4 9 8|7 7 8|7 14 14 14 4 2 43 17 20 22 22 17 35 35 27 27 24 31 31 31 27 33 31 33 22 38 38 41 41 41 35 41 43 45 43 43 73 50 50 47 50 51|52 51|52 51|52 51|52 51|52 51|52 51|52 59 52|53 52 52|53 59 52 66 66 66 52 66 69 67 47 73 73 73 75 73 73 82 82 82 82 84 82 88 88|85 88 88|85 84 90 84 82 96 96 96 96 96 97 97 101 100|97 97 100|97 106 106 106 97 106 107 110 107 110 110 110 110 118 117 117 118 107 96 124 124 124 124 125 128 126 126 126 132 130 134 132 136 134 136 140 140 130 144 144 144 125 124 146 146 151 150 148 146 154 154 151 158 158 158 154 160 158 163 163 160 165 163 169 169 169 158 172 172 154 172 172 146 177 180 180 180 180 183 183 180 185 183 185 188 186 188 188|189 188 188|189 194 194 180 194 194 180 200 209 209 204 204 209 206 204 209 209 209 209 211 211 217 217 217 217 211 217 220 218 222 220|221 220 220|221 222 222 211 230 230 244 232 230 232 230 237 237 234 242 242 242 242 237 230 244 246 244 248 246|247 246 246|247 251 246 244 255 256 256 256 259 257 261 259 264 264 261 266 261 256	Association
23364847	Chemical	Gene	D003024	23216	True	0	What is [PHARMGKB] between @ChemicalSrc$ clozapine @/ChemicalSrc$ and @GeneTgt$ TBC1D1 @/GeneTgt$ ? [SEP] Exploratory study on association of genetic variation in @GeneTgt$ TBC1D1 @/GeneTgt$ with antipsychotic-induced weight gain . BACKGROUND : Previous studies have shown that antipsychotics with high propensity for antipsychotic-induced weight gain ( AIWG ) influence glucose transporter type 4 ( GLUT4 ) mediated glucose intake . Variation in the gene encoding @GeneTgt$ TBC1 domain family member 1 @/GeneTgt$ ( @GeneTgt$ TBC1D1 @/GeneTgt$ ) , a Rab-GTPase activating protein regulating GLUT4 trafficking , has been associated with obesity . Therefore , we investigated the impact of @GeneTgt$ TBC1D1 @/GeneTgt$ polymorphisms on AIWG . METHODS : We analyzed rs9852 and rs35859249 in @GeneTgt$ TBC1D1 @/GeneTgt$ in 195 schizophrenia subjects treated mostly with @ChemicalSrc$ clozapine @/ChemicalSrc$ or olanzapine for up to 14 weeks . Association was tested using analysis of variance and analysis of covariance with change ( % ) from baseline weight as the dependent variable . RESULTS : Analysis of covariance showed a non-significant trend for lower weight gain in carriers of the T-allele of rs9852 than in C-allele homozygotes ( p = 0.063 ) . This effect was more pronounced in the subgroup of patients treated with @ChemicalSrc$ clozapine @/ChemicalSrc$ or olanzapine ( p = 0.024 ) . For rs35859249 , no significant association with AIWG could be detected . CONCLUSIONS : This is the first study examining the association between @GeneTgt$ TBC1D1 @/GeneTgt$ and AIWG . The moderate association of rs9852 , located in the 3'UTR near a miRNA binding site , indicates an influence of @GeneTgt$ TBC1D1 @/GeneTgt$ on AIWG . Further investigations remain necessary to elucidate the role of this gene in AIWG .	2 2 4 2 7 7 4 9 8|7 7 8|7 14 14 14 4 2 43 17 20 22 22 17 35 35 27 27 24 31 31 31 27 33 31 33 22 38 38 41 41 41 35 41 43 45 43 43 73 50 50 47 50 51|52 51|52 51|52 51|52 51|52 51|52 51|52 59 52|53 52 52|53 59 52 66 66 66 52 66 69 67 47 73 73 73 75 73 73 82 82 82 82 84 82 88 88|85 88 88|85 84 90 84 82 96 96 96 96 96 97 97 101 100|97 97 100|97 106 106 106 97 106 107 110 108|107 107 108|107 110 110 118 117 117 118 107 96 124 124 124 124 125 128 126 126 126 132 130 134 132 136 134 136 140 140 130 144 144 144 125 124 146 146 151 150 148 146 154 154 151 158 158 158 154 160 158 163 163 160 165 163 169 169 169 158 172 172 154 172 172 146 177 180 180 180 180 183 183 180 185 183 185 188 186|187 186 186|187 188 188 194 194 180 194 194 180 200 209 209 204 204 209 206 204 209 209 209 209 211 211 217 217 217 217 211 217 220 218 222 220|221 220 220|221 222 222 211 230 230 244 232 230 232 230 237 237 234 242 242 242 242 237 230 244 246 244 248 246|247 246 246|247 251 246 244 255 256 256 256 259 257 261 259 264 264 261 266 261 256	Association
23609392	Chemical	Gene	D018967	1576	False	1	What is [PHARMGKB] between @ChemicalSrc$ Risperidone @/ChemicalSrc$ and @GeneTgt$ CYP3A @/GeneTgt$ ? [SEP] Pharmacogenetic study on @ChemicalSrc$ risperidone @/ChemicalSrc$ long-acting injection : influence of cytochrome P450 2D6 and pregnane X receptor on @ChemicalSrc$ risperidone @/ChemicalSrc$ exposure and drug-induced side-effects . @ChemicalSrc$ Risperidone @/ChemicalSrc$ is metabolized by polymorphic enzymes , and a large variability in plasma concentration and therapeutic response is observed . @ChemicalSrc$ Risperidone @/ChemicalSrc$ long-acting injection ( RLAI ) avoids the first-pass effect , and little is known about the influence of gene polymorphisms involved in its pharmacokinetics . The influence on plasma concentrations of risperidone ( RIS ) , its metabolite 9-hydroxy-risperidone , and on adverse effects were investigated for polymorphisms of cytochrome P450 2D6 ( CYP2D6 ) ( * 3 , * 4 , * 5 , * 6 ) , @GeneTgt$ CYP3A @/GeneTgt$ ( @GeneTgt$ CYP3A4 * 1B @/GeneTgt$ , @GeneTgt$ CYP3A4 @/GeneTgt$ rs4646437 , CYP3A5 * 3 , CYP3A7 * 1C ) , ABCB1 ( 1236C&gt;T , 2677G&gt;T , 3435C&gt;T ) , NR1/2 coding for pregnane X receptor ( rs1523130 , rs2472677 , rs7643645 ) , and for @GeneTgt$ CYP3A @/GeneTgt$ activity measured by a phenotyping test . Forty-two patients with at least 4 consecutive unchanged doses of RLAI were included in a multicenter cross-sectional study . A 55 % lower dose-adjusted plasma levels of RIS were observed for CYP2D6 ultrarapid metabolizers ( n = 5 ) as compared with CYP2D6 intermediate metabolizers ( P & lt ; 0.007 ) . NR1/2 polymorphism ( rs7643645A&gt;G ) influenced RIS exposure with a 2.8-fold lower active moiety ( P = 0.031 ) in GG compared with the AA genotype . This was confirmed in a second independent cohort ( n = 16 ) . Furthermore , high-density lipoprotein cholesterol was positively correlated with @GeneTgt$ CYP3A @/GeneTgt$ activity ( P = 0.01 ) , and the NR1/2 ( rs2472677 ) polymorphism was associated with different adverse effects including prolactin plasma levels adjusted for age and sex . In conclusion , our results confirmed the influence of CYP2D6 genotype on plasma levels of RIS . This is the first report on the influence of NR1/2 polymorphisms on RLAI exposure and on drug-induced adverse effects . These results should be validated in larger cohorts .	2 2 7 3|7 7 3|7 7 2 2 2 13 13 13 9 13 17 17 13 21 17|21 21 17|21 9 21 24 21 2 27|31 31 27|31 31 31 34 34 31 31 31 39 39 47 42 42 39 42 45 42 47 31 47 49|53 53 49|53 53 57 55 53 55 57 60 60 57 57 57 65 65 57 68 68 65 71 71 68 71 75 75 72 57 79 98 82 82 79 84 82 86 84 86 84 91 91 84 84 82 96 96 82 98 98 100 98 104 104 104 132 106 104 106 104 104 104 104 104 104 104 104 104 104 104 104 119 104 125|121 125 125|121 125 125|104|123 125|104|123 125|104|123 125|104 125|104|123 125 125|132 132 125|132 100 132 132 134 134 132 140 140 132 132 100 100 143 143 145 145 145 98 98 98 153 98 157 157 157 153 159 157 159 159 159 159 159 157 157 170 170|162 170 170|162 157 170 175 175 175 171 98 182 193 185 185 186 189 189 189 193 191 189 193 193 198 198 198 198 193 193 202 202 203 206 206 206 210 208 206 210 210 214 214 214 210 216 214 216 217 216 221 210 225 225 225 221 227 225 227 227 231 227 231 210 235 239 237 235 237 239 241 239 247 247 245 247 247 241 250 250 247 250 250 254 247 239 259 259 259 255 239 263 263 263 268 268 267 268 263 270 268 270 271 270 263 282 282 279 279 282 282 282 282 286 283|286 286 283|286 282 288 286 288 289 288 282 282 299 299 297 295 299 301 301 282 305 305 305 301 309 309 309 305 282 312 310 312 312 282 318 322 322 321 322 322 324 322 327 327 324 330 330 324 332 330 322 338 338 338 338 338 341 341 338 344 344 341 347 347 341 347 352 352 352 347 338 355 358 358 358 358 361 361 358 358	Association
23628510	Chemical	Gene	C545203	1080	True	0	What is [PHARMGKB] between @ChemicalSrc$ ivacaftor @/ChemicalSrc$ and @GeneTgt$ CFTR @/GeneTgt$ ? [SEP] The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation . BACKGROUND : @ChemicalSrc$ Ivacaftor @/ChemicalSrc$ , a @GeneTgt$ cystic fibrosis transmembrane regulator @/GeneTgt$ ( @GeneTgt$ CFTR @/GeneTgt$ ) potentiator , decreased sweat chloride concentrations and improved clinical measures in cystic fibrosis ( CF ) patients with the G551D mutation . RESULTS : Sweat chloride measurements at day 15 had an overall positive predictive value ( PPV ) of 86.3 % , a negative predictive value ( NPV ) of 65.5 % , sensitivity of 73.9 % , and specificity of 80.9 % for an FEV1 improvement of & gt;=5 % from baseline at week 16 . For @ChemicalSrc$ ivacaftor @/ChemicalSrc$ patients the median FEV1 improvement was 16.7 % ; for placebo patients 0.4 % . For patients aged 6 - 11 years who received @ChemicalSrc$ ivacaftor @/ChemicalSrc$ and who had a sweat chloride decrease of & gt;=40 mmol/L from baseline at day 15 , a median weight gain of 11.2 % at week 16 , compared to 6 % for those with a smaller decrease was observed . CONCLUSIONS : Changes in sweat chloride concentration at day 15 following treatment with @ChemicalSrc$ ivacaftor @/ChemicalSrc$ may have sufficient predictive potential to identify individuals that show improvement in pulmonary function and weight gain after 16 weeks of treatment .	3 3 3 8 8 8 8 3 12 12 12 8 16 16 16 12 3 18 18 19|35 35 19|35 20 33 33|22 33|22 33|22 33|22 33 33|22 33 33|24 33 33|24 33 20 20 18 38 38 35 35 35 42 40 49 49 44 47 49 47 42 53 53 53 49 18 58 58 62 62 66 64 62 64 58 71 71 71 71 66 73 71 73 77 77 71 77 82 82 82 77 84 82 84 88 88 82 71 71 93 93 90 90 71 71 99 99 96 103 103 103 96 107 104 107 103 109 103 111 103 111 58 117 114|117 117 114|117 124 121 121 121 117 124 124 124 124 128 128 124 130 128 124 134 183 139 138 138 139 134 141 139 141 141 141 141 146 141 150 150 150 146 154 151 154 150 156 150 158 150 158 150 164 164 164 150 167 167 164 169 164 169 139 134 175 175 172 177 175 181 181 181 177 183 183 183 202 186 202 192 192 192 188 194 192 194 197 188 199 197|198 197 197|198 202 202 205 205 202 207 205 207 210 208 210 214 214 211 214 217 214 220 220 211 222 220 202	Association
23703421	Chemical	Gene	D006853	4988	True	0	What is [PHARMGKB] between @ChemicalSrc$ hydrocodone @/ChemicalSrc$ and @GeneTgt$ OPRM1 @/GeneTgt$ ? [SEP] The role of hydromorphone and @GeneTgt$ OPRM1 @/GeneTgt$ in postoperative pain relief with @ChemicalSrc$ hydrocodone @/ChemicalSrc$ . BACKGROUND : Postoperative pain management remains a challenge for clinicians due to unpredictable patient responses to opioid therapy . Some of this variability may result from single nucleotide polymorphisms ( SNPs ) of the human opioid mu-1 receptor ( @GeneTgt$ OPRM1 @/GeneTgt$ ) that modify receptor binding or signal transduction . The @GeneTgt$ OPRM1 @/GeneTgt$ variant with the highest frequency is the A118 G SNP . However , previous studies have produced inconsistent results regarding the clinical effects of A118 G on opioid response . We hypothesized that measurement of serum opioid concentrations , in addition to determining total opioid consumption , may provide a more precise method of assessing the effects of A118 G on analgesic response . The current study evaluated the relationship of analgesia , side effects , total @ChemicalSrc$ hydrocodone @/ChemicalSrc$ consumption , quantitative serum @ChemicalSrc$ hydrocodone @/ChemicalSrc$ and hydromorphone concentrations , and A118 G SNP in postoperative patients following Cesarean section . METHODS : 158 women scheduled for Cesarean section were enrolled prospectively in the study . The patients had bupivacaine spinal anesthesia for surgery and received intrathcal morphine with the spinal anesthetic or parenteral morphine for the first 24 hours after surgery . Thereafter , patients received @ChemicalSrc$ hydrocodone/acetaminophen @/ChemicalSrc$ for postoperative pain control . On postoperative day 3 , venous blood samples were obtained for @GeneTgt$ OPRM1 @/GeneTgt$ A118 G genotyping and serum opioid concentrations . RESULTS : 131 ( 82.9 % ) of the subjects were homozygous for the 118A allele of @GeneTgt$ OPRM1 @/GeneTgt$ ( AA ) and 27 ( 17.1 % ) carried the G allele ( AG/GG ) . By regression analysis , pain relief was significantly associated with total @ChemicalSrc$ hydrocodone @/ChemicalSrc$ dose in the AA group ( P = 0.01 ) , but not in the AG/GG group ( P = 0.554 ) . In contrast , there was no association between pain relief and serum @ChemicalSrc$ hydrocodone @/ChemicalSrc$ concentration in either group . However , pain relief was significantly associated with serum hydromorphone concentration ( a metabolite of @ChemicalSrc$ hydrocodone @/ChemicalSrc$ ) in the AA group ( P = 0.004 ) , but not in the AG/GG group ( P = 0.724 ) . Conversely , side effects were significantly higher ( P & lt ; 0.04 ) in the AG/GG group ( mean = 6.4 ) than in the AA group ( mean = 4.4 ) , regardless of adjustment for BMI , pain level , or total dose of @ChemicalSrc$ hydrocodone @/ChemicalSrc$ . CONCLUSION : This study found a correlation between pain relief and total @ChemicalSrc$ hydrocodone @/ChemicalSrc$ dose in patients homozygous for the 118A allele ( AA ) of the @GeneTgt$ OPRM1 @/GeneTgt$ gene , but not in patients with the 118 G allele ( AG/GG ) . However , pain relief in 118A patients did not correlate with serum @ChemicalSrc$ hydrocodone @/ChemicalSrc$ concentrations , but rather with serum hydromorphone levels , the active metabolite of @ChemicalSrc$ hydrocodone @/ChemicalSrc$ . This suggests that pain relief with @ChemicalSrc$ hydrocodone @/ChemicalSrc$ may be due primarily to hydromorphone . Although pain relief did not correlate with opioid dose in AG/GG patients , they had a higher incidence of opioid side effects . The correlations identified in this study may reflect the fact that serum opioid concentrations were measured directly , avoiding the inherent imprecision associated with relying solely on total opioid consumption as a determinant of opioid effectiveness . Thus , measurement of serum opioid concentrations is recommended when assessing the role of @GeneTgt$ OPRM1 @/GeneTgt$ variants in pain relief . This study supports pharmacogenetic analysis of @GeneTgt$ OPRM1 @/GeneTgt$ in conjunction with serum opioid concentrations when evaluating patient responses to opioid therapy .	2 2 4 2 4 4|5 4 4|5 11 11 11 2 13 11 11 11 2 18 18 22 22 23 18 25 23 27 25 32 28 32 32 25 35 35 32 23 42 40 40 37 42 42 46 46 46 42 48 46 48 55 55 55 55 55 46 57 55|56 55 55|56 57 61 55 61 62 63 66 63 42 72 69|72 72 69|72 81 76 76 76 72 81 81 81 81 81 81 89 89 87 89 89 89 91 89 95 95 95 91 98 98 95 101 101 95 89 104 104 121 121 110 110 110 106 110 113 115 115 106 118 118 115 106 121 104 125 124 125 121 127 125 129 127 132 132 129 135 135 129 104 139 139 140 140 142 140 144 142 144 147 144 144 152 152|149 152 152|149 144 152 156 156 152|154 152 152|154 156 160 156 152 144 165 165 144 168 168 142 171 171 168 140 175 184 178 184 178 182 182 179 184 175 184 188 188 184 184 191 192 192 192 195 193 197 195 193 192 201 199 205 205 205 199 205 208 205 213 213 213 213 199 215 199 192 220 220 220 220 220 220 220 226 226 226 220 220 231 231 238 231 238 236 236 238 238 238 244 244|239 244 244|239 244 244 238 244 248 248 244 238 251 251 262 256 256 253 256 260 260 253 262 251 266 266 266 262 268 266|267 266 266|267 271 268 271 268 268 277 277 266 277 262 282 282 279 284 282 284 251 290 290 296 296 293 296 296 296 296 301 301 298|301 301 298|301 296 305 305 305 301 307 305 307 308 308 307 305 317 317 317 317 305 320 320 317 320 320 296 326 329 329 329 329 331 329 334 334 331 334 339 336|339 339 336|339 334 342 342 331 329 351 351 348 351 351 351 351 355 355 355 351 358 358 355 360 358|359 358 358|359 360 366 366 366 358 369 369 358 369 369 358 374 378 378 378 378 358 381 381 378 381 381 351 392 392 389 392 392 392 392 394 392 394 394 398 394 398 403 403 403 394 405 406 394 406 406 413 413 413 413 394 415 416 413 416 416 394 394 422 420 424 422 424 427 424 427 424 431 424 433 431|432 431 431|432 392 437 441 440 441 437 443 441 446 446 443 446 451 448|451 451 448|451 446 453 451 453 458 458 458 454 460 458 460 466 466 462|466 466 462|466 458 466 458 471 471 453 476 476 476 476 471 478 476 478 437 492 492 486 492 489 489 486 492 492 492 497 497 494|497 497 494|497 492 497 497 504 500 503 504 497 504 508 508 504 510 508 508 508 492 516 516 528 519 517 521 519|520 519 519|520 525 525 517 525 528 516 516 536 533 536 536 536 545 539 539 536 542 542 539 545 545 545 548 548 545 552 552 552 548 545 555 561 555 559 559 556 561 561 563 561 569 567 567 569 569 563 569 569 569 575 575 572 575 578 576 578 583 583 583 578 586 586 578 589 589 586 561 599 599 599 597 597 597 593 599 599 601 599 603 601 607 607|604 607 607|604 603 610 610 603 599 614 615 615 617 615 619 617|618 617 617|618 622 617 626 626 626 622 628 615 630 628 633 633 630 615	Association
23752739	Chemical	Gene	D005472	6323	True	0	What is [PHARMGKB] between @ChemicalSrc$ 5-FU @/ChemicalSrc$ and @GeneTgt$ SCN1A @/GeneTgt$ ? [SEP] Gender-specific profiling in @GeneTgt$ SCN1A @/GeneTgt$ polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant @ChemicalSrc$ 5-fluoruracil @/ChemicalSrc$ chemotherapy . This study was designed to analyze the gender-related association between @GeneTgt$ SCN1A @/GeneTgt$ polymorphisms ( voltage-gated sodium channels ; alpha-subunit ) and time-to-recurrence ( TTR ) in patients with colorectal cancer ( CRC ) treated with @ChemicalSrc$ 5-fluoruracil @/ChemicalSrc$ @ChemicalSrc$ (5-FU)-based @/ChemicalSrc$ adjuvant chemotherapy . We enrolled from a prospective database patients with stage II and III CRC treated with adjuvant @ChemicalSrc$ 5-FU-based @/ChemicalSrc$ chemotherapy . Genotypes for @GeneTgt$ SCN1A @/GeneTgt$ rs3812718 and rs229877 were determined by direct DNA sequencing . One hundred twenty-seven males and 107 females were included in the study . In the univariate and multivariate analysis , the shortest TTR was associated with female patients carrying the rs3812718-TT genotype ( hazard ratio ( HR ): 2.26 ( 95 % confidence interval ( CI ): 0.89 , 5.70 ) , P=0.039 ) but with male patients carrying the rs3812718-CC genotype ( HR : 0.49 ( 95 % CI : 0.18 , 1.38 ) , P=0.048 ) . For rs229877 the CT genotype was associated with a trend for shorter TTR in both gender populations . The study validated gender-dependent association between genomic @GeneTgt$ SCN1A @/GeneTgt$ rs3812718 polymorphism and TTR in CRC patients treated with adjuvant @ChemicalSrc$ 5-FU-based @/ChemicalSrc$ chemotherapy . This study confirms that voltage-gated Na+ channels may be a potential therapeutic target and a useful predictive biomarker before @ChemicalSrc$ 5-FU @/ChemicalSrc$ infusion .	2 2 6 3|6 6 3|6 2 6 6 10 6 15 15 15 15 10 15 21 21 17|21 21 17|21 16 2 26 28 28 28 30 28 33 33 30 37 34|37 37 34|37 33 41 41 41 37 41 41 43 37 37 48 46 48 51 37 54 54 51 56 54 56 54 65 65|58 65 65|58 59|60 60 59|60 65 58 28 71 71 76 76 76 76 71 78 76 78 78 78 78 76 88 88 85|88 88 85|88 83 71 99 95 92|95 95 92|95 91 95 95 99 99 103 103 103 99 99 108 108 109 114 109 112 109 114 114 117 117 114 114 121 121 130 121 121 121 130 128 128 130 130 130 133 133 130 133 136 134 136 140 140 136 142 140 142 142 149 147 149 149 142 151 149 151 151 153 151 151 149 149 158 130 163 163 130 163 167 167 164 169 167 169 175 174 174 175 169 179 179 177 175 179 175 169 169 130 186 191 189 189 191 191 191 194 194 191 197 197 194 201 201 201 194 191 204 205 205 207 205 213 213 213|209 213 213|209 213 207 213 213 218 218 213 218 224 224 220|224 224 220|224 219 205 229 230 230 240 234 234 240 240 240 240 240 240 230 240 245 245 245 240 249 246|249 249 246|249 240 230	Association
23817222	Chemical	Gene	D005472	81029	True	0	What is [PHARMGKB] between @ChemicalSrc$ 5-fluorouracil @/ChemicalSrc$ and @GeneTgt$ WNT5B @/GeneTgt$ ? [SEP] Association of common gene variants in the @GeneTgt$ WNT/beta-catenin @/GeneTgt$ pathway with colon cancer recurrence . @GeneTgt$ Wnt/beta-catenin @/GeneTgt$ signaling has a central role in the development and progression of most colon cancers ( CCs ) . Germline variants in @GeneTgt$ Wnt/beta-catenin @/GeneTgt$ pathway genes may result in altered gene function and/or activity , thereby causing inter-individual differences in relation to tumor recurrence capacity and chemoresistance . We investigated germline polymorphisms in a comprehensive panel of @GeneTgt$ Wnt/beta-catenin @/GeneTgt$ pathway genes to predict time to tumor recurrence ( TTR ) in patients with stage III and high-risk stage II CC . A total of 234 patients treated with @ChemicalSrc$ 5-fluorouracil-based @/ChemicalSrc$ chemotherapy were included in this study . Whole-blood samples were analyzed for putative functional germline polymorphisms in SFRP3 , SFRP4 , DKK2 , DKK3 , Axin2 , APC , TCF7L2 , @GeneTgt$ WNT5B @/GeneTgt$ , CXXC4 , NOTCH2 and GLI1 genes by PCR-based restriction fragment-length polymorphism or direct DNA sequencing . Polymorphisms with statistical significance were validated in an independent study cohort . The minor allele of @GeneTgt$ WNT5B @/GeneTgt$ rs2010851 T&gt;G was significantly associated with a shorter TTR ( 10.7 vs 4.9 years ; hazard ratio : 2.48 ; 95 % CI , 0.96 - 6.38 ; P=0.04 ) in high-risk stage II CC patients . This result remained significant in multivariate Cox 's regression analysis . This study shows that the @GeneTgt$ WNT5B @/GeneTgt$ germline variant rs2010851 was significantly identified as a stage-dependent prognostic marker for CC patients after @ChemicalSrc$ 5-fluorouracil-based @/ChemicalSrc$ adjuvant therapy .	1 5 5 5 1 10 10 10|7 10 10|7 1 14 14 14 1 1 16|19 19 16|19 20 20 23 23 20 26 26 23 26 26 32 32 32 26 34 32 34 20 39 46 44 40|44 44 40|44 44 39 46 46 50 50 50 46 50 50 46 55 46 57 55 59 57 63 62 63 59 63 63 46 69 69 71 69 75 75 75 69 80 76|80 80 76|80 80 75 82 69 82 86 86 83 88 86 88 91 86 93 91 93 93 99 99 99 93 69 103 113 106 106 103 106 111 111|108 111 111|108 107 113 113 116 116 113 113 120 122 122 122 127 127 127 127 122 129 127 129 129 129 129 129 129 129 129 129 129 129 129 129 142|129 129 142|129 129 129 129 129 129 151 129 156 156 156 156 122 156 160 160 156 122 168 166 166 163 168 168 173 173 173 173 168 168 177 177 185 182 182|178 182 182|178 182 177 185 185 185 189 189 189 185 194 194 191 191 189 185 197 185 197 203 199 202 203 197 203 203 205 205 203 203 209 216 216 216 216 216 203 185 220 221 221 221 228 228 228 225 228 222 221 231 232 232 242 238 238|234 238 238|234 238 242 242 242 242 232 247 247 247 247 242 250 250 247 255 255|250 255 255|250 255 242 232	Association
23880023	Chemical	Gene	D008694	2902	True	0	What is [PHARMGKB] between @ChemicalSrc$ METH @/ChemicalSrc$ and @GeneTgt$ GRIN1 @/GeneTgt$ ? [SEP] Genetic variation of @GeneTgt$ GRIN1 @/GeneTgt$ confers vulnerability to @ChemicalSrc$ methamphetamine-dependent @/ChemicalSrc$ psychosis in a Thai population . @GeneTgt$ GRIN1 @/GeneTgt$ is a gene that encodes the N-methyl-d aspartate ( NMDA ) receptor subunit1 ( @GeneTgt$ NR1 @/GeneTgt$ ) . Variations of @GeneTgt$ GRIN1 @/GeneTgt$ have been identified as a risk factor for schizophrenia and drug dependence , supporting hypotheses of glutamatergic dysfunction in these disorders . @ChemicalSrc$ Methamphetamine @/ChemicalSrc$ ( @ChemicalSrc$ METH @/ChemicalSrc$ ) is a psychostimulant drug which can induce psychotic symptoms reminiscent of those found in schizophrenia ; thus @GeneTgt$ GRIN1 @/GeneTgt$ is a candidate gene for vulnerability to @ChemicalSrc$ METH @/ChemicalSrc$ dependence or @ChemicalSrc$ METH-dependent @/ChemicalSrc$ psychosis . The present study examined two polymorphisms of @GeneTgt$ GRIN1 @/GeneTgt$ , rs11146020 ( G1001C ) and rs1126442 ( G2108A ) , in 100 male Thai @ChemicalSrc$ METH-dependent @/ChemicalSrc$ patients and 103 healthy controls using PCR-RFLP techniques . Neither polymorphism was significantly associated with @ChemicalSrc$ METH @/ChemicalSrc$ dependence , although rs1126442 was highly significantly associated with @ChemicalSrc$ METH-dependent @/ChemicalSrc$ psychosis , in which the A allele showed reduced frequency ( P&lt;0.00001 ) . The present findings indicate that the rs1126442 of @GeneTgt$ GRIN1 @/GeneTgt$ contributes to the genetic vulnerability to psychosis in @ChemicalSrc$ METH-dependent @/ChemicalSrc$ subjects in the Thai population .	2 6 4 2|3 2 2|3 6 6 11 11|7 11 11|7 7 15 15 15 6 6 18|23 23 18|23 23 23 23 25 23 33 33 33 33 33 33 33 25 35 33 33 33 35 23 47 43 41|42 41 41|42 47 47 47 51 51 51 47 53 56 53 53 51 47 47 58 62 62 59 65 65 59 47 67|77 77 67|77 71 68|69 68 68|69 71 77 77 77 77 80 80 77 82 80 82 85 83 85 88 86 77 96 96|88 96 96|88 96 96 96 77 98 96 102 102|96 102 102|96 98 102 99|106 106 99|106 102 96 115 115 116 116 118 116 120 118|119 118 118|119 120 120 125 123 125 120 120 130 118 130 118 139 139 139 139 139|135 139 139|135 118 139 143 143 139 116 146 144 116 151 154 154 154 154 158 158|155 158 158|155 154 154 165 165 165 165 165 154 169 165|169 169 165|169 165 169 172 176 175 175 176 154 178 176 180 178 180 154 187 187 188 188 195 191 195 193 192|191 191 192|191 188 199 199 199 195 201 199 205 201|205 205 201|205 201 209 209 209 199 188	Association
24819158	Chemical	Gene	C098320	3586	False	2	What is [PHARMGKB] between @ChemicalSrc$ efavirenz @/ChemicalSrc$ and @GeneTgt$ interleukin-10 @/GeneTgt$ ? [SEP] @GeneTgt$ Interleukin-10 @/GeneTgt$ gene polymorphism ( -1082G/A ) and allergy to efavirenz in patients infected with human immunodeficiency virus . The aim of the present study was to investigate the association between polymorphism in the @GeneTgt$ interleukin-10 @/GeneTgt$ gene promoter at position -1082 in human immunodeficiency virus-infected patients who had presented allergic reaction due to efavirenz . The study included 63 patients treated at the Hospital Sao Jose de Doencas Infecciosas , Fortaleza , Ceara , Brazil . Twenty-one patients who had presented allergic reaction to @ChemicalSrc$ efavirenz @/ChemicalSrc$ were compared to 42 patients with no allergic reaction following exposure to this drug . Blood samples were collected for DNA extraction and submitted to the restriction fragment length polymorphism - polymerase chain reaction technique . The -1082AA genotype was significantly more frequent in allergic patients as compared to non-allergic patients ( p=0.019 ; chi(2)=5.534 ; OR=3.625 ; 95 % CI=1.210 - 10.860 ) . Likewise the allele @GeneTgt$ IL-10 @/GeneTgt$ -1082A was identified significantly more often among efavirenz allergic patients than in the non-allergic group ( p=0.009 ; chi(2)=6.787 ; OR=3.029 ; 95 % CI=1.290 - 7.111 ) . These findings suggest that the polymorphism in the @GeneTgt$ interleukin-10 @/GeneTgt$ gene promoter -1082G/A can be related to the development of allergic reactions to efavirenz .	0|4 4 0|4 4 4 6 4 6 4 4 11 9 13 9 13 18 18 18 14 4 22 27 26 26 26 22 27 29 27 31 29 33 31 39 39 39|35 39 39|35 39 33 41 33 41 47 47 46 47 41 50 50 47 52 50 55 53 52 27 59 60 60 62 60 62 71 71 71 71 71 71 71 63 71 71 73 73 75 75 60 80 90 83 83 80 85 83 87 86|85 85 86|85 90 90 93 93 90 97 97 97 93 99 97 102 102 99 90 106 108 108 108 111 111 108 108 108 124 124 124 124 124 121 121 124 124 124 113 108 128 128 132 132 132 132 132 135 135 132 137 132 140 140 137 142 144 144 132 144 144 146 149 146 149 152 150 144 132 162 157 160 157|160 160 157|160 162 162 162 165 165 162 169 169 169 165 174 174 174 174 162 176 174 176 176 178 178 180 183 180 183 186 184 176 162 191 192 192 205 195 205 201 201 197|201 201 197|201 201 202 195 205 205 192 208 208 205 211 211 208 213 211 192	Association
24858579	Chemical	Gene	D005283	4988	False	1	What is [PHARMGKB] between @ChemicalSrc$ fentanyl @/ChemicalSrc$ and @GeneTgt$ OPRM1 @/GeneTgt$ ? [SEP] Association of mu-opioid receptor gene ( @GeneTgt$ OPRM1 @/GeneTgt$ ) haplotypes with postoperative nausea and vomiting . Genetic variants , such as single-nucleotide polymorphisms ( SNPs ) , of the mu-opioid receptor gene ( @GeneTgt$ OPRM1 @/GeneTgt$ ) might be associated with individual differences in opioid sensitivity , as well as with the incidence and severity of postoperative nausea and vomiting ( PONV ) . The goal of the present study was to determine , in a cohort of Japanese surgical patients , genotypes and haplotypes of several SNPs in the @GeneTgt$ OPRM1 @/GeneTgt$ gene , and their association with PONV during the early ( first 24 h ) postoperative period . We examined the incidence and severity of PONV , during the first 24 h after surgery , in 85 Japanese patients receiving intravenous patient-controlled analgesia @ChemicalSrc$ fentanyl @/ChemicalSrc$ analgesia for postoperative pain control . Eight tag SNPs of the @GeneTgt$ OPRM1 @/GeneTgt$ gene ( rs1799971 , A/G ; rs510769 , G/A ; rs4870266 , G/A ; rs3798683 , G/A ; rs1323042 , A/C ; rs609623 , C/T ; rs9397685 , A/G ; and rs644261 , C/G ) were selected based on their minor allele frequency ( & gt;10 % ) and linkage disequilibrium strength ( & lt;80 % ) , and genotyped for haplotype analysis and determination of associations with PONV . Only one out of eight investigated SNPs , rs9397685 , in the intronic part of the @GeneTgt$ OPRM1 @/GeneTgt$ gene was associated with differences in the occurrence and severity of PONV . We also found four common haplotypes with a frequency of & gt;10 % in the investigated patients , including GGGAACAC ( 33 % ) , AGGGACAC ( 19 % ) , GGGAACGC ( 12 % ) , and AGAGACAC ( 10 % ) . The severity of PONV in carriers of the GGGAACGC haplotype was significantly lower than in the carriers of the other haplotypes ( P & lt ; 0.05 ) . One intronic SNP , rs9397685 , and haplotypes constructed from eight SNPs within the @GeneTgt$ OPRM1 @/GeneTgt$ gene locus might be involved in the severity of PONV associated with general anesthesia and opioid administration . This novel finding , if validated and verified in larger and additional ethnic cohorts , might contribute to better knowledge of the contribution of the @GeneTgt$ OPRM1 @/GeneTgt$ gene to PONV .	1 10 10 5 10 10 10|6 10 10|6 10 1 13 13 1 13 13 1 19 40 19 24 21 24 19 26 24 26 24 33 33 33 33 24 35 33|34 33 33|34 35 40 40 40 43 43 40 46 46 43 46 46 48 48 53 53 46 53 53 58 58 53 58 58 62 58 62 40 67 72 71 71 71 67 72 74 72 74 78 78 74 82 82 82 78 82 82 84 84 89 89 84 94 94 91|94 94 91|94 84 74 74 98 74 100 98 107 107 107 107 107 107 98 107 110 98 72 114 114 116 114 116 116 120 116 114 126 126 126 126 114 128 126 114 133 133 133 114 133 140 135 140 137|140 140 137|140 134 144 144 144 140 114 149 149 190 154 154 154|151 154 154|151 149 156 154 156 156 156 156 156 156 156 156 156 156 156 156 168 168 168 174 174 156 156 156 176 156 156 156 180 156 156 156 156 156 156 156 190 190 190 196 196 196 196 191 196 196 200 196 196 190 205 205 190 205 205 209 205 205 190 190 190 216 216 213 216 216 220 218 222 220 190 226 245 226 229 231 231 226 231 231 231 238 238 238 226 243 243 240|243 243 240|243 238 245 245 247 245 250 250 247 250 250 254 250 245 259 259 259 262 262 259 265 265 262 269 266 266 265 273 273 273 265 273 276 273 279 279 276 279 276 276 285 285 282 285 282 282 291 291 288 291 288 288 288 298 298 295 298 259 302 313 304 302 306 302 310 310 310 306 313 313 313 317 317 317 313 321 321 321 317 323 321 323 323 323 323 323 313 332 332 350 332 332 334 334 334 337 341 341 338 347 347 347|343 347 347|343 347 341 350 350 350 353 353 350 355 353 353 359 359 356 359 362 359 350 367 367 381 381 370 381 370 370 378 378 374 374 378 372 381 381 381 384 384 381 387 387 384 392 392 389|392 392 389|392 387 394 387 381	Association
25084201	Chemical	Gene	D008727	1719	True	0	What is [PHARMGKB] between @ChemicalSrc$ MTX @/ChemicalSrc$ and @GeneTgt$ DHFR @/GeneTgt$ ? [SEP] Polymorphisms in genes involved in the mechanism of action of @ChemicalSrc$ methotrexate @/ChemicalSrc$ : are they associated with outcome in rheumatoid arthritis patients ? BACKGROUND : @ChemicalSrc$ Methotrexate @/ChemicalSrc$ ( @ChemicalSrc$ MTX @/ChemicalSrc$ ) is the first-line treatment option for newly diagnosed rheumatoid arthritis ( RA ) patients . However , 50 - 70 % of the patients respond to treatment and 30 % suffer toxicity . AIM : To identify pharmacogenetic markers of outcome in RA patients treated with @ChemicalSrc$ MTX @/ChemicalSrc$ . PATIENTS & amp ; METHODS : We analyzed 27 genetic variants in @GeneTgt$ DHFR @/GeneTgt$ , TYMS , MTHFR , ATIC and CCND1 genes . RESULTS : We included 124 RA patients treated with @ChemicalSrc$ MTX @/ChemicalSrc$ monotherapy . In multivariate analyses two variants in the MTHFR gene were associated with response , rs17421511 ( p = 0.024 ) and rs1476413 ( p = 0.0086 ) , as well as one in the @GeneTgt$ DHFR @/GeneTgt$ gene , rs1643650 ( p = 0.026 ) . The ATIC rs16853826 variant was associated with toxicity ( p = 0.039 ) . CONCLUSION : MTHFR , @GeneTgt$ DHFR @/GeneTgt$ and ATIC genetic variants can be considered as pharmacogenetic markers of outcome in RA patients under @ChemicalSrc$ MTX @/ChemicalSrc$ monotherapy .	16 3 1 3 7 7 4 9 7 11 9|10 9 9|10 1 16 16 16 18 16 22 22 22 18 16 25 25 26|37 37 26|37 30 27|28 27 27|28 30 37 37 37 37 25 46 40 46 46 46 44 46 44 37 25 59 59 55 54 55 59 58 58 55 59 61 59 61 64 65 59 65 65 68 71 71 68 73 71 75 73 78 78 75 78 81 79|80 79 79|80 68 85 85 85 85 85 92 92 85 95 95 92 97 96|107 107 96|107 97 97 97 97 97 97 97 97 95 92 110 110 113 110 116 116 113 116 121 118|121 121 118|121 117 110 126 126 134 128 134 132 132 132 128 134 134 136 134 136 136 141 141 138 141 141 136 136 148 148 145 148 148 148 136 154 152 136 160 160 157|160 160 157|160 155 155 136 165 165 162 165 165 134 173 172 173 175 175 175 177 175 180 180 177 180 180 175 184 184 196 186 186|187 186 186|187 186 193 193 186 196 196 184 199 199 196 201 199 204 204 201 208 208|204 208 208|204 204 184	Association
25084201	Chemical	Gene	D008727	471	True	0	What is [PHARMGKB] between @ChemicalSrc$ MTX @/ChemicalSrc$ and @GeneTgt$ ATIC @/GeneTgt$ ? [SEP] Polymorphisms in genes involved in the mechanism of action of @ChemicalSrc$ methotrexate @/ChemicalSrc$ : are they associated with outcome in rheumatoid arthritis patients ? BACKGROUND : @ChemicalSrc$ Methotrexate @/ChemicalSrc$ ( @ChemicalSrc$ MTX @/ChemicalSrc$ ) is the first-line treatment option for newly diagnosed rheumatoid arthritis ( RA ) patients . However , 50 - 70 % of the patients respond to treatment and 30 % suffer toxicity . AIM : To identify pharmacogenetic markers of outcome in RA patients treated with @ChemicalSrc$ MTX @/ChemicalSrc$ . PATIENTS & amp ; METHODS : We analyzed 27 genetic variants in DHFR , TYMS , MTHFR , @GeneTgt$ ATIC @/GeneTgt$ and CCND1 genes . RESULTS : We included 124 RA patients treated with @ChemicalSrc$ MTX @/ChemicalSrc$ monotherapy . In multivariate analyses two variants in the MTHFR gene were associated with response , rs17421511 ( p = 0.024 ) and rs1476413 ( p = 0.0086 ) , as well as one in the DHFR gene , rs1643650 ( p = 0.026 ) . The @GeneTgt$ ATIC @/GeneTgt$ rs16853826 variant was associated with toxicity ( p = 0.039 ) . CONCLUSION : MTHFR , DHFR and @GeneTgt$ ATIC @/GeneTgt$ genetic variants can be considered as pharmacogenetic markers of outcome in RA patients under @ChemicalSrc$ MTX @/ChemicalSrc$ monotherapy .	16 3 1 3 7 7 4 9 7 11 9|10 9 9|10 1 16 16 16 18 16 22 22 22 18 16 25 25 26|37 37 26|37 30 27|28 27 27|28 30 37 37 37 37 25 46 40 46 46 46 44 46 44 37 25 59 59 55 54 55 59 58 58 55 59 61 59 61 64 65 59 65 65 68 71 71 68 73 71 75 73 78 78 75 78 81 79|80 79 79|80 68 85 85 85 85 85 92 92 85 95 95 92 97 107 97 97 97 97 97 102|97 97 102|97 97 97 95 92 110 110 113 110 116 116 113 116 121 118|121 121 118|121 117 110 126 126 134 128 134 132 132 132 128 134 134 136 134 136 136 141 141 138 141 141 136 136 148 148 145 148 148 148 136 154 152 136 159 159 159 155 155 136 164 164 161 164 164 134 172 168|171 171 168|171 172 174 174 174 176 174 179 179 176 179 179 174 184 184 196 186 186 186 193|189 193 193|189 193 186 196 196 184 199 199 196 201 199 204 204 201 208 208|204 208 208|204 204 184	Association
25084201	Chemical	Gene	D008727	4524	True	0	What is [PHARMGKB] between @ChemicalSrc$ MTX @/ChemicalSrc$ and @GeneTgt$ MTHFR @/GeneTgt$ ? [SEP] Polymorphisms in genes involved in the mechanism of action of @ChemicalSrc$ methotrexate @/ChemicalSrc$ : are they associated with outcome in rheumatoid arthritis patients ? BACKGROUND : @ChemicalSrc$ Methotrexate @/ChemicalSrc$ ( @ChemicalSrc$ MTX @/ChemicalSrc$ ) is the first-line treatment option for newly diagnosed rheumatoid arthritis ( RA ) patients . However , 50 - 70 % of the patients respond to treatment and 30 % suffer toxicity . AIM : To identify pharmacogenetic markers of outcome in RA patients treated with @ChemicalSrc$ MTX @/ChemicalSrc$ . PATIENTS & amp ; METHODS : We analyzed 27 genetic variants in DHFR , TYMS , @GeneTgt$ MTHFR @/GeneTgt$ , ATIC and CCND1 genes . RESULTS : We included 124 RA patients treated with @ChemicalSrc$ MTX @/ChemicalSrc$ monotherapy . In multivariate analyses two variants in the @GeneTgt$ MTHFR @/GeneTgt$ gene were associated with response , rs17421511 ( p = 0.024 ) and rs1476413 ( p = 0.0086 ) , as well as one in the DHFR gene , rs1643650 ( p = 0.026 ) . The ATIC rs16853826 variant was associated with toxicity ( p = 0.039 ) . CONCLUSION : @GeneTgt$ MTHFR @/GeneTgt$ , DHFR and ATIC genetic variants can be considered as pharmacogenetic markers of outcome in RA patients under @ChemicalSrc$ MTX @/ChemicalSrc$ monotherapy .	16 3 1 3 7 7 4 9 7 11 9|10 9 9|10 1 16 16 16 18 16 22 22 22 18 16 25 25 26|37 37 26|37 30 27|28 27 27|28 30 37 37 37 37 25 46 40 46 46 46 44 46 44 37 25 59 59 55 54 55 59 58 58 55 59 61 59 61 64 65 59 65 65 68 71 71 68 73 71 75 73 78 78 75 78 81 79|80 79 79|80 68 85 85 85 85 85 92 92 85 95 95 92 97 107 97 97 97 100|97 97 100|97 97 97 97 97 95 92 110 110 113 110 116 116 113 116 121 118|121 121 118|121 117 110 126 126 135 128 135 133 133 133|130 133 133|130 128 135 135 137 135 137 137 142 142 139 142 142 137 137 149 149 146 149 149 149 137 155 153 137 160 160 160 156 156 137 165 165 162 165 165 135 173 172 173 175 175 175 177 175 180 180 177 180 180 175 184 184 185|196 196 185|196 186 186 186 193 193 186 196 196 184 199 199 196 201 199 204 204 201 208 208|204 208 208|204 204 184	Association
25182707	Chemical	Gene	D000077157	3791	True	0	What is [PHARMGKB] between @ChemicalSrc$ sorafenib @/ChemicalSrc$ and @GeneTgt$ KDR @/GeneTgt$ ? [SEP] The relationship of @GeneTgt$ kinase insert domain receptor @/GeneTgt$ gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with @ChemicalSrc$ sorafenib @/ChemicalSrc$ . @GeneTgt$ Kinase insert domain receptor @/GeneTgt$ ( @GeneTgt$ KDR @/GeneTgt$ ) is the principal receptor that promotes the pro-angiogenic action of vascular endothelial growth factor and has been the principal target of anti-angiogenic therapies . Our aim was to determine whether single-nucleotide polymorphisms ( SNPs ) in @GeneTgt$ KDR @/GeneTgt$ gene are associated with clinical outcomes after first-line @ChemicalSrc$ sorafenib @/ChemicalSrc$ therapy in advanced hepatocellular carcinoma ( HCC ) . The SNPs in @GeneTgt$ KDR @/GeneTgt$ were tested in 78 advanced HCC patients receiving first-line @ChemicalSrc$ sorafenib @/ChemicalSrc$ . Correlations with clinicopathological features and survival were analyzed . Patients with AA genotype of rs1870377 and AA genotype of rs2305948 were significantly associated with a better response and longer time to progression ( TTP ) ( 5.8 vs 4.0 months , P=0.001 ; 5.8 vs 4.5 months , P=0.016 , respectively ) . Patients harboring AA genotype in rs1870377 and TT/TC genotype in rs2071559 had a longer overall survival ( OS ) ( 15.0 vs 9.6 months , P=0.001 ; 13.0 vs 9.0 months , P=0.007 , respectively ) . At multivariate analysis , major vascular invasion and rs1870377 were independent factors in TTP and performance status , rs1870377 , and rs2071559 were independent factors in OS . Our results suggest that SNPs in @GeneTgt$ KDR @/GeneTgt$ gene can predict clinical outcome in advanced HCC patients receiving first-line @ChemicalSrc$ sorafenib @/ChemicalSrc$ .	2 2 10 10|3 10|3 10|3 10|3 10 10|3 10 2 10 13 10 18 18 18 18 10 18 21 16|19 19 16|19 2 25|26|38 25|26|38 25|26|38 25|26|38 26|38 25|26|38 32 26|27 26 26|27 32 38 38 38 38 40 38 43 43 40 48 48 48 48 43 40 54 54 54 54 40 57 57 54 38 62 65 65 65 65 77 68 77 70 68 70 75 72|75 75 72|75 68 77 65 80 80 77 85 85 85|81 85 85|81 77 89 89 89 85 91 89 91 65 97 102 99 97|98 97 97|98 102 102 107 107 107 107 102 107 110 108 108 108 102 122 118 118 115 118 118 122 122 122 137 127 127 124 129 127 129 129 129 134 132 137 137 137 141 141 141 137 141 144 141 146 141 148 146 148 154 154 151 151 141 156 154 156 161 158 158 156 156 156 156 156 154 137 179 168 171 169 173 171 173 176 173 178 176 179 183 182 183 179 185 183 185 191 191 188 188 183 191 191 193 198 195 195 193 200 191 200 200 179 179 207 207 216 216 211 211 216 211 211 216 216 216 218 216 218 221 218 218 218 218 216 229 229 229 216 231 229 229 234 235 235 243 243 241 241|238 241 241|238 237 243 235 245 243 249 249 249 245 249 252 250 250 250 235	Association
25755212	Chemical	Gene	C545203	1080	True	0	What is [PHARMGKB] between @ChemicalSrc$ ivacaftor @/ChemicalSrc$ and @GeneTgt$ CFTR @/GeneTgt$ ? [SEP] Efficacy response in CF patients treated with @ChemicalSrc$ ivacaftor @/ChemicalSrc$ : post-hoc analysis . Clinical studies in patients with cystic fibrosis and @GeneTgt$ G551D-CFTR @/GeneTgt$ showed that the group treated with @ChemicalSrc$ ivacaftor @/ChemicalSrc$ had improved clinical outcomes . To better understand the effect of @ChemicalSrc$ ivacaftor @/ChemicalSrc$ therapy across the distribution of individual FEV(1 ) responses , data from Phase 3 studies ( STRIVE/ENVISION ) were re-examined . In this post-hoc analysis of patients ( n = 209 ) who received 48 weeks of @ChemicalSrc$ ivacaftor @/ChemicalSrc$ or placebo , patients were assigned to tertiles according to FEV(1 ) response . These groups were then used to evaluate response ( FEV(1 ) , sweat chloride , weight , CFQ-R , and pulmonary exacerbation ) . The number needed to treat ( NNT ) was calculated for specific thresholds for each outcome . Across all tertiles , numerical improvements in FEV(1 ) , sweat chloride , CFQ-R and the frequency of pulmonary exacerbations were observed in @ChemicalSrc$ ivacaftor-treated @/ChemicalSrc$ patients : the treatment difference versus placebo was statistically significant for all outcomes in the upper tertile and for some outcomes in the lower and middle tertiles . The NNT for a & gt;= 5 % improvement in % predicted FEV(1 ) was 1.90 , for a & gt;= 5 % body weight increase was 5.74 , and to prevent a pulmonary exacerbation was 3.85 . This analysis suggests that the majority of patients with clinical characteristics similar to STRIVE/ENVISION patients have the potential to benefit from @ChemicalSrc$ ivacaftor @/ChemicalSrc$ therapy .	2 2 5 5 2 5 8 6|7 6 6|7 2 12 2 2 16 25 18 16 21 21 18 21 22|21 21 22|21 25 34 28 34 28 31 29 29 29 34 25 36 34 25 42 42 67 44 42 48 48|45 48 48|45 44 51 51 44 54 54 51 54 51 56 67 62 62 62 58 64 62 64 67 67 67 73 73 73 93 75 73 77 75 77 78 77 82 75 84 82 86 85|84 84 85|84 86 86 93 93 93 93 95 93 98 96 100 100 95 93 104 107 107 107 107 109 107 109 112 110 112 110 116 110 116 116 118 118 120 120 124 116 110 107 128 136 128 131 129 133 131 133 136 136 139 139 136 142 142 139 136 146 146 165 165 149 165 151 149 151 149 155 149 155 155 155 160 155 163 163 160 165 165 169 169|166 169 169|166 165 165 173 173 178 173 173 178 178 165 181 181 178 185 185 185 181 178 189 189 178 195 195 195 192 192 189 165 199 213 206 206 201 201 205 206 199 208 206 210 208 210 213 213 213 223 223 218 216 220 223 223 223 213 225 213 213 213 229 213 232 232 229 234 213 213 237 238 238 251 241 251 243 241 246 246 243 246 250 250 247 238 253 251 255 253 259 259|256 259 259|256 255 238	Association
26111150	Chemical	Gene	D017257	154	True	0	What is [PHARMGKB] between @ChemicalSrc$ ramipril @/ChemicalSrc$ and @GeneTgt$ ADRB2 @/GeneTgt$ ? [SEP] Association of the @GeneTgt$ ADRB2 @/GeneTgt$ ( rs2053044 ) polymorphism and angiotensin-converting enzyme-inhibitor blood pressure response in the African American Study of Kidney Disease and Hypertension . AIM/OBJECTIVES/BACKGROUND : Hypertension is a risk factor for cardiovascular and kidney disease and is most prevalent in African-American adults . The renin-angiotensin-aldosterone system is integral in blood pressure regulation ; angiotensin-converting enzyme inhibitors such as @ChemicalSrc$ ramipril @/ChemicalSrc$ are first-line treatment options . As decreases in angiotensin result in catecholamine release , beta-adrenergic receptor ( ADRB ) polymorphisms may influence blood pressure response to @ChemicalSrc$ ramipril @/ChemicalSrc$ . METHODS : Associations between ADRB polymorphisms and blood pressure response to @ChemicalSrc$ ramipril @/ChemicalSrc$ were analyzed in the African American Study of Kidney Disease and Hypertension , a randomized clinical trial . A total of 336 participants were included in this analysis . Six polymorphisms were analyzed here : ( a ) ADRB1 rs1801252 ( Ser49Gly ) and rs1801253 ( Gly389Arg ) ; and ( b ) @GeneTgt$ ADRB2 @/GeneTgt$ rs2053044 , rs1042711 , rs1042713 ( Arg16Gly ) , and rs1042714 ( Gln27Glu ) . Time to reach a mean arterial pressure ( MAP ) of 107 mmHg within the first 60 days after randomization was studied using Kaplan-Meier and Cox proportional hazards modeling for univariate and adjusted analyses . RESULTS : Genotypes at rs2053044 , upstream from the @GeneTgt$ ADRB2 @/GeneTgt$ 5 ' untranslated region , were associated with time to reach target MAP among those randomized to the usual treatment group . Participants with the GG genotype achieved target MAP on average 12.2 days ( 38.1 % ) later than in comparison with those with the A allele ( P=0.01 ) . After adjusting for covariates , those with the AA/AG genotype had 2.09 greater odds of reaching MAP of 107 mmHg or less within 60 days of treatment in comparison with those with a GG genotype ( hazard ratio=2.09 , 95 % confidence interval=1.21 - 3.60 ) . CONCLUSION : Results suggest that @GeneTgt$ ADRB2 @/GeneTgt$ rs2053044 genotypes may be a determinant of blood pressure response to @ChemicalSrc$ ramipril @/ChemicalSrc$ . Additional studies are needed to clarify the effect of rs2053044 and other 5 ' untranslated region polymorphisms on gene expression and blood pressure response to angiotensin-converting enzyme inhibitors .	1 9 9 9|3 9 9|3 7 4 7 1 1 15 15 15 15 1 20 20 20 20 15 23 23 20 23 23 1 28 34 34 34 34 34 28 36 34 36 39 36 34 43 43 34 46 46 43 34 50 50 52 52 52 56 56 56 52 52 60 60 68 63 61 60|62 60 60|62 68 68 68 52 52 72 87 75 75 72 78 78 75 87 85 85 83 85 83 87 87 87 90 90 87 92 90|91 90 90|91 87 110 110 110 101 101 98 101 105 105 101 107 105|106 105 105|106 110 110 115 115 115 115 110 118 118 115 118 118 115 125 125 125 115 110 129 134 132 132 129 134 134 137 137 134 134 140 142 142 142 142 142 146 149 149 149 142 151 149 151 149 149 156 154 156 149 149 161 163 163 162|149 149 162|149 149 149 149 167 149 171 169 171 149 149 149 177 175 177 142 202 183 181 187 187 187 183 189 187 189 193 193 187 198 198 198 198 199 200 183 202 202 202 203 204 204 208 203 208 211 209 211 211 211 202 216 216 233 220 218 218 218 230 230 224|230 230 224|230 230 230 230 222 218 233 216 235 233 237 233 239 237 241 237 241 247 247 247 247 242 216 255 254 254 254 250 255 257 255 261 261 261 255 264 264 261 264 255 269 269 255 271 269 275 275 275 271 277 275 277 255 281 290 283 281 290 290 289 289 289 285 290 293 293 290 295 304 295 299 299 296 295 295 304 304 293 306 304 308 293 310 308 314 314 314 310 317 317 314 317 320 324 322 320 322 317 317 290 330 330 330 330 339 334|331 334 334|331 335 339 339 339 339 330 343 343 343 339 345 343 343 343 330 351 353 353 353 355 353 357 355 359 357 359 366 366 366 366 366 359 369 369 357 369 373 373 369 377 377 377 369 353	Association
26141406	Chemical	Gene	D015742	1555	True	0	What is [PHARMGKB] between @ChemicalSrc$ propofol @/ChemicalSrc$ and @GeneTgt$ CYP2B6 @/GeneTgt$ ? [SEP] Impact of the @GeneTgt$ Cytochrome P450 2B6 @/GeneTgt$ ( @GeneTgt$ CYP2B6 @/GeneTgt$ ) Gene Polymorphism c.516G&gt;T ( rs3745274 ) on @ChemicalSrc$ Propofol @/ChemicalSrc$ Dose Variability . BACKGROUND AND OBJECTIVES : @ChemicalSrc$ Propofol @/ChemicalSrc$ is the most commonly used hypnotic worldwide , but its effective dose varies greatly between individuals . The present study sought to investigate the relationship between the c.516G&gt;T polymorphism in the @GeneTgt$ CYP2B6 @/GeneTgt$ ( @GeneTgt$ cytochrome P450 2B6 @/GeneTgt$ ) gene and the required @ChemicalSrc$ propofol @/ChemicalSrc$ dose . METHODS : One hundred and eight patients treated with @ChemicalSrc$ propofol @/ChemicalSrc$ were recruited , and environmental , clinical and surgical data were collected . Genotyping for the c.516G&gt;T polymorphism was performed by real-time PCR . Multiple linear regression analysis was performed to estimate the predictive variables of the total @ChemicalSrc$ propofol @/ChemicalSrc$ dose . RESULTS : For patients under general anaesthesia , the predictive variables of the total @ChemicalSrc$ propofol @/ChemicalSrc$ dose were surgery duration ( partial R ( 2 ) = 19.9 % ) , age ( partial R ( 2 ) = 10.5 % ) , weight ( partial R ( 2 ) = 10.1 % ) and presence of the T allele ( partial R ( 2 ) = 6.8 % ) . From the estimated coefficient of regression values , the surgery duration and weight were the factors that increased the @ChemicalSrc$ propofol @/ChemicalSrc$ dose , while age and presence of the T allele decreased the total dose of the drug needed . The total @ChemicalSrc$ propofol @/ChemicalSrc$ doses based on the GG or GT/TT genotypes were 151.5 + - 64.2 mg and 129.3 + - 44.6 mg , respectively ( p = 0.043 ) . CONCLUSIONS : Our results indicate that 34 % of the variance in the required @ChemicalSrc$ propofol @/ChemicalSrc$ dose may be explained by these factors and that @GeneTgt$ CYP2B6 @/GeneTgt$ c.516G&gt;T polymorphism , which decreases the metabolism of the drug , accounts for approximately 7 % of the drug dosage . Our results show the possible influence of @GeneTgt$ CYP2B6 @/GeneTgt$ c.516G&gt;T genetic variant on @ChemicalSrc$ propofol @/ChemicalSrc$ dose in patients under general anaesthesia .	1 13 13 3|13 3|13 3|13 13 3|13 9 13|5 13 13|5 9 13 1 1 16 14 16 22 14|22 22 14|22 22 1 1 45 27 27 39 30|39 39 30|39 39 39 36 37 39 39 27 39 39 44 44 45 45 45 48 45 45 53 53 54 54 56 54 58 56 62 62 62 58 73 73 64|73 73 64|73 73 66|73 66|73 66|73 73 66|73 73 62 62 79 79 79|72 79 79|72 62 54 96 96 87 90 87 87 96 90 93 91|92 91 91|92 96 96 96 96 96 99 99 101 101 106 106 96 106 115 113 113 113 109 115 115 118 118 115 115 123 123 123 125 125 125 127 125 130 130 127 136 136 136 136|133 136 136|133 130 125 139 139 142 158 145 145 142 158 149 149 158 155 155 155 155|152 155 155|152 149 158 158 139 161 161 194 163 161 163 161 167 165 165 161 161 173 173 161 175 173 175 173 179 177 177 173 173 185 185 173 185 185 187 185 191 189 189 173 139 198 198 198 194 201 201 198 203 201 203 201 207 205 201 139 214 214 214 226 217 217 214 217 221 221 217 221 221 226 226 226 228 226 232 229|232 232 229|232 228 228 242 242 235 235 241 241 241 235 228 245 245 242 248 248 245 248 226 256 256 253|256 256 253|256 265 256 260 260 257 260 260 260 265 265 265 265 269 265 269 265 271 274 271 265 275 280 280 280 265 280 265 265 285 285 288 289 285 304 292 304 295 295 292 301 301 301 301|298 301 301|298 295 304 304 289 307 307 304 304 323 308|313 313 308|313 313 323 313 316 313 318 316 321 321 318 313 304 327 326 327 323 331 331 331 327 285 336 337 337 340 340 337 346 346|341 346 346|341 346 346 340 350 350|346 350 350|346 346 352 346 355 355 352 337	Association
26401715	Chemical	Gene	D008687	3553	True	0	What is [PHARMGKB] between @ChemicalSrc$ metformin @/ChemicalSrc$ and @GeneTgt$ IL1B @/GeneTgt$ ? [SEP] @GeneTgt$ IL-1B @/GeneTgt$ rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowing efficacy of @ChemicalSrc$ metformin @/ChemicalSrc$ in Chinese overweight or obese Type 2 diabetes mellitus patients . AIM : To investigate the potential genetic effect on @ChemicalSrc$ metformin @/ChemicalSrc$ efficacy in overweight or obese Chinese Type 2 diabetes mellitus ( T2DM ) patients . PATIENTS & amp ; METHODS : 768 SNPs in or close to 207 genes were genotyped in 84 patients treated with @ChemicalSrc$ metformin @/ChemicalSrc$ + glibenclamide/Xiaoke Pill . Significant SNPs were then verified in 107 recent-onset overweight or obese T2DM patients treated with @ChemicalSrc$ metformin @/ChemicalSrc$ alone . Genotyping was done by Illumina GoldenGate Assay . RESULTS : In the discovery stage , 22 SNPs were nominally significant . @GeneTgt$ IL1B @/GeneTgt$ rs1143623 ( p = 0.011 ) and EEF1A1P11-RPL7P9 rs10783050 ( p = 0.021 ) were still significantly associated with the relative change of HbA1c in the replication stage . CONCLUSION : @GeneTgt$ IL1B @/GeneTgt$ rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms may contribute to @ChemicalSrc$ metformin @/ChemicalSrc$ 's glucose-lowing efficacy in overweight or obese Chinese T2DM patients .	0|3 3 0|3 8 3 6 7 8 8 11 11 8 13 11 11 11 17 17 13 17 17 24 24 24 24 17 8 31 31 31 31 35 35 35 31 39 36|39 39 36|39 35 41 35 41 41 48 48 48 48 52 50 52 52 41 31 55 55 55 55 55 59 62 70 68 63 67 67 68 62 70 55 73 73 70 73 76 74|75 74 74|75 76 80 76 70 84 87 87 87 87 91 91 91 87 91 91 95 91 95 98 96|97 96 96|97 98 87 105 105 105 109 109 109 105 105 111 111 116 116 116 122 122 119 122 122 122 111 122 123|126 126 123|126 143 129 129 126 129 129 126 134 126 137 137 134 137 137 143 143 143 143 147 147 147 143 149 147 153 153 153 147 143 156 156 157|160 160 157|160 166 160 163 164 160 166 156 172 172|166 172 172|166 168 172 166 174 179 174 174 179 179 172 156	Association
26876050	Chemical	Gene	D003024	2904	True	0	What is [PHARMGKB] between @ChemicalSrc$ clozapine @/ChemicalSrc$ and @GeneTgt$ GRIN2B @/GeneTgt$ ? [SEP] Genetic association analysis of N-methyl-D-aspartate receptor subunit gene @GeneTgt$ GRIN2B @/GeneTgt$ and clinical response to @ChemicalSrc$ clozapine @/ChemicalSrc$ . OBJECTIVE : Approximately 30 % of patients with schizophrenia fail to respond to antipsychotic therapy and are classified as having treatment-resistant schizophrenia . @ChemicalSrc$ Clozapine @/ChemicalSrc$ is the most efficacious drug for treatment-resistant schizophrenia and may deliver superior therapeutic effects partly by modulating glutamate neurotransmission . Response to @ChemicalSrc$ clozapine @/ChemicalSrc$ is highly variable and may depend on genetic factors as indicated by twin studies . We investigated eight polymorphisms in the N-methyl-D-aspartate glutamate receptor subunit gene @GeneTgt$ GRIN2B @/GeneTgt$ with response to @ChemicalSrc$ clozapine @/ChemicalSrc$ . METHODS : @GeneTgt$ GRIN2B @/GeneTgt$ variants were genotyped using standard TaqMan procedures in 175 European patients with schizophrenia deemed resistant or intolerant to treatment . Response was assessed using change in Brief Psychiatric Rating Scale scores following six months of @ChemicalSrc$ clozapine @/ChemicalSrc$ therapy . Categorical and continuous response was assessed using chi-squared test and analysis of covariance , respectively . RESULTS : No associations were observed between the variants and response to @ChemicalSrc$ clozapine @/ChemicalSrc$ . A-allele carriers of rs1072388 responded marginally better to @ChemicalSrc$ clozapine @/ChemicalSrc$ therapy than GG-homozygotes ; however , the difference was not statistically significant ( p = 0.067 , uncorrected ) . CONCLUSIONS : Our findings do not support a role for these @GeneTgt$ GRIN2B @/GeneTgt$ variants in altering response to @ChemicalSrc$ clozapine @/ChemicalSrc$ in our sample . Investigation of additional glutamate variants in @ChemicalSrc$ clozapine @/ChemicalSrc$ response is warranted .	3 3 3 9 9 9 9 9 8|3 3 8|3 9 13 9 15 13 13 13 3 29 20 23 24 29 26 24 28 26 29 31 29 34 34 31 29 37 29 39 37 41 39 29 42|49 49 42|49 49 49 48 49 49 52 52 49 49 55 49 58 58 55 61 61 55 63 61 49 72 68 66|67 66 66|67 72 72 72 72 75 72 78 78 75 80 75 83 83 80 72 87 87 89 87 97 97 97 97 97 97 97 96|89 89 96|89 100 87 102 100 100 100 87 113 113 108|111 111 108|111 113 113 113 113 117 117 114 121 121 121 117 123 121 113 124 125 125 129 125 113 134 134 134 134 135 142 142 141 141 142 136 145 145 135 149 149|146 149 149|146 145 134 155 152 152 157 157 157 157 160 158 160 160 164 162 158 158 157 168 168 171 173 173 168 176 176 173 176 176 180 178|179 178 178|179 168 185 188 187 185 188 190 188 194 191|194 194 191|194 190 196 188 188 205 205 201 205 205 205 205 188 208 208 205 208 209 208 208 188 215 215 218 221 221 221 215 223 221 228 228 225|228 228 225|228 223 230 221 230 233 231 231 231 237 237 231 215 251 245 245 245 241 249 249|246 249 249|246 241 251 251 251	Association
27261537	Chemical	Gene	D000069604	5243	True	0	What is [PHARMGKB] between @ChemicalSrc$ dabigatran @/ChemicalSrc$ and @GeneTgt$ ABCB1 @/GeneTgt$ ? [SEP] Pharmacogenetics of @ChemicalSrc$ dabigatran etexilate @/ChemicalSrc$ interindividual variability . INTRODUCTION : @ChemicalSrc$ Dabigatran etexilate @/ChemicalSrc$ is given in fixed doses without coagulation monitoring for the prevention of blood clots in at risk adults . A high inter-individual variability in blood concentrations of the active metabolite of @ChemicalSrc$ dabigatran @/ChemicalSrc$ has been reported . @GeneTgt$ ABCB1 @/GeneTgt$ and CES1 exert an important effect in the metabolism of @ChemicalSrc$ dabigatran etexilate @/ChemicalSrc$ and allele variants at these two loci are likely to play a pivotal role . To investigate whether screening for polymorphisms within the @GeneTgt$ ABCB1 @/GeneTgt$ and the CES1 genes would explain a portion of the inter-individual variability in blood concentrations of the active metabolite of @ChemicalSrc$ dabigatran @/ChemicalSrc$ . MATERIAL AND METHODS : In a cohort of patients who had atrial fibrillation and on anticoagulant prophylaxis with @ChemicalSrc$ dabigatran etexilate @/ChemicalSrc$ , we investigated whether genotypes at rs4148738 ( @GeneTgt$ ABCB1 @/GeneTgt$ ) , rs8192935 ( CES1 ) , and rs2244613 ( CES1 ) loci would affect plasma @ChemicalSrc$ dabigatran @/ChemicalSrc$ trough and peak concentrations . RESULTS AND DISCUSSION : Among 92 patients ( median age : 72.0years , range : 52 - 92 ) analyzed , no clinical variable or genotype was associated with a significant difference in @ChemicalSrc$ dabigatran @/ChemicalSrc$ peak concentrations . As for trough concentrations , in addition to creatinine clearance , and sex a significant association with the CES1 SNP rs8192935 ( p=0.023 ) was detected . The mean adjusted plasma levels were higher among patients with the CC genotype ( 86.3ng/dl ) than in those carrying the T allele ( 62.1ng/dl ) . No significant effect was found for the @GeneTgt$ ABCB1 @/GeneTgt$ SNP rs4148738 . The CES1 SNP rs8192935 significantly influenced the @ChemicalSrc$ dabigatran @/ChemicalSrc$ trough concentrations and carriers of the T allele showed significantly lower concentrations than did carriers of the CC genotype .	1 7 2|7 2|7 7 2|7 7 1 1 16 16 11|12|16 11|12|16 12|16 11|12|16 16 16 19 19 16 22 22 16 25 25 22 28 28 25 32 32 32 25 16 38 38 38 51 41 41 38 45 45 45 41 47 45|46 45 45|46 51 51 51 51 53|58 58 53|58 54 54 58 61 61 58 64 64 58 66 64|66 64|66 64|66 64|66 66 66 66 75 75 75 71 77 58 79 77 82 82 79 58 87 87 89 87 91 89 94 94 93|91 91 93|91 91 99 99 91 101 87 103 101 107 107 107 103 110 110 107 114 114 114 110 116 114 114 114 87 144 121 121 144 127 127 144 129 127 131 129 133 131 129 137 137 129 139 137|138|139 137|138|139 137|139 137|138|139 144 144 144 166 166 148 146 150 147|148 148 147|148 150 148 148 156 154 156 148 148 148 162 160 164 146 166 144 170 170|164 170 170|164 166 170 170 170 144 197 178 178 178 184 184 191 187 187 184 187 184 189 178 191 195 195 191 195 205 197 201 201 205 201 201 205 205 209 209 209 205 214 210|214 214 210|214 214 209 205 232 220 220 217 217 223 217 226 226 223 217 217 217 232 232 242 237 237 237 237 232 239 237 239 242 242 242 245 248 248 248 250 250 250 252 250 256 256 256 252 258 256 258 262 262 250 262 266 266 263 268 266 268 250 273 273 275 275 275 281 281 281|277 281 281|277 281 275 275 286 286 287 289 289 289 294 294|290 294 294|290 294 289 294 294 300 300 300 296 289 303 304 301 306 304 306 311 311 311 307 289	Association
27498158	Chemical	Gene	D010984	2067	True	0	What is [PHARMGKB] between @ChemicalSrc$ platinum @/ChemicalSrc$ and @GeneTgt$ ERCC1 @/GeneTgt$ ? [SEP] Pharmacogenetic predictors of toxicity to @ChemicalSrc$ platinum @/ChemicalSrc$ based chemotherapy in non-small cell lung cancer patients . @ChemicalSrc$ Platinum-based @/ChemicalSrc$ chemotherapy is the standard treatment for NSCLC patients with EGFR wild-type , and as alternative to failure to EGFR inhibitors . However , this treatment is aggressive and most patients experience grade 3 - 4 toxicities . @GeneTgt$ ERCC1 @/GeneTgt$ , ERCC2 , ERCC5 , XRCC1 , MDM2 , ABCB1 , MTHFR , MTR , SLC19A1 , IL6 and IL16 gene polymorphisms may contribute to individual variation in toxicity to chemotherapy . The aim of this study was to evaluate the effect of these polymorphisms on @ChemicalSrc$ platinum-based @/ChemicalSrc$ chemotherapy in NSCLC patients . A prospective cohorts study was conducted , including 141 NSCLC patients . Polymorphisms were analyzed by PCR Real-Time with Taqman ( ) probes and sequencing . Patients with @GeneTgt$ ERCC1 @/GeneTgt$ C118T-T allele ( p=0.00345 ; RR=26.05 ; CI95%=4.33 , 515.77 ) and ERCC2 rs50872-CC genotype ( p=0.00291 ; RR=4.06 ; CI95%=1.66 , 10.65 ) had higher risk of general toxicity for @ChemicalSrc$ platinum-based @/ChemicalSrc$ chemotherapy . ERCC2 Asp312Asn G-alelle , ABCB1 C1236T-TT and the IL1B rs12621220-CT/TT genotypes conferred a higher risk to present multiple adverse events . The subtype toxicity analysis also revealed that ERCC2 rs50872-CC genotype ( p=0.01562 ; OR=3.23 ; CI95%=1.29 , 8.82 ) and IL16 rs7170924-T allele ( p=0.01007 ; OR=3.19 ; CI95%=1.35 , 7.97 ) were associated with grade 3 - 4 hematological toxicity . We did not found the influence of @GeneTgt$ ERCC1 @/GeneTgt$ C8092A , ERCC2 Lys751Gln , ERCC2 Asp312Asn , ERCC5 Asp1104His , XRCC1 Arg194Trp , MDM2 rs1690924 , ABCB1 C3435 T , ABCB1 Ala893Ser/Thr , MTHFR A1298C , MTHFR C677 T , IL1B rs1143623 , IL1B rs16944 , and IL1B rs1143627 on platinum-based chemotherapy toxicity . In conclusion , @GeneTgt$ ERCC1 @/GeneTgt$ C118 T , ERCC2 rs50872 , ERCC2 Asp312Asn , ABCB1 C1236 T , IL1B rs12621220 and IL16 rs7170924 polymorphisms may substantially act as prognostic factors in NSCLC patients treated with @ChemicalSrc$ platinum-based @/ChemicalSrc$ chemotherapy .	2 2 4 2 9 8|5 8 8|5 9 4 15 15 15 15 15 9 2 17|20 20 17|20 24 24 24 24 24 27 27 24 30 30 24 24 24 34 24 36 34 39 39 34 24 47 47 45 47 47 47 47 47 51 47 51 55 55 56 51 47 57|83 83 57|83 58 58 58 58 58 58 58 58 67 67 67 67 67 67 67 67 67 67 58 80 81 58 83 83 86 86 83 88 86 90 88 83 94 98 97 97 94 98 100 98 102 100 105 105 102 109 109|106 109 109|106 102 112 112 109 98 118 118 118 120 120 120 120 125 125 125 120 120 129 129 129 132 132 129 134 132 137 137 134 137 137 129 169 146 142|146 146 142|146 146 141 148 146 148 148 148 148 152 152 152 148 158 159 148 161 148 161 161 161 161 165 161 161 169 171 169 174 174 171 178 174|178 178 174|178 174 169 184 184 193 184 187 184 184 192 192 190 184 193 196 196 193 198 196 201 201 198 193 206 206 206 208 208 208 236 211 212 236 214 212 214 220 216 220 220 214 214 212 225 225 212 227 225 227 227 229 227 233 212 233 236 208 238 243 238 241 239 243 236 208 248 248 248 248 250 248 254 254|251 254 254|251 250 254 257 254 254 260 254 254 263 254 254 266 254 254 269 254 254 273 273 254 254 276 254 276 279 254 254 283 283 254 254 286 254 254 289 254 254 254 293 254 297 297 297 250 248 301 326 326 302|306 306 302|306 306 326 306 309 306 306 312 306 306 316 316 306 306 319 306 306 323 323 306 326 326 326 329 329 326 332 332 329 332 337 333|337 337 333|337 333 326	Association
27738808	Chemical	Gene	D003630	873	False	4	What is [PHARMGKB] between @ChemicalSrc$ Daunorubicin @/ChemicalSrc$ and @GeneTgt$ CBR1 @/GeneTgt$ ? [SEP] Population pharmacokinetics of @ChemicalSrc$ Daunorubicin @/ChemicalSrc$ in adult patients with acute myeloid leukemia . PURPOSE : Chemotherapy drug resistance and relapse of the disease have been the major factors limiting the success of acute myeloid leukemia ( AML ) therapy . Several factors , including the pharmacokinetics ( PK ) of Cytarabine ( Ara-C ) and @ChemicalSrc$ Daunorubicin @/ChemicalSrc$ ( Dnr ) , could contribute to difference in treatment outcome in AML . METHODS : In the present study , we evaluated the plasma PK of Dnr , the influence of genetic polymorphisms of genes involved in transport and metabolism of Dnr on the PK , and also the influence of these factors on clinical outcome . Plasma levels of Dnr and its major metabolite , Daunorubicinol ( DOL ) , were available in 70 adult de novo AML patients . PK parameters ( Area under curve ( AUC ) and clearance ( CL ) ) of Dnr and DOL were calculated using nonlinear mixed-effects modeling analysis performed with Monolix . Genetic variants in ABCB1 , ABCG2 , @GeneTgt$ CBR1 @/GeneTgt$ , and CBR3 genes as well as RNA expression of @GeneTgt$ CBR1 @/GeneTgt$ , ABCB1 , and ABCG2 were compared with Dnr PK parameters . RESULTS : The AUC and CL of Dnr and DOL showed wide inter-individual variation . Patients with an exon1 variant of rs25678 in @GeneTgt$ CBR1 @/GeneTgt$ had significantly higher plasma Dnr AUC [ p = 0.05 ] compared to patients with wild type . Patients who achieved complete remission ( CR ) had significantly lower plasma Dnr AUC , Cmax , and higher CL compared to patients who did not achieve CR . CONCLUSION : Further validation of these findings in a larger cohort of AML patients is warranted before establishing a therapeutic window for plasma Dnr levels and targeted dose adjustment .	2 2 4 2|3 2 2|3 8 8 2 12 12 12 8 2 15 15 19 19 15 19 19 24 24 21 29 29 29 29 19 29 32 30 40 40 40 40 40 40 40 32 15 43 64 43 47 47 43 49 47 49 52 47 54 52 54 52 52|56 52 52|56 60 57 60 43 64 64 66 64 69 69 66 71 69 64 82 82 79 79 79 82 82 82 82 85 85 82 87 85 85 90 85 93 93 90 95 93 95 98 96 98 98 102 98 105 105 98 85 82 110 110 82 113 113 110 116 116 110 82 119 133 121 119 121 125 125 121 125 125 129 127 129 121 133 133 140 140 140 140 137 140 133 133 143 162 145 143 147 145 149 147 149 147 147 154 152 154 154 158 152 158 158 162 162 162 165 167 167 163 167 170 168 162 173 199 175 173 175 175 175 175|178 175 175|178 175 175 175 175 175 185 185 189 175 191 189 189 189 191 191 191 191 191 199 199 203 203 203 199 199 217 207 210 217 210 210 214 210 214 214 217 220 220 217 217 232 226 226 226 222 228 226 230 229|226 226 229|226 232 234 237 237 237 232 240 240 237 240 240 232 245 243 248 248 245 232 259 253 251 255 253 257 255 257 259 261 264 264 264 259 264 264 266 264 270 264 259 273 271 277 277 277 273 277 259 280 280 283 295 286 286 283 290 290 290 283 293 293 290 295 280 297 295 300 300 297 304 304 304 300 297 297 308 306 295	Association
27779245	Chemical	Gene	D007980	1813	True	0	What is [PHARMGKB] between @ChemicalSrc$ levodopa @/ChemicalSrc$ and @GeneTgt$ DRD2 @/GeneTgt$ ? [SEP] Association between @GeneTgt$ DRD2 @/GeneTgt$ and DRD3 gene polymorphisms and gastrointestinal symptoms induced by @ChemicalSrc$ levodopa @/ChemicalSrc$ therapy in Parkinson 's disease . @ChemicalSrc$ Levodopa @/ChemicalSrc$ is the most used drug to treat motor symptoms in Parkinson 's disease ( PD ) . However , dopaminergic side effects such as nausea and vomiting may occur . Several evidences indicate a major role for @GeneTgt$ dopamine receptors D2 @/GeneTgt$ ( @GeneTgt$ DRD2 @/GeneTgt$ ) and D3 ( DRD3 ) in emetic activity . The aim of this study was to investigate the relationship of @GeneTgt$ DRD2 @/GeneTgt$ rs1799732 and DRD3 rs6280 gene polymorphisms with gastrointestinal ( GI ) symptoms induced by @ChemicalSrc$ levodopa @/ChemicalSrc$ in PD patients . Two hundred and seventeen PD patients on @ChemicalSrc$ levodopa @/ChemicalSrc$ therapy were investigated . @GeneTgt$ DRD2 @/GeneTgt$ rs1799732 and DRD3 rs6280 polymorphisms were genotyped by PCR-based methods . Multiple Poisson regression method with robust variance estimators was performed to assess the association between polymorphisms and gastrointestinal symptoms . The analyses showed that @GeneTgt$ DRD2 @/GeneTgt$ Ins/Ins ( prevalence ratio (PR)=2.374 , 95 % confidence interval ( CI ): 1.105 - 5.100 ; P=0.027 ) and DRD3 Ser/Ser genotypes ( PR=1.677 , 95 % CI 1.077 - 2.611 ; P=0.022 ) were independent and predictors of gastrointestinal symptoms associated with @ChemicalSrc$ levodopa @/ChemicalSrc$ therapy . Despite all the efforts to alleviate GI symptoms , this adverse effect still occurs in PD patients . Pharmacogenetic studies of GI symptoms induced by @ChemicalSrc$ levodopa @/ChemicalSrc$ therapy have the potential to display new ways to better understand the molecular mechanisms involved in these side effects .	1 3 1|2 1 1|2 3 3 8 3 3 11 3 1 16 16|12 16 16|12 12 20 20 18 16 1 23|30 30 23|30 30 30 29 30 30 32 30 34 32 38 38 36 34 40 38 40 30 55 55 48 48 55 51 49 48 51 51 55 55 55 58 59 59 62 62 59 64 64|62|63 64|62|63 64|62|63 64|62 64|62|63 69 64|65 64 64|65 69 64 75 75 64 75 79 79 62 59 84 88 87 87 84 88 90 88 92 90 96 93|96 96 93|96 92 96 99 101 101 96 107 107 105 103 105 101 107 110 108 108 108 114 114 110 88 119 123 119 119 123 129 127 127|124 127 127|124 123 129 129 129 131|134 134 131|134 140 134 137 138 140 140 140 143 143 140 140 147 149 149 155 153 153 153 149 155 155 157 155 159 157 161 159 161 164 161 155 167 168 168 208 169|172 172 169|172 208 175 175 172 175 181 181 181 181 172 183 181 183 187 187 183 183 183 189 183 194 194 183 196 194 196 199 196 199 199 201 199 196 196 196 208 168 208 208 213 213 210 213 218 214|218 218 214|218 214 168 225 225 225 235 227 225 229 227 235 233 233 235 235 235 238 238 235 235 241 250 244 244 241 244 249 249|246 249 249|246 245 250 252 250 254 252 256 254 259 259 256 262 262 259 262 267 267 267 263 250	Association
28117434	Chemical	Gene	D000077210	28234	False	1	What is [PHARMGKB] between @ChemicalSrc$ sunitinib @/ChemicalSrc$ and @GeneTgt$ SLCO1B3 @/GeneTgt$ ? [SEP] Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with @ChemicalSrc$ sunitinib @/ChemicalSrc$ . This study aimed to identify single-nucleotide polymorphisms ( SNPs ) that are associated with outcome to treatment with @ChemicalSrc$ sunitinib @/ChemicalSrc$ in patients with advanced gastrointestinal stromal tumors ( GIST ) . Forty-nine SNPS involved in the pharmacokinetic and pharmacodynamic pathway of @ChemicalSrc$ sunitinib @/ChemicalSrc$ were associated with progression-free survival ( PFS ) and overall survival ( OS ) in 127 patients with advanced GIST who have been treated with @ChemicalSrc$ sunitinib @/ChemicalSrc$ . PFS was significantly longer in carriers of the TT genotype in POR rs1056878 ( hazards ratio ( HR ) 4.310 , 95 % confidence interval (CI):1.457 - 12.746 , P=0.008 ) . The presence of the T-allele in @GeneTgt$ SLCO1B3 @/GeneTgt$ rs4149117 ( HR 2.024 , 95 % CI:1.013 - 4.044 , P=0.046 ) , the CCC-CCC alleles in SLC22A5 haplotype ( HR 2.603 , 95 % CI : 1.216 - 5.573 , P=0.014 ) , and the GC-GC alleles in the IL4 R haplotype ( HR 7.131 , 95 % CI:1.518 - 33.496 , P=0.013 ) were predictive for OS . This shows that polymorphisms in the pharmacokinetic and pharmacodynamic pathways of @ChemicalSrc$ sunitinib @/ChemicalSrc$ are associated with survival in GIST . This may help to identify patients that benefit more from treatment with @ChemicalSrc$ sunitinib @/ChemicalSrc$ .	2 2 5 5 2 7 5 9 7 13 13 13 9 13 16 14|15 14 14|15 2 21 22 22 24 22 26 24 28 26 28 32 32 26 34 32 36 34 38 36|37 36 36|37 41 36 46 46 46 46 41 48 46 48 22 53 65 53 60 60 60 57 57 54 62 60|61 60 60|61 65 65 68 68 65 70 68 70 68 74 68 76 74 76 80 80 74 83 83 80 87 87 87 80 89 87 87 87 65 97 97 97 97 99 97 103 103 103 99 106 106 103 109 109 106 111 109 111 109 113 118 118 118 106 118 119 119 123 118 106 97 127 191 130 130 127 132 127|131 127 127|131 132 136 132 136 136 140 136 143 143 140 136 136 136 132 150 150 132 153 153 150 155 160 155 155 159 155 127 160 166 162 162 164 160 166 160 127 172 172 127 177 177 177 177 172 179 177 179 179 183 179 179 186 184 179 179 179 191 191 193 191 191 197 197 210 210 205 205 205 202 202 199 207 205|206 205 205|206 210 197 212 210 214 212 197 219 219 219 221 219 221 224 222 224 227 224 229 227|228 227 227|228 219	Association
28289864	Chemical	Gene	D000077157	9429	True	0	What is [PHARMGKB] between @ChemicalSrc$ sorafenib @/ChemicalSrc$ and @GeneTgt$ ABCG2 @/GeneTgt$ ? [SEP] Correlation between clinical response to @ChemicalSrc$ sorafenib @/ChemicalSrc$ in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein ( ABCB1 ) and of @GeneTgt$ breast cancer resistance protein @/GeneTgt$ ( @GeneTgt$ ABCG2 @/GeneTgt$ ): monocentric study . OBJECTIVES : We studied the relation between the polymorphism of P-glycoprotein ( P-gp ) and of @GeneTgt$ breast cancer resistance protein @/GeneTgt$ ( @GeneTgt$ BCRP @/GeneTgt$ ) , encoded by ABCB1 and @GeneTgt$ ABCG2 @/GeneTgt$ genes , respectively , and the pharmacokinetic variability and clinical response during the treatment with @ChemicalSrc$ sorafenib @/ChemicalSrc$ of hepatocellular carcinoma . METHODS : At the Paul Brousse Hospital in Villejuif , France , 47 consecutive patients with advanced HCC treated with a single agent @ChemicalSrc$ sorafenib @/ChemicalSrc$ , were enrolled . @ChemicalSrc$ Sorafenib @/ChemicalSrc$ exposure was measured by its plasma concentration 3 h after oral administration of 400 mg ( bid ) by liquid chromatography . All enrolled patients were genotyped for ABCB1 ( rs2032582 ; rs1045642 ) and @GeneTgt$ ABCG2 @/GeneTgt$ ( rs2231137 ; rs2231142 ; rs2622604 ) by blood genomic DNA extraction and Mass ARRAY genotyping . The clinical response was evaluated after 3months of treatment according to the RECIST criteria . KEY FINDINGS : Significant associations between @ChemicalSrc$ sorafenib @/ChemicalSrc$ exposure and the studied polymorphisms were observed for ABCB1 3435C&gt;T , @GeneTgt$ ABCG2 @/GeneTgt$ 34G&gt;A , @GeneTgt$ ABCG2 @/GeneTgt$ 1143C&gt;T and @GeneTgt$ ABCG2 @/GeneTgt$ 421C&gt;A , but not for ABCB1 2677G&gt;TA SNP . In heterozygous patients for ABCB1 3435 C&gt;T , @GeneTgt$ ABCG2 @/GeneTgt$ 34 G&gt;A and @GeneTgt$ ABCG2 @/GeneTgt$ 1143 C&gt;T polymorphisms were significantly associated with the lowest @ChemicalSrc$ sorafenib @/ChemicalSrc$ plasma levels . Those patients presented a tendency to have the best clinical evolution . CONCLUSION : Heterozygous forms of the studied polymorphisms could be associated with a better therapeutic response .	1 4 4 1 6 4|5 4 4|5 11 11 11 4 11 11 15 13 17 15 17 15 27 27|19 27|19 27|19 27|19 27 27|19 27 21|31 31 21|31 31 31 1 1 39 39 39 39 41 39 44 44 41 46 44 48 46 48 46 52 51|52|46 51|52|46 51|52|46 51|52|46 52|46 51|52|46 58 52|53 52 52|53 58 52 52 64 62 64 60|64 64 60|64 64 68 62 52 44 75 75 44 75 78 75 81 81 75 83 76|81 81 76|81 87 87 83 39 120 107 99 99 98 99 107 101 99 99 99 103 107 107 120 110 110 107 107 116 116 116 116 111|115 111 111|115 107 120 120 120 122|125 125 122|125 127 127 127 133 133 133 133 133 127 136 136 127 141 139 141 141 136 141 145 145 136 127 149 149 152 152 149 154 152 156 154 156 156 158 156 156|160 156 156|160 164 161 164 164 164 164 168 174 174 174 174 152 174 177 178 174 149 183 183 185 185 185 187 185 189 187 194 190 194 194 189 185 197 210 210 200 210 204 204|201 204 204|201 200 204 208 208 204 210 210 212 210 212 212 212|213 212 212|213 215 212 212|216 212 212|216 219 212 219|212 212 219|212 212 212 228 230 230 232 232 212 210 240 240 258 242 244 244 240 244 245|249 249 245|249 249 244 244 255|249 255 255|249 254 255 258 258 258 258 265 265 265 265|259 265 265|259 265 258 258 271 272 272 274 272 276 274 280 280 278 276 272 282 282 285 292 289 289 289 285 292 292 282 297 297 296 297 292 292	Association
28430711	Chemical	Gene	D000077210	3791	True	0	What is [PHARMGKB] between @ChemicalSrc$ sunitinib @/ChemicalSrc$ and @GeneTgt$ VEGFR @/GeneTgt$ ? [SEP] Evaluation of @GeneTgt$ KDR @/GeneTgt$ rs34231037 as a predictor of @ChemicalSrc$ sunitinib @/ChemicalSrc$ efficacy in patients with metastatic renal cell carcinoma . The identification of biomarkers able to predict clinical benefit from @GeneTgt$ vascular endothelial growth factor receptor @/GeneTgt$ ( @GeneTgt$ VEGFR @/GeneTgt$ ) tyrosine kinase inhibitors is urgently needed . Recently , Maitland and colleagues described an association between @GeneTgt$ KDR-rs34231037 @/GeneTgt$ and soluble @GeneTgt$ VEGFR2 @/GeneTgt$ levels as well as pazopanib pharmacodynamics . We investigated in a well-characterized series of metastatic clear cell renal cell carcinoma patients whether rs34231037 could influence @ChemicalSrc$ sunitinib @/ChemicalSrc$ response . Clinical data and DNA were available from an international series of 276 patients . @GeneTgt$ KDR-rs34231037 @/GeneTgt$ association with @ChemicalSrc$ sunitinib @/ChemicalSrc$ response , clinical benefit , and progression-free survival was analyzed using logistic and Cox regression analyses . We found that G-allele carriers were over-represented among patients with clinical benefit during @ChemicalSrc$ sunitinib @/ChemicalSrc$ treatment compared with those refractory to the treatment ( odds ratio : 3.78 ; 95 % confidence interval : 1.02 - 14.06 ; P=0.047 , multivariable analysis ) . In conclusion , rs34231037 variant carriers seemed to have better @ChemicalSrc$ sunitinib @/ChemicalSrc$ response than wild-type patients . Moreover , the association with tumor size reduction suggests that this single nucleotide polymorphism might also identify patients with successful tumor downsizing under @GeneTgt$ anti-VEGFR @/GeneTgt$ therapy .	1 5 2|5 5 2|5 1 8 8 1 12 8|12 12 8|12 8 14 12 19 19 19 19 14 1 24 27 26 24 27 29 27 31 29 45 32|33|45 32|33|45 32|33|45 32|33|45 32|33|45 33|45 32|33|45 40 34|45 45 34|45 45 45 45 31 48 48 27 27 57 57 57 54 54 57 59 57 61 59|60 59 59|60 61 61 67|63 67 67|63 61 61 68 68 72 61 57 77 77 81 81 81 77 89 89 89 89 89 89 89 81 93 93 93 77 93|96 96 93|96 93 77 100 104 100 100 104 104 108 108 108 104 111 111 108 104 112|115 115 112|115 128 119 115|119 119 115|119 115 119 122 119 119 119 126 119 128 128 128 129 130 130 134 130 128 139 139 144 142 144 144 139 146 144 149 149 146 153 153|150 153 153|150 144 144 156 154 156 160 160 157 163 163 156 163 163 165 170 170 170 165 170 174 174 170 174 179 179 179 144 179 139 184 189 189 188 188 189 189 191 189 195 192|195 195 192|195 191 198 198 195 189 209 209 204 209 208 208 208 204 209 217 214 214 214 217 217 217 209 217 222 222 222 218 226 226|223 226 226|223 222 209	Association
29210328	Chemical	Gene	D008727	1719	False	1	What is [PHARMGKB] between @ChemicalSrc$ methotrexate @/ChemicalSrc$ and @GeneTgt$ DHFR @/GeneTgt$ ? [SEP] DNA variants in @GeneTgt$ DHFR @/GeneTgt$ gene and response to treatment in children with childhood B ALL : revisited in AIEOP-BFM protocol . AIM : We have previously reported an association of @GeneTgt$ dihydrofolate reductase @/GeneTgt$ promoter polymorphisms with reduced event-free survival in childhood acute lymphoblastic leukemia ( ALL ) patients treated with Dana Farber Cancer Institute protocol . Here , we assessed whether these associations are applicable to other protocol , based on different @ChemicalSrc$ methotrexate @/ChemicalSrc$ doses . METHODS : Genotypes for six tag polymorphisms and resulting haplotypes were analyzed for an association with ALL outcome . RESULTS : The association was found with the polymorphisms A-680C , A-317 G and C-35 T in high-risk group patients . Carriers of haplotype * 1 had a remarkably higher risk of events compared with noncarriers and a lower probability of event-free survival ( 21.4 vs 81.3 % ) . CONCLUSION : The role of @GeneTgt$ DHFR @/GeneTgt$ variants in predicting the outcome of childhood ALL extends beyond single-treatment protocol and can be useful biomarker in personalizing treatment .	2 2 6 3|6 6 3|6 2 6 6 10 8 12 10 16 16 16 12 2 2 21 21 18 2 29 29 29 29 29 29 31 29 37 32|37 32|37 37 32|37 37 31 41 41 41 31 50 50 50 50 50 48 50 48 41 50 57 54 56 56 57 51 29 63 63 63 63 68 66 68 68 63 71 71 68 68 78 78 78 75|78 78 75|78 68 63 92 92 92 87 87 87 83 87 90 83 92 92 95 95 92 98 98 95 92 100 100 103 105 105 100 108 108 105 108 108 112 108 112 112 112 119 119 119 108 100 126 123 121 125 123 126 130 129 130 126 132 130 126 135 133 135 139 139 135 142 142 139 147 147 144 144 142 147 126 150 150 153 165 157 157|154 157 157|154 153 159 153 161 159 164 164 161 150 168 168 165 165 173 173 173 165 176 176 173 165	Association
29938344	Chemical	Gene	D004317	1557	False	1	What is [PHARMGKB] between @ChemicalSrc$ doxorubicin @/ChemicalSrc$ and @GeneTgt$ CYP2C19 @/GeneTgt$ ? [SEP] Association of @GeneTgt$ CYP2C19 @/GeneTgt$ * 2 and ALDH1A1 * 1/*2 variants with disease outcome in breast cancer patients : results of a global screening array . PURPOSE : Cyclophosphamide and @ChemicalSrc$ doxorubicin @/ChemicalSrc$ ( adjuvant chemotherapy ) are commonly used to treat breast cancer patients . Variation in the genes involved in pharmacodynamics and pharmacokinetics of these drugs plays an important role in prediction of drug response and survival . The present study was carried out with an aim to evaluate the variation in all the genes involved in pharmacokinetic and pharmacodynamics pathways of cyclophosphamide and @ChemicalSrc$ doxorubicin @/ChemicalSrc$ , and correlate specific variants with disease outcome in breast cancer patients from the Malwa region of Punjab . METHODS : A total of 250 confirmed breast cancer patients were involved in the study . Genotyping was performed on an Illumina Infinium HD assay platform using a Global Screening Array ( GSA ) microchip . GenomeStudio ( Illumina , Inc. ) was used for data preprocessing and a p value less than or equal to 5 x 10 - 8 was considered statistically significant . To rule out the influence of confounding risk factors , a step-wise multivariate regression analysis was carried out to evaluate the association of genotype with overall clinical outcome . RESULTS : Two gene variants , @GeneTgt$ CYP2C19 @/GeneTgt$ ( G681A ) and ALDH1A1 * 2 ( 17 bp deletion ) , were found to be significantly associated with the disease outcome , including overall survival , recurrence and metastasis , in breast cancer patients on adjuvant therapy . Both these genes are involved in the pharmacokinetics of cyclophosphamide . However , none of the variants in the genes involved in pharmacokinetics and pharmacodynamics of @ChemicalSrc$ doxorubicin @/ChemicalSrc$ were found to have any significant impact on disease outcome in the studied group . CONCLUSION : @GeneTgt$ CYP2C19 @/GeneTgt$ ( G681A ) variant and ALDH1A1 * 2 emerged as two important biomarkers associated with bad outcome in breast cancer patients on adjuvant therapy .	1 3 1|2 1 1|2 3 3 3 3 1 11 1 14 14 11 18 18 18 14 1 1 25 25 25 25 20 1 28 28 40 30 30|31 30 30|31 36 36 32 36 40 40 28 42 40 45 45 42 28 60 51 51 48 51 54 52 54 54 59 59 56 60 63 63 60 65 60 68 68 65 68 68 60 74 74 76 76 76 76 80 80 76 82 80 84 82 88 88 88 84 88 91 89 91 91 91 96 94 96 96|97 96 96|97 76 76 76 104 102 107 107 104 111 111 111 107 115 115 115 111 117 115 76 126 126 123 126 125 123 126 129 129 126 131 126 134 134 131 126 138 138 138 145 145 145 145 145 145 138 145 154 154 150 154 154 154 154 146 138 163 160 160 160 156 160 163 163 166 166 163 166 170 170 166 163 171 171 176 176 171 176 176 180 182 182 163 184 182 163 187 202 187 190 187 192 190 194 192 202 200 200 200 200 202 202 202 202 205 202 207 205 209 207 213 213 213 207 202 237 215 219 219 215 219 233|220 233 233|220 224 221 224 221 221 227 233 233 232 233 219 219 215 237 237 241 241 241 237 245 245 245 241 245 249 249 245 249 249 251 251 249 258 258 258 249 261 261 258 237 266 266 268 268 268 271 271 268 273 271 268 293 293 293 280 280 277 283 283 280 283 286 284 286 286 290 286|289 286 286|289 293 293 295 293 298 298 295 301 301 298 305 305 305 301 293 320 308 315|309 315 315|309 313 315 315 308 315 315 308 320 320 324 324 324 320 324 328 328 325 332 332 332 328 335 335 332 320	Association
30489455	Chemical	Gene	D016559	8856	False	1	What is [PHARMGKB] between @ChemicalSrc$ TAC @/ChemicalSrc$ and @GeneTgt$ NR1I2 @/GeneTgt$ ? [SEP] Effect of @ChemicalSrc$ tacrolimus @/ChemicalSrc$ dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation . BACKGROUND : CYP3A4/5 and P-glycoprotein ( P-gp , ABCB1 ) affect @ChemicalSrc$ tacrolimus @/ChemicalSrc$ ( @ChemicalSrc$ TAC @/ChemicalSrc$ ) exposure in T cells and kidney cells . Genetic variability of these genes has been widely studied for effects on acute rejection and kidney function after transplantation , but findings remain contradictory . In addition , cytochrome P450 reductase ( POR ) is important for CYP3A4/5 activity , and the @GeneTgt$ pregnane X receptor @/GeneTgt$ ( @GeneTgt$ NR1I2 @/GeneTgt$ ) regulates CYP3A4/5 and P-gp expression . However , the relationship between POR and @GeneTgt$ NR1I2 @/GeneTgt$ genetics and acute rejection and kidney function has not been extensively investigated . OBJECTIVE : The aim of this study was to investigate the effect of ABCB1 ( 61A > G , 1199G > A , 1236C > T , 2677G > T , 3435C > T ) , CYP3A4 * 22 , CYP3A5 * 3 , @GeneTgt$ NR1I2 @/GeneTgt$ ( 8055C > T , 63396C > T ) and POR*28 genotypes/haplotypes on acute rejection and kidney function in the first 3 months after transplant . PARTICIPANTS AND METHODS : The study included 165 kidney transplant recipients , who received @ChemicalSrc$ TAC @/ChemicalSrc$ , mycophenolate and prednisolone , and 129 donors . @ChemicalSrc$ TAC @/ChemicalSrc$ dose was adjusted to target trough blood concentrations of 8 - 15 ng/ml by therapeutic drug monitoring . Recipient and donor genotype/haplotype differences in acute rejection incidence within the first 2 weeks after transplant were assessed by logistic regression , adjusting for induction therapy , human leucocyte antigen mismatches , kidney transplant number , peak panel-reactive antibodies and donor type . Recipient and donor genotype/haplotype differences in estimated glomerular filtration rate in the first 3 months after transplant were assessed by linear mixed effects analysis , adjusting for acute rejection , delayed graft function and donor type . RESULTS : No genetic factors significantly affected acute rejection or estimated glomerular filtration rate after correction for multiple comparisons ( P>0.004 ) . CONCLUSION : Recipient and donor dispositional genetics had no significant effect on short-term clinical outcomes in kidney transplant patients receiving @ChemicalSrc$ TAC @/ChemicalSrc$ therapeutic drug monitoring .	1 6 2|6 6 2|6 6 1 9 9 1 14 14 14 14 1 1 1 19 19 16 24 24 24 24 19 27 27 19 1 30 30 40 32 32 36 34 38 36 36 30 47|40 47 47|40 44 41|42 41 41|42 44 40 50 50 47 50 53 50 30 58 65 61 61 58 65 65 65 65 67 65 70 70 67 70 73 70 75 73 65 65 79 65 79 79 83 92 92 87 87 92 89 87 89 92 92 95 95 92 92 92 99 98|99|107 98|99|107 98|99|107 99|107 98|99|107 104 99|100 99 99|100 104 92 107 108 108 108 92 135 135 118 135 120 118 120 120|121 120 120|121 120 120 127 120 127 130 127 135 135 135 135 135 135 138 138 141 145 144 144 141 138 147 145 149 147 151 155 153 155 155 149 155 159 159 155 159 159 163 161 163 167 167 163 171 171 171 163 171 159 159 174 174 159 159 178 178 159 181|159 159 181|159 185 182 187 185 191 191 191 185 191 185 185 185 198 198 185 198 201 198 206 206 206 206 185 208 185 145 211 211 211 211 216 217 211 221 221 221 217 221 224 221 224 224 224 221 221 228 228 221 221 234 221 217 236|239 239 236|239 241 241 241 246 246 246 246 241 251 250 250 251 246 255 255 255 241 241 258 258 258 258 258 266 266 266 262 271 271 271 271 266 275 275 275 258 278 278 275 275 275 283 283 280 258 288 288 288 258 258 292 292 258 258 258 296 258 296 299 296 258 319 301 301 301 301 310 310 310 310 305 315 315 315 315 310 317 301 319 319 324 324 321 324 319 319 319 329 329 326 319 333 333 319 333 336 333 319 338 338 342 342 344 344 338 346 344 344 344 351 351 348 353 348 356 356 353 358 356 358 338 368 361 368 363 363 367 363 368 371 371 368 375 375 375 368 379 379 379 375 379 385|380 385 385|380 385 385 380 368	Association
30967597	Chemical	Gene	C056516	1588	False	1	What is [PHARMGKB] between @ChemicalSrc$ exemestane @/ChemicalSrc$ and @GeneTgt$ CYP19A1 @/GeneTgt$ ? [SEP] Prognostic impact of genetic variants of @GeneTgt$ CYP19A1 @/GeneTgt$ and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer . Polymorphisms of genes involved in estrogen synthesis have been linked to breast cancer risk , prognosis , and treatment response . We investigated the prognostic impact of a deletion spanning the entire UGT2B17 gene ( UGT2B17 * 2 ) and genetic variants of the aromatase @GeneTgt$ CYP19A1 @/GeneTgt$ and estrogen receptor alpha ( ESR1 ) in 125 postmenopausal women with ER-positive breast cancer enrolled in a randomized pre-surgical trial . The UGT2B17 * 2 was estimated by copy number variation assays and the @GeneTgt$ CYP19A1 @/GeneTgt$ rs10046/rs4646 and ESR1 rs2077647/rs2234693/rs9340799 by TaqMan allelic discrimination assays . Serum @ChemicalSrc$ exemestane/17-hydroxy @/ChemicalSrc$ exemestane were determined by MS and estrone (E1)/estradiol (E2)/ by GC-MS/MS . The association of genetic polymorphisms with " any event " was assessed by the Cox proportional hazards models adjusted for confounders . The UGT2B17 * 2 was associated with higher levels of 17-hydroxy exemestane ( P = 0.04 ) and better prognosis ( HR = 0.45 ; 95 % CI : 0.20 - 1.01 ; P = 0.05 ) compared with homozygote UGT2B17 wt . The @GeneTgt$ CYP19A1 @/GeneTgt$ rs10046 A and rs4646 C alleles were associated with higher estrogen levels : rs10046 AA vs. AG/GG genotypes had median E1 of 35.9 vs. 27.4 pg/mL ( P = 0.05 ) and E2 of 7.57 vs. 3.9 pg/mL ( P & lt ; 0.004 ) . After a median follow-up of 7 years , women carrying the " low estrogen " alleles rs10046 G and rs4646 A had a better prognosis compared with homozygote wt for both polymorphisms ( HR = 0.40 ; 95 % CI : 0.17 - 0.93 ; P = 0.03 ) . Our analysis points to an impact of UGT2B17 and @GeneTgt$ CYP19A1 @/GeneTgt$ in postmenopausal endocrine responsive breast cancer . Carriers of UGT2B17 * 2 and @GeneTgt$ CYP19A1 @/GeneTgt$ low estrogen variants may have better prognosis , supporting studies addressing the role of these polymorphisms in optimizing endocrine therapy . Trial registration : http://www.isrctn.com/ISRCTN86894592 .	2 2 5 5 2 7 5|6 5 5|6 7 7 14 14 14 2 19 19 19 19 14 2 31 24 22 24 28 28 25 31 31 31 35 34 35 31 35 35 35 35 41 35 31 44 44 47 47 44 50 50 47 50 55 55 55 51 57 55 57 57 57 55 63 55 67 67 67 66|63 63 66|63 67 72 72 67 74 72 74 79 79 79 51 83 83 83 79 47 89 89 89 89 84 44 93 97 93 93 97 97 102 102 102 102 97 102 107 107|104 107 107|104 102 107 107 102 115 115 115 115 97 97 121 118|121 121 118|121 123 123 123 125 123 125 125 125 123 131 123 123 135 145 138 138 135 142 142 142 135 142 145 145 151 151 149 151 151 145 151 154 152 145 157 161 157 157 161 161 164 164 161 167 167 164 169 167 169 170 170 167 175 167 177 175 177 178 178 182 183 161 183 187 185 190 190 190 183 190 190 161 195 193 197 195 161 203 199|203 203 199|203 203 209 203 203 207 209 209 209 213 213 213 209 209 216 220 219 219 216 209 222 220 227 227 224 224 222 230 230 227 230 230 222 222 236 239 236 239 234 241 239 241 241 245 241 245 220 252 252 252 270 255 255 252 270 270 257 264 264 264 264 264 258 266 264 266 269 266 270 273 273 270 270 277 277 274 280 280 277 282 277 282 283 283 287 288 282 282 282 292 290 295 295 282 295 282 270 301 301 301 304 304 301 306 304 306 306|307 306 306|307 315 315 315 315 315 304 301 330 320 318 320 318 318 328|323 328 328|323 328 328 318 330 330 332 330 330 335 330 335 338 336 341 341 338 343 336 345 343 330 349 349 349 349 349	Association
31940240	Chemical	Gene	D003932	4986	False	1	What is [PHARMGKB] between @ChemicalSrc$ Heroin @/ChemicalSrc$ and @GeneTgt$ OPRK1 @/GeneTgt$ ? [SEP] kappa Opioid Receptor 1 Single Nucleotide Polymorphisms were Associated with the Methadone Dosage . Background : @ChemicalSrc$ Heroin @/ChemicalSrc$ use disorder ( HUD ) is a complex brain disease that includes multiple phenotypes . @ChemicalSrc$ Heroin @/ChemicalSrc$ acts primarily as a mu-opioid receptor ( OPRM1 ) agonist . The kappa opioid receptor 1 ( @GeneTgt$ OPRK1 @/GeneTgt$ ) is critically involved in abstinence and remission . Multiple studies confirm that the OPRM1 and @GeneTgt$ OPRK1 @/GeneTgt$ genes are associated with HUD . However , their relationship with the addictive phenotype is still unclear . This study was designed to identify the genetic polymorphisms within OPRM1 and @GeneTgt$ OPRK1 @/GeneTgt$ with six HUD phenotypes . Methods : A total of 801 patients with HUD were recruited from the Methadone Maintenance Treatment Program in Xi'an . We identified eight potential functional single nucleotide polymorphisms ( SNPs ) in the two genes that were genotyped using SNaPshot SNP technology . We then performed a case-control association analysis , investigated particular disease phenotypes , and assessed the extent of epistasis among the variants of the two genes . Results : The @GeneTgt$ OPRK1 @/GeneTgt$ rs3802279 , rs3802281 , and rs963549 genotypes were significantly associated with methadone dosage analyzed by Pearson 's chi-square test or binary logistic regression to correct for covariates . The rs3802279 CC , rs3802281 TT , and rs963549 CC genotype carriers required a lower methadone maintenance dose per day . Multifactor dimensionality reduction analysis indicated strong interactions between sex and @GeneTgt$ OPRK1 @/GeneTgt$ rs963549 . The results of the OPRM1 genotyping did not reveal any associations with the various HUD phenotypes . Conclusion : These findings support an important role of the @GeneTgt$ OPRK1 @/GeneTgt$ polymorphism in determining the daily methadone dose and may guide future studies in identifying additional genetic risk factors for HUD .	7 7 7 7 7 7 9 9 9 13 13 13 9 9 28 15 16|19 19 16|19 20 15 22 20 22 28 28 28 28 28 30 28 32 30 28 34|37 37 34|37 37 37 46 46 42 46 44 42 44 37 37 52 52 52 60 52 55 52|54 52 52|54 55 60 60 60 62 60 62 62 60 68 69 69 78 72 78 72 72|73 72 72|73 72 78 69 80 78 69 93 93 86 93 90 90 90 86 93 93 93 93 96 98 98 98 100 98 103 103 100 105 103 105 105|106 105 105|106 112 112 112 100 98 115 115 118 125 121 121 118 123 121 125 115 131 131 130 130 131 125 133 131 125 136 136 142 142 142 142 142 136 144 142 144 149 149 149 142 152 152 149 152 156 156 153 136 160 160 160 164 164 164 160 164 160 169 169 166 160 160 160 174 172 176 174 179 179 174 183 183 183 179 160 185 185 188 187|199 199 187|199 188 190 190 190 188 196 199 199 199 185 202 202 199 202 208 208 205 208 203 208 212 212 208 214 203 216 214 199 221 221 231 221 224 221 224 221 230 230 230 231 231 236 236 236 236 231 238 231 231 241 243 243 244 244 246 244 248 246 248 248|249 248 248|249 248 244 256 263 260 260 260 256 263 263 263 265 263 270 270 270 270 265 263 272 276 275 276 272 279 279 276 284 284 281|284 284 281|284 279 286 276 290 290 290 286 276 293 276 295 293 297 293 301 301 301 297 303 301 272	Association
31940240	Chemical	Gene	D008691	4986	True	0	What is [PHARMGKB] between @ChemicalSrc$ methadone @/ChemicalSrc$ and @GeneTgt$ OPRK1 @/GeneTgt$ ? [SEP] kappa Opioid Receptor 1 Single Nucleotide Polymorphisms were Associated with the @ChemicalSrc$ Methadone @/ChemicalSrc$ Dosage . Background : Heroin use disorder ( HUD ) is a complex brain disease that includes multiple phenotypes . Heroin acts primarily as a mu-opioid receptor ( OPRM1 ) agonist . The kappa opioid receptor 1 ( @GeneTgt$ OPRK1 @/GeneTgt$ ) is critically involved in abstinence and remission . Multiple studies confirm that the OPRM1 and @GeneTgt$ OPRK1 @/GeneTgt$ genes are associated with HUD . However , their relationship with the addictive phenotype is still unclear . This study was designed to identify the genetic polymorphisms within OPRM1 and @GeneTgt$ OPRK1 @/GeneTgt$ with six HUD phenotypes . Methods : A total of 801 patients with HUD were recruited from the @ChemicalSrc$ Methadone @/ChemicalSrc$ Maintenance Treatment Program in Xi'an . We identified eight potential functional single nucleotide polymorphisms ( SNPs ) in the two genes that were genotyped using SNaPshot SNP technology . We then performed a case-control association analysis , investigated particular disease phenotypes , and assessed the extent of epistasis among the variants of the two genes . Results : The @GeneTgt$ OPRK1 @/GeneTgt$ rs3802279 , rs3802281 , and rs963549 genotypes were significantly associated with @ChemicalSrc$ methadone @/ChemicalSrc$ dosage analyzed by Pearson 's chi-square test or binary logistic regression to correct for covariates . The rs3802279 CC , rs3802281 TT , and rs963549 CC genotype carriers required a lower @ChemicalSrc$ methadone @/ChemicalSrc$ maintenance dose per day . Multifactor dimensionality reduction analysis indicated strong interactions between sex and @GeneTgt$ OPRK1 @/GeneTgt$ rs963549 . The results of the OPRM1 genotyping did not reveal any associations with the various HUD phenotypes . Conclusion : These findings support an important role of the @GeneTgt$ OPRK1 @/GeneTgt$ polymorphism in determining the daily @ChemicalSrc$ methadone @/ChemicalSrc$ dose and may guide future studies in identifying additional genetic risk factors for HUD .	7 7 7 7 7 7 9 9 9 14 14 11|14 14 11|14 9 9 29 17 20 21 17 23 21 23 29 29 29 29 29 31 29 33 31 29 36 36 36 45 45 41 45 43 41 43 36 36 50 50 50 58 50 53 50|52 50 50|52 53 58 58 58 60 58 60 60 58 66 67 67 76 70 76 70 70|71 70 70|71 70 76 67 78 76 67 91 91 84 91 88 88 88 84 91 91 91 91 94 96 96 96 98 96 101 101 98 103 101 103 103|104 103 103|104 110 110 110 98 96 113 113 116 123 119 119 116 121 119 123 113 130 130 129|125 129 129|125 129 130 123 132 130 123 136 136 142 142 142 142 142 136 144 142 144 149 149 149 142 152 152 149 152 156 156 153 136 160 160 160 164 164 164 160 164 160 169 169 166 160 160 160 174 172 176 174 179 179 174 183 183 183 179 160 185 185 188 187|199 199 187|199 188 190 190 190 188 196 199 199 199 185 203 203|199 203 203|199 199 203 209 209 206 209 204 209 213 213 209 215 204 217 215 199 223 223 233 223 226 223 226 223 232 232 232 233 233 239 239 239|235 239 239|235 239 233 241 233 233 245 247 247 248 248 250 248 252 250 252 252|253 252 252|253 252 248 260 267 264 264 264 260 267 267 267 269 267 274 274 274 274 269 267 276 280 279 280 276 283 283 280 288 288 285|288 288 285|288 283 290 280 295 295 291|295 295 291|295 290 280 298 280 300 298 302 298 306 306 306 302 308 306 276	Association
32308134	Chemical	Gene	D000068900	2740	False	1	What is [PHARMGKB] between @ChemicalSrc$ sitagliptin @/ChemicalSrc$ and @GeneTgt$ GLP1R @/GeneTgt$ ? [SEP] Genetic variants associated with glycaemic response to treatment with dipeptidylpeptidase 4 inhibitors . Aim : We examined associations of eight SNPs in/near seven candidate genes with glycaemic response to 6 month treatment with DPP4 inhibitors . Patients & methods : 206 patients with type 2 diabetes ( 116 men and 90 women ) were treated with @ChemicalSrc$ sitagliptin @/ChemicalSrc$ or vildagliptin ( both 100 mg/day ) in combination with metformin or metformin/sulphonylurea over 6 months , and the reduction in glycated haemoglobin ( HbA1c ) was measured . Results : Rs6923761 in @GeneTgt$ GLP1R @/GeneTgt$ was significantly associated with a reduction in HbA1c ( adjusted p = 0.006 ) . Homozygotes for the minor A allele had smaller reduction in HbA1c by 0.4 % ( 4 mmol/mol ) than the G allele carriers ( p = 0.016 ) . Conclusion : The missense variant rs6923761 in the @GeneTgt$ GLP1R @/GeneTgt$ gene was associated with a smaller glycaemic response to 6 month gliptin therapy in diabetic patients of Central European origin .	2 2 2 6 6 3 8 6 12 12 12 8 2 17 17 17 17 17 21 21 18 25 25 25 21 28 28 18 32 32 32 28 35 35 32 17 55 37 37 37 42 37 46 46 46 42 49 49 46 49 52 49 49 55 55 57 55|56 55 55|56 57 57 64 64 64 57 64 67 55 69 67 69 69 74 74 69 55 55 78 86 81 81 78 83 81 83 86 55 86 89 89 97 93 91|92 91 91|92 97 97 89 100 100 97 102 100 106 105 106 100 106 106 89 117 116 116 116 116 111 117 119 117 121 119 124 124 117 127 127 124 127 133 133 133 133 117 136 136 133 136 136 117 140 140 145 145 145 152 150 150 147|150 150 147|150 145 152 140 157 157 157 157 152 162 162 159 162 157 165 165 162 169 168 169 165 140	Association
32308134	Chemical	Gene	D000077597	2740	False	1	What is [PHARMGKB] between @ChemicalSrc$ vildagliptin @/ChemicalSrc$ and @GeneTgt$ GLP1R @/GeneTgt$ ? [SEP] Genetic variants associated with glycaemic response to treatment with dipeptidylpeptidase 4 inhibitors . Aim : We examined associations of eight SNPs in/near seven candidate genes with glycaemic response to 6 month treatment with DPP4 inhibitors . Patients & methods : 206 patients with type 2 diabetes ( 116 men and 90 women ) were treated with sitagliptin or @ChemicalSrc$ vildagliptin @/ChemicalSrc$ ( both 100 mg/day ) in combination with metformin or metformin/sulphonylurea over 6 months , and the reduction in glycated haemoglobin ( HbA1c ) was measured . Results : Rs6923761 in @GeneTgt$ GLP1R @/GeneTgt$ was significantly associated with a reduction in HbA1c ( adjusted p = 0.006 ) . Homozygotes for the minor A allele had smaller reduction in HbA1c by 0.4 % ( 4 mmol/mol ) than the G allele carriers ( p = 0.016 ) . Conclusion : The missense variant rs6923761 in the @GeneTgt$ GLP1R @/GeneTgt$ gene was associated with a smaller glycaemic response to 6 month gliptin therapy in diabetic patients of Central European origin .	2 2 2 6 6 3 8 6 12 12 12 8 2 17 17 17 17 17 21 21 18 25 25 25 21 28 28 18 32 32 32 28 35 35 32 17 55 37 37 37 42 37 46 46 46 42 49 49 46 49 52 49 49 55 55 57 55 57 57|58 57 57|58 64 64 64 57 64 67 55 69 67 69 69 74 74 69 55 55 78 86 81 81 78 83 81 83 86 55 86 89 89 97 93 91|92 91 91|92 97 97 89 100 100 97 102 100 106 105 106 100 106 106 89 117 116 116 116 116 111 117 119 117 121 119 124 124 117 127 127 124 127 133 133 133 133 117 136 136 133 136 136 117 140 140 145 145 145 152 150 150 147|150 150 147|150 145 152 140 157 157 157 157 152 162 162 159 162 157 165 165 162 169 168 169 165 140	Association
32371615	Chemical	Gene	D012312	10242	True	0	What is [PHARMGKB] between @ChemicalSrc$ ritodrine @/ChemicalSrc$ and @GeneTgt$ KCNMB2 @/GeneTgt$ ? [SEP] Effects of @GeneTgt$ KCNMB2 @/GeneTgt$ gene polymorphisms on @ChemicalSrc$ ritodrine @/ChemicalSrc$ therapy outcomes in women with preterm labor . OBJECTIVE : The present prospective follow-up study aimed to evaluate the effects of @GeneTgt$ KCNMB2 @/GeneTgt$ gene polymorphisms on @ChemicalSrc$ ritodrine @/ChemicalSrc$ efficacy and adverse drug events ( ADEs ) in patients with preterm labor . METHODS : A total of 163 preterm labor patients were included in this single-center study . Nine single nucleotide polymorphisms ( SNPs ) in the @GeneTgt$ KCNMB2 @/GeneTgt$ gene ( rs10936979 , rs7624046 , rs7429015 , rs7625907 , rs6443559 , rs9839376 , rs9637454 , rs11918114 , and rs1382045 ) were assessed . The primary endpoint was time to delivery , and the secondary endpoint was @ChemicalSrc$ ritodrine-induced @/ChemicalSrc$ ADEs . RESULTS : Patients with variant homozygotes of two SNPs ( rs7624046 and rs9839376 ) , which were in linkage disequilibrium , showed 2.06 [ 95 % confidence interval ( CI ) , 1.14 - 3.73 ] and 2.68 ( 95 % CI , 1.16 - 6.20 ) times the hazard of time to delivery compared to wild-type allele carriers , respectively . Among demographic characteristics , gestational age at start of drug therapy and modified Bishop score were significant factors for time to delivery . Regarding safety outcomes , patients with variant homozygotes of rs7625907 had fewer ADEs compared to those with other genotypes ( odds ratio , 0.32 ; 95 % CI , 0.13 - 0.83 ) . CONCLUSIONS : This pharmacogenomic study suggests that @ChemicalSrc$ ritodrine @/ChemicalSrc$ efficacy and ADEs are associated with @GeneTgt$ KCNMB2 @/GeneTgt$ gene polymorphisms in patients with preterm labor .	1 6 2|6 6 2|6 6 1 11 11|6 11 11|6 11 1 13 11 16 16 13 1 20 20 26 26 26 26 20 26 29 27 31 29 36 36|32 36 36|32 36 31 40 36|40 40 36|40 31 40 44 44 40 46 44 46 49 40 52 52 49 20 66 66 59 66 64 64 64 64 59 66 66 70 70 70 66 66 75 75 75 105 77 75 77 83 83 80|83 83 80|83 75 85 83 85 85 85 85 85 85 85 85 93 93 95 95 97 97 99 99 99 85 105 105 105 110 110 112 112 112 114 112 112 112 119 119 123 123 123|120 123 123|120 112 123 126 126 147 131 131 128 134 134 131 136 134 136 136 136 134 145 145 145 145 128 128 126 153 153 151 153 153 147 155 153 155 153 160 160 153 160 153 153 166 166 167 153 167 171 171 167 167 147 175 147 177 175 179 175 147 184 184 184 180 147 147 147 190 190 205 190 193 190 195 193 198 198 195 198 202 202 205 205 205 205 207 205 209 205 205 213 213 221 221 221 218 218 215 220 218 221 223 221 223 226 224 229 229 226 232 232 229 232 232 232 237 238 232 242 242 242 238 232 221 245 245 249 249 250 245 258 254|251 254 254|251 258 254 254 258 250 263 263|258 263 263|258 263 258 265 263 268 268 265 245	Association
8897013	Chemical	Gene	D014044	3767	True	0	What is [PHARMGKB] between @ChemicalSrc$ tolbutamide @/ChemicalSrc$ and @GeneTgt$ Kir6.2 @/GeneTgt$ ? [SEP] Sequence variations in the human @GeneTgt$ Kir6.2 @/GeneTgt$ gene , a subunit of the beta-cell ATP-sensitive K-channel : no association with NIDDM in while Caucasian subjects or evidence of abnormal function when expressed in vitro . The ATP-sensitive K-channel plays a central role in insulin release from pancreatic beta cells . This channel consists of two subunits : a sulphonyl-urea receptor , SUR1 , and an inwardly rectifying K-channel subunit , @GeneTgt$ Kir6.2 @/GeneTgt$ . We screened 135 white Caucasian patients with non-insulin-dependent diabetes mellitus ( NIDDM ) and 90 non-diabetic subjects for mutations in the @GeneTgt$ Kir6.2 @/GeneTgt$ gene by single-stranded conformational polymorphism ( SSCP ) analysis . We identified one silent mutation ( A190A ) and four missense mutations ( E23 K , L270V , I337V and S385C ) in normal and diabetic individuals . In a single diabetic subject , we identified a two-amino acid insertion ( 380KP ) . We also screened 39 Afro-Caribbean diabetic subjects and identified one additional missense ( L355P ) and one more silent ( S363S ) mutation . The E23 K and I337V variants were completely linked . The common variants ( E23 K , 1337V and L270V ) were found with similar frequency in diabetic and normal subjects . Diabetic subjects with the variants responded normally to sulphonylurea therapy . When mutant @GeneTgt$ Kir6.2 @/GeneTgt$ subunits were coexpressed with SUR1 in Xenopus oocytes , there was no difference in the sensitivity of the whole-cell currents to metabolic inhibition or to the sulphonylurea @ChemicalSrc$ tolbutamide @/ChemicalSrc$ . We therefore conclude that mutations in @GeneTgt$ Kir6.2 @/GeneTgt$ are unlikely to be a major cause of NIDDM .	2 2 8 8 8 8|5 8 8|5 2 8 11 8 16 16 16 16 11 2 19 2 21 19 25 22 25 19 25 25 30 30 27 32 25 34 32 2 39 39 40 40 43 43 40 46 46 40 50 50 50 46 40 53 54 54 57 57 54 54 61 61 54 61 61 61 61 70 68 70 70 61 70 70|71 70 70|71 54 77 77 81 81 81 77 85 85 85 81 87 85 87 85 92 92 85 94 92 99 99 99|96 99 99|96 94 103 103 103 92 105 107 107 77 77 111 111 114 114 111 116 114 116 114 121 121 114 126 126 126 124 121 126 126 126 126 126 133 114 133 133 133 111 142 142 141 142 145 145 145 145 149 149 149 145 151 149 151 145 156 156 156 160 160 160 156 156 156 167 167 167 167 162 167 162 176 172 176 174 176 176 162 156 183 183 183 180 180 186 186 186 186 186 190 190 200 193 193 190 193 193 195 195 193 200 200 203 203 200 205 203 205 205 205 200 211 215 214 214 211 215 215 219 219 215 215 227 225 222|225 225 222|225 227 227 235 229 227 232 232 227 235 235 235 237 235 240 240 237 244 244 244 240 247 247 240 247 252 252 252 247|250 247 247|250 235 259 259 259 266 266 263 261|262 261 261|262 266 259 271 271 271 271 266 273 271 259	Association
11593098	Chemical	Gene	D001262	185	True	0	What is [PHARMGKB] between @ChemicalSrc$ atenolol @/ChemicalSrc$ and @GeneTgt$ angiotensin II type 1 receptor @/GeneTgt$ ? [SEP] Angiotensin converting enzyme gene polymorphism predicts blood pressure response to @GeneTgt$ angiotensin II receptor type 1 @/GeneTgt$ antagonist treatment in hypertensive patients . OBJECTIVES : To determine whether polymorphisms in the renin-angiotensin system can predict blood pressure-lowering response to antihypertensive treatment ; more specifically , in response to treatment with irbesartan or @ChemicalSrc$ atenolol @/ChemicalSrc$ . DESIGN AND METHODS : Eighty-six patients with hypertension were randomized to double-blind treatment with either the @GeneTgt$ angiotensin II type 1 receptor @/GeneTgt$ antagonist irbesartan or the beta1 adrenergic receptor blocker @ChemicalSrc$ atenolol @/ChemicalSrc$ and followed for 3 months . We analysed angiotensinogen T174 M and M235 T , angiotensin converting enzyme ( ACE ) I/D and @GeneTgt$ angiotensin II type 1 receptor @/GeneTgt$ A1166C polymorphisms and related them to blood pressure reduction . RESULTS : The mean reductions in blood pressure were similar for both treatments . In the irbesartan group , individuals homozygous for the ACE gene I allele showed a greater reduction in diastolic blood pressure , exceeding those with the D allele ( -18 + /- 11 SD versus -7 + /- 10 mmHg , P = 0.0096 ) . This was not the case during treatment with @ChemicalSrc$ atenolol @/ChemicalSrc$ , and the interaction term between type of treatment and ACE II genotype was significant ( P = 0.0176 ) . The angiotensinogen and @GeneTgt$ angiotensin II type 1 receptor @/GeneTgt$ polymorhisms were not related to the response to treatment . CONCLUSIONS : ACE genotyping predicted the blood pressure-lowering response to antihypertensive treatment with irbesartan but not @ChemicalSrc$ atenolol @/ChemicalSrc$ . Thus , specific genotypes might predict the response to specific antihypertensive treatment .	5 5 5 5 6 6 9 9 6 18 10|18 10|18 10|18 10|18 10|18 18 10|18 18 9 21 21 18 6 24 27 27 24 35 35 33 33 33 29 35 27 38 38 35 41 41 38 27 44 27 44 47 44 49 47 51 49 51 51|52 51 51|52 24 57 57 57 66 62 66 64 62 66 57 69 69 66 80 80 80 72|73|79 72|73|79 72|73|79 72|73|79 72|73|79 73|79 72|73|79 80 69 80 86 86 86 86 80 81|66 66 81|66 66 66 93 93 90 66 98 98 101 101 98 101 104 101 101 108 108 101 110 108 110 101 112 113|114|121 113|114|121 113|114|121 113|114|121 113|114|121 121|114 113|114|121 121 101 98 98 123 128 128 128 123 98 131 131 135 135 140 138 138 135 140 131 143 143 140 131 148 148 148 158 158 158 150 157 157 157 157 157 151 158 161 161 158 165 165 165 161 161 161 167 172 172 172 168 174 172 174 174 178 174 178 178 174 174 184 174 187 187 158 187 187 158 195 195 195 195 195 197 195 199 198|197 197 198|197 195 195 205 205 215 207 205 209 207 209 213 213 209 215 195 218 218 215 218 218 195 224 235 224 232|225 232|225 232|225 232|225 232|225 232 232|225 224 235 235 235 238 238 235 240 238 235 243 243 246 247 243 251 251 251 247 254 254 251 256 254 258 256 258|256 256 258|256 247 268 268 266 268 268 268 270 268 274 274 274 270 268	Association
12042669	Chemical	Gene	D011345	5465	True	0	What is [PHARMGKB] between @ChemicalSrc$ fenofibrate @/ChemicalSrc$ and @GeneTgt$ PPARalpha @/GeneTgt$ ? [SEP] Effect of apolipoprotein E , @GeneTgt$ peroxisome proliferator-activated receptor alpha @/GeneTgt$ and lipoprotein lipase gene mutations on the ability of @ChemicalSrc$ fenofibrate @/ChemicalSrc$ to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients . @ChemicalSrc$ Fenofibrate @/ChemicalSrc$ is a @GeneTgt$ peroxisome proliferator-activated receptor alpha @/GeneTgt$ ( @GeneTgt$ PPARalpha @/GeneTgt$ ) agonist which regulates the transcription of genes encoding proteins involved in triglyceride (TG)-rich lipoproteins and lipoprotein lipase ( LPL ) metabolism . The aim of the present study was to investigate the relation between TG-related parameters considered in different clinical guidelines used in industrialized countries for the management of lipid disorders ( namely fasting plasma TG , high density-lipoprotein cholesterol ( HDL-C ) , non-HDL-C concentrations and total-C/HDL-C ratio ) and the presence of LPL-null ( P207L ) , LPL-defective ( D9N ) , @GeneTgt$ PPARalpha @/GeneTgt$ -L162V , apolipoprotein ( apo ) E and PPARgamma-P12A gene mutations , in a sample of 292 hypertriglyceridemic subjects treated with fenofibrate for 3 months . Although @ChemicalSrc$ fenofibrate @/ChemicalSrc$ induced a decrease in plasma TG level and an increase in HDL-C level in all studied genotypes , mutation-specific differences were observed . After adjustment for age , gender , body mass index and the presence of apo E2 genotype , the LPL-P207L mutation was associated with residual post-treatment hypertriglyceridemia [ TG & gt ; 2.0 mmol/l , odds ratio ( OR ) = 3.07 , P = 0.005 ] and total-C/HDL-C ratio & gt ; 5 ( OR = 2.68 ; P = 0.03 ) . This effect was significantly related to higher plasma TG concentrations at baseline among carriers of a LPL-null mutation . Compared to apo E3 and E4 variants , the apo E2 allele was associated with a better response to @ChemicalSrc$ fenofibrate @/ChemicalSrc$ on all lipid parameter , especially among @GeneTgt$ PPARalpha @/GeneTgt$ -L162V carriers , whereas the simultaneous presence of apo E2 and @GeneTgt$ PPARalpha @/GeneTgt$ -L162V tended to improve @ChemicalSrc$ fenofibrate @/ChemicalSrc$ response among LPL-P207L heterozygotes . Finally , the LPL-D9N and PPARgamma -P12A mutations did not affect @ChemicalSrc$ fenofibrate @/ChemicalSrc$ lipid-lowering action . This study suggests that frequent genetic variations in genes encoding proteins involved in TG-rich lipoprotein metabolism could modulate the response to @ChemicalSrc$ fenofibrate @/ChemicalSrc$ treatment , as defined in clinical guidelines .	1 4 4 15 4 4|5|6 4|5|6 4|5|6 4|5|6 4|6 4|5|6 4 14 14 15 1 18 18 1 20 18|15 18 18|15 23 18 25 23 23 23 30 30 27 33 33 30 1 36|50 50 36|50 50 50 39|41|50 39|41|50 39|41|50 39|41|50 41|50 39|41|50 47 41 41 41 47 50 52 50 54 52 56 54 56 57 58 63 63 63 59 63 66 70 68 66 68 63 50 76 81 80 80 80 76 81 83 81 85 83 88 88 85 88 93 93 93 89 93 97 97 94 100 100 97 103 103 100 108 106 108 108 103 108 112 112 108 114 112 114 108 118 103 103 121 103 93 88 125 88 127 125 129 127 129 127 125 134 132 134 132 139|136 139 139|136 125 125 145 145 142 145 125 145 145 149 145 88 153 153 85 157 157 157 153 157 160 158 163 163 158 81 169 166|169 169 166|169 190 171 169 175 175 175 171 171 178 171 181 181 178 185 185 185 178 190 188 190 190 190 190 194 215 196 194 196 196 198 202 202 198 202 205 202 209 209 209 205 215 213 213 215 215 215 219 219 219 215 221 219 221 221 221 226 221 226 229 226 231 229 231 229 233 237 237 215 237 238 237 242 237 242 242 237 249 248 249 237 249 249 253 249 253 237 215 258 261 261 261 261 266 266 266 266 261 268 266 270 268 274 274 274 270 261 282 279 279 282 279 279 289 289 287 287 287 289 289 289 293 293 293 289 295 293|294 293 293|294 300 300 300 293 300 307 307 307|302 307 307|302 307 300 289 289 312 312 320 315 315 312 315 319|314 319 319|314 315 289 322 320 325|319 325 325|319 322 328 328 325 289 344 344 337 341 337 337 337 344 344 344 344 344|348 348 344|348 348 344 344 352 353 353 368 357 357 368 359 357 359 360 361 366 366 366 362 368 353 370 368 374 374|371 374 374|371 370 368 377 368 380 380 377 353	Association
12151923	Chemical	Gene	D006221	6261	True	0	What is [PHARMGKB] between @ChemicalSrc$ halothane @/ChemicalSrc$ and @GeneTgt$ RYR1 @/GeneTgt$ ? [SEP] Results of contracture tests with @ChemicalSrc$ halothane @/ChemicalSrc$ , caffeine , and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations . BACKGROUND : More than 20 mutations in the gene encoding for the ryanodine receptor ( @GeneTgt$ RYR1 @/GeneTgt$ ) , a Ca2 + release channel of the skeletal muscle sarcoplasmic reticulum , have been found to be associated with malignant hyperthermia ( MH ) . This study was designed to investigate the effects of different mutations in the @GeneTgt$ RYR1 @/GeneTgt$ gene on contracture development in in vitro contracture tests ( IVCT ) with @ChemicalSrc$ halothane @/ChemicalSrc$ , caffeine , and ryanodine . METHODS : Ninety-three MH-susceptible ( MHS ) patients , diagnosed by the standard IVCT with @ChemicalSrc$ halothane @/ChemicalSrc$ and caffeine , were included in this prospective study . Surplus muscle specimens were used for an IVCT with 1 microm ryanodine . The contracture course during the ryanodine IVCT was described by the attainment of different time points : onset time of contracture and times when contracture reached 2 mN or 10 mN. In addition , all patients were screened for mutations of the @GeneTgt$ RYR1 @/GeneTgt$ gene . RESULTS : In 36 patients , four different mutations of the @GeneTgt$ RYR1 @/GeneTgt$ gene ( C487-T , G1021-A , C1840-T , G7300-A ) were found . The IVCT threshold concentrations of @ChemicalSrc$ halothane @/ChemicalSrc$ and caffeine were lower in patients with the C487-T mutation compared with patients without a detected mutation in the @GeneTgt$ RYR1 @/GeneTgt$ gene . In the IVCT with ryanodine , contracture levels of 2 mN and 10 mN were reached earlier in muscle specimens from patients with C487-T , C1840-T , and G7300-A mutations compared with specimens from patients with the G1021-A mutation and patients without detected mutation in the @GeneTgt$ RYR1 @/GeneTgt$ gene . CONCLUSIONS : The differences between the groups in the @ChemicalSrc$ halothane @/ChemicalSrc$ and caffeine IVCT threshold concentrations and in the time course of contracture development in the ryanodine IVCT underline the hypothesis that certain mutations in the @GeneTgt$ RYR1 @/GeneTgt$ gene could make the ryanodine receptor more sensitive to specific ligands . This may be an explanation for varying clinical symptoms of MH crisis in humans .	13 4 4 1 6 4|5 4 4|5 6 6 6 6 6 13 21 21 21 21 21 21 21 13 13 57 24 28 28 29 24 32 32 29 32 37 37 37 47 39 37|38 37 37|38 39 37 44 37 44 44 33 53 53 53 53 53 47 24 57 57 57 60 60 57 63 63 60 65 63 65 57 70 72 72 72 74 72 76 74 79 79 76 84 84 84|81 84 84|81 76 87 87 76 92 92 89 92 76 94 92 94 97 92|95 92 92|95 97 97 97 97 97 72 128 128 114 109 112 110 112 128 114 114 120 120 120 116 122 120|121 120 120|121 122 122 114 128 128 132 132 132 128 128 136 137 139 139 139 142 142 139 146 145 146 139 139 150 150 156 154 154 154 150 156 185 159 159 156 163 163 163 159 163 166 159 168 166 168 168 173 173 156 175 173 175 178 175 180 173 185 183 185 185 185 187 185 192 192 189|192 192 189|192 187 185 195 195 199 199 219 219 203 203 219 208 208 205|208 208 205|208 203 210 203 210 210 210 210 216 210 210 219 195 219 225 225 225 232 227 225|226 225 225|226 227 227 232 232 234 232 238 238 238 234 241 241 232 245 245 245 241 250 250 246|250 250 246|250 245 232 256 256 269 258 256 269 261 269 264 264 261 264 267 264 269 269 269 273 273 269 275 273 277 275 277 277 277 277 277 277 286 286 269 288 286 292 292 292 288 292 292 297 297 288 302 302 302|299 302 302|299 297 269 305 305 308 333 311 311 308 314 314 313|311 311 313|311 314 314 320 320 314 311 325 325 325 311 328 328 325 332 332 332 308 305 335 333 345 338 345 343 343 339|343 343 339|343 338 345 335 348 348 350 350 345 353 353 350 305 361 361 361 361 361 365 365 365 361 368 368 365 370 365 361	Association
15976989	Chemical	Gene	D009853	5243	False	1	What is [PHARMGKB] between @ChemicalSrc$ omeprazole @/ChemicalSrc$ and @GeneTgt$ MDR1 @/GeneTgt$ ? [SEP] Effect of CYP2C19 and @GeneTgt$ MDR1 @/GeneTgt$ polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection . A proton pump inhibitor ( PPI ) plus two antibiotics ( amoxicillin and either clarithromycin or metronidazole ) are recommended for treatment of acid-related disorders with Helicobacter pylori ( H. pylori ) infection . The aim of this pharmacogenetic study was to evaluate the efficacy of triple therapy with PPIs on eradication of H. pylori infection in relation to cytochrome P450 2C19 ( CYP2C19 ) and P-glycoprotein ( @GeneTgt$ MDR1 @/GeneTgt$ ) gene polymorphisms . The retrospective study involved 70 Polish Caucasian patients with H. pylori infection , diagnosed and treated with one of the two different triple therapy regimens [ @ChemicalSrc$ omeprazole @/ChemicalSrc$ , amoxicillin , and clarithromycin ( OAC ) or pantoprazole , amoxicillin , and metronidazole ( PAM ) ] . Using genomic DNA , CYP2C19 ( * 2 and * 3 ) and C3435 T @GeneTgt$ MDR1 @/GeneTgt$ alleles were determined by means of polymerase chain reaction-restriction fragment length polymorphism assays . A significantly higher prevalence ( P&lt;0.05 ) of heterozygous extensive metabolizers ( hetEM ) with CYP2C19 * 1/*2 genotype ( 32.4 % versus 8.3 % ) and homozygous with 3435TT @GeneTgt$ MDR1 @/GeneTgt$ genotype ( 38.2 % versus 13.9 % ) was found in patients cured after the first cycle of triple therapy than in patients with failure of eradication after the first cycle . CYP2C19 * 1/*2 and 3435TT @GeneTgt$ MDR1 @/GeneTgt$ genotypes as well as PAM regimen of treatment were also predictive of successful eradication of H. pylori infection after the first cycle of triple therapy at univariate/multivariate logistic regression analysis . This pharmacogenetic study on the influence of different CYP2C19 and C3435 T @GeneTgt$ MDR1 @/GeneTgt$ genotypes on H. pylori eradication suggests that CYP2C19 and @GeneTgt$ MDR1 @/GeneTgt$ polymorphisms may be independent predictable determinants of the efficacy of triple therapy including PPI . The PAM regimen of treatment seems to be more effective after the first cycle of the therapy than the OAC regimen .	1 3 1 3 3|4 3 3|4 3 10 10 1 12 10 15 15 12 19 19 19 12 1 25 25 25 41 27 25 27 25 31 25 33 31 33 36 33 36 36 33 41 41 43 41 46 46 43 49 49 54 52 52 49 52 43 41 57 62 61 61 61 57 62 64 62 66 64 69 69 66 71 69 73 66 77 77 77 73 79 66 83 83 83 94 85 83 85 83 83 90 89|94 94 89|94 94 94 79 62 99 99 100 100 104 104 104 100 108 108 108 104 104 104 110 110 114 112 121 121 121 121 121 121 114 123 121|122 121 121|122 123 123 123 123 123 131 129 131 123 123 123 123 123 123 123 141 139 141 100 100 146 148 146 148 148 148 153 148 153 156 153 156 153 163 163 163|160 163 163|160 148 165 146 167 165 175 175 171 175 175 175 175 167 146 181 180 181 219 183 181 183 188 188 188 181 190 188 190 193 188 196 196 193 199 199 196 199 202 199 199 196 196 210 210 210|207 210 210|207 205 213 213 210 213 216 213 213 219 219 221 219 221 226 226 226 222 229 229 226 232 232 229 234 232 236 234 240 240 240 222 219 260 245 243 245 245 250|247 250 250|247 245 250 251 251 255 250 257 255 260 260 260 263 263 260 267 267 267 263 271 271 271 263 274 274 271 279 279 279 279 271 260 284 284 301 287 287 284 290 290 287 290 290 296 293|296 296 293|296 290 300 300 300 287 301 312 312 303 303 303 303 303 312 312 312 312 301 315 315 312 318 318 315 320 318 301 326 326 329 328 326 329 333 333 333 329 337 337 337 333 340 340 337 344 344 344 340 329	Association
16513877	Chemical	Gene	D000077152	1813	True	0	What is [PHARMGKB] between @ChemicalSrc$ olanzapine @/ChemicalSrc$ and @GeneTgt$ DRD2 @/GeneTgt$ ? [SEP] @GeneTgt$ DRD2 @/GeneTgt$ promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients . OBJECTIVE : All antipsychotics act on the @GeneTgt$ dopamine D(2 ) receptor @/GeneTgt$ . The present study extends prior pharmacogenetic investigations of the D(2 ) receptor gene ( @GeneTgt$ DRD2 @/GeneTgt$ ) by examining , in first-episode schizophrenia patients , promoter region variation as a predictor of response time to two first-line atypical antipsychotics . METHOD : Patients experiencing their first episode of schizophrenia ( N=61 ) were genotyped for two @GeneTgt$ DRD2 @/GeneTgt$ promoter region polymorphisms ( A-241 G and -141C Ins/Del ) and were randomly assigned to receive 16 weeks of treatment with either risperidone or @ChemicalSrc$ olanzapine @/ChemicalSrc$ . Time until sustained response ( two consecutive ratings without significant positive symptoms ) for rare allele carriers versus wild types was examined by using Kaplan-Meier curves . RESULTS : Relative to wild type homozygotes , G carriers ( A-241 G ) exhibited a significantly faster time until response , whereas -141C Del carriers took a significantly longer time to respond . Diplotype analysis revealed similar results . CONCLUSIONS : These findings suggest that variation in the D(2 ) receptor gene can , in part , explain variation in the timing of clinical response to antipsychotics in patients with first-episode schizophrenia .	0|4 4 0|4 4 5 5 8 8 5 11 11 8 14 14 11 18 18 18 14 5 25 21 24 25 25 28 28 28|25|27 28|25|27 28|25|27 28|25|27 28|25 28|25|27 25 37 37 38 38 41 41 38 47 47 47 47 47 41 49 47|48 47 47|48 49 53 38 53 58 58 58 53 62 61 62 38 65 65 62 68 68 65 73 73 73 71 65 38 76 76 89 78 82 82 79 84 82 86 84 86 89 76 96 96 91|96 96 91|96 96 96 89 99 99 96 99 99 99 99 89 107 107 89 109 107 111 109 113 111 116 116 113 116 116 116 116 89 144 126 126 144 130 130 130 126 134 134 134 130 134 139 139 139 134 142 142 139 144 144 146 144 148 146 144 164 150 156 156 156 156 150 164 159 164 162 162 159 162 164 168 167 168 164 170 164 164 176 175 175 176 164 180 179 180 176 182 180 164 185 186 186 188 186 186 190 190 193 194 190 208 208 202 202 202 202 202 196 208 208 206 208 208 194 208 212 212 209 215 215 212 217 215 219 217 222 222 219 190	Association
16595597	Chemical	Gene	D008687	3767	False	1	What is [PHARMGKB] between @ChemicalSrc$ metformin @/ChemicalSrc$ and @GeneTgt$ KCNJ11 @/GeneTgt$ ? [SEP] The E23 K variant of @GeneTgt$ KCNJ11 @/GeneTgt$ encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit @GeneTgt$ Kir6.2 @/GeneTgt$ is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes . CONTEXT : Several studies suggest that genetic factors may play a role in the different responses to antidiabetic therapy ; however , conclusive evidence is still lacking . OBJECTIVE : The objective of the study was to investigate whether diabetic patients carrying the E23 K variant in @GeneTgt$ KCNJ11 @/GeneTgt$ are at increased risk for secondary sulfonylurea failure . DESIGN : Secondary sulfonylurea failure was defined as fasting plasma glucose greater than 300 mg/dl despite @ChemicalSrc$ sulfonylurea-metformin @/ChemicalSrc$ combined therapy and appropriate diet , in the absence of other conditions causing hyperglycemia . SETTING : The study was conducted in an ambulatory care facility . PATIENTS : A total of 525 Caucasian type 2 diabetic patients were enrolled in the study . INTERVENTION : Sulfonylurea treatment was followed by @ChemicalSrc$ sulfonylurea-metformin @/ChemicalSrc$ combined therapy and then insulin treatment . MAIN OUTCOME MEASURE : Secondary failure was the main outcome measure . RESULTS : Of the diabetic patients enrolled in the study , 38.5 % were E23E homozygous , 51.4 % were E23 K heterozygous , and 10.1 % were K23 K homozygous . The frequency of carriers of the K allele was 58 and 66.8 % among patients treated with oral therapy or secondary sulfonylurea failure , respectively ( odds ratio , 1.45 ; 95 % confidence interval , 1.01 - 2.09 ; P = 0.04 ) . Adjustment for age , gender , fasting glycemia , glycosylated hemoglobin , age at diagnosis , and duration of diabetes in a logistic regression analysis did not change this association ( odds ratio , 1.69 ; 95 % confidence interval , 1.02 - 2.78 ; P = 0.04 ) . Islets isolated from carriers of the K allele showed no differences in glucose-stimulated insulin secretion and a tendency toward reduced response upon glibenclamide stimulation ( P = 0.09 ) . After 24-h exposure to high ( 16.7 mmol/liter ) glucose concentration , impairment of glibenclamide-induced insulin release was significantly ( P = 0.01 ) worse with the E23 K variant . CONCLUSIONS : These data suggest that the E23 K variant in @GeneTgt$ KCNJ11 @/GeneTgt$ may influence the variability in the response of patients to sulfonylureas , thus representing an example of pharmacogenetics in type 2 diabetes .	4 4 4 20 6 4|5 4 4|5 4 17 17 17 17 17 17 17 17 8|15 8 8|15 20 20 24 24 24 20 27 27 24 29 27 31 29 35 35 35 31 20 43 43 42 43 43 48 46 48 48 43 50 48 54 54 54 48 57 57 54 43 65 65 62 65 65 65 43 43 67 67 70 74 73 73 70 67 76 74 91 79 91 79 84 84 84 80 86 84|85 84 84|85 91 91 91 76 95 95 95 91 74 98 98 102 102 104 104 98 108 108 108 104 112 111 112 104 117 113|117 117 113|117 117 112 117 120 117 104 124 124 104 127 127 124 127 128 104 137 132 135 137 137 137 142 142 142 142 137 137 144 144 147 156 154 154 154 154 154 154 147 156 144 159 159 156 156 161 161 164 166 166 161 171 171|167 171 171|167 171 166 171 175 175 166 161 179 180 180 188 183 188 188 188 188 188 180 180 190 190 195 195 195 205 195 199 199 196 205 202 205 205 205 190 212 208 212 212 212 212 205 212 212 216 220 220 220 220 205 190 223 234 225 223 229 229 229 225 234 234 231 231 234 236 234 236 240 240 237 240 244 244 240 234 249 249 249 234 249 249 249 254 256 256 249 256 260 260 256 263 263 249 263 234 234 294 269 267 269 269 271 274 271 274 277 274 277 277 281 279 277 269 269 286 284 291 291 291 291 284 294 294 294 296 294 299 299 296 299 299 299 304 306 306 299 306 310 310 306 313 313 306 313 299 294 325 317 320 318 324 324 324 320 325 327 325 331 331 331 327 327 334 327 337 337 334 340 340 337 343 343 334 343 343 325 349 349 371 351 349 354 354 351 354 357 351 351 371 363 363 363 359 371 371 371 371 367 368 369 371 376 376 376 376 371 371 378 378 381 382 378 392 387 387 387 392 389 387|388 387 387|388 392 382 394 392 397 397 394 399 397 401 397 392 404 392 406 404 408 406 412 412 412 406 378	Association
18004211	Chemical	Gene	C422415	6338	False	2	What is [PHARMGKB] between @ChemicalSrc$ farglitazar @/ChemicalSrc$ and @GeneTgt$ SCNN1B @/GeneTgt$ ? [SEP] Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist @ChemicalSrc$ farglitazar @/ChemicalSrc$ . Peroxisome proliferator-activated receptor gamma ( PPARgamma ) agonists are highly effective in the treatment of type 2 diabetes . In some patients , PPARgamma ligands are associated with fluid retention/oedema , for which the mechanism is not fully understood . A pharmacogenetic study was undertaken to investigate effects of variations in 21 candidate genes related to epithelial sodium channel ( ENaC ) pathways on oedema . This study used DNA samples collected from type 2 diabetes phase III clinical trials of the PPARgamma agonist @ChemicalSrc$ farglitazar @/ChemicalSrc$ ( administered alone or in combination with insulin or glyburide ) and investigated oedema reported as an adverse event as phenotype . Initial case-control analysis of oedema identified candidate gene single nucleotide polymorphisms with significant associations . These included three polymorphisms in @GeneTgt$ ENaCbeta @/GeneTgt$ subunit ( @GeneTgt$ SCNN1B @/GeneTgt$ ) that showed significant associations ( P&lt;0.05 ) with the two combination treatments in discrete regions of the gene , but not farglitazar treatment alone . Sequencing of @GeneTgt$ SCNN1B @/GeneTgt$ in 207 Caucasian participants receiving farglitazar plus insulin or glyburide combination therapies , identified additional polymorphisms that were also significantly associated with oedema ( P&lt;0.0005 ) and maintained the treatment-regional associations . Further covariate analysis accounting for clinical factors influencing oedema supported these observations . One of the @GeneTgt$ SCNN1B @/GeneTgt$ polymorphisms , at position -405 of the 5 ' flanking region ( rs34241435 ) , was predicted to modify transcriptional interactions and in a transfected COS cell luciferase reporter gene assay exhibited higher promoter activity . These exploratory studies provide clinical pharmacogenetic and functional genomic evidence to support a pivotal role for ENaC regulation in PPARgamma-induced oedema and provide insight into mechanisms and possible management of this side effect .	2 8 7 7 7 7 2 8 10 8 15 15 15 15 10 15 23 23 23 23 23 23 16|22 16 16|22 8 34 30 30 27 32 30 32 37 37 37 37 40 40 37 44 44 44 40 37 48 48 53 53 51 53 53 53 56 56 53 56 59 65 61 65 65 65 65 56 53 69 69 71 71 71 73 71 73 76 74 80 80 80 76 80 89 89 85 89 87 89 87 81 91 89 71 94 95 95 97 95 97 106 106 106 106 106 106 106 98 111 111 111 111 110|106 106 110|106 114 97 116 114 118 114 120 118 120 120 114 95 95 125 126 131 131 131 127 133 131 95 138 138 141 140 138 141 143 146 146 146 141 149 149 141 141 152 152 154 152 158 158|155 158 158|155 154 160 158 158 158 160 164 154 166 164 168 166 168 174 174 174 174 166 177 177 174 180 180 177 180 183 180 185 174 185 152 207 192 190|191 190 190|191 197 197 197 190 197 198 199 199 199 199 205 199 207 207 209 207 214 214 214 214 209 216 214 218 216 218 214 214 224 224 221 207 229 229 236 229 233 233 230 233 234 236 238 236 236 261 245 245 242|245 245 242|245 240 240 248 240 248 255 255 255 255 255 249 257 255 257 240 261 261 263 261 265 263 265 275 275 275 275 275 275 275 275 265 261 279 279 276 261 284 284 285 285 287 291 287 287 291 285 293 291 296 296 293 299 299 296 302 302 299 293 293 304 307 305 307 310 307 314 314 314 310 285	Association
18997459	Chemical	Gene	D000069059	7124	True	0	What is [PHARMGKB] between @ChemicalSrc$ atorvastatin @/ChemicalSrc$ and @GeneTgt$ TNFalpha @/GeneTgt$ ? [SEP] Effect of the @GeneTgt$ TNFalpha-308 @/GeneTgt$ G/A polymorphism on the changes produced by @ChemicalSrc$ atorvastatin @/ChemicalSrc$ in bone mineral density in patients with acute coronary syndrome . AIMS : To evaluate the effect of @ChemicalSrc$ atorvastatin @/ChemicalSrc$ on bone mass and markers of bone remodeling in patients with acute coronary syndrome depending on the @GeneTgt$ tumor necrosis factor-alpha @/GeneTgt$ @GeneTgt$ (TNFalpha)-308 @/GeneTgt$ G/A polymorphism . METHODS : Sixty-two patients with acute coronary syndrome ( 35 males and 27 females ) , average age 60 + /- 10 years , were included . Patients were given low ( 10 - 20 mg ) and high doses ( 40 - 80 mg ) @ChemicalSrc$ atorvastatin @/ChemicalSrc$ according to their baseline levels of cholesterol and triglycerides and their index of vascular risk . Patients were studied during hospital admission ( baseline ) and at 12 months of follow-up . Cholesterol , triglycerides , total calcium , phosphorus , magnesium , osteocalcin and urinary deoxypyridinoline were determined in all patients at baseline and at 12 months of follow-up . Densitometric studies were conducted in the lumbar spine ( L(2)-L(4 ) ) , femoral neck and trochanter using an X-ray densitometer . The @GeneTgt$ TNFalpha-308 @/GeneTgt$ G/A polymorphism was determined by the polymerase chain reaction . RESULTS : Forty-five patients were homozygous for G/G ( 72.5 % ) and 17 were heterozygous for G/A ( 27.5 % ) . The prevalence of osteoporosis ( T score & lt ; or = 2.5 in the lumbar spine and/or hip ) was 33 % for the G/G genotype and 35 % for the G/A genotype , with no statistically significant differences between groups . There was a statistically significant increase in bone mineral density ( BMD ) in the lumbar spine ( 1.107 + /- 0.32 vs. 1.129 + /- 0.23 ; p = 0.0001 ) in patients with the G/G genotype . No changes were observed in patients with the G/A genotype . CONCLUSION : In patients with acute coronary syndrome , @ChemicalSrc$ atorvastatin @/ChemicalSrc$ increases lumbar spine BMD solely in patients with the G/G genotype of the @GeneTgt$ TNFalpha-308 @/GeneTgt$ G/A polymorphism .	1 7 7 3|7 7 3|7 7 1 10 10 1 10 13 11 11 11 18 18 18 11 20 18 24 24 24 20 1 28 31 31 28 33 31 35 33|34 33 33|34 39 39 33 39 39 44 44 39 46 44 50 50 50 46 54 54 54 52|61|54 52|61|54 52|61|54 61|54 52|61|54 53|61 61 53|61 61 31 28 91 91 69 91 73 73 73 69 76 76 73 76 79 76 76 73 83 73 83 73 69 88 69 69 91 91 91 95 95 95 95 101 101 101 101 96 101 96 105 95 110 110 110 110 112 110 111|105 105 111|105 118 114 118 118 95 120 118 120 120 118 125 118 128 128 125 95 133 133 133 136 136 133 138 136 138 136 143 143 136 145 143 133 149 149 163 163 152 163 152 152 154 154 154 154 152 161 152 163 163 166 166 163 168 166 166 172 172 166 174 172 163 177 179 179 179 183 183 183 179 185 183 185 183 183 190 183 190 190 179 196 196 193 179 202 198|202 202 198|202 202 204 204 204 209 209 209 209 204 204 227 212 215 217 217 212 219 217 222 222 219 222 219 219 227 227 229 227 232 232 229 232 227 236 257 238 236 241 241 238 241 241 241 238 236 246 251 251 251 246 251 251 246 257 257 257 261 261 261 257 257 264 257 268 268 268 264 257 274 274 273 274 257 276 274 257 279 279 283 282 283 279 287 287 287 283 289 287 289 294 294 294 287 296 294 296 296 296 299 299 296 296 296 307 307 296 307 307 311 296 315 315 315 311 279 318 320 320 320 322 320 326 326 326 322 320 328 328 331 339 335 335 335 331 339 336|339 339 336|339 328 342 342 339 345 345 339 349 349 349 345 355 355 355|350 355 355|350 355 349 328	Association
19255940	Chemical	Gene	D008874	1576	True	0	What is [PHARMGKB] between @ChemicalSrc$ midazolam @/ChemicalSrc$ and @GeneTgt$ CYP3A4 @/GeneTgt$ ? [SEP] Functional characterization of @GeneTgt$ CYP3A4.16 @/GeneTgt$ : catalytic activities toward @ChemicalSrc$ midazolam @/ChemicalSrc$ and carbamazepine . 1 . To assess the substrate-dependent effects of the low-activity allele of human @GeneTgt$ CYP3A4 @/GeneTgt$ , @GeneTgt$ CYP3A4 @/GeneTgt$ * 16 ( Thr185Ser ) , a recombinant wild-type ( @GeneTgt$ CYP3A4.1 @/GeneTgt$ ) or variant ( @GeneTgt$ CYP3A4.16 @/GeneTgt$ ) protein was co-expressed with human NADPH-P450 reductase in Sf21 insect cells using a baculovirus-insect cell system . 2 . The @GeneTgt$ holo-CYP3A4 @/GeneTgt$ protein level of @GeneTgt$ CYP3A4.16 @/GeneTgt$ in insect microsomes was slightly higher than that of @GeneTgt$ CYP3A4.1 @/GeneTgt$ , while no difference in total ( apo- and holo- ) @GeneTgt$ CYP3A4 @/GeneTgt$ protein levels was observed between them . 3 . When @ChemicalSrc$ midazolam @/ChemicalSrc$ was used as a substrate , K(m ) and V(max ) for 1'-hydroxylation in @GeneTgt$ CYP3A4.16 @/GeneTgt$ were significantly higher and lower , respectively , than those in the wild-type , resulting in a 50 % decrease in intrinsic clearance ( V(max)/K(m ) ) of the variant . In contrast , intrinsic clearance for 4-hydroxylation of the variant was decreased by 30 % due to a significant increase in K(m ) without a difference in V(max ) . 4 . Both the wild-type and variant exhibited sigmoidal kinetic profiles for carbamazepine 10,11-epoxide formation . When the modified two-site equation was applied for the analysis of kinetic parameters , K(m2 ) and V(max2 ) of @GeneTgt$ CYP3A4.16 @/GeneTgt$ were approximately two times higher and lower than those of the wild-type , resulting in a 74 % decrease in intrinsic clearance . 5 . These results demonstrated that @GeneTgt$ CYP3A4.16 @/GeneTgt$ shows the substrate-dependent altered kinetics compared with @GeneTgt$ CYP3A4.1 @/GeneTgt$ .	2 2 4 2|3 2 2|3 2 8 2 10 8 8 8 10 10 2 20 17 20 20 23 23 20 27 27 27 23 30 30 27|29 27 27|29 30 30|31 30 30|31 38 35 38 30 38 30 43 43 30 45 42|43 43 42|43 45 43 54 51 54|47 54 54|47 54 27 56 20 60 60 60 56 64 64 64 60 56 69 69 69 65 20 75 75 81 77|81 81 77|81 81 90 83 81 81 81 87 87 83 90 90 90 92 90 94 91|92 92 91|92 90 112 99 112 101 99 103 101 103 103 109 109|103 109 109|103 110 112 112 90 114 112 90 143 120 126 122|126 126 122|126 126 143 129 129 126 129 129 131 129 129 134 137 126 139 137|126 126 137|126 143 143 143 143 143 145 143 143 150 143 153 153 150 143 143 160 160 159 160 155 163 163 160 165 163 165 165 170 170 163 143 175 185 185 178 185 180 178 183 183 180 185 185 188 188 185 193 189 193 193 185 195 193 195 199 199 193 201 199 193 185 204 204 208 208 211 208 208 211 214 214 211 218 218 218 214 211 226 224 224 224 226 226 246 229 229 226 232 232 229 232 232 232 229 229 237 240 229|239 229 229|239 246 244 245 246 246 246 246 250 248 253 253 250 248 248 260 260 259 260 255 263 263 260 246 266 266 269 270 270 274 271|274 274 271|274 270 278 278 278 274 270 281 279 279 279 270	Association
19290018	Chemical	Gene	D009538	1137	True	0	What is [PHARMGKB] between @ChemicalSrc$ nicotine @/ChemicalSrc$ and @GeneTgt$ CHRNA4 @/GeneTgt$ ? [SEP] Association of nicotinic acetylcholine receptor subunit alpha 4 polymorphisms with @ChemicalSrc$ nicotine @/ChemicalSrc$ dependence in 5500 Germans . Polymorphisms in the @GeneTgt$ CHRNA4 @/GeneTgt$ gene coding the nicotinic acetylcholine receptor subunit alpha 4 have recently been suggested to play a role in the determination of smoking-related phenotypes . To examine this hypothesis , we conducted a genetic association study in three large samples from the German general population ( N(1)=1412 ; N(2)=1855 ; N(3)=2294 ) . Five single-nucleotide polymorphisms in @GeneTgt$ CHRNA4 @/GeneTgt$ were genotyped in 5561 participants , including 2707 heavily smoking cases ( regularly smoking at least 20 cigarettes per day ) and 2399 never-smoking controls ( & lt;or=100 cigarettes over lifetime ) . We examined associations of the polymorphisms with smoking case-control status and with the extent of @ChemicalSrc$ nicotine @/ChemicalSrc$ dependence as measured by the Fagerstrom test of @ChemicalSrc$ nicotine @/ChemicalSrc$ dependence ( FTND ) score ( N=1030 ) . The most significant association was observed between rs2236196 and FTND ( P=0.0023 ) , whereas the closely linked rs1044396 had most statistical support in the case-control models ( P=0.0080 ) . The consistent effect estimates across three independent cohorts elaborate on recently published functional studies of rs2236196 from the @GeneTgt$ CHRNA4 @/GeneTgt$ 3'-untranslated region and seem to converge with accumulating evidence to firmly implicate the variant G allele of this polymorphism in the intensification of @ChemicalSrc$ nicotine @/ChemicalSrc$ dependence .	1 9 9 9 9 9 9 9 1 13 10|13 13 10|13 1 16 16 13 1 36 24 24 21|24 24 21|24 19 24 31 31 31 31 31 25 31 36 36 36 36 38 36 40 38 43 43 38 46 46 43 36 50 55 52 50 55 55 55 59 59 59 55 63 63 63 59 68 68 68 68 63 70 55 70 70 74 70 70 55 79 79 84 81 79|80 79 79|80 84 84 87 87 84 87 93 93 92 93 87 96 96 93 98 99 100 96 102 100 96 93 107 107 93 107 107 111 107 113 107 107 84 118 118 118 122 122 119 126 126 126 119 126 130 130 126 134 134|131 134 134|131 130 136 118 140 140 140 136 148 140|144 144 140|144 148 146 148 148 140 150 148 150 118 158 157 158 160 160 160 162 160 162 162 166 162 166 160 160 173 172 173 174 160 176 177 174 181 181 181 174 183 181 183 160 188 188 189 194 193 193 193 189 194 199 197 199 199 194 201 199 207 207 203|207 207 203|207 207 199 194 194 211 209 214 214 211 217 217 214 221 221 221 217 224 224 221 227 227 217 231 227|231 231 227|231 227 194	Association
19388002	Chemical	Gene	D015283	775	False	2	What is [PHARMGKB] between @ChemicalSrc$ citalopram @/ChemicalSrc$ and @GeneTgt$ CACNA1C @/GeneTgt$ ? [SEP] Phenotypic effects of a bipolar liability gene among individuals with major depressive disorder . Variations in voltage-dependent calcium channel L-type , alpha 1C subunit ( @GeneTgt$ CACNA1C @/GeneTgt$ ) gene have been associated with bipolar disorder in a recent meta-analysis of genome-wide association studies [ Ferreira et al. , 2008 ] . The impact of these variations on other psychiatric disorders has not been yet investigated . Caucasian non-Hispanic participants in the STAR*D study of treatment for depression for whom DNA was available ( N = 1213 ) were genotyped at two single-nucleotide polymorphisms ( SNPs ) ( rs10848635 and rs1006737 ) in the @GeneTgt$ CACNA1C @/GeneTgt$ gene . We examined putative phenotypic indicators of bipolarity among patients with major depression and elements of longitudinal course suggestive of latent bipolarity . We also considered remission and depression severity following @ChemicalSrc$ citalopram @/ChemicalSrc$ treatment . The rs10848635 risk allele was significantly associated with lower levels of baseline agitation ( P = 0.03 ; beta = -0.09 ) . The rs1006737 risk allele was significantly associated with lesser baseline depression severity ( P = 0.04 ; beta = -0.4 ) and decreased likelihood of insomnia ( P = 0.047 ; beta = -0.22 ) . Both markers were associated with an increased risk of @ChemicalSrc$ citalopram-emergent @/ChemicalSrc$ suicidality ( rs10848635 : OR = 1.29 , P = 0.04 ; rs1006737 : OR = 1.34 , P = 0.02 ) . In this exploratory analysis , treatment-emergent suicidality was associated with two risk alleles in a putative bipolar liability gene .	2 2 7 7 7 7 2 9 7 13 13 13 9 2 32 29 29 19 29 29 29 24 24 29 29 25|29 29 25|29 29 15 32 32 32 35 35 32 39 39 39 32 43 43 43 39 45 32 47 45 47 45 45 32 54 66 57 57 54 61 61 61 57 66 66 66 66 66 66 70 70 70 74 74 74 70 76 74 78 76 80 83 83 83 78 90 90 85 86 85 90 70 94 94 94 90 96 94 96 99 94 99 99 99 107 107 107|104 107 107|104 94 70 111 111 114 114 111 116 114 118 116 121 121 118 121 121 126 126 123 126 130 130 127 111 134 134 134 134 135 138 135 142 139|142 142 139|142 135 134 148 148 148 151 151 151 151 154 154 151 157 157 154 160 160 157 160 160 164 160 164 160 151 171 171 171 174 174 174 174 179 179 179 179 174 181 179 181 182 181 181 185 186 186 174 191 174 193 191 196 196 193 196 196 200 196 200 196 174 205 207 207 207 211 211 211 207 215 212|215 215 212|215 211 217 215 217 220 217 220 220 224 220 224 220 220 217 230 217 230 230 234 230 230 217 207 242 242 242 247 247 245 247 247 247 251 251 251 247 257 257 257 257 257 247 247	Association
19786980	Chemical	Gene	D010984	2067	False	6	What is [PHARMGKB] between @ChemicalSrc$ platinum @/ChemicalSrc$ and @GeneTgt$ ERCC1 @/GeneTgt$ ? [SEP] Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients . @ChemicalSrc$ Platinum @/ChemicalSrc$ drugs are among the most active and widely used agents in the treatment of different cancers . However , the great individual variability in both outcome and toxicity of @ChemicalSrc$ platinum @/ChemicalSrc$ chemotherapy requires the identification of genetic markers that can be used to screen patients before treatment . In this study , 21 polymorphisms in 10 genes , the protein activities of which may be addressed in different aspects of cisplatin metabolism , were tested for correlations with efficacy and toxicity of cisplatin-cyclophosphamide regimen in 104 ovarian cancer patients . The glutathione S-transferase P1 ( GSTP1 ) Ile105Val polymorphism was strongly associated with progression-free survival ( chi(2)=12.12 , P=0.002 ) . The allelic status of the GSTA1 -69 C&gt;T polymorphism correlated with the overall survival : patients with T/T genotype survived longer than C/C carriers ( P=0.044 ) . Thrombocytopenia , anemia and neuropathy were less frequent among patients with the GSTM1-null or GSTM3 intron 6 AGG/AGG genotypes . Severe neutropenia was associated with the TP53 72 Pro/Pro , XPD 312 Asp/Asn and XRCC1 399 Arg/Arg genotypes . A higher risk of nephrotoxicity was noted for patients with the heterozygous @GeneTgt$ ERCC1 @/GeneTgt$ 19007 T/C and 8092 C/A genotypes . No correlations were found between genotypes and complete tumor responses .	2 2 2 5 2 5 5 10 10 5 14 14 14 5 2 15|18 18 15|18 27 27 27 27 23 27 23 26 23 27 30 30 27 33 33 30 27 51 51 41 41 41 51 44 44 41 44 44 50 47|50 50 47|50 46 51 53 51 56 56 53 60 60 60 56 62 60 62 65 63 51 70 70 85 85 73 85 76 76 73 85 80 80 85 82 80 85 85 85 88 88 85 91 91 88 85 94 85 96 94 98 96 98 98 103 103 98 108 108 108 108 98 85 118 118 113 118 115 118 118 118 121 121 121 121 124 124 121 126 124 128 126 126 121 133 133 140 139 139 139 139 139 133 140 144 144 144 140 144 150 149 149 146 140 150 154 154 150 156 154 156 140 166 159 159 161 161 166 166 166 168 166 171 171 168 171 171 171 177 177 171 166 180 182 182 182 187 187 187 187 182 187 187 191 196 191 191 193 191 187 182 200 200 204 202 200 204 204 206 204 213 213 213 213|209 213 213|209 213 206 213 217 217 213 204 221 223 223 223 225 223 225 229 229 225 223	Association
19904013	Chemical	Gene	D000069059	5444	True	0	What is [PHARMGKB] between @ChemicalSrc$ Atorvastatin @/ChemicalSrc$ and @GeneTgt$ PON1 @/GeneTgt$ ? [SEP] Effect of @ChemicalSrc$ atorvastatin @/ChemicalSrc$ on @GeneTgt$ paraoxonase1 @/GeneTgt$ ( @GeneTgt$ PON1 @/GeneTgt$ ) and oxidative status . It has been proposed that @GeneTgt$ paraoxonase1 @/GeneTgt$ ( @GeneTgt$ PON1 @/GeneTgt$ ) , a high density lipoprotein (HDL)-associated esterase/lactonase , has anti-atherosclerotic properties . The activity of @GeneTgt$ PON1 @/GeneTgt$ is influenced by @GeneTgt$ PON1 @/GeneTgt$ polymorphisms . However , the influence of @GeneTgt$ PON1 @/GeneTgt$ polymorphisms on @GeneTgt$ PON1 @/GeneTgt$ activity and oxidative stress in response to lipid-lowering drugs remains poorly understood . The objective of the present study was to investigate the effects of @ChemicalSrc$ atorvastatin @/ChemicalSrc$ on @GeneTgt$ PON1 @/GeneTgt$ activity and oxidative status . The influence of @GeneTgt$ PON1 @/GeneTgt$ polymorphisms on @GeneTgt$ PON1 @/GeneTgt$ activity and oxidative status in response to @ChemicalSrc$ atorvastatin @/ChemicalSrc$ treatment was also evaluated . In total , 22 hypercholesterolemic patients were treated with @ChemicalSrc$ atorvastatin @/ChemicalSrc$ at a dose of 10 mg/day for 3 months . Lipid profile , lipid oxidation markers ( malondialdehyde ( MDA ) , conjugated diene ( CD ) , total peroxides ( TP ) ) , total antioxidant substance ( TAS ) , oxidative stress index ( OSI ) , and @GeneTgt$ paraoxonase1 @/GeneTgt$ activity were determined before and after treatment . L55 M , Q192R , and T(-107)C @GeneTgt$ PON1 @/GeneTgt$ polymorphisms were also determined . @ChemicalSrc$ Atorvastatin @/ChemicalSrc$ treatment significantly reduced the levels of total cholesterol ( 24.5 % ) , low density lipoprotein ( LDL ) cholesterol ( 25.4 % ) , triglycerides ( 24.4 % ) , CD ( 4.4 % ) , MDA ( 15.2 % ) , TP ( 13.0 % ) and OSI ( 24.0 % ) , and significantly increased the levels of TAS ( 27.3 % ) , and @GeneTgt$ PON1 @/GeneTgt$ activity ( 14.0 % ) . Interestingly , the increase in @GeneTgt$ PON1 @/GeneTgt$ activity and the reduction in oxidative stress in response to @ChemicalSrc$ atorvastatin @/ChemicalSrc$ were influenced only by the @GeneTgt$ PON1 @/GeneTgt$ T-107C polymorphism . @ChemicalSrc$ Atorvastatin @/ChemicalSrc$ treatment improved the lipid profile , lipid oxidation , and oxidative/antioxidative status markers including the activity of @GeneTgt$ PON1 @/GeneTgt$ towards paraoxon . These beneficial effects may be attributed to the antioxidant properties of statins and the increase in @GeneTgt$ PON1 @/GeneTgt$ activity . The increase in @GeneTgt$ PON1 @/GeneTgt$ activity was enhanced by the @GeneTgt$ PON1 @/GeneTgt$ T-107C polymorphism .	1 3 1|2 1 1|2 6 1|4 1 1|4 9 6 6 6 9 6 14 6 1 22 22 22 22 38 27|23 27 27|23 27 38|25 38 38|25 27 27 36 36 34 36 36 27 27 22 40 38 22 45 50 47 45|46 45 45|46 50 50 54 54|50 54 54|50 50 50 78 78 61 78 65 65|62 65 65|62 61 69 65|69 69 65|69 61 69 72 69 74 61 77 77 74 78 80 78 78 85 90 89 89 89 85 90 92 90 94 92 96 94|95 94 94|95 101 101|97 101 101|97 94 101 104 101 90 109 129 113 110|113 113 110|113 109 117 117|113 117 117|113 109 117 120 117 122 109 126 126|121 126 126|121 122 129 129 129 129 135 141 141 139 139 141 141 141 143 141|142 141 141|142 147 147 141 150 150 147 153 153 141 141 157 168 157 161 161 158 165 165 165 161 165 161 168 168 171 169 171 169 175 169 177 175 177 169 168 183 183 200 185 183 185 183 190 190 183 192 190 192 183 183 195|198 198 195|198 183 200 168 204 201 204 200 168 208 208 208 208 210 208 208 216|213 216 216|213 219 219 219 208 219 221|224 224 221|224 226 226 226 228 226 231 231 228 234 234 231 234 231 243 243 243 241 243 243 231 246 246 243 246 243 228 252 252 249 252 249 249 258 258 255 258 249 249 264 264 261 264 261 249 270 270 267 270 226 226 276 276 273 276 273 226 281 226 283 281 285 283 288 288 285 288 285 285 294|290 294 294|290 285 297 297 294 297 226 322 322 305 322 309 309|306 309 309|306 305 305 312 305 315 315 312 317 312 319 317 317 317 322 322 322 329 329 329|323 329 329|323 329 322 322 333|336 336 333|336 337 337 340 340 337 340 343 340 340 340 348 348 340 351 351 348 353 351 351 351 356 351 337 362 362 365 365 365 365 369 369 369 365 371 369 369 374 369 378 375|378 378 375|378 374 365 382 388 386 383|386 386 383|386 382 388 388 394 394 389|394 394 389|394 394 388 388	Association
20619611	Chemical	Gene	D016666	1312	True	0	What is [PHARMGKB] between @ChemicalSrc$ fluvoxamine @/ChemicalSrc$ and @GeneTgt$ COMT @/GeneTgt$ ? [SEP] Effect of @GeneTgt$ catechol-O-methyltransferase @/GeneTgt$ Val(108/158)Met polymorphism on antidepressant efficacy of @ChemicalSrc$ fluvoxamine @/ChemicalSrc$ . RATIONALE : The @GeneTgt$ catechol-O-methyltransferase @/GeneTgt$ ( @GeneTgt$ COMT @/GeneTgt$ ) enzyme inactivates catecholamines , and the @GeneTgt$ COMT @/GeneTgt$ Val(108/158)Met polymorphism ( rs4680 ) influences the enzyme activity . Recent clinical studies found a significant effect of rs4680 on antidepressant response to fluoxetine and paroxetine , but several other studies were negative . No study considered drug plasma levels as possible nuisance covariate . OBJECTIVES : We studied the effect of rs4680 on response to @ChemicalSrc$ fluvoxamine @/ChemicalSrc$ antidepressant monotherapy . PATIENTS AND METHODS : Forty-one consecutively admitted inpatients affected by a major depressive episode in course of major depressive disorder were administered @ChemicalSrc$ fluvoxamine @/ChemicalSrc$ for 6 weeks . Changes in severity of depression were assessed with weekly Hamilton Depression ratings and analyzed with repeated measures ANOVA in the context of General Linear Model , with rs4680 and @ChemicalSrc$ fluvoxamine @/ChemicalSrc$ plasma levels as factors . RESULTS : rs4680 significantly interacted with time in affecting antidepressant response to @ChemicalSrc$ fluvoxamine @/ChemicalSrc$ , with outcome being inversely proportional to the enzyme activity : better effects in Met-carriers , worse effects in Val/Val homozygotes . The effect became significant at the fourth week of treatment , and influence final response rates . @ChemicalSrc$ Fluvoxamine @/ChemicalSrc$ plasma levels had marginal effects on outcome . CONCLUSIONS : This is the first study that reports a positive effect of rs4680 on response to @ChemicalSrc$ fluvoxamine @/ChemicalSrc$ , and the third independent report of its influence on response to selective 5-HT reuptake inhibitors ( SSRIs ) . Our findings support the hypothesis that factors affecting catecholaminergic neurotransmission might contribute to shape the individual response to antidepressants irrespective of their primary molecular target .	1 6 2|6 6 2|6 6 1 9 9 1 11 9 9 9 1 16 16 25 25|18 25 25|18 22 19|20 19 19|20 22 26 16 26 26 26 34 34|28 34 34|28 34 38 36 34 36 26 41 41 38 16 48 48 49 49 52 52 49 54 52 57 57 52 59 57 59 59 49 49 66 66 68 68 49 49 71 72 72 75 75 72 79 79 79 72 72 81 84 84 81 86 84 88 86 90 86 95 91|95 95 91|95 95 90 84 98 98 98 98 105 104 105 119 105 111 111 111 111 106 113 111 117 117 117 113 119 98 119 119 119 124 124 119 119 133 129 127 131 129 133 133 138 138 137 138 133 133 133 143 143 144 140 147 147 140 151 151 151 147 140 154 140 154 154|155 154 154|155 159 154 161 154 133 190 164 168 168 164 170 168 172 168 174 172 176 174|175 174 174|175 168 180 183 183 183 168 187 187 187 183 168 190 190 192 195 192 195 190 198 198 195 190 202 203 203 203 208 208 208 204 210 208 203 203 203 216 216 213 203 217|221 221 217|221 221 222 222 224 222 226 222 222 229 229 235 235 235 235 229 237 235 240 240 237 242 240 244 240 246 244|245 244 244|245 237 235 253 252 253 235 256 256 253 258 256 263 263 263 263 258 265 263 265 229 270 271 271 273 271 280 280 275 278 276 280 273 282 280 285 285 282 287 285 282 293 293 293 293 288 271	Association
20826553	Chemical	Gene	D009661	2784	True	0	What is [PHARMGKB] between @ChemicalSrc$ nortriptyline @/ChemicalSrc$ and @GeneTgt$ GNB3 @/GeneTgt$ ? [SEP] Variation in @GeneTgt$ GNB3 @/GeneTgt$ predicts response and adverse reactions to antidepressants . There is substantial inter-individual variation in response and adverse reactions to antidepressants , and genetic variation may , in part , explain these differences . @GeneTgt$ GNB3 @/GeneTgt$ encodes the beta3 subunit of the G protein complex , which is involved in the downstream signalling cascade following monoamine receptor activation . A functional polymorphism in this gene ( C825 T ) has been associated with response to antidepressants . Several lines of evidence suggest that @GeneTgt$ GNB3 @/GeneTgt$ moderates improvement in the neurovegetative symptoms of depression ( such as sleep and appetite ) and related adverse reactions independently of change in core mood symptoms . We here report analysis of data from GENDEP , a part-randomized pharmacogenomic trial , on the outcome of 811 subjects with major depression undergoing treatment with either escitalopram or @ChemicalSrc$ nortriptyline @/ChemicalSrc$ in which the C825 T SNP and three further SNPs in @GeneTgt$ GNB3 @/GeneTgt$ were genotyped . The TT genotype was significantly associated with a superior response to @ChemicalSrc$ nortriptyline @/ChemicalSrc$ and these effects were specific to improvements in neurovegetative symptoms . In addition , the same genotype predicted fewer incidents of treatment-emergent insomnia and greater weight gain on the same drug . Our results are consistent with previous associations with @GeneTgt$ GNB3 @/GeneTgt$ and emphasize the importance of signalling genes in antidepressant response .	5 3 1|2 1 1|2 5 5 6 9 6 11 6 5 15 15 18 18 15 20 18 20 23 20 25 20 25 25 29 25 35 35 33 35 35 15 37 35 15 38|41 41 38|41 41 44 44 41 49 49 49 49 44 49 53 53 44 58 58 58 58 53 62 62 62 58 41 67 67 77 70 70 67 73 73 70 73 77 77 77 79 77 81 79 77 84 87 86 84 87 91 91|88 91 91|88 87 91 96 96 96 92 98 96 98 102 100 98 102 102 102 96 109 109 96 109 112 110 116 116 116 112 87 121 121 121 121 124 122 126 124 126 131 131 131 126 131 135 135 131 138 138 135 141 141 138 141 142 146 146 143 146 146|147 146 146|147 151 164 155 155 155 164 155 159 159 155 161 159 159 159 164 146 121 170 170 173 173 173 173 177 177 177 173 179 177|178 177 177|178 173 183 185 185 173 187 185 190 190 187 185 194 199 199 198 198 199 199 201 199 204 204 201 204 208 208 204 212 212 212 208 199 215 217 217 217 220 220 217 222 221|220 220 221|220 217 217 227 225 230 230 227 233 233 227 217	Association
22388796	Chemical	Gene	D016572	1576	True	0	What is [PHARMGKB] between @ChemicalSrc$ cyclosporine @/ChemicalSrc$ and @GeneTgt$ CYP3A4 @/GeneTgt$ ? [SEP] The new @GeneTgt$ CYP3A4 @/GeneTgt$ intron 6 C&gt;T polymorphism ( @GeneTgt$ CYP3A4 @/GeneTgt$ * 22 ) is associated with an increased risk of delayed graft function and worse renal function in @ChemicalSrc$ cyclosporine-treated @/ChemicalSrc$ kidney transplant patients . OBJECTIVE : Cyclosporine A ( CsA ) is a substrate of @GeneTgt$ cytochrome P450 3A4 @/GeneTgt$ ( @GeneTgt$ CYP3A4 @/GeneTgt$ ) . Recently , a newly discovered intron 6 single-nucleotide polymorphism in @GeneTgt$ CYP3A4 @/GeneTgt$ ( rs35599367 C&gt;T ) , defining the @GeneTgt$ CYP3A4 @/GeneTgt$ * 22 allele , has been linked to reduced hepatic expression and activity of @GeneTgt$ CYP3A4 @/GeneTgt$ . In the present study , the clinical impact of this single-nucleotide polymorphism was investigated in a cohort of patients receiving a CsA-based immunosuppressive regimen . MATERIALS AND METHODS : A total of 172 de-novo kidney transplant recipients , receiving CsA/mycophenolate mofetil as immunosuppressive therapy and participating in the Fixed-Dose Concentration Controlled study , were genotyped for the new @GeneTgt$ CYP3A4 @/GeneTgt$ * 22 allele . CsA C(0 ) and/or C(2 ) levels were measured on days 3 and 10 and in months 1 , 3 , 6 , and 12 after transplantation . Plasma creatinine concentrations , delayed graft function ( DGF ) , and biopsy-proven acute rejection were recorded . RESULTS : The @GeneTgt$ CYP3A4 @/GeneTgt$ * 22 allele was significantly associated with a higher risk of DGF compared with the @GeneTgt$ CYP3A4 @/GeneTgt$ * 1/*1 patients after adjustment for known risk factors [ odds ratio (OR)=6.34 , confidence interval ( CI(95 % ): 1.38 - 29.3 ) , P=0.015 ] . Mixed-model analysis demonstrated that the overall creatinine clearance was 20 % lower in @GeneTgt$ CYP3A4 @/GeneTgt$ * 22 allele carriers compared with @GeneTgt$ CYP3A4 @/GeneTgt$ * 1/*1 patients [ CI(95 % ) ( -33.1 to -7.2 % ) , P=0.002 ] . For ABCB1 3435C&gt;T , T-variant carriers had a decreased risk of developing DGF compared with CC patients [ CT : OR=0.30 , CI(95 % ) ( 0.11 - 0.77 ) , P=0.011 ; TT : OR=0.18 , CI(95 % ) ( 0.05 - 0.67 ) , P=0.011 ] . CONCLUSION : @GeneTgt$ CYP3A4 @/GeneTgt$ * 22 constitutes a risk factor for DGF and worse creatinine clearance in patients receiving CsA-based immunosuppressive therapy . Therefore , pretransplant genotyping for the @GeneTgt$ CYP3A4 @/GeneTgt$ * 22 allele might help clinicians to identify patients at risk of DGF and poor renal function when treated with CsA.	8 8 2|5 5 2|5 8 8 8 16 10 8 8 8 10 10 10 16 16 20 20 20 16 24 24 24 20 24 28 28 24 34 34|27 34 34|27 34 34 28 16 39 39 42 48 44 42 44 48 48 39 50 48|49|50 48|49|50 48|49|50 48|50 48|49|50 55 50|51 50 50|51 55 48 88 88 69 65 66 69 69 69 88 71 69|70 69 69|70 75 75 71 75 69 69 84 84|78 84 84|78 84 84 78 69 88 88 88 92 92 92 88 92 92 96 92|93 92 92|93 88 105 105 105 115 115 109 109 115 113 113 113 109 115 115 118 118 115 120 118 120 125 125 125 121 115 156 127 127 127 132 127 138 138 138 138 138 132 127 127 142 140 145 145 140 140 140 153 153 153 153 153 147 127 156 156 164 164 164 159|164 164 159|164 164 164 156 156 168 168 168 168 168 171 175 175 168 177 175 177 178 178 177 183 177 183 184 184 186 186 184 184 184 193 191 175 197 197 211 197 201 201 197 203 201 203 201 197 209 209 197 211 211 211 213 213 220 220|215 220 220|215 220 220 223 223 223 213 227 227 227 223 229 227 223 237 237 237|231 237 237|231 237 237 230 239 237 243 243 243 239 246 246 237 250 250 250 246 253 253 250 253 257 257 253 253 250 250 250 213 266 267 267 276 272 272 272 276 276 275 276 267 283 283|277 283 283|277 283 283 283 276 290 290 290|284 290 290|284 290 290 276 293 293 290 293 299 298 298 299 290 299 290 290 302 267 308 313 308 313 312 313 313 316 316 313 318 316 318 313 323 323 320 325 323 325 313 327 330 327 327 333 335 335 327 327 327 327 327 327 327 327 342 345 342 342 348 350 350 342 342 327 327 327 313 356 356 357|362 362 357|362 358 358 356 365 365 362 367 365 365 371 371 365 373 371 373 377 377 374 362 392 392 383 392 390 390 390|385 390 390|385 390 390 383 392 392 392 395 392 395 398 396 400 398 398 404 404 398 406 395 408 406	Association
22415532	Chemical	Gene	D006221	6261	False	3	What is [PHARMGKB] between @ChemicalSrc$ halothane @/ChemicalSrc$ and @GeneTgt$ RYR1 @/GeneTgt$ ? [SEP] Novel double and single @GeneTgt$ ryanodine receptor 1 @/GeneTgt$ variants in two Austrian malignant hyperthermia families . BACKGROUND : Malignant hyperthermia ( MH ) is a potentially lethal genetic disorder in response to volatile anesthetics and depolarizing muscle relaxants . To support the claim that a novel genetic variant causes MH , it is necessary to demonstrate that it has significant effects on the sensitivity of the ryanodine receptor ( @GeneTgt$ RYR1 @/GeneTgt$ ) calcium channel . In this study we focused on 2 Austrian families with strong MH disposition and new @GeneTgt$ RYR1 @/GeneTgt$ variants . METHODS : We sequenced the entire coding region of the @GeneTgt$ RYR1 @/GeneTgt$ from 2 Austrian MH individuals . Genotype-phenotype segregation and evolutionary conservation of the variants were considered . On a functional level , Ca(2 + ) release experiments with fura-2-acetoxymethyl ester were performed in cultured skeletal muscle cells derived from individuals carrying the new variants and compared with control cells from nonsusceptible individuals . Caffeine , 4-chloro-m-cresole ( 4-CmC ) , and @ChemicalSrc$ halothane @/ChemicalSrc$ were used as specific Ca(2 + ) releasing agents . RESULTS : The variant p. A612P in family A segregated with an MH-susceptible phenotype and cells showed an increased sensitivity for all Ca(2+)-releasing substances tested . In family B , 2 variants ( p. R2458H/p . R3348C ) were identified . While p. R2458H and p. R2458H/p . R3348C segregated with an MH-susceptible diagnosis , p. R3348C alone showed an MH equivocal diagnosis . Ca(2+)-release experiments showed that exchanges of these highly conserved amino acids increased the sensitivities for the substances tested ( except 4-CmC with p. R2458H and p. R3348C ) when compared with the MH-negative control group . CONCLUSIONS : Our results suggest that these variants are new causative MH variants .	2 2 2 2 9|4 9|4 9|4 9 9|4 2 15 15 15 15 15 2 2 18 18 21 30 23 21 23 30 30 28 30 30 18 32 30 35 35 32 35 39 39 35 18 42 55 44 42 50 49 49 49 50 44 50 55 55 55 55 57 55 60 60 57 62 60 65 65 60 75 75 69 75 71 75|70 75 75|70 75 75 65 55 80 80 82 82 82 86 86 86 82 90 90 90 86 90 95 95|92 95 95|92 90 82 101 101 101 101 105 105 105 101 108 108 105|107 105 105|107 114 114 113 114 105 101 118 126 118 121 118 124 124 121 126 126 126 131 131 131 136 136 132 133 133 142 136 140 140 137 142 142 147 147 147 147 142 147 150 148 150 154 154 151 142 142 159 159 156 162 162 159 142 175 164 164 168 166 168 164 164 171|164 164 171|164 175 175 178 178 175 178 182 182 178 175 201 185 190 190 190 194 193 193 190 185 198 198 198 194 198 198 201 204 204 201 208 208 208 204 208 201 213 213 216 216 216 216 218 216 218 216 224 221 224 224 224 227 227 227 227 227 230 232 234 234 238 238 238 234 243 241 243 241 234 247 246 247 243 243 250 251 251 260 260 259 259 257 259 259 253 251 262 260 265 265 262 265 269 269 260 271 269 271 271 271 274 269 278 260 283 283 283 283 278 251 285 285 288 289 285 297 292 297 297 297 297 297 289 285	Association
22495427	Chemical	Gene	D001379	316	True	0	What is [PHARMGKB] between @ChemicalSrc$ AZA @/ChemicalSrc$ and @GeneTgt$ AOX1 @/GeneTgt$ ? [SEP] Polymorphism of genes involved in purine metabolism ( XDH , @GeneTgt$ AOX1 @/GeneTgt$ , MOCOS ) in kidney transplant recipients receiving @ChemicalSrc$ azathioprine @/ChemicalSrc$ . BACKGROUND : Xanthine dehydrogenase ( XDH ) , @GeneTgt$ aldehyde oxidase1 @/GeneTgt$ ( @GeneTgt$ AOX1 @/GeneTgt$ ) , and molybdenum cofactor sulfurase ( MOCOS ) are enzymes involved in purine metabolism . The aim of this study was to investigate single nucleotide polymorphisms ( SNPs ) in XDH , @GeneTgt$ AOX1 @/GeneTgt$ , and MOCOS genes in relation to clinical parameters and risk of drug side effects in a cohort of kidney transplant recipients treated with @ChemicalSrc$ azathioprine @/ChemicalSrc$ ( @ChemicalSrc$ AZA @/ChemicalSrc$ ) as a part of standard immunosuppressive regimen . METHODS : One hundred fifty-six patients receiving @ChemicalSrc$ AZA @/ChemicalSrc$ for the first year from the surgery were genotyped for the presence of common SNPs in the coding regions of XDH , @GeneTgt$ AOX1 @/GeneTgt$ , and MOCOS genes using TaqMan assays . RESULTS : @GeneTgt$ AOX1 @/GeneTgt$ rs55754655 variant allele carriers received a higher mean @ChemicalSrc$ AZA @/ChemicalSrc$ dose 3 , 6 , and 12 months after transplantation ( P & lt ; 0.05 ) . The patients inheriting rs594445 MOCOS minor allele required significantly lower doses of @ChemicalSrc$ AZA @/ChemicalSrc$ for efficient treatment compared with wild-type heterozygotes at 3 , 6 , and 12 months from the transplantation ( mean values : 1.39 versus 1.59 , 1.38 versus 1.58 , and 1.33 versus 1.53 mg kg 24 h ) and displayed lower mean RBC count at the time points evaluated . Multivariate analysis has shown that the effect of MOCOS rs594445 polymorphism is independent of other investigated gene variations and might influence @ChemicalSrc$ AZA @/ChemicalSrc$ dosage , similarly to TPMT heterozygosity . The authors have not observed an association between any of the studied XDH SNPs and clinical parameters of @ChemicalSrc$ AZA-treated @/ChemicalSrc$ patients . CONCLUSIONS : The results of this study should be regarded as preliminary . However , if the observed association between SNPs : @GeneTgt$ AOX1 @/GeneTgt$ rs55754655 , MOCOS rs594445 , and @ChemicalSrc$ AZA @/ChemicalSrc$ dose requirements would be positively confirmed in further independent studies , it could be introduced into clinical practice to individualize thiopurine treatment .	1 3 1 3 7 7 4 9 7 9 9|10 9 9|10 9 9 9 19 19 19 7 19 19|20 20 19|20 1 26 26 29 50 31 29 31 29 33|34|29 33|34|29 34|29 33|34|29 38 34|35 34 34|35 38 29 29 45 45 29 47 45 47 50 26 50 54 54 51 26 59 63 62 62 59 63 65 63 68 68 65 70 68 70 73 68 73 73|74 73 73|74 73 73 80 73 82 65 85 85 82 85 85 91 91 91 87 94 94 82 98 98 98 94 98 101 99 99 99 104 101 101 101 104 109 109 99 113 113 113 109 63 135 135 121 122 123 135 123 124 124 124 130 130 130 124 133 133 130 135 135 138 138 135 141 141 138 145 145 145 138 147 145 147 147 147 147 147 147 154 147 135 157 155 135 161 161 162|165 165 162|165 168 168 168 169 161 175 175 171 171|175 175 171|175 169 175 176 175 175 175 182 175 184 182 186 184 186 186 186 186 186 161 196 197 197 201 201 201 197 197 204 205 202 207 205|206 205 205|206 211 211 202 197 215 215 212 217 223 217 217 217 217 217 212 226 226 223 229 229 223 229 246 231 231 231 231 235 235 231 231 231 240 240 246 243 246 229 229 197 197 253 250 253 249 257 257 257 253 257 197 262 264 264 264 273 267 273 271 270 271 267 273 264 278 278 278 278 273 273 281 273 284|281 284 284|281 281 281 289 289 289 281 264 293 296 296 296 296 298 296 300 298 305 305 305 305 300 305 308 305 312 309|312 312 309|312 308 296 315 315 318 324 321 321 318 324 324 315 324 325 315 361 361 352 333 333 352 335 333 333 336|339 339 336|339 333 339 342 339 339 339 343|348 348 343|348 348 352 352 352 352 361 356 356 356 352 361 361 361 361 361 364 364 361 366 364 368 366 361	Association
22495427	Chemical	Gene	D001379	55034	True	0	What is [PHARMGKB] between @ChemicalSrc$ AZA @/ChemicalSrc$ and @GeneTgt$ MOCOS @/GeneTgt$ ? [SEP] Polymorphism of genes involved in purine metabolism ( XDH , AOX1 , @GeneTgt$ MOCOS @/GeneTgt$ ) in kidney transplant recipients receiving @ChemicalSrc$ azathioprine @/ChemicalSrc$ . BACKGROUND : Xanthine dehydrogenase ( XDH ) , aldehyde oxidase1 ( AOX1 ) , and @GeneTgt$ molybdenum cofactor sulfurase @/GeneTgt$ ( @GeneTgt$ MOCOS @/GeneTgt$ ) are enzymes involved in purine metabolism . The aim of this study was to investigate single nucleotide polymorphisms ( SNPs ) in XDH , AOX1 , and @GeneTgt$ MOCOS @/GeneTgt$ genes in relation to clinical parameters and risk of drug side effects in a cohort of kidney transplant recipients treated with @ChemicalSrc$ azathioprine @/ChemicalSrc$ ( @ChemicalSrc$ AZA @/ChemicalSrc$ ) as a part of standard immunosuppressive regimen . METHODS : One hundred fifty-six patients receiving @ChemicalSrc$ AZA @/ChemicalSrc$ for the first year from the surgery were genotyped for the presence of common SNPs in the coding regions of XDH , AOX1 , and @GeneTgt$ MOCOS @/GeneTgt$ genes using TaqMan assays . RESULTS : AOX1 rs55754655 variant allele carriers received a higher mean @ChemicalSrc$ AZA @/ChemicalSrc$ dose 3 , 6 , and 12 months after transplantation ( P & lt ; 0.05 ) . The patients inheriting rs594445 @GeneTgt$ MOCOS @/GeneTgt$ minor allele required significantly lower doses of @ChemicalSrc$ AZA @/ChemicalSrc$ for efficient treatment compared with wild-type heterozygotes at 3 , 6 , and 12 months from the transplantation ( mean values : 1.39 versus 1.59 , 1.38 versus 1.58 , and 1.33 versus 1.53 mg kg 24 h ) and displayed lower mean RBC count at the time points evaluated . Multivariate analysis has shown that the effect of @GeneTgt$ MOCOS @/GeneTgt$ rs594445 polymorphism is independent of other investigated gene variations and might influence @ChemicalSrc$ AZA @/ChemicalSrc$ dosage , similarly to TPMT heterozygosity . The authors have not observed an association between any of the studied XDH SNPs and clinical parameters of @ChemicalSrc$ AZA-treated @/ChemicalSrc$ patients . CONCLUSIONS : The results of this study should be regarded as preliminary . However , if the observed association between SNPs : AOX1 rs55754655 , @GeneTgt$ MOCOS @/GeneTgt$ rs594445 , and @ChemicalSrc$ AZA @/ChemicalSrc$ dose requirements would be positively confirmed in further independent studies , it could be introduced into clinical practice to individualize thiopurine treatment .	1 3 1 3 7 7 4 9 7 9 9 9 9|12 9 9|12 9 19 19 19 7 19 19|20 20 19|20 1 26 26 29 50 31 29 31 29 35 29 37 35 37 29 29 41|29|40 41|29|40 41|29|40 41|29 41|29|40 46 41|42 41 41|42 46 50 26 50 54 54 51 26 59 63 62 62 59 63 65 63 68 68 65 70 68 70 73 68 73 73 73 73 77|80 80 77|80 73 82 65 85 85 82 85 85 91 91 91 87 94 94 82 98 98 98 94 98 101 99 99 99 104 101 101 101 104 109 109 99 113 113 113 109 63 135 135 121 122 123 135 123 124 124 124 130 130 130 124 133 133 130 135 135 138 138 135 141 141 138 145 145 145 138 147 145 147 147 147 147 150|154 154 150|154 147 135 157 155 135 161 161 164 167 167 167 168 161 174 174 170 171|174 174 171|174 168 174 175 174 174 174 181 174 183 181 185 183 185 185 185 185 185 161 194 195 195 200 200|196 200 200|196 200 195 195 203 204 201 206 204 204 204 210 210 201 195 214 214 211 216 222 216 216 216 216 216 211 225 225 222 228 228 222 228 245 230 230 230 230 234 234 230 230 230 239 239 245 242 245 228 228 195 195 252 249 252 248 256 256 256 252 256 195 262 264 264 264 274 267 274 272 268|271 271 268|271 272 267 274 264 279 279 279 279 274 274 282 274 285|281 285 285|281 282 282 290 290 290 282 264 295 298 298 298 298 300 298 302 300 307 307 307 307 302 307 310 307 314 311|314 314 311|314 310 298 317 317 320 326 323 323 320 326 326 317 326 327 317 363 363 354 335 335 354 337 335 335 340 335 340 341|344 344 341|344 340 340 340 345|350 350 345|350 350 354 354 354 354 363 358 358 358 354 363 363 363 363 363 366 366 363 368 366 370 368 363	Association
22516052	Chemical	Gene	D002945	1317	True	0	What is [PHARMGKB] between @ChemicalSrc$ cisplatin @/ChemicalSrc$ and @GeneTgt$ CTR1 @/GeneTgt$ ? [SEP] Prediction of @GeneTgt$ copper transport protein 1 @/GeneTgt$ ( @GeneTgt$ CTR1 @/GeneTgt$ ) genotype on severe @ChemicalSrc$ cisplatin @/ChemicalSrc$ induced toxicity in non-small cell lung cancer ( NSCLC ) patients . BACKGROUND : @ChemicalSrc$ Cisplatin @/ChemicalSrc$ toxicity severely obstacles successful chemotherapy in lung cancer patients . @ChemicalSrc$ Cisplatin @/ChemicalSrc$ uptake is considered as one of the major factors contributing to the side effects of @ChemicalSrc$ cisplatin @/ChemicalSrc$ . Genetic variances of core genes also affect @ChemicalSrc$ cisplatin @/ChemicalSrc$ toxicity . It has been identified that @GeneTgt$ CTR1 @/GeneTgt$ , copper transporter protein 1 , plays an essential role in @ChemicalSrc$ cisplatin @/ChemicalSrc$ uptake . The purpose of this study is to investigate whether @GeneTgt$ CTR1 @/GeneTgt$ polymorphism is associated with platinum toxicity in non-small cell lung cancer ( NSCLC ) patients . METHOD : 204 incident NSCLC patients from three different institutions were enrolled and followed up . These patients were histologically confirmed with non-small cell lung cancer . All patients have accepted @ChemicalSrc$ cisplatin-based @/ChemicalSrc$ chemotherapy for at least two cycles . Twenty SNPs of @GeneTgt$ CTR1 @/GeneTgt$ were detected in these patients . RESULT : @GeneTgt$ CTR1 @/GeneTgt$ rs10981694 A&gt;C polymorphism is associated with @ChemicalSrc$ cisplatin @/ChemicalSrc$ induced severe toxicity in NSCLC patients . C-carrier subjects presented poorer tolerance to ototoxicity ( p&lt;0.05 ) . The survival times of patients with different rs10981694 genetic polymorphism were not significantly different . CONCLUSION : NSCLC patients carrying C allele of @GeneTgt$ CTR1 @/GeneTgt$ rs10981694 presented more sensitivity to ototoxicity after @ChemicalSrc$ cisplatin @/ChemicalSrc$ treatment . @GeneTgt$ CTR1 @/GeneTgt$ plays an essential role in @ChemicalSrc$ cisplatin @/ChemicalSrc$ toxicity and could be considered as a predictor for pretreatment evaluation in lung cancer patients .	17 12 2|3|12 2|3|12 2|3|12 2|3|12 3|12 2|3|12 9 4|12 12 4|12 9 1 15 15 9|1 1 9|1 17 17 27 23 23 23 27 25 27 27 18 17 32 32 33|36 36 33|36 38 38 32 40 38 44 44 44 40 32 46|49 49 46|49 51 51 51 53 51 57 57 57 53 57 62 62 62 58 64 62 62 62 51 70 75 73 73 70 75 75 78|75 78 78|75 75 75 84 84 84 84 94 85|94 94 85|94 86 91 91 86 91 86 84 97 97 94 101 97|101 101 97|101 94 84 106 110 109 109 106 110 112 110 118 113|116 116 113|116 118 118 112 121 121 118 126 126 126 126 130 128 130 130 121 110 133 133 136 144 138 144 142 142 142 138 144 133 144 144 146 144 150 153 153 153 153 158 158 158 158 153 153 161 163 163 163 163|166 166 163|166 163 171 169 170 171 166 163 175 180 177 175|176 175 175|176 180 180 183 183 180 180 198 186 187|192 192 187|192 192 192 194 194 186 196 194 194 194 198 200 198 203 203 200 198 208 209 209 211 209 213 211 215 213 215 209 220 220 231 222 220 227 227 226 227 222 231 231 231 231 231 233 233 236 244 236 239 237 243 240|243 243 240|243 239 233 246 244 248 246 252 248|252 252 248|252 244 233 255|258 258 255|258 258 261 261 258 265 265|261 265 265|261 258 258 269 269 258 272 272 269 275 275 272 279 279 279 275 258	Association
22577108	Chemical	Gene	D000069449	846	True	0	What is [PHARMGKB] between @ChemicalSrc$ cinacalcet @/ChemicalSrc$ and @GeneTgt$ CASR @/GeneTgt$ ? [SEP] MEN1-related hyperparathyroidism : response to @ChemicalSrc$ cinacalcet @/ChemicalSrc$ and its relationship with the @GeneTgt$ calcium-sensing receptor @/GeneTgt$ gene variant Arg990Gly . OBJECTIVE : Primary hyperparathyroidism ( PHPT ) is a challenging problem in type 1 multiple endocrine neoplasia ( MEN1 ) due to the high postsurgery recurrence rate . The aim was to evaluate the efficacy of @ChemicalSrc$ cinacalcet @/ChemicalSrc$ in MEN1 patients in comparison with patients with sporadic PHPT ( sPHPT ) and the effect of Arg990Gly @GeneTgt$ calcium-sensing receptor @/GeneTgt$ ( @GeneTgt$ CASR @/GeneTgt$ ) polymorphism on the response to treatment . DESIGN : This is a randomized , crossover , double-blind study carried out in the University Hospitals . METHODS : Fifteen MEN1 patients with PHPT were randomized to two groups , one administered with 30 mg daily @ChemicalSrc$ cinacalcet @/ChemicalSrc$ , titrated until calcium normalization , and one with placebo . After 3 months , patients were reassessed and after washout switched to the other treatment . For comparison , 20 sPHPT patients with similar calcium levels were administered with @ChemicalSrc$ cinacalcet @/ChemicalSrc$ for 3 months . Ionized and total calcium , phosphate , and parathyroid hormone ( PTH ) were evaluated . @GeneTgt$ CASR @/GeneTgt$ Arg990Gly was genotyped on blood DNA by direct sequencing . RESULTS : @ChemicalSrc$ Cinacalcet @/ChemicalSrc$ normalized calcium , increased phosphate , and reduced PTH levels in all patients . @ChemicalSrc$ Cinacalcet @/ChemicalSrc$ dosage required to normalize calcium in MEN1 and sPHPT was not significantly different ( 45 + -21 vs 54 + -25 mg/day ) . Few mild adverse events , not requiring drug withdrawal , were observed in both the groups . No association between Arg990Gly @GeneTgt$ CASR @/GeneTgt$ polymorphism and response to @ChemicalSrc$ cinacalcet @/ChemicalSrc$ was found . CONCLUSIONS : This short-term prospective study demonstrated that the efficacy profile of @ChemicalSrc$ cinacalcet @/ChemicalSrc$ in patients with MEN1-related PHPT and in those with sPHPT was similar and was not influenced by the 990 @GeneTgt$ CASR @/GeneTgt$ variant . Although long-term safety and efficacy data are required , @ChemicalSrc$ cinacalcet @/ChemicalSrc$ might be considered a treatment option in MEN1 patients who have contraindications to surgery or persistent PHPT after surgery .	2 2 2 2 6 4|5 4 4|5 4 10 4 18 18 18|11 18|11 18 18|11 18 18 10 2 22 22 25 32 27 25 27 32 32 32 22 38 38 38 38 38 32 40 38 40 48 42 48 48 48 48 32 32 51 54 54 54 54 56 54 58 57|56 56 57|56 62 62 56 64 56 66 64 69 69 66 71 69 71 66 75 64 85 85 76|85 76|85 85 76|85 82 85|78 85 85|78 85 75 88 88 75 90 88 54 95 95 102 102 102 102 100 95 106 105 106 102 106 111 111 111 106 102 121 113 117 117 121 119 117 121 121 124 124 121 124 124 126 132 130 132 132 131|127 127 131|127 124 124 138 138 135 135 124 124 143 141 121 148 148 152 152 152 152 152 152 155 156 152 160 160 160 156 152 163 173 173 167 167 173 171 171 171 167 173 173 175 173|174 173 173|174 179 179 173 173 182 182 182 187 187 182 182 182 191 196 193 191 193 196 182 196 197|200 200 197|200 202 202 202 205 205 202 208 208 202 202 211 211 212|215 215 212|215 211 215 216 219 216 215 215 215 224 222 227 227 224 211 229|232 232 229|232 233 233 235 233 235 238 236 238 238 244 244 244 233 246 253 246 246 248 248 250 250 244 244 233 260 260 260 268 260 263 260 265 263 260 268 268 272 272 272 268 268 275 287 280 280 277|280 280 277|280 275 280 280 284 282 282 282 287 287 287 291 291 296 296 296 297 291 316 301 301 316 303 301|302 301 301|302 306 303 309 309 306 306 312 306 314 312 316 297 316 320 320 316 326 326 326 322|326 326 322|326 320 291 337 332 337 332 332 332 337 343 343 338|343 343 338|343 343 343 343 346 346 343 349 349 346 351 349 351 354 352 354 357 354 359 351 343	Association
23215884	Chemical	Gene	D000074	2626	True	0	What is [PHARMGKB] between @ChemicalSrc$ acenocoumarol @/ChemicalSrc$ and @GeneTgt$ GATA-4 @/GeneTgt$ ? [SEP] Evaluation of the effect of genetic variations in @GeneTgt$ GATA-4 @/GeneTgt$ on the phenprocoumon and @ChemicalSrc$ acenocoumarol @/ChemicalSrc$ maintenance dose . AIM : To investigate whether the phenprocoumon and @ChemicalSrc$ acenocoumarol @/ChemicalSrc$ maintenance doses are influenced by genetic variations in @GeneTgt$ GATA-4 @/GeneTgt$ , a transcription factor of CYP2C9 . PATIENTS & amp ; METHODS : The influence of seven @GeneTgt$ GATA-4 @/GeneTgt$ SNPs on the coumarin maintenance dose was investigated by performing an analysis of variance trend analysis , stratified for CYP2C9 genotypes . Results of the best-explaining SNP were validated in the Rotterdam Study cohort . RESULTS : The largest dose differences were found for rs3735814 in patients using @ChemicalSrc$ acenocoumarol @/ChemicalSrc$ and having the common allele for CYP2C9 . The mean dosages decreased from 2.92 mg/day for the patients having the @GeneTgt$ GATA-4 @/GeneTgt$ common alleles to 2.65 mg/day for the patients carrying one @GeneTgt$ GATA-4 @/GeneTgt$ variant allele and to 2.37 mg/day for patients carrying two @GeneTgt$ GATA-4 @/GeneTgt$ variant alleles ( p = 0.004 ) . Results could not be replicated in the validation cohort . For phenprocoumon , no significant effects were observed . CONCLUSION : Genetic variation in @GeneTgt$ GATA-4 @/GeneTgt$ does not seem relevant for clinical implementation .	1 4 4 1 7 7 4 9 8|7 7 8|7 18 18 18 13 13 13 13 18 4 1 25 25 25 25 35 28 35 28 29|28 28 29|28 33 28 35 25 38 38 35 40 38 38 38 40 45 45 40 47 45 25 51 51 51 51 51 51 58 70 63 63 60|63 63 60|63 58 68 68 68 68 58 70 51 72 70 74 72 78 78 78 74 72 51 83 83 80 51 92 90 90 90 86 92 92 97 97 97 97 92 92 99 99 104 104 104 106 106 99 108 106 110 108 110 111 111 111 111 106 118 118 115 120 118 99 125 125 126 126 129 129 126 132 132 129 132 138 138|134 138 138|134 138 133 141 141 133 144 144 141 144 150 150|145 150 150|145 150 145 150 154 154 150 156 154 156 162 162|156 162 162|156 162 157 165 165 129 165 165 126 176 176 176 176 176 180 180 180 176 176 183 189 189 187 187 189 189 189 189 191 200 194 200 196 194|195 194 194|195 200 200 191 200 204 204 201 191	Association
23223006	Chemical	Gene	D009538	4988	True	0	What is [PHARMGKB] between @ChemicalSrc$ nicotine @/ChemicalSrc$ and @GeneTgt$ OPRM1 @/GeneTgt$ ? [SEP] @GeneTgt$ OPRM1 @/GeneTgt$ genetic polymorphisms are associated with the plasma @ChemicalSrc$ nicotine @/ChemicalSrc$ metabolite cotinine concentration in methadone maintenance patients : a cross sectional study . Majority of the heroin-dependent patients smoke cigarettes . Although it has been reported that the @GeneTgt$ OPRM1 @/GeneTgt$ genetic polymorphism is associated with the brain mu-opioid receptor binding potential in cigarette smokers , there is no direct evidence showing the impact of plasma cotinine , a @ChemicalSrc$ nicotine @/ChemicalSrc$ metabolite , on treatment responses to methadone maintenance treatment ( MMT ) . In this study , we aimed to test the hypothesis that the genetic polymorphisms in the @GeneTgt$ OPRM1 @/GeneTgt$ are associated with the methadone treatment responses and the severity of cigarette smoking directly measured by the plasma concentration of cotinine in a Taiwanese MMT cohort . Fifteen @GeneTgt$ OPRM1 @/GeneTgt$ single-nucleotide polymorphisms ( SNPs ) were selected and genotyped on DNA samples of 366 MMT patients . Plasma concentrations of cotinine were measured by cotinine enzyme-linked immunosorbent assay . The plasma cotinine concentration had positive correlation with concentrations of methadone ( P = 0.042 ) and its metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenyl-pyrrolidine ( P = 0.037 ) . Methadone treatment non-responders , defined by a positive urine morphine test , had a higher plasma concentration of cotinine ( P = 0.005 ) , but a lower plasma concentration-to-dose ratio of both R- and S-methadone ( P = 0.001 and 0.012 , respectively ) than the responders . @GeneTgt$ OPRM1 @/GeneTgt$ genetic variants , rs1074287 , rs6912029 , rs1799971 , rs12209447 , rs510769 , rs3798676 , rs553202 , rs7748401 , rs495491 , rs10457090 , rs589046 , rs3778152 and rs563649 , were significantly associated with the plasma concentration of cotinine when using recessive model for genotypes ( general linear model ( GLM ) , P&lt;0.038 ; false discovery rate (FDR)&lt;0.035 ) and additive model for allele types ( GLM , P&lt;0.03 ; FDR&lt;0.049 ) in association analyses . The G allele carriers of SNP rs1799971 ( A118 G ) on exon 1 of @GeneTgt$ OPRM1 @/GeneTgt$ gene had a lower plasma cotinine concentration than the A allele carriers ( GLM , P = 0.029 ) . @GeneTgt$ OPRM1 @/GeneTgt$ genetic polymorphisms are associated with the plasma concentration of cotinine in a Taiwanese MMT cohort . Carriers with the major allele of SNP rs1799971 had a higher plasma cotinine concentration .	0|3 3 0|3 4 6 6 6 14 14 14 8|14 14 8|14 14 14 6 18 18 18 14 6 23 23 23 6 6 32 31 31 31 27 32 32 32 39 39 39 39 60 47 45 45|41 45 45|41 45 47 47 39 54 54 54 54 54 54 47 57 57 54 60 60 60 63 63 60 63 66 64 69 69 66 69 74 74|70 74 74|70 69 69 78 78 66 82 82 82 78 84 82 84 60 91 91 94 94 94 94 96 94 98 96 108 102 102 108 105 105 104|102 102 104|102 108 98 113 113 113 113 108 108 116 108 118 119 116 121 119 125 125 125 121 127 125 132 132 132 132 125 94 139 135|139 139 135|139 139 144 141 139 141 144 144 144 144 149 149 146 153 153 153 149 144 157 161 159 157 161 161 166 166 166 166 161 161 171 171 171 172 172 174 172 176 174 178 176 181 181 178 181 181 176 187 187 176 190 190 187 190 190 172 195 196 206 196 196 204 204 204 204 204 198 206 206 210 210 210 206 212 210 215 215 212 215 215 206 206 224 224 224 224 206 227 227 224 227 227 231 232 227 232 233 233 232 232 232 241 241 224 206 242|246 246 242|246 246 276 246 246 248 248 248 248 248 248 248 248 248 248 248 248 248 248 248 248 264 248 266 248 248 248 270 270 246 276 276 276 280 280 280 276 282 280 284 276 286 284 288 286 292 292 292 288 294 292 294 292 292 292 301 301 302 292 292 288 306 288 309 309 306 311 309 311 315 315 311 311 319 319 286 276 325 325 325 340 328 328 325 331 331 328 331 334 325 334 339 339|336 339 339|336 334 340 345 345 345 345 340 350 350 350 350 345 352 350 355 355 352 355 352 340 359|362 362 359|362 363 365 365 365 369 369 369 365 371 369 376 376 376 376 369 365 387 383 383 383 379 386 386 383 387 392 392 392 392 387 387	Association
23223006	Chemical	Gene	D003367	4988	True	0	What is [PHARMGKB] between @ChemicalSrc$ cotinine @/ChemicalSrc$ and @GeneTgt$ OPRM1 @/GeneTgt$ ? [SEP] @GeneTgt$ OPRM1 @/GeneTgt$ genetic polymorphisms are associated with the plasma nicotine metabolite @ChemicalSrc$ cotinine @/ChemicalSrc$ concentration in methadone maintenance patients : a cross sectional study . Majority of the heroin-dependent patients smoke cigarettes . Although it has been reported that the @GeneTgt$ OPRM1 @/GeneTgt$ genetic polymorphism is associated with the brain mu-opioid receptor binding potential in cigarette smokers , there is no direct evidence showing the impact of plasma @ChemicalSrc$ cotinine @/ChemicalSrc$ , a nicotine metabolite , on treatment responses to methadone maintenance treatment ( MMT ) . In this study , we aimed to test the hypothesis that the genetic polymorphisms in the @GeneTgt$ OPRM1 @/GeneTgt$ are associated with the methadone treatment responses and the severity of cigarette smoking directly measured by the plasma concentration of @ChemicalSrc$ cotinine @/ChemicalSrc$ in a Taiwanese MMT cohort . Fifteen @GeneTgt$ OPRM1 @/GeneTgt$ single-nucleotide polymorphisms ( SNPs ) were selected and genotyped on DNA samples of 366 MMT patients . Plasma concentrations of @ChemicalSrc$ cotinine @/ChemicalSrc$ were measured by @ChemicalSrc$ cotinine @/ChemicalSrc$ enzyme-linked immunosorbent assay . The plasma @ChemicalSrc$ cotinine @/ChemicalSrc$ concentration had positive correlation with concentrations of methadone ( P = 0.042 ) and its metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenyl-pyrrolidine ( P = 0.037 ) . Methadone treatment non-responders , defined by a positive urine morphine test , had a higher plasma concentration of @ChemicalSrc$ cotinine @/ChemicalSrc$ ( P = 0.005 ) , but a lower plasma concentration-to-dose ratio of both R- and S-methadone ( P = 0.001 and 0.012 , respectively ) than the responders . @GeneTgt$ OPRM1 @/GeneTgt$ genetic variants , rs1074287 , rs6912029 , rs1799971 , rs12209447 , rs510769 , rs3798676 , rs553202 , rs7748401 , rs495491 , rs10457090 , rs589046 , rs3778152 and rs563649 , were significantly associated with the plasma concentration of cotinine when using recessive model for genotypes ( general linear model ( GLM ) , P&lt;0.038 ; false discovery rate (FDR)&lt;0.035 ) and additive model for allele types ( GLM , P&lt;0.03 ; FDR&lt;0.049 ) in association analyses . The G allele carriers of SNP rs1799971 ( A118 G ) on exon 1 of @GeneTgt$ OPRM1 @/GeneTgt$ gene had a lower plasma @ChemicalSrc$ cotinine @/ChemicalSrc$ concentration than the A allele carriers ( GLM , P = 0.029 ) . @GeneTgt$ OPRM1 @/GeneTgt$ genetic polymorphisms are associated with the plasma concentration of @ChemicalSrc$ cotinine @/ChemicalSrc$ in a Taiwanese MMT cohort . Carriers with the major allele of SNP rs1799971 had a higher plasma @ChemicalSrc$ cotinine @/ChemicalSrc$ concentration .	0|3 3 0|3 4 6 6 6 14 14 14 14 14 10|14 14 10|14 6 18 18 18 14 6 23 23 23 6 6 32 31 31 31 27 32 32 32 39 39 39 39 60 47 45 45|41 45 45|41 45 47 47 39 54 54 54 54 54 54 47 57 57 54 60 60 60 63 63 60 63 66 64 69 69 66|67 66 66|67 69 74 74 69 69 78 78 66 82 82 82 78 84 82 84 60 91 91 94 94 94 94 96 94 98 96 108 102 102 108 105 105 104|102 102 104|102 108 98 113 113 113 113 108 108 116 108 118 119 116 121 119 125 125 125 121 127 125 125 125 133 133 133 133 125 94 141 137|141 141 137|141 141 146 143 141 143 146 146 146 146 151 151 148 155 155 155 151 146 159 164 161 159|160 159 159|160 164 164 170 170|164 170 170|164 170 170 164 164 178 178 175|178 178 175|178 179 179 181 179 183 181 185 183 188 188 185 188 188 183 194 194 183 197 197 194 197 197 179 203 204 214 204 204 212 212 212 212 212 206 214 214 218 218 218 214 220 218|219 218 218|219 224 224 220 224 224 214 214 233 233 233 233 214 236 236 233 236 236 240 241 236 241 242 242 241 241 241 250 250 233 214 252|256 256 252|256 256 286 256 256 258 258 258 258 258 258 258 258 258 258 258 258 258 258 258 258 274 258 276 258 258 258 280 280 256 286 286 286 290 290 290 286 292 290 294 286 296 294 298 296 302 302 302 298 304 302 304 302 302 302 311 311 312 302 302 298 316 298 319 319 316 321 319 321 325 325 321 321 329 329 296 286 335 335 335 350 338 338 335 341 341 338 341 344 335 344 349 349|346 349 349|346 344 350 356 356 356 356|352 356 356|352 350 361 361 361 361 356 363 361 366 366 363 366 363 350 371|374 374 371|374 375 377 377 377 381 381 381 377 383 381 381 381 389 389 389 389 381 377 401 397 397 397 393 400 400 397 401 407 407 407 404|407 407 404|407 401 401	Association
23281610	Chemical	Gene	D012254	282617	True	0	What is [PHARMGKB] between @ChemicalSrc$ ribavirin @/ChemicalSrc$ and @GeneTgt$ IL-28B @/GeneTgt$ ? [SEP] Effects of @GeneTgt$ IL-28B @/GeneTgt$ gene polymorphism on response to peginterferon plus @ChemicalSrc$ ribavirin @/ChemicalSrc$ combination therapy for genotype 2 chronic hepatitis C. AIM : Interleukin (IL)-28B gene polymorphism is closely linked with treatment response to peginterferon plus @ChemicalSrc$ ribavirin @/ChemicalSrc$ combination therapy for hepatitis C virus genotype 1 . However , few studies have reported its effects on therapy for genotype 2 . We aimed to examine the effects of @GeneTgt$ IL-28B @/GeneTgt$ gene polymorphism on treatment response in hepatitis C virus genotype 2 patients . METHODS : In a retrospective study of 101 patients infected with either genotype 2a ( n = 65 ) or 2b ( n = 36 ) and treated with peginterferon plus @ChemicalSrc$ ribavirin @/ChemicalSrc$ , we investigated predictive factors for a sustained virological response ( SVR ) , including genetic variations near the @GeneTgt$ IL-28B @/GeneTgt$ gene ( rs8099917 , rs11881222 and rs8103142 ) and clinical variables such as age , sex , body mass index , stage of fibrosis and drug adherence . RESULTS : Ultra-rapid virological response , rapid virological response ( RVR ) , end-of-treatment response , SVR and relapse rates were 22.2 % , 61.4 % , 95.0 % , 87.1 % and 7.9 % , respectively . In univariate analysis , RVR and @GeneTgt$ IL-28B @/GeneTgt$ single nucleotide polymorphisms ( SNP ) ( rs8099917 , rs11881222 and rs8103142 ) were significantly associated with SVR . In subgroup analysis , @GeneTgt$ IL-28B @/GeneTgt$ SNP were significantly associated with SVR in genotype 2a patients but not in genotype 2b patients . In multiple logistic regression analysis , RVR and @GeneTgt$ IL-28B @/GeneTgt$ SNP ( rs8099917 ) were independently associated with SVR . Furthermore , @GeneTgt$ IL-28B @/GeneTgt$ SNP was significantly associated with relapse but RVR was not . CONCLUSION : In genotype 2 patients treated with peginterferon plus @ChemicalSrc$ ribavirin @/ChemicalSrc$ combination therapy , @GeneTgt$ IL-28B @/GeneTgt$ gene polymorphism was a significant independent predictor of SVR as well as RVR . @GeneTgt$ IL-28B @/GeneTgt$ major allele may favor reduced relapse rates in patients with genotype 2 chronic hepatitis C.	1 6 2|6 6 2|6 6 1 8 1 10 15 10 10 10 10 15 8 21 21 21 21 21 15 24 24 29 29 29 32 32 32 24 35 35 32 42 42 37 37|38 37 37|38 42 35 47 47 47 47 42 47 32 56 56 54 56 56 56 58 56 60 58 62 60 62 56 66 66 68 66 70 68 75 75|71 75 75|71 75 70 78 78 70 85 85 85 85 85 85 78 66 123 123 93 93 93 123 96 96 93 96 101 101 101 97 103 104 101 104 104 101 101 110 108 110 111 110 93 93 117 115 117 117|118 117 117|118 123 123 123 125 123 130 130 130 130 125 132 130 132 130 137 137 130 142 142 138|142 142 138|142 137 144 142 144 144 144 144 144 142 152 142 155 153 152 155 155 155 161 161 155 161 161 165 163 165 165 165 123 172 172 176 176 194 176 180 180 176 182 180 182 176 186 176 186 186 186 191 186 194 194 172 194 197 194 197 200 197 200 203 200 203 206 203 206 194 172 212 212 233 233 233 214 220|215 220 220|215 220 220 214 222 220 222 225 220 225 225 225 225 225 233 233 233 235 233 233 240 240 247 247 241|244 244 241|244 247 247 247 247 249 247 253 253 253 249 253 259 259 259 259 253 247 266 266 266 266 278 278 278 268 269|272 272 269|272 268 274 272 274 278 278 278 280 278 278 290 290 284|287 287 284|287 290 290 290 290 292 290 290 295 290 295 295 299 299 304 304 304 322 304 312 312 307 307|308 307 307|308 312 305 322 317|312 317 317|312 317 322 322 322 322 322 299 324 322 322 325 325 322 299 331|335 335 331|335 335 337 337 337 340 340 337 342 340 344 342 348 348 348 344	Association
23567490	Chemical	Gene	D005472	595	True	0	What is [PHARMGKB] between @ChemicalSrc$ 5-fluorouracil @/ChemicalSrc$ and @GeneTgt$ CCND1 @/GeneTgt$ ? [SEP] The @GeneTgt$ cyclin D1 @/GeneTgt$ ( @GeneTgt$ CCND1 @/GeneTgt$ ) rs9344 G&gt;A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant @ChemicalSrc$ 5-FU-based @/ChemicalSrc$ chemotherapy . Recent evidence indicates a potential prognostic and predictive value for germline polymorphisms in genes involved in cell cycle control . We investigated the effect of @GeneTgt$ cyclin D1 @/GeneTgt$ ( @GeneTgt$ CCND1 @/GeneTgt$ ) rs9344 G&gt;A in stage II/III colon cancer patients and validated the findings in an independent study cohort . For evaluation and validation set , a total of 264 and 234 patients were included . Patients treated with @ChemicalSrc$ 5-fluorouracil-based @/ChemicalSrc$ chemotherapy , carrying the @GeneTgt$ CCND1 @/GeneTgt$ rs9344 A/A genotype had significantly decreased time-to-tumor recurrence ( TTR ) in univariate analysis and multivariate analysis ( hazard ratio ( HR ) 2.47 ; 95 % confidence interval ( CI ) 1.16 - 5.29 ; P=0.019 ) . There was no significant association between @GeneTgt$ CCND1 @/GeneTgt$ rs9344 G&gt;A and TTR in patients with curative surgery alone . In the validation set , the A allele of @GeneTgt$ CCND1 @/GeneTgt$ rs9344 G&gt;A remained significantly associated with decreased TTR in univariate and multivariate analyses ( HR 1.94 ; 95 % CI 1.05 - 3.58 ; P=0.035 ) . @GeneTgt$ CCND1 @/GeneTgt$ rs9344 G&gt;A may be a predictive and/or prognostic biomarker in stage II/III colon cancer patients , however , prospective trials are warranted to confirm our findings .	11 1|2|11 1|2|11 2|11 1|2|11 6 11|3 11 11|3 11 11 11 12 12 14 12 18 18 18 14 18 24 24 24|18 24 24|18 19 12 30 31 31 34 34 31 34 34 34 40 40 34 42 40 42 47 47 47 43 31 50 50 52 50 61 61|53 61|53 61 61|53 58 61|55 61 61|55 61 62 52 68 68 68 68 68 52 50 50 72 70 77 77 77 77 72 50 82 85 82 82 85 85 88 85 90 93 90 90 95 95 85 95 113 97 102 99|102 102 99|102 98 97 97 110 104|110 110 104|110 110 110 104 113 113 113 115 113 117 115 117 121 121 115 121 124 121 127 127 115 129 127 129 129 129 134 138 136 138 138 129 138 138 140 138 144 129 144 113 150 150 153 153 150 158 158|154 158 158|154 158 153 158 158 162 153 165 165 162 165 150 171 171 172 182 182 176 176 182 180 177|180 180 177|180 176 176 182 184 182 187 187 184 189 184 189 189 189 194 192 194 194 198 199 194 199 202 199 194 194 194 182 207|211 211 207|211 211 218 218 218 218 218 215 215 218 224 224 224 224 224 218 218 218 231 229 231 231 218 233 231 235 233 231	Association
23930676	Chemical	Gene	D019821	5465	True	0	What is [PHARMGKB] between @ChemicalSrc$ simvastatin @/ChemicalSrc$ and @GeneTgt$ PPARA @/GeneTgt$ ? [SEP] Genetic variation in the @GeneTgt$ PPARA @/GeneTgt$ gene is associated with @ChemicalSrc$ simvastatin-mediated @/ChemicalSrc$ cholesterol reduction in the Rotterdam Study . AIM : Recently , minor alleles of two strongly linked polymorphisms in the @GeneTgt$ PPARA @/GeneTgt$ gene , rs4253728 G&gt;A and rs4823613 A&gt;G , were related to decreased CYP3A4 expression and activity . We studied whether they were associated with the cholesterol-lowering effect of @ChemicalSrc$ simvastatin @/ChemicalSrc$ . MATERIALS & amp ; METHODS : We identified 123 incident users with cholesterol measurements before and after starting statin therapy in a prospective population-based cohort study . Associations between @GeneTgt$ PPARA @/GeneTgt$ polymorphisms and change in total and low-density lipoprotein (LDL)-cholesterol levels were analyzed using linear regression . RESULTS : The minor G allele of the rs4823613 A&gt;G polymorphism was associated with a 0.258 mmol/l ( 95 % CI : -0.470 to -0.046 ) and a 0.294 mmol/l ( 95 % CI : -0.495 to -0.093 ) larger reduction in total and LDL-cholesterol , respectively , after starting @ChemicalSrc$ simvastatin @/ChemicalSrc$ therapy . Results were similar for the rs4253728 G&gt;A polymorphism . CONCLUSION : The minor alleles of the @GeneTgt$ PPARA @/GeneTgt$ rs4253728 and rs4823613 polymorphisms are associated with a better total and LDL-cholesterol-lowering response to @ChemicalSrc$ simvastatin @/ChemicalSrc$ , possibly through influence on CYP3A4 .	2 9 7 7 4|7 7 4|7 2 9 9 14 9|14 14 9|14 14 9 18 18 18 14 9 22 22 46 46 27 46 29 32 31 32 27 37 37 37|34 37 37|34 32 37 40 37 37 43 37 32 46 22 48 46 50 48 50 50 46 56 56 60 60 60 56 64 64 64 60 66 64|65 64 64|65 56 70 70 70 70 70 77 77 70 79 80 77 83 83 80 77 84 84 77 89 87 95 95 95 95 95 87 77 112 101 98|101 101 98|101 97 101 101 105 103 105 105 109 110 112 112 112 112 115 113 112 118 118 123 123 123 130 128 128 128 128 123 130 118 134 134 134 130 138 137 138 134 138 142 142 138 142 134 147 147 134 151 150 151 147 151 158 155 153 155 158 130 160 158 160 160 158 158 130 167 130 167|170 170 167|170 167 118 175 175 175 180 180 180 180 175 175 182 182 186 186 196 191 191 191|188 191 191|188 186 191 191 191 196 182 203 203 200 203 200 200 196 205 203 203 203 196 196 210 208 212 210 182	Association
23974086	Chemical	Gene	D020123	5465	True	0	What is [PHARMGKB] between @ChemicalSrc$ SRL @/ChemicalSrc$ and @GeneTgt$ PPARA @/GeneTgt$ ? [SEP] Effect of CYP3A4 * 22 , POR*28 , and @GeneTgt$ PPARA @/GeneTgt$ rs4253728 on @ChemicalSrc$ sirolimus @/ChemicalSrc$ in vitro metabolism and trough concentrations in kidney transplant recipients . BACKGROUND : Recent studies have identified new candidate polymorphisms in the genes related to CYP3A activity or calcineurin inhibitor dose requirements in kidney transplant recipients . These genes and polymorphisms are CYP3A4 ( cytochrome P450 , family 3 , subfamily A , polypeptide 4 ) ( rs35599367-C&gt;T ; * 22 ) ; POR [ P450 ( cytochrome ) oxidoreductase ] ( rs1057868-C&gt;T ; * 28 ) ; and @GeneTgt$ PPARA @/GeneTgt$ ( @GeneTgt$ peroxisome proliferator-activated receptor alpha @/GeneTgt$ ) ( rs4253728-G&gt;A ) . We investigated the impact of these polymorphisms on @ChemicalSrc$ sirolimus @/ChemicalSrc$ ( SRL ) in vitro hepatic metabolism , SRL trough concentrations ( C0 ) , and SRL adverse events in kidney transplant recipients . METHODS : The clinical study included 113 stable kidney transplant patients switched from a calcineurin inhibitor to SRL ( SRL C0 measured at 1 , 3 , and 6 months thereafter ) . We investigated SRL metabolism in vitro using human liver microsomes derived from individual donors ( n = 31 ) . Microsomes and patients were genotyped by use of Taqman allelic discrimination assays . The effects of polymorphisms and covariates were studied using multilinear regression imbedded in linear mixed-effect models or logistic regressions . RESULTS : In vitro , the CYP3A4 * 22 allele resulted in approximately 20 % lower metabolic rates of @ChemicalSrc$ SRL @/ChemicalSrc$ ( P = 0.0411 ) . No significant association was found between CYP3A4 , CYP3A5 , or @GeneTgt$ PPARA @/GeneTgt$ genotypes and SRL dose , C0 , or C0/dose in kidney transplant patients . POR*28 was associated with a minor but significant decrease in SRL log-transformed C0 [ CT/TT vs CC , beta = -0.15 ( 0.05 ) ; P = 0.0197 ] but this did not have any impact on the dose administered , which limited the relevance of the finding . After adjustment for nongenetic covariates and correction for false discovery finding , none of the single-nucleotide polymorphisms tested showed significant association with SRL adverse events . CONCLUSIONS : These recently described polymorphisms do not seem to substantially influence the pharmacokinetics of SRL or the occurrence of SRL adverse events in kidney transplant recipients .	1 3 1 3 3 5 5 7 3 9|12 12 9|12 3 14 12 12 12 18 16 1 18 21 18 25 25 25 21 1 29 29 32 34 34 29 37 37 34 40 40 37 40 44 44 41 44 49 49 49 44 53 53 53 44 29 56 60 56 56 60 60 63 63 60 63 63 65 63 69 63 63 63 71 63 75 60 78 78 75 78 75 87 87 87 87 87 87 75 87 90 75 93 93 90 93 90 60 96|60 60 96|60 100 97|98|100 97|98|100 97|98|100 97|98|100 97|100 97|98|100 100 107 100 107 60 113 113 115 113 118 118 115 120 119|115 115 119|115 123 120 123 128 125 128 115 128 132 132 128 134 132 134 128 113 140 140 113 144 144 144 140 113 147 147 151 151 152 147 157 157 157 157 152 157 162 162 162 158 164 158 167 167 157 157 170 168 170 170 170 170 170 170 170 152 152 181 181 183 181 185 181 181 189 189 186 189 193 193 190 195 181 195 196 195 181 204 200 200 204 204 206 204 211 211 211 211 206 204 214 220 216 214 216 216 220 220 220 223 221 223 228 228 228 224 228 231 228 220 243 233 236 243 243 242 242 242 242 243 243 247 246 247 250 250 250 243 252 250|251 250 250|251 256 256 250 256 256 243 263 263 265 265 265 267 265 267 267 267 267 271|274 274 271|274 267 267 277 267 277 277 277 267 267 286 286 286 267 265 291 291 291 294 294 297 294 294 291 299 297 301 299 303 301 303 303 305 303 307 308 311 308 311 315 315 291 315 315 291 322 322 322 291 324 322 327 327 324 327 327 331 327 333 331 336 336 333 322 339 356 342 342 339 342 342 348 347 348 344 356 356 354 354 354 350 354 356 358 356 362 362 362 358 356 364 364 368 368 364 372 372 372 364 375 375 372 377 375 379 377 379 382 377 386 386 386 382 390 390 390 386 364	Association
23974086	Chemical	Gene	D020123	5447	True	0	What is [PHARMGKB] between @ChemicalSrc$ SRL @/ChemicalSrc$ and @GeneTgt$ POR @/GeneTgt$ ? [SEP] Effect of CYP3A4 * 22 , @GeneTgt$ POR*28 @/GeneTgt$ , and PPARA rs4253728 on @ChemicalSrc$ sirolimus @/ChemicalSrc$ in vitro metabolism and trough concentrations in kidney transplant recipients . BACKGROUND : Recent studies have identified new candidate polymorphisms in the genes related to CYP3A activity or calcineurin inhibitor dose requirements in kidney transplant recipients . These genes and polymorphisms are CYP3A4 ( cytochrome P450 , family 3 , subfamily A , polypeptide 4 ) ( rs35599367-C&gt;T ; * 22 ) ; @GeneTgt$ POR @/GeneTgt$ [ @GeneTgt$ P450 ( cytochrome ) oxidoreductase @/GeneTgt$ ] ( rs1057868-C&gt;T ; * 28 ) ; and PPARA ( peroxisome proliferator-activated receptor alpha ) ( rs4253728-G&gt;A ) . We investigated the impact of these polymorphisms on @ChemicalSrc$ sirolimus @/ChemicalSrc$ ( SRL ) in vitro hepatic metabolism , SRL trough concentrations ( C0 ) , and SRL adverse events in kidney transplant recipients . METHODS : The clinical study included 113 stable kidney transplant patients switched from a calcineurin inhibitor to SRL ( SRL C0 measured at 1 , 3 , and 6 months thereafter ) . We investigated SRL metabolism in vitro using human liver microsomes derived from individual donors ( n = 31 ) . Microsomes and patients were genotyped by use of Taqman allelic discrimination assays . The effects of polymorphisms and covariates were studied using multilinear regression imbedded in linear mixed-effect models or logistic regressions . RESULTS : In vitro , the CYP3A4 * 22 allele resulted in approximately 20 % lower metabolic rates of @ChemicalSrc$ SRL @/ChemicalSrc$ ( P = 0.0411 ) . No significant association was found between CYP3A4 , CYP3A5 , or PPARA genotypes and SRL dose , C0 , or C0/dose in kidney transplant patients . @GeneTgt$ POR*28 @/GeneTgt$ was associated with a minor but significant decrease in SRL log-transformed C0 [ CT/TT vs CC , beta = -0.15 ( 0.05 ) ; P = 0.0197 ] but this did not have any impact on the dose administered , which limited the relevance of the finding . After adjustment for nongenetic covariates and correction for false discovery finding , none of the single-nucleotide polymorphisms tested showed significant association with SRL adverse events . CONCLUSIONS : These recently described polymorphisms do not seem to substantially influence the pharmacokinetics of SRL or the occurrence of SRL adverse events in kidney transplant recipients .	1 3 1 3 3 5 5|6 5 5|6 7 3 12 3 14 12 12 12 18 16 1 18 21 18 25 25 25 21 1 29 29 32 34 34 29 37 37 34 40 40 37 40 44 44 41 44 49 49 49 44 53 53 53 44 29 56 60 56 56 60 60 63 63 60 63 63 65 63 69 63 63 63 71 63 75 60 78 78 75 78 75 80|84 84 80|84 84 82|75|84 82|75|84 82|75|84 82|75|84 82|75|84 75|84 82|75|84 84 92 75 95 95 92 95 92 60 60 104 104 104 104 99 104 107 104 107 60 113 113 115 113 118 118 115 120 119|115 115 119|115 123 120 123 128 125 128 115 128 132 132 128 134 132 134 128 113 140 140 113 144 144 144 140 113 147 147 151 151 152 147 157 157 157 157 152 157 162 162 162 158 164 158 167 167 157 157 170 168 170 170 170 170 170 170 170 152 152 181 181 183 181 185 181 181 189 189 186 189 193 193 190 195 181 195 196 195 181 204 200 200 204 204 206 204 211 211 211 211 206 204 214 220 216 214 216 216 220 220 220 223 221 223 228 228 228 224 228 231 228 220 243 233 236 243 243 242 242 242 242 243 243 247 246 247 250 250 250 243 252 250|251 250 250|251 256 256 250 256 256 243 263 263 265 265 265 267 265 267 267 267 267 273 267 267 276 267 276 276 276 267 267 285 285 285 267 265 286|290 290 286|290 290 290 293 293 296 293 293 290 298 296 300 298 302 300 302 302 304 302 306 307 310 307 310 314 314 290 314 314 290 321 321 321 290 323 321 326 326 323 326 326 330 326 332 330 335 335 332 321 339 356 342 342 339 342 342 348 347 348 344 356 356 354 354 354 350 354 356 358 356 362 362 362 358 356 364 364 368 368 364 372 372 372 364 375 375 372 377 375 379 377 379 382 377 386 386 386 382 390 390 390 386 364	Association
24311107	Chemical	Gene	D000069059	2224	True	0	What is [PHARMGKB] between @ChemicalSrc$ atorvastatin @/ChemicalSrc$ and @GeneTgt$ FDPS @/GeneTgt$ ? [SEP] Polymorphisms of the @GeneTgt$ farnesyl diphosphate synthase @/GeneTgt$ gene modulate bone changes in response to @ChemicalSrc$ atorvastatin @/ChemicalSrc$ . Although their primary therapeutic indications are different , aminobisphosphonates and statins target enzymes in the mevalonate pathway , which is critical for bone homeostasis . Previous studies have shown that some polymorphisms of the gene encoding @GeneTgt$ farnesyl diphosphate synthase @/GeneTgt$ ( @GeneTgt$ FDPS @/GeneTgt$ ) , the main target of aminobisphosphonates , modulate the response to these drugs . In this study , we explored whether those single nucleotide polymorphisms ( SNPs ) also influence the changes in bone mineral density ( BMD ) following therapy with statins . Sixty-six patients with coronary heart disease were studied at baseline and after 1-year therapy with @ChemicalSrc$ atorvastatin @/ChemicalSrc$ . BMD was measured by DXA . Three SNPs of the @GeneTgt$ FDPS @/GeneTgt$ gene ( rs2297480 , rs11264359 and rs17367421 ) were analyzed by using Taqman assays . The results showed that there was no association between the SNPs and basal BMD . However , rs2297480 and rs11264359 alleles , which are in linkage disequilibrium , were associated with changes in hip BMD following @ChemicalSrc$ atorvastatin @/ChemicalSrc$ therapy . Thus , patients with AA genotype at the rs2297480 locus had a 0.8 + - 0.8 % increase in BMD at the femoral neck , whereas in patients with AC/CC genotypes , BMD showed a 2.3 + - 0.8 % decrease ( p = 0.02 ) . Similar results were obtained regarding changes of BMD at the femoral trochanter and when alleles at the rs11264359 locus were analyzed . However , there was no association between BMD and rs17367421 alleles . In conclusion , these results suggest that polymorphisms of the @GeneTgt$ FDPS @/GeneTgt$ gene may influence the bone response to various drugs targeting the mevalonate pathway , including not only aminobisphosphonates but also statins .	9 8 8 8|3 8|3 8|3 8 8|3 1 9 11 9 13 9 15 11|13 13 11|13 9 26 24 23 24 26 26 26 26 26 28 26 32 30 36 36 36 30 36 40 40 36 43 43 40 26 46 48 48 48 71 51 71 54 54 51 54 55|56 55|56 55|56 55|56 55|56 61 56|57 56 56|57 61 56 67 67 56 69 67 71 48 73 71 76 76 73 48 82 82 85 85 85 85 95 90 90 90 95 92 90 92 95 85 97 95 101 101 101 97 103 101 103 106 101 108 106 85 111 117 115 115 115 111 117 117 119 117 119 123 123 119 125 123|124 123 123|124 117 131 131 131 133 131 131 136 150 141 141 138|141 141 138|141 136 143 141 143 143 145 145 143 150 150 152 150 154 152 150 158 159 159 162 162 159 164 162 167 167 164 167 170 167 159 186 186 177 174 174 186 177 183 183 183 183 177 177 186 186 188 186 191 191 188 195 195|192 195 195|192 188 186 208 208 208 203 203 200 207 207 207 200 208 215 214 210 213 210 215 208 217 215 221 221 221 215 208 231 225 231 228 228 225 231 231 208 238 237 233 236 233 238 231 241 241 238 241 241 208 246 248 248 248 250 248 252 250 256 256 256 250 250 265 265 263 263 263 259 265 248 248 270 270 270 270 272 270 274 277 274 274 272 270 280 284 284 283 284 284 293 293 291 291 288|291 291 288|291 286 293 284 296 296 293 299 299 296 299 303 303 300 303 308 307 308 303 308 311 308 284	Association
24345815	Chemical	Gene	D000078306	5447	True	0	What is [PHARMGKB] between @ChemicalSrc$ CLB @/ChemicalSrc$ and @GeneTgt$ POR @/GeneTgt$ ? [SEP] Effects of CYP2C19 and @GeneTgt$ P450 oxidoreductase @/GeneTgt$ polymorphisms on the population pharmacokinetics of @ChemicalSrc$ clobazam @/ChemicalSrc$ and N-desmethylclobazam in japanese patients with epilepsy . BACKGROUND : @ChemicalSrc$ Clobazam @/ChemicalSrc$ ( @ChemicalSrc$ CLB @/ChemicalSrc$ ) is a 1,5-benzodiazepine with antiepileptic properties . More than 70 % of administered @ChemicalSrc$ CLB @/ChemicalSrc$ is dealkylated to yield N-desmethylclobazam ( N-CLB ) , a pharmacologically active metabolite , by cytochrome P450 ( CYP ) 3A4 and CYP2C19 . The subsequent inactivation of N-CLB is primarily catalyzed by CYP2C19 . Meanwhile , @GeneTgt$ P450 oxidoreductase @/GeneTgt$ ( @GeneTgt$ POR @/GeneTgt$ ) is the obligatory electron donor to all microsomal CYP enzymes . The aim of this study was to evaluate the impact of the CYP2C19 and @GeneTgt$ POR @/GeneTgt$ genotypes on the pharmacokinetic parameters of @ChemicalSrc$ CLB @/ChemicalSrc$ and N-CLB . METHODS : This retrospective study included 85 Japanese patients with epilepsy who were treated with @ChemicalSrc$ CLB @/ChemicalSrc$ . CYP2C19 * 2 , * 3 , and @GeneTgt$ P450 oxidoreductase @/GeneTgt$ ( @GeneTgt$ POR @/GeneTgt$ ) * 28 ( rs1057868C&gt;T ) polymorphisms were evaluated . A total of 128 steady-state concentrations for both @ChemicalSrc$ CLB @/ChemicalSrc$ and N-CLB were collected from the patients . A nonlinear mixed-effects model identified the pharmacokinetics of CLB and N-CLB ; the covariates included CYP2C19 and @GeneTgt$ POR @/GeneTgt$ genotypes , weight , gender , daily @ChemicalSrc$ CLB @/ChemicalSrc$ dose , and coadministered antiepileptic drugs . RESULTS : Among the 85 patients , the allele frequencies of CYP2C19 * 2 , CYP2C19 * 3 , and @GeneTgt$ POR*28 @/GeneTgt$ were 27.6 % , 12.9 % , and 41.2 % , respectively . A one-compartment model with first-order absorption and/or elimination showed that the clearance of @ChemicalSrc$ CLB @/ChemicalSrc$ and N-CLB was significantly lower by 18.1 % and 84.9 % , respectively , in the CYP2C19 poor metabolizers compared with the homozygous extensive metabolizers . The CLB clearance was 44 % higher in subjects homozygous for the @GeneTgt$ POR*28 @/GeneTgt$ T allele than in those homozygous for the @GeneTgt$ POR*28 @/GeneTgt$ C allele , although the genotypes did not affect the N-CLB clearance . The concomitant use of phenobarbital , phenytoin , and zonisamide significantly affected the @ChemicalSrc$ CLB @/ChemicalSrc$ clearance , whereas that of carbamazepine , phenytoin , and valproic acid affected the N-CLB clearance . The weight also significantly influenced the @ChemicalSrc$ CLB @/ChemicalSrc$ clearance and volume of distribution of both @ChemicalSrc$ CLB @/ChemicalSrc$ and N-CLB . CONCLUSIONS : Our results showed that the CYP2C19 and/or @GeneTgt$ POR @/GeneTgt$ genotypes have an impact on the CLB and/or N-CLB clearance . These results suggest that determining the CYP2C19 and/or @GeneTgt$ POR @/GeneTgt$ genotypes is helpful for obtaining appropriate serum @ChemicalSrc$ CLB @/ChemicalSrc$ and N-CLB concentrations and preventing an overdose when starting @ChemicalSrc$ CLB @/ChemicalSrc$ therapy .	1 3 1 3 8|3|4 8|3|4 8|3 8|3|4 3 12 12 12 1 14 11|12 12 11|12 14 14 20 20 12 22 20 1 26 26 27|36 36 27|36 31 28|29 28 28|29 31 36 36 26 39 39 36 26 45 45 46 52 49 49 46|48 46 46|48 52 52 54 52 54 57 55 57 55 63 62 63 55 54 67 67 54 69 67 69 69 69 69 52 78 78 83 80 78 83 83 83 85 83 83 100 100 88|89|100 88|89|100 89|100 88|89|100 93 89|90 89 89|90 93 100 100 100 100 100 105 105 105 105 100 100 110 114 113 113 110 114 116 114 118 116 121 121 118 121 121|122 121 121|122 121 129 129 129 118 131 129 129 129 131 131 114 143 143 142 142 143 143 146 146 143 148 146 151 151 148 153 151|152 151 151|152 143 157 157 157 157 157 157 162 157 164|165|157 164|165|157 165|157 164|165|157 169 166|177 177 166|177 169 169 172 175 173 175 179 179 157 179 184 196 188 188 188 184 191 191 190|188 188 190|188 191 191 196 196 199 199 196 196 205 205 205 206 206 208 206 210 208 210 210 206 215 216 206 216 217 217|218 217 217|218 217 221 217 223 223 225 230 226|230 230 226|230 225 217 217 216 235 233 206 239 239 244 244 244 263 263 248 248 263 250 248 250 250 250 250 254 254 250 250 258|250 250 258|250 263 263 239 263 266 263 263 263 270 263 270 263 239 277 277 283 280 280 277 280 280 283 294 286 294 288 286|287 286 286|287 288 288 294 294 283 297 297 294 297 300 297 300 294 294 308 308 307 308 294 314 314 314 314 314 294 283 319 319 323 323 322 323 323 325 323 325 332 332 332|328 332 332|328 332 326 336 335 336 323 342 342 342|337 342 342|337 342 336 323 349 346 349 349 349 323 352 352 349 323 358 358 367 360 358 360 360 360 360 360 367 367 371 371|368 371 371|368 367 367 383 383 376 374 376 376 376 376 382 376 367 386 386 383 367 390 393 393 393 393 397 397|394 397 397|394 393 397 397 401 399 404 404 401|402 401 401|402 404 404 393 411 411 414 415 411 423 418 423 418 418|419 418 418|419 418 415 425 423 428 428 425 428 428 428 411 435 436 436 438 436 446 446 440 441|440 440 441|440 440 446 438 448 446 451 451 449|448 448 449|448 451 451 451 448 448 459 457 461 457 459|464 464 459|464 461 436	Association
24384557	Chemical	Gene	D002220	3172	True	0	What is [PHARMGKB] between @ChemicalSrc$ carbamazepine @/ChemicalSrc$ and @GeneTgt$ HNF4alpha @/GeneTgt$ ? [SEP] Pregnane X receptor and @GeneTgt$ hepatocyte nuclear factor 4alpha @/GeneTgt$ polymorphisms are cooperatively associated with @ChemicalSrc$ carbamazepine @/ChemicalSrc$ autoinduction . OBJECTIVE : We attempted to clarify the influence of polymorphisms of nuclear receptors on @ChemicalSrc$ carbamazepine @/ChemicalSrc$ therapy . PARTICIPANTS AND METHODS : The common polymorphisms of nuclear receptors -- a tentative pregnane X receptor (PXR)*1B , @GeneTgt$ hepatocyte nuclear factor 4alpha @/GeneTgt$ ( @GeneTgt$ HNF4alpha @/GeneTgt$ ) rs2071197 ( c.115 + 308G&gt;A ) , and cytochrome P450 3A5 * 3 polymorphisms -- were genotyped in 168 Japanese patients with epilepsy . The associations of these polymorphisms with the disposition , clinical efficacy , and incidence of adverse effects of @ChemicalSrc$ carbamazepine @/ChemicalSrc$ treatment were retrospectively investigated in 104 patients treated with @ChemicalSrc$ carbamazepine @/ChemicalSrc$ alone . The associations with disposition were also assessed in 64 patients treated with @ChemicalSrc$ carbamazepine @/ChemicalSrc$ and other antiepileptic drugs , which constituted the internal replication group , and in the combined 168 patients . RESULTS : Neither polymorphism alone affected the @ChemicalSrc$ carbamazepine @/ChemicalSrc$ disposition , but a significant interactive effect of PXR*1B and @GeneTgt$ HNF4alpha @/GeneTgt$ rs2071197 polymorphisms on the concentration-to-dose ( C/D ) ratios was observed ( P=0.027 ) . The C/D ratios among patients with the @GeneTgt$ HNF4alpha @/GeneTgt$ G/G genotype were higher in PXR*1B carriers than in PXR*1B noncarriers , which was confirmed in the internal replication and combined groups . In patients with the @GeneTgt$ HNF4alpha @/GeneTgt$ G/G genotype , the rate of freedom from seizures until 3 months after starting @ChemicalSrc$ carbamazepine @/ChemicalSrc$ therapy was significantly greater and the time required to reach the dose required for seizure freedom was shorter in PXR*1B carriers than in PXR*1B noncarriers . CONCLUSION : These results suggest that PXR*1B , in combination with @GeneTgt$ HNF4alpha @/GeneTgt$ rs2071197 , might be associated with the C/D ratios and the duration to reach the maintenance dose of @ChemicalSrc$ carbamazepine @/ChemicalSrc$ therapy , thus indicating an influence upon the autoinduction of the @ChemicalSrc$ carbamazepine @/ChemicalSrc$ metabolism .	3 3 13 3 10|4 10|4 10|4 10|4 10 10|4 13 13 13 13 17 17|10 17 17|10 13 13 24 24 24 24 26 24 28 26 30 28 33 33 30 37 37|34 37 37|34 28 24 40 40 40 40 46 46 83 49 49 46 46 55 55 55 55 46 55 55 57|58|67 57|58|67 57|58|67 57|58|67 58|67 57|58|67 64 58|59 58 58|59 64 46 69 46 69 69 69 46 46 77 77 80 80 80 46 80 83 40 87 87 87 83 89 87 83 94 116 97 97 94 100 100 94 100 103 100 103 100 100 109 109 106 113 110|113 113 110|113 109 116 116 116 119 119 116 119 122 120 120 120 122 116 129 134 131 129 134 134 134 137 137 134 137 140 138|139 138 138|139 140 144 145 140 145 148 145 152 152 152 148 145 134 159 159 159 159 134 134 162 162 165 167 165 162 171 171|168 171 171|168 167 167 167 177 177 175 193 179 184 179 179 179 179 179 177 191 191 191 189 187 189 177 193 167 195 193 195 162 202 202 212 204 202 210 210 210|206 210 210|206 210 204 212 212 215 215 212 219 219 219 212 219 223 223 219 227 227 227 223 227 230 227 212 234 243 240 240 240|236 240 240|236 240 234 243 243 258 245 243 247 245 250 250 243 252 243 251|255 255 251|255 252 258 258 258 258 261 262 258 264 262 266 264 266 270 270 267 272 258 275 275 272 279 279 279 272 258 287 287 286 287 287 300 300 289 292 289 294 293|296 296 293|296 292 289 300 300 287 304 304 304 300 300 307 300 309 307 312 312 309 316 316|312 316 316|312 312 300 319 300 321 319 324 324 321 329 329 324|329 329 324|329 324 287	Association
24590773	Chemical	Gene	C056516	1588	True	0	What is [PHARMGKB] between @ChemicalSrc$ exemestane @/ChemicalSrc$ and @GeneTgt$ CYP19A1 @/GeneTgt$ ? [SEP] Germline variants in the @GeneTgt$ CYP19A1 @/GeneTgt$ gene are related to specific adverse events in aromatase inhibitor users : a substudy of Dutch patients in the TEAM trial . Musculoskeletal adverse events ( MSAEs ) and vasomotor symptoms ( VMSs ) are known side-effects of aromatase inhibitors , and may be related to genetic variations of the aromatase gene ( @GeneTgt$ CYP19A1 @/GeneTgt$ ) . We investigated the relationship between these specific AEs and single nucleotide polymorphisms ( SNPs ) in the @GeneTgt$ CYP19A1 @/GeneTgt$ gene in postmenopausal , hormone receptor-positive early breast cancer ( BC ) patients treated with adjuvant @ChemicalSrc$ exemestane @/ChemicalSrc$ for 5 years . Dutch patients who were randomized to receive 5 years of @ChemicalSrc$ exemestane @/ChemicalSrc$ in the Tamoxifen Exemestane Adjuvant Multinational ( TEAM ) trial were included . A tagging-SNP approach was performed , covering 80 % of variations of the @GeneTgt$ CYP19A1 @/GeneTgt$ gene with 30 SNPs . Logistic regression analyses were used to assess the risk of reporting VMSs or MSAEs in relation to genotypes within selected SNPs . Of 737 included patients , 281 patients reported at least one MSAE ( n = 210 ) or VMS ( n = 163 ) . Homozygous AA genotype of rs934635 was associated with a significantly higher odds of MSAEs ( multivariate odds ratio ( OR ) 4.66 , p = 0.008 ) and VMSs ( multivariate OR 2.78 , p = 0.044 ) . Regarding both rs1694189 and rs7176005 , the homozygous variant genotypes ( TT ) were associated with a higher odds of VMSs , but not MSAEs ( OR 1.758 , p = 0.025 and OR 6.361 , p = 0.021 , respectively ) . Our exploratory analysis demonstrated that some @GeneTgt$ CYP19A1 @/GeneTgt$ gene variations may be associated with MSAEs and/or VMSs . Specifically , patients with the homozygous variant rs934635 genotype reported more MSAEs and VMSs . Although further confirmatory studies are warranted , genomic profiling can help identify patients at an increased risk of reporting these specific AEs , potentiating further personalized BC treatment .	2 9 7 7 4|7 7 4|7 2 9 9 13 13 13 9 17 16 17 13 9 20 9 23 23 20 27 27 27 20 9 32 32 43 34 32 34 32 38 32 40 38 40 43 44 44 47 47 44 44 44 52 52 44 55 55 52 59 59 59 55 61 59|60 59 59|60 61 44 67 67 69 67 73 73 73 69 73 77 77 73 79 77 79 85 85 82|85 85 82|85 73 97 97 90 90 87 97 93 97 95 93 95 85 97 101 101 98|99 98 98|99 105 105 98 67 110 132 113 113 110 115 113 117 115 119 117|118 117 117|118 130 130 126 126 126 130 128 126 128 115 132 132 132 137 137 139 139 139 139 139 143 141 145 143 150 150 150|147 150 150|147 145 153 153 145 139 158 158 160 160 160 162 160 164 162 166 164 166 167 167 171 166 173 171 176 176 173 160 179 180 180 180 185 184 185 180 187 188 189 185 191 192 189 192 192 189 189 198 196 198 199 198 185 205 205 209 207 205 209 209 214 214 213 214 209 216 214 220 219 220 216 222 220 222 222 227 227 209 227 227 209 209 233 231 233 233 238 238 233 238 238 209 244 244 256 244 244 256 251 251 251 256 253 251 253 256 256 260 260 260 256 262 260 262 265 262 262 272 272 268 272 272 266 272 272 272 272 272 279 272 279 279 279 272 256 287 287 288 288 297 294 293|290 293 293|290 294 297 297 297 288 299 297 299 299 288 313 313 313 312 312 312 312 312 306 313 315 313 315 315 313 324 322 322 324 324 329 324 327 329 329 329 329 330 335 335 335 330 337 335 340 340 337 340 340 344 346 346 342 329	Association
24663076	Chemical	Gene	D005473	5243	True	0	What is [PHARMGKB] between @ChemicalSrc$ fluoxetine @/ChemicalSrc$ and @GeneTgt$ ABCB1 @/GeneTgt$ ? [SEP] Effect of CYP2D6 , CYP2C9 and @GeneTgt$ ABCB1 @/GeneTgt$ genotypes on @ChemicalSrc$ fluoxetine @/ChemicalSrc$ plasma concentrations and clinical improvement in children and adolescent patients . There is little known about pharmacogenetic of @ChemicalSrc$ fluoxetine @/ChemicalSrc$ in children and adolescents . In this study , we evaluate , for the first time , the influence of CYP2D6 , CYP2C9 and @GeneTgt$ ABCB1 @/GeneTgt$ genotypes on the steady-state plasma concentrations of @ChemicalSrc$ fluoxetine @/ChemicalSrc$ and its active metabolite (S)-norfluoxetine , and on the clinical improvement in children and adolescent patients receiving @ChemicalSrc$ fluoxetine @/ChemicalSrc$ treatment . The assessment was performed in 83 patients after 8 and 12 weeks of treatment . @ChemicalSrc$ Fluoxetine/(S)-norfluoxetine @/ChemicalSrc$ ratio was negatively correlated with the number of active CYP2D6 alleles ( r : -0.450 ; P&lt;0.001 ) . Regarding the G2677 T @GeneTgt$ ABCB1 @/GeneTgt$ polymorphism , T allele carriers showed significantly higher improvements on the majority of scales including the Clinical Global Impression-Improvement scale ( P&lt;0.001 ) . Our results confirm the influence of CYP2D6 genetic variants in @ChemicalSrc$ fluoxetine @/ChemicalSrc$ pharmacokinetics and provide evidence for the potential effect of the @GeneTgt$ ABCB1 @/GeneTgt$ genotype on the clinical improvement in children and adolescent patients treated with @ChemicalSrc$ fluoxetine @/ChemicalSrc$ .	1 3 9 3 3 3 3|6 3 3|6 1 14 9|14 14 9|14 14 1 14 17 14 19 17 19 19 19 1 27 27 29 27 31 29 33 31|32 31 31|32 36 33 36 36 27 43 43 46 46 46 46 46 51 51 51 46 51 54 46 56 54 56 56 56 56|59 56 56|59 56 67 67 67 67 54 69 67 67 67 69 75 75 75 69 67 67 81 81 81 67 83 81 83 83 83 86 90|85 90 90|85 87 46 96 98 98 98 101 101 98 103 106 103 103 101 108 106 98 109|115 115 109|115 115 115 115 115 118 118 115 122 122 122 118 124 115 124 124 126 124 124 115 138 138 138 138 135|138 138 135|138 143 143 142 142 143 143 145 146 143 149 149 146 151 149 157 157 157 157 157 151 159 157 159 143 164 165 165 167 165 171 171 171 167 175 172|175 175 172|175 167 165 165 177 182 182 182 178 187 187 187|183 187 187|183 182 191 191 191 182 193 191 193 193 193 196 199 196|197 197 196|197 165	Association
24712521	Chemical	Gene	D008727	84159	True	0	What is [PHARMGKB] between @ChemicalSrc$ methotrexate @/ChemicalSrc$ and @GeneTgt$ ARID5B @/GeneTgt$ ? [SEP] Associations of novel genetic variations in the folate-related and @GeneTgt$ ARID5B @/GeneTgt$ genes with the pharmacokinetics and toxicity of high-dose @ChemicalSrc$ methotrexate @/ChemicalSrc$ in paediatric acute lymphoblastic leukaemia . High-dose @ChemicalSrc$ methotrexate @/ChemicalSrc$ ( HD-MTX ) plays an important role in the consolidation therapy of acute lymphoblastic leukaemia ( ALL ) in many treatment regimens worldwide . However , there is a large interpatient variability in the pharmacokinetics and toxicity of the drug . We investigated the influence of single nucleotide polymorphisms ( SNPs ) in genes of the folate metabolic pathway , transporter molecules and transcription proteins on the pharmacokinetics and toxicity of MTX and 7-hydroxy-methotrexate ( 7-OH-MTX ) . 63 SNPs of 14 genes were genotyped and a total of 463 HD-MTX courses ( administered according to the ALL-BFM 95 and ALL IC-BFM 2002 protocols ) were analysed . Haematological , hepatic and renal toxicities , estimated by routine laboratory parameters were evaluated . Random forest and regression trees were used for variable selection and model building . Linear mixed models were established to prove the significance of the selected variables . SNPs ( rs4948502 , rs4948496 , rs4948487 ) of the @GeneTgt$ ARID5B @/GeneTgt$ gene were associated with the serum levels of MTX ( P & lt ; 0 02 ) , serum levels and area under the curve of 7-OH-MTX ( P & lt ; 0 02 ) and with hypoproteinaemia ( P = 0 004 ) . SLCO1B1 rs4149056 also showed a significant association with serum MTX levels ( P & lt ; 0 001 ) . Our findings confirm the association of novel genetic variations in folate-related and @GeneTgt$ ARID5B @/GeneTgt$ genes with the serum MTX levels and acute toxicity .	1 5 5 5 1 8 8 1 8 8|9 8 8|9 8 15 15 8 15 15 20 20 18|15 15 18|15 26 26 26 26 15 1 31 30|36 36 30|36 34 31 34 36 39 39 36 43 43 43 36 47 47 47 43 49 47 49 54 54 54 43 36 36 61 61 61 61 65 65 65 61 68 68 65 68 68 73 73 68 61 76 76 78 76 82 82 82 78 84 82 84 87 78 92 92 92 92 87 87 95 87 95 98 95 101 101 95 101 101 105 101 105 105 109 105 109 76 113 118 116 116 113 118 118 118 121 118 125 125 125 121 127 125 131 128 131 127 131 131 137 137 137 131 137 140 118 118 155 142 142 142 142 142 147 147 153 153 153 149 155 155 155 158 161 158 158 163 163 163 166 166 163 166 169 166 163 173 173 175 175 175 177 175 179 177 183 183 183 179 175 199 187 185 187 187 187 187 191 197 197 194|197 197 194|197 187 199 199 203 203 203 199 205 203 207 205 207 207 207 212 207 212 207 216 207 216 216 221 221 216 223 221 225 223 225 225 225 230 225 230 221 234 221 236 234 236 239 237 236 199 246 243 246 246 249 249 246 253 253 253 249 255 253 255 255 255 260 255 255 246 264 265 265 267 265 271 271 271 267 273 267 273 273|274 273 273|274 273 282 282 282 282 267 282 285 282 265	Association
25704243	Chemical	Gene	D000077144	1066	True	0	What is [PHARMGKB] between @ChemicalSrc$ clopidogrel @/ChemicalSrc$ and @GeneTgt$ CES1 @/GeneTgt$ ? [SEP] @GeneTgt$ Carboxylesterase 1 @/GeneTgt$ c.428G&gt;A single nucleotide variation increases the antiplatelet effects of @ChemicalSrc$ clopidogrel @/ChemicalSrc$ by reducing its hydrolysis in humans . @GeneTgt$ Carboxylesterase 1 @/GeneTgt$ ( @GeneTgt$ CES1 @/GeneTgt$ ) hydrolyzes the prodrug @ChemicalSrc$ clopidogrel @/ChemicalSrc$ to an inactive carboxylic acid metabolite . We studied the pharmacokinetics and pharmacodynamics of 600 mg oral @ChemicalSrc$ clopidogrel @/ChemicalSrc$ in healthy white volunteers , including 10 carriers and 12 noncarriers of @GeneTgt$ CES1 @/GeneTgt$ c.428G&gt;A ( p. Gly143Glu , rs71647871 ) single nucleotide variation ( SNV ) . Clopidogrel carboxylic acid to @ChemicalSrc$ clopidogrel @/ChemicalSrc$ area under the plasma concentration-time curve from 0 hours to infinity ( AUC0- ) ratio was 53 % less in @GeneTgt$ CES1 @/GeneTgt$ c.428G&gt;A carriers than in noncarriers ( P = 0.009 ) , indicating impaired hydrolysis of @ChemicalSrc$ clopidogrel @/ChemicalSrc$ . Consequently , the AUC0- of @ChemicalSrc$ clopidogrel @/ChemicalSrc$ and its active metabolite were 123 % ( P = 0.004 ) and 67 % ( P = 0.009 ) larger in the c.428G&gt;A carriers than in noncarriers . Consistent with these findings , the average inhibition of P2Y12 -mediated platelet aggregation 0 - 12 hours after @ChemicalSrc$ clopidogrel @/ChemicalSrc$ intake was 19 percentage points higher in the c.428G&gt;A carriers than in noncarriers ( P = 0.036 ) . In conclusion , the @GeneTgt$ CES1 @/GeneTgt$ c.428G&gt;A SNV increases @ChemicalSrc$ clopidogrel @/ChemicalSrc$ active metabolite concentrations and antiplatelet effects by reducing @ChemicalSrc$ clopidogrel @/ChemicalSrc$ hydrolysis to inactive metabolites .	0|1|7 0|1|7 1|7 0|1|7 7 7 7 8 8 11 11 8 13 10|11 11 10|11 16 8 18 16 20 18 8 23|28 23|28 28 23|28 28 31|25 31 31|25 28 31 34 34 31|30 31 31|30 41 41 41 41 41 31 31 47 47 49 47 49 49 56 54 56 56 55|49 49 55|49 61 61 61 49 61 65 65 61 65 68 65 70 72|68 72 72|68 68 75 75 68 75 75 77 81 81 68 83 81 83 47 90 90 112 94 91|94 94 91|94 90 99 99 99 99 94 102 102 90 104 90 106 104 106 112 112 111 112 112 117 112|117 117 112|117 117 112 120 120 112 123 123 120 123 123 112 112 129 127 131 128|129 129 128|129 112 150 150 140 150 142 140|141 140 140|141 142 147 147 142 150 150 150 153 153 150 153 153 150 158 150 161 161 158 161 161 150 168 168 168 164 171 171 164 150 199 177 177 174 199 181 181 199 186 184 186 186 181 190 187 190 181 198 191|194 194 191|194 198 198 198 198 199 199 203 203 203 199 206 206 199 209 209 206 209 209 199 215 222 222 221 221|217 221 221|217 221 222 222 221|227 227 221|227 227 227 222 227 230 227 232 222 230|235 235 230|235 232 238 238 232 222	Association
26352872	Chemical	Gene	D000077146	10057	True	0	What is [PHARMGKB] between @ChemicalSrc$ irinotecan @/ChemicalSrc$ and @GeneTgt$ ABCC5 @/GeneTgt$ ? [SEP] @GeneTgt$ ABCC5 @/GeneTgt$ and ABCG1 polymorphisms predict @ChemicalSrc$ irinotecan-induced @/ChemicalSrc$ severe toxicity in metastatic colorectal cancer patients . OBJECTIVE : @ChemicalSrc$ Irinotecan @/ChemicalSrc$ is a cytotoxic agent used widely for the treatment of solid tumors , particularly for metastatic colorectal cancers . Treatment with this drug frequently results in severe neutropenia and diarrhea that can markedly impact the course of treatment and patients ' quality of life . Pharmacogenomic tailoring of @ChemicalSrc$ irinotecan-based @/ChemicalSrc$ chemotherapy has been the subject of several investigations , but with limited data on ATP-binding cassette ( ABC ) and solute carrier ( SLC ) transporter genes . MATERIALS AND METHODS : In this study , we aimed to discover toxicity-associated markers in seven transporter genes participating in @ChemicalSrc$ irinotecan @/ChemicalSrc$ pharmacokinetics involving the ABC transporter genes ABCB1 , ABCC1 , ABCC2 , @GeneTgt$ ABCC5 @/GeneTgt$ , ABCG1 , and ABCG2 and the solute carrier organic anion transporter gene SLCO1B1 and using a haplotype-tagging single-nucleotide polymorphisms ( n=210 htSNPs ) strategy . The profiles of 167 metastatic colorectal cancer Canadian patients treated with FOLFIRI-based regimens were examined and the findings were replicated in an independent cohort of 250 Italian patients . RESULTS : In combined cohorts , a two-marker @GeneTgt$ ABCC5 @/GeneTgt$ rs3749438 and rs10937158 haplotype ( T-C ) predicted lower risk of severe diarrhea [ odds ratio ( OR ) of 0.43 ; P=0.001 ] . The co-occurrence of ABCG1 rs225440 T and @GeneTgt$ ABCC5 @/GeneTgt$ rs2292997A predicted the risk of severe neutropenia ( OR=5.93 ; P=0.0002 ) , which was further improved when incorporating the well-known risk marker UGT1A1 * 28 rs8175347 ( OR=7.68 ; P&lt;0.0001 ) . In contrast , carriers of one protective marker ( UGT1 rs11563250 G ) but none of these risk alleles experienced significantly less severe neutropenia ( 8.2 vs. 34.0 % ; P&lt;0.0001 ) . CONCLUSION : This combination of predictive genetic markers could potentially lead to better risk assessment and may thus improve personalized treatment .	0|6 6 0|6 1 1 6 6 10|5 10 10|5 10 6 15 15 15 15 10 6 19 26 26|20 26 26|20 26 26 26 19 26 27 31 31 27 34 34 31 31 40 40 40 40 31 19 48 46 46 43 48 48 51 51 48 51 51 57 57 57 48 59 57 61 59 61 61 63 61 67 65 48 70 78 74 71|74 74 71|74 70 78 78 78 78 81 81 78 78 78 86 86 78 89 89 86 91 89 91 89 89 100 100 100 100 100 89 78 103 103 103 103 109 109 112 112 112 103 114 112 116 114 120 120 120 116 120 125 122|125 125 122|125 121 125 130 130 130 126 130 131 131 131 131 131 135|131 131 135|131 131 131 131 131 131 116 152 152 152 152 152 152 152 116 114 114 158 158 158 163 161 161 163 163 154 103 168 181 175 175 175 175 175 175 168 175 179 179 176 181 181 181 184 186 186 181 190 190 190 186 194 194 194 190 181 196 196 200 200 213 200 206 206 203|206 206 203|206 200 206 209 206 211 209 211 196 215 213 218 218 215 221 221 218 223 221 223 226 221 221 221 228 196 233 242 235 233 235 235 235 241|238 241 241|238 235 242 244 242 247 247 244 249 247 249 249 251 249 257 257 257 249 259 257 264 264 263 264 259 267 267 264 269 267 269 269 269 242 276 294 294 294 282 282 282 278 284 282 286 284 284 278 278 293 293 293 289 294 296 297 298 294 303 303 300 303 298 303 303 303 294 308 318 311 318 315 315 315 311 318 318 308 322 322 322 318 318 326 326 318 328 326 308	Association
26895070	Chemical	Gene	D006918	445	True	0	What is [PHARMGKB] between @ChemicalSrc$ hydroxyurea @/ChemicalSrc$ and @GeneTgt$ ASS1 @/GeneTgt$ ? [SEP] Genomic variants in the @GeneTgt$ ASS1 @/GeneTgt$ gene , involved in the nitric oxide biosynthesis and signaling pathway , predict @ChemicalSrc$ hydroxyurea @/ChemicalSrc$ treatment efficacy in compound sickle cell disease/beta-thalassemia patients . AIM : Hemoglobinopathies exhibit a remarkable phenotypic diversity that restricts any safe association between molecular pathology and clinical outcomes . PATIENTS & amp ; METHODS : Herein , we explored the role of genes involved in the nitric oxide biosynthesis and signaling pathway , implicated in the increase of fetal hemoglobin levels and response to @ChemicalSrc$ hydroxyurea @/ChemicalSrc$ treatment , in 119 Hellenic patients with beta-type hemoglobinopathies . RESULTS : We show that two @GeneTgt$ ASS1 @/GeneTgt$ genomic variants ( namely , rs10901080 and rs10793902 ) can serve as pharmacogenomic biomarkers to predict hydroxyurea treatment efficacy in sickle cell disease/beta-thalassemia compound heterozygous patients . CONCLUSION : These markers may exert their effect by inducing nitric oxide biosynthesis , either via altering splicing and/or miRNA binding , as predicted by in silico analysis , and ultimately , increase gamma-globin levels , via guanylyl cyclase targeting .	2 19 7 7 4|7 7 4|7 2 7 7 14 14 14 14 9 14 17 14 19 19 18|23 23 18|23 23 19 29 28 28 28 29 23 19 36 36 36 36 40 40 40 36 42 40 45 45 42 48 48 45 48 51 48 36 62 53 53 53 53 57 62 62 62 62 64 62 66 64 66 72 72 72 72 67 72 75 72 64 64 80 80 77 84 84 84 80 80 80 90 87|90 90 87|90 86 77 95 95 95 77 98 98 95 62 104 104 104 104 119 110 110|106 110 110|106 110 119 114 114 114 110 114 114 114 119 104 122 122 119 124 119 127 127 124 134 134 131 134 134 134 127 104 137 142 140 142 142 137 144 142 146 142 149 149 146 146 154 154 154 146 154 154 154 142 160 142 164 164 164 160 164 164 142 142 142 171 169 169 176 176 176 169 137	Association
27533851	Chemical	Gene	D000077157	10599	True	0	What is [PHARMGKB] between @ChemicalSrc$ sorafenib @/ChemicalSrc$ and @GeneTgt$ SLCO1B1 @/GeneTgt$ ? [SEP] Polymorphisms in @GeneTgt$ SLCO1B1 @/GeneTgt$ and UGT1A1 are associated with @ChemicalSrc$ sorafenib-induced @/ChemicalSrc$ toxicity . AIM : @ChemicalSrc$ Sorafenib-treated @/ChemicalSrc$ patients display a substantial variation in the incidence of toxicity . We aimed to investigate the association of genetic polymorphisms with observed toxicity on @ChemicalSrc$ sorafenib @/ChemicalSrc$ . PATIENTS & amp ; METHODS : We genotyped 114 patients that were treated with @ChemicalSrc$ sorafenib @/ChemicalSrc$ at the Erasmus MC Cancer Institute , the Netherlands , for @GeneTgt$ SLCO1B1 @/GeneTgt$ , SLCO1B3 , ABCC2 , ABCG2 , UGT1A1 and UGT1A9 . RESULTS : The UGT1A1 ( rs8175347 ) polymorphism was associated with hyperbilirubinemia and treatment interruption . Polymorphisms in @GeneTgt$ SLCO1B1 @/GeneTgt$ ( rs2306283 , rs4149056 ) were associated with diarrhea and thrombocytopenia , respectively . None of the investigated polymorphisms was associated with overall or progression-free survival in hepatocellular cancer patients . CONCLUSION : Polymorphisms in @GeneTgt$ SLCO1B1 @/GeneTgt$ and UGT1A1 are associated with several different @ChemicalSrc$ sorafenib @/ChemicalSrc$ side effects .	8 3 1|2 1 1|2 3 3 8 8 12 8|12 12 8|12 8 8 16 21 17|20 20 17|20 21 16 24 24 21 27 27 24 29 27 21 33 33 35 33 37 35 40 40 37 43 43 37 45 43|44 43 43|44 33 49 49 49 49 49 56 56 49 58 56 61 61 58 63 61|62 61 61|62 70 70 70 70 70 61 70 73 70 73 76 73|74 73 73|74 76 76 76 76 76 76 76 76 76 76 56 91 91 98 98 96 94 98 100 100 91 102 100 102 102 102 91 117 109 107|108 107 107|108 112 109 112 112 112 117 117 119 117 119 119 117 117 117 132 130 130 130 126 132 132 137 137 134 134 132 141 141 141 137 132 143 143 152 147 145|146 145 145|146 147 147 152 143 159 159 159 159|154 159 159|154 159 152 143	Association
27747372	Chemical	Gene	D016559	28952	True	0	What is [PHARMGKB] between @ChemicalSrc$ tacrolimus @/ChemicalSrc$ and @GeneTgt$ CCDC22 @/GeneTgt$ ? [SEP] FOXP3 rs3761548 polymorphism is associated with @ChemicalSrc$ tacrolimus-induced @/ChemicalSrc$ acute nephrotoxicity in renal transplant patients . PURPOSE : The purpose of this study was to investigate the potential impact of FOXP3 and @GeneTgt$ CCDC22 @/GeneTgt$ gene polymorphisms on efficacy and safety of @ChemicalSrc$ tacrolimus @/ChemicalSrc$ ( TAC ) in renal transplant patients . METHODS : Genetic polymorphisms were detected in 114 Chinese renal transplant patients who were on TAC-based maintenance immunosuppression and were followed up for at least 2 years . The relationships between FOXP3 rs3761547 , rs3761548 , rs3761549 , rs2232365 , rs2280883 , and @GeneTgt$ CCDC22 @/GeneTgt$ rs2294021 polymorphisms and clinical outcomes such as acute rejection , TAC-induced acute nephrotoxicity , and pneumonia were investigated by using Kaplan-Meier estimates and multivariate Cox regression analysis . The influence of these gene polymorphisms on the change in estimated glomerular filtration rate over time was evaluated by linear mixed model . RESULTS : Patients with FOXP3 rs3761548 AA and AC genotypes had a 10-fold higher risk for TAC-induced acute nephrotoxicity than those with CC genotype . We did not find any association between other genetic variants and TAC-related outcomes in renal transplant patients . CONCLUSIONS : Our study demonstrated the TAC-induced acute nephrotoxicity was associated with FOXP3 rs3761548 polymorphism in renal transplant patients . FOXP3 rs3761548 might serve as a biomarker to prevent TAC toxicity and help progression toward individualized therapy of TAC .	3 3 5 5 5 10 10|6 10 10|6 10 5 14 14 14 10 5 24 17 20 24 23 23 20 24 26 24 29 29 26 31 29 31 32|31 31 32|31 36 31 38 29 38 38 42 40|38 38 40|38 45 42 45 50 50 50 38 24 59 59 57 59 59 59 65 65 65 65 65 59 71 71 71 71 71 65 59 74 59 74 78 78 79 80 74 59 83 116 85 83 85 86 86 88 88 86 85 92 92 92 85 85|96 85 85|96 100 85 100 103 100 107 104 107 103 107 111 111 107 107 107 107 116 116 118 116 120 118 120 120 125 125 120 116 129 145 133 133 133 129 136 136 129 141 141 141 141 136 143 129 145 145 149 149 149 145 145 161 151 161 157 157 157 153 157 157 157 161 165 164 165 161 169 169 169 165 171 169 174 174 171 161 179 179 179 179 181 179 185 185 185 181 185 188 185 192 192 192 188 179 194 194 197 198 194 202 202 202 204 204 198 208 208 208 204 212 212 212 208 194 215 217 217 217 220 220 217 222 220 224 222 222 222 226 230 230 227 232 230 217	Association
27747372	Chemical	Gene	D016559	50943	True	0	What is [PHARMGKB] between @ChemicalSrc$ tacrolimus @/ChemicalSrc$ and @GeneTgt$ FOXP3 @/GeneTgt$ ? [SEP] @GeneTgt$ FOXP3 @/GeneTgt$ rs3761548 polymorphism is associated with @ChemicalSrc$ tacrolimus-induced @/ChemicalSrc$ acute nephrotoxicity in renal transplant patients . PURPOSE : The purpose of this study was to investigate the potential impact of @GeneTgt$ FOXP3 @/GeneTgt$ and CCDC22 gene polymorphisms on efficacy and safety of @ChemicalSrc$ tacrolimus @/ChemicalSrc$ ( TAC ) in renal transplant patients . METHODS : Genetic polymorphisms were detected in 114 Chinese renal transplant patients who were on TAC-based maintenance immunosuppression and were followed up for at least 2 years . The relationships between @GeneTgt$ FOXP3 @/GeneTgt$ rs3761547 , rs3761548 , rs3761549 , rs2232365 , rs2280883 , and CCDC22 rs2294021 polymorphisms and clinical outcomes such as acute rejection , TAC-induced acute nephrotoxicity , and pneumonia were investigated by using Kaplan-Meier estimates and multivariate Cox regression analysis . The influence of these gene polymorphisms on the change in estimated glomerular filtration rate over time was evaluated by linear mixed model . RESULTS : Patients with @GeneTgt$ FOXP3 @/GeneTgt$ rs3761548 AA and AC genotypes had a 10-fold higher risk for TAC-induced acute nephrotoxicity than those with CC genotype . We did not find any association between other genetic variants and TAC-related outcomes in renal transplant patients . CONCLUSIONS : Our study demonstrated the TAC-induced acute nephrotoxicity was associated with @GeneTgt$ FOXP3 @/GeneTgt$ rs3761548 polymorphism in renal transplant patients . @GeneTgt$ FOXP3 @/GeneTgt$ rs3761548 might serve as a biomarker to prevent TAC toxicity and help progression toward individualized therapy of TAC .	0|4 4 0|4 4 6 6 6 11 11|6 11 11|6 11 6 15 15 15 11 6 26 19 22 26 25 25 22 26 28 26 31 31 28 33 31|32 31 31|32 33 33 38 33 40 31 40 40 44 42|40 40 42|40 47 44 47 52 52 52 40 26 61 61 59 61 61 61 67 67 67 67 67 61 73 73 73 73 73 67 61 76 61 76 80 80 81 82 76 61 85 118 87 85|86 85 85|86 87 89 89 91 91 89 87 95 95 95 87 87 102 87 102 105 102 109 106 109 105 109 113 113 109 109 109 109 118 118 120 118 122 120 122 122 127 127 122 118 131 147 135 135 135 131 138 138 131 143 143 143 143 138 145 131 147 147 151 151 151 147 147 164 153 164 160 160|156 160 160|156 160 155 160 160 160 164 168 167 168 164 172 172 172 168 174 172 177 177 174 164 183 183 183 183 185 183 189 189 189 185 189 192 189 196 196 196 192 183 198 198 201 202 198 206 206 206 208 208 202 213 213|209 213 213|209 213 208 217 217 217 213 198 219|222 222 219|222 224 224 224 227 227 224 229 227 231 229 229 229 233 237 237 234 239 237 224	Association
28550509	Chemical	Gene	D000431	55902	True	0	What is [PHARMGKB] between @ChemicalSrc$ ethanol @/ChemicalSrc$ and @GeneTgt$ ACSS2 @/GeneTgt$ ? [SEP] Possible involvement of @GeneTgt$ ACSS2 @/GeneTgt$ gene in alcoholism . Alcoholism is a psychiatric disorder that composes one of the principal causes of health disabilities in the world population . Furthermore , the available pharmacotherapy is limited . Therefore , this research was carried out to better understand the basis of the underlying neurobiological processes of this disorder and to discover potential therapeutic targets . Real-time PCR analysis was performed in the amygdala nuclei region of the brain of mice exposed to a chronic three-bottle free-choice model ( water , 5 and 10 % v/v @ChemicalSrc$ ethanol @/ChemicalSrc$ ) . Based on individual @ChemicalSrc$ ethanol @/ChemicalSrc$ intake , the mice were classified into three groups : " compulsive-like " ( i.e. , @ChemicalSrc$ ethanol @/ChemicalSrc$ intake not affected by quinine adulteration ) , " @ChemicalSrc$ ethanol-preferring @/ChemicalSrc$ " and " @ChemicalSrc$ ethanol @/ChemicalSrc$ non-preferring " . A fourth group had access only to tap water ( control group ) . The candidate gene @GeneTgt$ ACSS2 @/GeneTgt$ was genotyped in human alcoholics by real-time polymerase chain reaction using the markers rs6088638 and rs7266550 . Seven genes were picked out ( @GeneTgt$ Acss2 @/GeneTgt$ , Acss3 , Acat1 , Acsl1 , Acaa2 , Hadh , and Hadhb ) and the mRNA level of the @GeneTgt$ Acss2 @/GeneTgt$ gene was increased only in the " compulsive-like " group ( p = 0.004 ) . The allele frequency of rs6088638 for the gene @GeneTgt$ ACSS2 @/GeneTgt$ was higher in the Alcoholic human group ( p = 0.03 ) , although sample size was very small . The gene @GeneTgt$ ACSS2 @/GeneTgt$ is associated with alcoholism , suggesting that biochemical pathways where it participates may have a role in the biological mechanisms susceptible to the @ChemicalSrc$ ethanol @/ChemicalSrc$ effects .	2 2 6 3|6 6 3|6 2 8 2 2 15 15 15 15 15 17 15 17 22 22 22 18 25 25 22 29 29 29 22 15 37 37 35 35 37 37 37 37 44 44 42 44 44 44 44 48 48 44 50 48 55 55 55 55 50 58 58 55 48 61 48 63 64 61 44 68 68 70 70 70 75 75 75 75 70 78 78 75 80 78 80 87 87 87 87 87 81 89 87 89 89 91 91 96 96 89|95 89 89|95 89 70 111 106 106 103|106 106 103|106 101 111 109 111 111 111 114 114 111 114 124 124 124 124 124 124 124|120 124 124|120 114 126 124 129 129 126 124 114 133 130|114 114 130|114 133 133 138 133|134 133 133|134 138 138 111 149 149 151 151 151 158 158 155 158 158 158 151 151 151 164 164 164 163|167 167 163|167 167 167 170 170 167 175 175 175 175 167 175 178 176 178 179 179 167 185 187 187 187 187 190 187|189 187 187|189 190 190 190 190 190 190 190 190 190 190 190 190 190 190 187 209 209 216 214 214 210|214 214 210|214 209 216 187 216 223 223 223 223 223 216 226 226 223 226 226 187 234 234 243 236 234 240 240 240 239|236 236 239|236 243 243 248 248 248 248 243 251 251 243 251 251 243 260 257 260 260 260 243 243 265 265 264|268 268 264|268 268 268 270 268 268 268 280 275 280 278 278 275 280 272 282 280 286 286 286 282 286 292 292 288|292 292 288|292 287 268	Association
28592191	Chemical	Gene	D000074	5447	True	0	What is [PHARMGKB] between @ChemicalSrc$ acenocoumarol @/ChemicalSrc$ and @GeneTgt$ POR @/GeneTgt$ ? [SEP] Influence of two variants of CYP450 oxidoreductase on the stable dose of @ChemicalSrc$ acenocoumarol @/ChemicalSrc$ in a Spanish population . AIM : To evaluate the influence of two variants of @GeneTgt$ P450 oxidoreductase @/GeneTgt$ ( @GeneTgt$ POR @/GeneTgt$ ) , rs2868177 and @GeneTgt$ POR*28 @/GeneTgt$ , on the stable dosage of @ChemicalSrc$ acenocoumarol @/ChemicalSrc$ . PATIENTS & amp ; METHODS : For this observational , cross-sectional study , patients were undergone stable anticoagulant treatment with @ChemicalSrc$ acenocoumarol @/ChemicalSrc$ . Univariate and multiple regression analyses were performed to assess the influence of @GeneTgt$ POR @/GeneTgt$ polymorphisms . RESULTS : About 340 patients were enrolled . Multiple regression had a coefficient of determination ( R2 ) of 51.5 % and an Akaike information criterion of 234.22 . The inclusion of @GeneTgt$ POR*28 @/GeneTgt$ polymorphisms increased the R2 to 52.0 % and reduced the Akaike information criteria to 230.58 . The @GeneTgt$ POR*28 @/GeneTgt$ heterozygote showed statistical significance in the algorithm . CONCLUSION : The @GeneTgt$ POR*28 @/GeneTgt$ heterozygote appears to be associated with the stable dose of @ChemicalSrc$ acenocoumarol @/ChemicalSrc$ , but its clinical contribution to the prediction of the dosing of this drug is minimal .	1 4 4 1 7 7 4 11 11 11 1 13 11|12 11 11|12 18 18 18 11 1 21 24 24 21 26 24 29 29 26 31 29|30|31 29|30|31 29|31 29|30|31 35 31|32 31 31|32 35 31 31 39 37|39 39 37|39 29 47 47 47 26 49 44|47 47 44|47 21 71 56 56 56 56 60 67 67 67 64 64 71 71 71 71 71 74 74 71 76 74|75 74 74|75 71 86 80 80 84 86 86 86 88 86 90 88 94 91|94 94 91|94 90 86 97 97 100 101 103 103 97 103 106 107 107 109 107 111 109 113 111 113 117 117 111 109 122 122 122 109 124 122 107 127 132 131 128|131 131 128|131 127 132 134 132 137 137 132 132 132 143 143 143 139 145 139 132 151 148|151 151 148|151 152 152 154 152 157 157 152 152 192 166 165 162|165 165 162|165 166 160 169 169 166 173 173 173 169 175 173 173 173 166 166 181 181 192 184 184 181 187 187 184 190 190 187 192 192 192	Association
28676933	Chemical	Gene	D020123	5243	True	0	What is [PHARMGKB] between @ChemicalSrc$ sirolimus @/ChemicalSrc$ and @GeneTgt$ ABCB1 @/GeneTgt$ ? [SEP] Association of NR1I2 , CYP3A5 and @GeneTgt$ ABCB1 @/GeneTgt$ genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer . PURPOSE : Temsirolimus is a mammalian target of rapamycin ( mTOR ) inhibitor that exhibits antitumor activity in renal cell carcinoma and mantle cell lymphoma . The metabolism of temsirolimus and its active metabolite @ChemicalSrc$ sirolimus @/ChemicalSrc$ mainly depends on cytochrome P450 3A4/5 ( CYP3A4/A5 ) and the @GeneTgt$ ABCB1 @/GeneTgt$ transporter . Differently from @ChemicalSrc$ sirolimus @/ChemicalSrc$ , no pharmacogenetic study on temsirolimus has been conducted . Therefore , the aim of this pilot study was to identify genetic determinants of the inter-individual variability in temsirolimus pharmacokinetics and toxicity . METHODS : Pharmacokinetic profiles were obtained for 16 patients with bladder cancer after intravenous infusion of 25 mg temsirolimus . Non-compartmental analysis was performed to calculate the pharmacokinetic parameters of temsirolimus and @ChemicalSrc$ sirolimus @/ChemicalSrc$ , its main metabolite . The presence of single nucleotide polymorphisms ( SNPs ) in CYP3A5 , @GeneTgt$ ABCB1 @/GeneTgt$ and in their transcriptional regulator NR1I2 ( PXR ) was assessed by genotyping . Non-parametric statistical tests were used to assess associations between candidate SNPs and temsirolimus pharmacokinetics and toxicity . RESULTS : The ratio between @ChemicalSrc$ sirolimus @/ChemicalSrc$ AUC and temsirolimus AUC was 1.6-fold higher in patients who experienced serious toxic events ( p = 0.034 ) . The frequency of adverse events was significantly higher in patients homozygous for the NR1I2-rs6785049 A allele ( OR = 0.065 , p = 0.04 ) or NR1I2-rs3814055 C allele ( OR = 0.032 , p = 0.006 ) . These NR1I2 SNPs were also predictive of temsirolimus half-life and global exposure to temsirolimus and @ChemicalSrc$ sirolimus @/ChemicalSrc$ . Finally , the effect of the @GeneTgt$ ABCB1-rs1128503 @/GeneTgt$ , @GeneTgt$ ABCB1-rs2032582 @/GeneTgt$ and CYP3A5 * 3 SNPs on @ChemicalSrc$ sirolimus @/ChemicalSrc$ pharmacokinetics was confirmed . CONCLUSIONS : Our findings suggest that SNPs of NR1I2 and its target genes CYP3A5 and @GeneTgt$ ABCB1 @/GeneTgt$ are genetic determinants of temsirolimus pharmacokinetics and toxicity in patients with bladder cancer .	1 3 1 3 3 3 3|6 3 3|6 10 3 12 1 15 15 12 15 15 19 12 23 23 23 19 1 26 26 32 32 32 32 26 38 38 38 38 38 32 40 38 42 40 46 46 46 42 46 50 50 46 32 53 63 55 53 53 60 60 60 59|53 53 59|53 63 63 67 67 67 63 69 67 69 67 75 75|71 75 75|71 67 63 91 81 80|91 91 80|91 91 86 86 91 88 86 91 91 91 91 102 102 97 102 101 101 101 97 102 104 102 106 104 110 110 110 106 113 113 110 113 113 102 122 122 120 122 122 122 125 125 122 128 128 125 131 131 122 135 134 135 131 122 138 140 140 140 142 140 145 145 142 147 145 147 147|148 147 147|148 147 154 154 147 140 158 181 162 162 162 158 164 162 164 167 162 167 167|168 167 167|168 167 175 175 175 167 175 178 176 178 181 181 183 181 181 188 188 190 190 190 192 190 192 196 196 193 196 199 196 196 196 190 203 203 206 216 210 210|207 210 210|207 206 210 213 210 216 216 203 218 216 220 218 223 223 220 226 226 223 226 226 203 232 238 235 235 232 238 238 238 240 238 240 246 246 246 246 241 249 249 246 249 249 253 249 253 254 253 259 259 249 262 262 259 262 266 266 262 266 262 238 272 272 275 275 275 275 278 278 275 278 281 278 283 281 283 283|284 283 283|284 275 310 310 292 310 295 295 292|294 292 292|294 295 296|295 295 296|295 298 298 304 304 295 308 308|303 308 308|303 304 310 310 310 315 315 318 319 315 334 334 323 321 323 327 327 323 327 328 328|329 328 328|329 334 334 319 337 337 334 337 337 341 337 344 344 341 315	None-PHARMGKB
28676933	Chemical	Gene	C401859	8856	True	0	What is [PHARMGKB] between @ChemicalSrc$ temsirolimus @/ChemicalSrc$ and @GeneTgt$ NR1I2 @/GeneTgt$ ? [SEP] Association of @GeneTgt$ NR1I2 @/GeneTgt$ , CYP3A5 and ABCB1 genetic polymorphisms with variability of @ChemicalSrc$ temsirolimus @/ChemicalSrc$ pharmacokinetics and toxicity in patients with metastatic bladder cancer . PURPOSE : @ChemicalSrc$ Temsirolimus @/ChemicalSrc$ is a mammalian target of rapamycin ( mTOR ) inhibitor that exhibits antitumor activity in renal cell carcinoma and mantle cell lymphoma . The metabolism of @ChemicalSrc$ temsirolimus @/ChemicalSrc$ and its active metabolite sirolimus mainly depends on cytochrome P450 3A4/5 ( CYP3A4/A5 ) and the ABCB1 transporter . Differently from sirolimus , no pharmacogenetic study on temsirolimus has been conducted . Therefore , the aim of this pilot study was to identify genetic determinants of the inter-individual variability in temsirolimus pharmacokinetics and toxicity . METHODS : Pharmacokinetic profiles were obtained for 16 patients with bladder cancer after intravenous infusion of 25 mg @ChemicalSrc$ temsirolimus @/ChemicalSrc$ . Non-compartmental analysis was performed to calculate the pharmacokinetic parameters of @ChemicalSrc$ temsirolimus @/ChemicalSrc$ and sirolimus , its main metabolite . The presence of single nucleotide polymorphisms ( SNPs ) in CYP3A5 , ABCB1 and in their transcriptional regulator @GeneTgt$ NR1I2 @/GeneTgt$ ( @GeneTgt$ PXR @/GeneTgt$ ) was assessed by genotyping . Non-parametric statistical tests were used to assess associations between candidate SNPs and temsirolimus pharmacokinetics and toxicity . RESULTS : The ratio between sirolimus AUC and temsirolimus AUC was 1.6-fold higher in patients who experienced serious toxic events ( p = 0.034 ) . The frequency of adverse events was significantly higher in patients homozygous for the @GeneTgt$ NR1I2-rs6785049 @/GeneTgt$ A allele ( OR = 0.065 , p = 0.04 ) or @GeneTgt$ NR1I2-rs3814055 @/GeneTgt$ C allele ( OR = 0.032 , p = 0.006 ) . These @GeneTgt$ NR1I2 @/GeneTgt$ SNPs were also predictive of temsirolimus half-life and global exposure to @ChemicalSrc$ temsirolimus @/ChemicalSrc$ and sirolimus . Finally , the effect of the ABCB1-rs1128503 , ABCB1-rs2032582 and CYP3A5 * 3 SNPs on sirolimus pharmacokinetics was confirmed . CONCLUSIONS : Our findings suggest that SNPs of @GeneTgt$ NR1I2 @/GeneTgt$ and its target genes CYP3A5 and ABCB1 are genetic determinants of temsirolimus pharmacokinetics and toxicity in patients with bladder cancer .	1 3 1|2 1 1|2 3 3 3 3 10 3 12 1 16 16|12 16 16|12 12 16 16 20 12 24 24 24 20 1 28 28 35|29 35 35|29 35 35 35 28 41 41 41 41 41 35 43 41 45 43 49 49 49 45 49 53 53 49 35 57 67 59 57|58 57 57|58 57 65 65 65 57 67 67 71 71 71 67 73 71 73 71 78 78 71 67 92 83 92 92 87 87 92 89 87 92 92 92 92 102 102 97 102 101 101 101 97 102 104 102 106 104 110 110 110 106 113 113 110 113 113 102 122 122 120 122 122 122 125 125 122 128 128 125 131 131 122 135 134 135 134|131 131 134|131 122 140 142 142 142 144 142 147 147 144 149 147|148 147 147|148 149 149 149 156 156 149 142 160 184 164 164 164 160 166 164 166 169 164 169 169 169 176 176 176 169 176 176 176 180 177|178 177 177|178 180 184 184 186 184 184 192 192 194 194 194 196 194 196 200 200 197 200 203 200 200 200 194 207 207 210 219 213 213 210 213 216 213 219 219 207 221 219 223 221 226 226 223 229 229 226 229 229 207 234 240 237 237 234 240 240 240 242 240 242 249 249 249|245 249 249|245 249 243 252 252 249 252 252 256 252 256 257 256 258|263 263 258|263 263 252 266 266 263 266 270 270 266 270 266 240 279 276|279 279 276|279 282 282 282 282 285 285 282 285 288 285 290 288 288 288 290 290 282 315 315 300 315 303 303 300 303 303 305 305 310 310 303 313 313 310 315 315 315 317 317 320 321 317 336 336 325 324|323 323 324|323 325 330 330 325 330 331 331 336 336 321 339 339 336 339 339 343 339 346 346 343 317	Association
28676933	Chemical	Gene	C401859	5243	True	0	What is [PHARMGKB] between @ChemicalSrc$ temsirolimus @/ChemicalSrc$ and @GeneTgt$ ABCB1 @/GeneTgt$ ? [SEP] Association of NR1I2 , CYP3A5 and @GeneTgt$ ABCB1 @/GeneTgt$ genetic polymorphisms with variability of @ChemicalSrc$ temsirolimus @/ChemicalSrc$ pharmacokinetics and toxicity in patients with metastatic bladder cancer . PURPOSE : @ChemicalSrc$ Temsirolimus @/ChemicalSrc$ is a mammalian target of rapamycin ( mTOR ) inhibitor that exhibits antitumor activity in renal cell carcinoma and mantle cell lymphoma . The metabolism of @ChemicalSrc$ temsirolimus @/ChemicalSrc$ and its active metabolite sirolimus mainly depends on cytochrome P450 3A4/5 ( CYP3A4/A5 ) and the @GeneTgt$ ABCB1 @/GeneTgt$ transporter . Differently from sirolimus , no pharmacogenetic study on temsirolimus has been conducted . Therefore , the aim of this pilot study was to identify genetic determinants of the inter-individual variability in temsirolimus pharmacokinetics and toxicity . METHODS : Pharmacokinetic profiles were obtained for 16 patients with bladder cancer after intravenous infusion of 25 mg @ChemicalSrc$ temsirolimus @/ChemicalSrc$ . Non-compartmental analysis was performed to calculate the pharmacokinetic parameters of @ChemicalSrc$ temsirolimus @/ChemicalSrc$ and sirolimus , its main metabolite . The presence of single nucleotide polymorphisms ( SNPs ) in CYP3A5 , @GeneTgt$ ABCB1 @/GeneTgt$ and in their transcriptional regulator NR1I2 ( PXR ) was assessed by genotyping . Non-parametric statistical tests were used to assess associations between candidate SNPs and temsirolimus pharmacokinetics and toxicity . RESULTS : The ratio between sirolimus AUC and temsirolimus AUC was 1.6-fold higher in patients who experienced serious toxic events ( p = 0.034 ) . The frequency of adverse events was significantly higher in patients homozygous for the NR1I2-rs6785049 A allele ( OR = 0.065 , p = 0.04 ) or NR1I2-rs3814055 C allele ( OR = 0.032 , p = 0.006 ) . These NR1I2 SNPs were also predictive of temsirolimus half-life and global exposure to @ChemicalSrc$ temsirolimus @/ChemicalSrc$ and sirolimus . Finally , the effect of the @GeneTgt$ ABCB1-rs1128503 @/GeneTgt$ , @GeneTgt$ ABCB1-rs2032582 @/GeneTgt$ and CYP3A5 * 3 SNPs on sirolimus pharmacokinetics was confirmed . CONCLUSIONS : Our findings suggest that SNPs of NR1I2 and its target genes CYP3A5 and @GeneTgt$ ABCB1 @/GeneTgt$ are genetic determinants of temsirolimus pharmacokinetics and toxicity in patients with bladder cancer .	1 3 1 3 3 3 3|6 3 3|6 10 3 12 1 16 16|12 16 16|12 12 16 16 20 12 24 24 24 20 1 28 28 35|29 35 35|29 35 35 35 28 41 41 41 41 41 35 43 41 45 43 49 49 49 45 49 53 53 49 35 57 67 59 57|58 57 57|58 57 65 65 65 57 67 67 71 71 71 67 73 71 73 71 79 79|75 79 79|75 71 67 94 85 94 94 89 89 94 91 89 94 94 94 94 104 104 99 104 103 103 103 99 104 106 104 108 106 112 112 112 108 115 115 112 115 115 104 124 124 122 124 124 124 127 127 124 130 130 127 133 133 124 137 136 137 136|133 133 136|133 124 142 144 144 144 146 144 149 149 146 151 149|150 149 149|150 151 151 151 158 158 151 144 162 185 166 166 166 162 168 166 168 171 166 171 171|172 171 171|172 171 179 179 179 171 179 182 180 182 185 185 187 185 185 192 192 194 194 194 196 194 196 200 200 197 200 203 200 200 200 194 207 207 210 219 213 213 210 213 216 213 219 219 207 221 219 223 221 226 226 223 229 229 226 229 229 207 234 240 237 237 234 240 240 240 242 240 242 248 248 248 248 243 251 251 248 251 251 255 251 255 256 255 261 261 251 264 264 261 264 268 268 264 268 264 240 274 274 277 277 277 277 280 280 277 280 283 280 285 283|284 283 283|284 285 285 277 311 311 294 311 297 297 294|296 294 294|296 297 298|297 297 298|297 300 300 306 306 297 309 309 306 311 311 311 315 315 318 319 315 334 334 323 321 323 327 327 323 327 328 328|329 328 328|329 334 334 319 337 337 334 337 337 341 337 344 344 341 315	Association
28676933	Chemical	Gene	D020123	8856	True	0	What is [PHARMGKB] between @ChemicalSrc$ sirolimus @/ChemicalSrc$ and @GeneTgt$ NR1I2 @/GeneTgt$ ? [SEP] Association of @GeneTgt$ NR1I2 @/GeneTgt$ , CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer . PURPOSE : Temsirolimus is a mammalian target of rapamycin ( mTOR ) inhibitor that exhibits antitumor activity in renal cell carcinoma and mantle cell lymphoma . The metabolism of temsirolimus and its active metabolite @ChemicalSrc$ sirolimus @/ChemicalSrc$ mainly depends on cytochrome P450 3A4/5 ( CYP3A4/A5 ) and the ABCB1 transporter . Differently from @ChemicalSrc$ sirolimus @/ChemicalSrc$ , no pharmacogenetic study on temsirolimus has been conducted . Therefore , the aim of this pilot study was to identify genetic determinants of the inter-individual variability in temsirolimus pharmacokinetics and toxicity . METHODS : Pharmacokinetic profiles were obtained for 16 patients with bladder cancer after intravenous infusion of 25 mg temsirolimus . Non-compartmental analysis was performed to calculate the pharmacokinetic parameters of temsirolimus and @ChemicalSrc$ sirolimus @/ChemicalSrc$ , its main metabolite . The presence of single nucleotide polymorphisms ( SNPs ) in CYP3A5 , ABCB1 and in their transcriptional regulator @GeneTgt$ NR1I2 @/GeneTgt$ ( @GeneTgt$ PXR @/GeneTgt$ ) was assessed by genotyping . Non-parametric statistical tests were used to assess associations between candidate SNPs and temsirolimus pharmacokinetics and toxicity . RESULTS : The ratio between @ChemicalSrc$ sirolimus @/ChemicalSrc$ AUC and temsirolimus AUC was 1.6-fold higher in patients who experienced serious toxic events ( p = 0.034 ) . The frequency of adverse events was significantly higher in patients homozygous for the @GeneTgt$ NR1I2-rs6785049 @/GeneTgt$ A allele ( OR = 0.065 , p = 0.04 ) or @GeneTgt$ NR1I2-rs3814055 @/GeneTgt$ C allele ( OR = 0.032 , p = 0.006 ) . These @GeneTgt$ NR1I2 @/GeneTgt$ SNPs were also predictive of temsirolimus half-life and global exposure to temsirolimus and @ChemicalSrc$ sirolimus @/ChemicalSrc$ . Finally , the effect of the ABCB1-rs1128503 , ABCB1-rs2032582 and CYP3A5 * 3 SNPs on @ChemicalSrc$ sirolimus @/ChemicalSrc$ pharmacokinetics was confirmed . CONCLUSIONS : Our findings suggest that SNPs of @GeneTgt$ NR1I2 @/GeneTgt$ and its target genes CYP3A5 and ABCB1 are genetic determinants of temsirolimus pharmacokinetics and toxicity in patients with bladder cancer .	1 3 1|2 1 1|2 3 3 3 3 10 3 12 1 15 15 12 15 15 19 12 23 23 23 19 1 26 26 32 32 32 32 26 38 38 38 38 38 32 40 38 42 40 46 46 46 42 46 50 50 46 32 53 63 55 53 53 60 60 60 59|53 53 59|53 63 63 67 67 67 63 69 67 69 67 74 74 67 63 89 79 78|89 89 78|89 89 84 84 89 86 84 89 89 89 89 100 100 95 100 99 99 99 95 100 102 100 104 102 108 108 108 104 111 111 108 111 111 100 120 120 118 120 120 120 123 123 120 126 126 123 129 129 120 133 132 133 129 120 136 138 138 138 140 138 143 143 140 145 143 145 145|146 145 145|146 145 152 152 145 138 156 180 160 160 160 156 162 160 162 165 160 165 165 165 172 172 172 165 172 172 172 176 173|174 173 173|174 176 180 180 182 180 180 188 188 190 190 190 192 190 192 196 196 193 196 199 196 196 196 190 203 203 206 216 210 210|207 210 210|207 206 210 213 210 216 216 203 218 216 220 218 223 223 220 226 226 223 226 226 203 232 238 235 235 232 238 238 238 240 238 240 247 247 247|243 247 247|243 247 241 250 250 247 250 250 254 250 254 255 254 256|261 261 256|261 261 250 264 264 261 264 268 268 264 268 264 238 277 274|277 277 274|277 280 280 280 280 283 283 280 283 286 283 288 286 288 288 288 288 280 314 314 298 314 301 301 298 301 301 303 303 308 308 301 312 312|309 312 312|309 308 314 314 314 317 317 320 321 317 336 336 325 324|323 323 324|323 325 330 330 325 330 331 331 336 336 321 339 339 336 339 339 343 339 346 346 343 317	Association
29790402	Chemical	Gene	C549273	1591	True	0	What is [PHARMGKB] between @ChemicalSrc$ DCV @/ChemicalSrc$ and @GeneTgt$ CYP24A1 @/GeneTgt$ ? [SEP] Vitamin D pathway gene polymorphisms affecting @ChemicalSrc$ daclatasvir @/ChemicalSrc$ plasma concentration at 2 weeks and 1 month of therapy . AIM : Vitamin D ( VD ) influences genetic expression through its receptor ( VDR ) . VD pathway gene polymorphisms seem to influence antiviral drug pharmacokinetics and therapeutic outcome/toxicity . We investigated the association between @ChemicalSrc$ daclatasvir @/ChemicalSrc$ ( @ChemicalSrc$ DCV @/ChemicalSrc$ ) plasma concentrations and genetic variants ( SNPs ) associated with the VD pathway . PATIENTS & amp ; METHODS : Chronic hepatitis C patients treated with @ChemicalSrc$ DCV @/ChemicalSrc$ from 2014 to 2016 were included . Genotypes were assessed through real-time PCR and plasma concentrations through liquid chromatography . RESULTS : A total of 52 patients were analyzed . @ChemicalSrc$ DCV @/ChemicalSrc$ levels were influenced by @GeneTgt$ CYP24A1 @/GeneTgt$ rs2248359T&gt;C polymorphism at 2 weeks and VDR Cdx2 A&gt;G at 1 month of treatment . Linear regression analysis showed baseline BMI , alanine aminotransferase and hematocrit as significant predictors of @ChemicalSrc$ DCV @/ChemicalSrc$ concentrations at 2 weeks , BMI and hematocrit at baseline , VDR Cdx2 AG/GG and FokI TC/CC at 1 month . CONCLUSION : These results showed a possible role of VD pathway gene polymorphisms in influencing @ChemicalSrc$ DCV @/ChemicalSrc$ plasma concentrations , but further studies are required .	5 5 5 5 5 5 10|6 10 10|6 10 6 13 13 10 5 16 5 18 16 5 28 21 24 28 26 24 26 28 30 28 33 33 28 35 33 35 28 41 41 41 42 42 44 42 47 47 44 47 50 47 42 53 53 55 53 64 64|56 64 64|56 60 64|58 64 64|58 60 64 55 64 67 64 69 67 69 55 75 75 75 71 53 79 79 79 79 79 83 88 88 88 98 88 91 89|90 89 89|90 94 89 96 89 98 79 98 103 103 103 106 106 103 106 109 106 112 112 103 103 114 114 117 122 120 120 117 122 114 122 123|126 126 123|126 128 128 128 133 133|128 133 133|128 133 128 136 136 128 128 140 140 128 143 143 128 145 143 128 151 151 152 152 154 152 154 157 154 154 154 162 162 152 166 166|163 166 166|163 162 169 169 162 152 151 171 171 175 171 175 179 179 175 175 182 175 185 185 152 152 188 192 191 192 188 195 195 192 200 200 200 200 195 202 192 206|202 206 206|202 206 202 192 192 210 212 212 192 188	Association
29914286	Chemical	Gene	D065819	5243	True	0	What is [PHARMGKB] between @ChemicalSrc$ voriconazole @/ChemicalSrc$ and @GeneTgt$ ABCB1 @/GeneTgt$ ? [SEP] Pharmacogenetic of @ChemicalSrc$ voriconazole @/ChemicalSrc$ antifungal agent in pediatric patients . AIM : We explored the role of SNPs within the SLCO1B3 , SLCO1B1 , SLC22A6 , @GeneTgt$ ABCB1 @/GeneTgt$ , ABCG2 , SLCO3A1 , CYP2C19 , ABCC2 , SLC22A1 , ABCB11 and NR1I2 genes on @ChemicalSrc$ voriconazole @/ChemicalSrc$ pharmacokinetics . PATIENTS & amp ; METHODS : 233 pediatric patients were enrolled . Drug plasma Ctrough was measured by a HPLC-MS method . Allelic discrimination was performed by qualitative real-time PCR . RESULTS : SLCO1B3 rs4149117 c.334 GT/TT ( p = 0.046 ) , ABCG2 rs13120400 c.1194 + 928 CC ( p = 0.029 ) and ABCC2 rs717620 c.-24 GA/AA ( p = 0.025 ) genotype groups significantly influenced Ctrough . ethnicity ( p = 0.042 ) , sex ( p = 0.033 ) , SLCO1B3 rs4149117 c.334 GT/TT ( p = 0.041 ) and @GeneTgt$ ABCB1 @/GeneTgt$ rs1045642 c.3435 TT ( p = 0.016 ) have been retained in linear regression model as @ChemicalSrc$ voriconazole @/ChemicalSrc$ predictor factors . CONCLUSION : Understanding how some gene polymorphisms affect the @ChemicalSrc$ voriconazole @/ChemicalSrc$ pharmacokinetic is essential to optimally dose this agent .	1 6 2|6 6 2|6 6 1 9 9 6 1 15 15 15 15 17 15 19 17 44 44 44 22 22 22 22 26 27|26 26 27|26 26 22 22 22 22 22 22 22 22 22 22 22 22 22 17 48 44|48 48 44|48 17 15 52 52 52 52 52 56 60 60 62 62 52 62 66 66 68 68 68 72 72 72 68 68 75 77 77 77 81 81 81 77 77 109 83 88 88 88 83 91 91 88 91 91 88 97 95 88 97 100 97 103 103 100 103 103 100 108 97 119 117 113 113 110 113 114 117 119 119 119 119 119 158 125 125 122 125 125 132 132 132 132 122 132 132 122 122 136 139 136 142 142 139 142 142 139 145|150 150 145|150 150 150 122 152 150 152 153 152 158 158 158 162 162 162 158 167 162|167 167 162|167 167 162 158 184 171 171 178 177 177 178 173 182 179|182 182 179|182 178 184 184 187 187 184 189 187 184	Association
29914286	Chemical	Gene	D065819	28234	True	0	What is [PHARMGKB] between @ChemicalSrc$ voriconazole @/ChemicalSrc$ and @GeneTgt$ SLCO1B3 @/GeneTgt$ ? [SEP] Pharmacogenetic of @ChemicalSrc$ voriconazole @/ChemicalSrc$ antifungal agent in pediatric patients . AIM : We explored the role of SNPs within the @GeneTgt$ SLCO1B3 @/GeneTgt$ , SLCO1B1 , SLC22A6 , ABCB1 , ABCG2 , SLCO3A1 , CYP2C19 , ABCC2 , SLC22A1 , ABCB11 and NR1I2 genes on @ChemicalSrc$ voriconazole @/ChemicalSrc$ pharmacokinetics . PATIENTS & amp ; METHODS : 233 pediatric patients were enrolled . Drug plasma Ctrough was measured by a HPLC-MS method . Allelic discrimination was performed by qualitative real-time PCR . RESULTS : @GeneTgt$ SLCO1B3 @/GeneTgt$ rs4149117 c.334 GT/TT ( p = 0.046 ) , ABCG2 rs13120400 c.1194 + 928 CC ( p = 0.029 ) and ABCC2 rs717620 c.-24 GA/AA ( p = 0.025 ) genotype groups significantly influenced Ctrough . ethnicity ( p = 0.042 ) , sex ( p = 0.033 ) , @GeneTgt$ SLCO1B3 @/GeneTgt$ rs4149117 c.334 GT/TT ( p = 0.041 ) and ABCB1 rs1045642 c.3435 TT ( p = 0.016 ) have been retained in linear regression model as @ChemicalSrc$ voriconazole @/ChemicalSrc$ predictor factors . CONCLUSION : Understanding how some gene polymorphisms affect the @ChemicalSrc$ voriconazole @/ChemicalSrc$ pharmacokinetic is essential to optimally dose this agent .	1 6 2|6 6 2|6 6 1 9 9 6 1 15 15 15 15 17 15 19 17 44 44 44|21 44 44|21 22 22 22 22 27 27 27 22 22 22 22 22 22 22 22 22 22 22 22 22 17 48 44|48 48 44|48 17 15 52 52 52 52 52 56 60 60 62 62 52 62 66 66 68 68 68 72 72 72 68 68 75 77 77 77 81 81 81 77 77 110 83 84|89 89 84|89 89 89 83 92 92 89 92 92 89 98 96 89 98 101 98 104 104 101 104 104 101 109 98 120 118 114 114 111 114 115 118 120 120 120 120 120 160 127 127 124 127 127 134 134 134 134 124 134 134 124 124|137 124 124|137 138 142 138 145 145 142 145 145 142 152 152 152 124 154 152 154 155 154 160 160 160 164 164 164 160 169 164|169 169 164|169 169 164 160 186 173 173 180 179 179 180 175 184 181|184 184 181|184 180 186 186 189 189 186 191 189 186	Association
29914286	Chemical	Gene	D065819	1244	True	0	What is [PHARMGKB] between @ChemicalSrc$ voriconazole @/ChemicalSrc$ and @GeneTgt$ ABCC2 @/GeneTgt$ ? [SEP] Pharmacogenetic of @ChemicalSrc$ voriconazole @/ChemicalSrc$ antifungal agent in pediatric patients . AIM : We explored the role of SNPs within the SLCO1B3 , SLCO1B1 , SLC22A6 , ABCB1 , ABCG2 , SLCO3A1 , CYP2C19 , @GeneTgt$ ABCC2 @/GeneTgt$ , SLC22A1 , ABCB11 and NR1I2 genes on @ChemicalSrc$ voriconazole @/ChemicalSrc$ pharmacokinetics . PATIENTS & amp ; METHODS : 233 pediatric patients were enrolled . Drug plasma Ctrough was measured by a HPLC-MS method . Allelic discrimination was performed by qualitative real-time PCR . RESULTS : SLCO1B3 rs4149117 c.334 GT/TT ( p = 0.046 ) , ABCG2 rs13120400 c.1194 + 928 CC ( p = 0.029 ) and @GeneTgt$ ABCC2 @/GeneTgt$ rs717620 c.-24 GA/AA ( p = 0.025 ) genotype groups significantly influenced Ctrough . ethnicity ( p = 0.042 ) , sex ( p = 0.033 ) , SLCO1B3 rs4149117 c.334 GT/TT ( p = 0.041 ) and ABCB1 rs1045642 c.3435 TT ( p = 0.016 ) have been retained in linear regression model as @ChemicalSrc$ voriconazole @/ChemicalSrc$ predictor factors . CONCLUSION : Understanding how some gene polymorphisms affect the @ChemicalSrc$ voriconazole @/ChemicalSrc$ pharmacokinetic is essential to optimally dose this agent .	1 6 2|6 6 2|6 6 1 9 9 6 1 15 15 15 15 17 15 19 17 44 44 44 22 22 22 22 26 26 26 22 22 22 22 22 22 35|22 22 35|22 22 22 22 22 22 22 17 48 44|48 48 44|48 17 15 52 52 52 52 52 56 60 60 62 62 52 62 66 66 68 68 68 72 72 72 68 68 75 77 77 77 81 81 81 77 77 110 83 88 88 88 83 91 91 88 91 91 88 97 95 88 97 100 97 103 103 100 103 103 100 106|109 109 106|109 97 120 118 114 114 111 114 115 118 120 120 120 120 120 159 127 127 124 127 127 134 134 134 134 124 134 134 124 124 138 141 138 144 144 141 144 144 141 151 151 151 124 153 151 153 154 153 159 159 159 163 163 163 159 168 164|168 168 164|168 168 163 159 184 171 171 178 177 177 178 173 182 179|182 182 179|182 178 184 184 187 187 184 189 187 184	Association
29914286	Chemical	Gene	D065819	9429	True	0	What is [PHARMGKB] between @ChemicalSrc$ voriconazole @/ChemicalSrc$ and @GeneTgt$ ABCG2 @/GeneTgt$ ? [SEP] Pharmacogenetic of @ChemicalSrc$ voriconazole @/ChemicalSrc$ antifungal agent in pediatric patients . AIM : We explored the role of SNPs within the SLCO1B3 , SLCO1B1 , SLC22A6 , ABCB1 , @GeneTgt$ ABCG2 @/GeneTgt$ , SLCO3A1 , CYP2C19 , ABCC2 , SLC22A1 , ABCB11 and NR1I2 genes on @ChemicalSrc$ voriconazole @/ChemicalSrc$ pharmacokinetics . PATIENTS & amp ; METHODS : 233 pediatric patients were enrolled . Drug plasma Ctrough was measured by a HPLC-MS method . Allelic discrimination was performed by qualitative real-time PCR . RESULTS : SLCO1B3 rs4149117 c.334 GT/TT ( p = 0.046 ) , @GeneTgt$ ABCG2 @/GeneTgt$ rs13120400 c.1194 + 928 CC ( p = 0.029 ) and ABCC2 rs717620 c.-24 GA/AA ( p = 0.025 ) genotype groups significantly influenced Ctrough . ethnicity ( p = 0.042 ) , sex ( p = 0.033 ) , SLCO1B3 rs4149117 c.334 GT/TT ( p = 0.041 ) and ABCB1 rs1045642 c.3435 TT ( p = 0.016 ) have been retained in linear regression model as @ChemicalSrc$ voriconazole @/ChemicalSrc$ predictor factors . CONCLUSION : Understanding how some gene polymorphisms affect the @ChemicalSrc$ voriconazole @/ChemicalSrc$ pharmacokinetic is essential to optimally dose this agent .	1 6 2|6 6 2|6 6 1 9 9 6 1 15 15 15 15 17 15 19 17 44 44 44 22 22 22 22 26 26 26 29|22 22 29|22 22 22 22 22 22 22 22 22 22 22 22 22 17 48 44|48 48 44|48 17 15 52 52 52 52 52 56 60 60 62 62 52 62 66 66 68 68 68 72 72 72 68 68 75 77 77 77 81 81 81 77 77 110 83 88 88 88 83 91 91 88 91 91 88 98|94 98 98|94 95 88 98 101 98 104 104 101 104 104 101 109 98 120 118 114 114 111 114 115 118 120 120 120 120 120 159 127 127 124 127 127 134 134 134 134 124 134 134 124 124 138 141 138 144 144 141 144 144 141 151 151 151 124 153 151 153 154 153 159 159 159 163 163 163 159 168 164|168 168 164|168 168 163 159 184 171 171 178 177 177 178 173 182 179|182 182 179|182 178 184 184 187 187 184 189 187 184	Association
30040020	Chemical	Gene	D003915	1564	True	0	What is [PHARMGKB] between @ChemicalSrc$ dextromethorphan @/ChemicalSrc$ and @GeneTgt$ CYP2D7 @/GeneTgt$ ? [SEP] Functional characterization of @GeneTgt$ CYP2D7 @/GeneTgt$ gene variants . The ultrarapid CYP2D6 metabolizer ( UM ) phenotype is caused by CYP2D6 gene duplications in some , but not all , UM individuals . CYP2D6 and the adjacent pseudogene @GeneTgt$ CYP2D7 @/GeneTgt$ are highly homologous ; however , @GeneTgt$ CYP2D7 @/GeneTgt$ harbors a premature stop codon , which is absent in carriers of the rare @GeneTgt$ CYP2D7 @/GeneTgt$ variant rs530303678 . We addressed whether rs530303678 could generate a functionally active protein , causing the UM phenotype . However , unlike CYP2D6 variants , two @GeneTgt$ CYP2D7 @/GeneTgt$ rs530303678 variant isoforms , previously described in liver , showed neither significant protein expression nor catalytic activity toward the CYP2D6 substrates bufuralol or @ChemicalSrc$ dextromethorphan @/ChemicalSrc$ . We conclude that loss of the stop codon in @GeneTgt$ CYP2D7 @/GeneTgt$ does not result in the generation of enzymatically active protein in human liver and thus , can not cause the UM phenotype .	2 2 7 3|7 7 3|7 7 2 2 17 17 13 17 15 17 15 19 19 19 23 23 23 19 25 23 25 28 29 25 32 32 19 19 43 34 39 39 39 34|38 34 34|38 43 43 43 43 49 49 49|45 49 49|45 43 53 53 53 49 53 57 57 53 59 57 65 65 65 65|60 65 65|60 59 57 43 72 72 76 76 76 72 80 79 80 76 76 76 85 85 82 72 105 105 91 91 105 105 94 98|93 98 98|93 98 98 105 98 101 98 103 101 98 105 109 109 109 105 109 112 109 116 116 116 109 116 117 117 117 117 105 125 125 137 137 131 131 131 127 133 132|127 127 132|127 137 137 125 140 140 137 144 143 144 140 147 147 144 137 153 153 153 153 137 156 156 153 125	Association
30799725	Chemical	Gene	D016572	3605	True	0	What is [PHARMGKB] between @ChemicalSrc$ cyclosporine @/ChemicalSrc$ and @GeneTgt$ IL-17 @/GeneTgt$ ? [SEP] The interleukin-17 G-197A polymorphism is associated with @ChemicalSrc$ cyclosporine @/ChemicalSrc$ metabolism and transplant rejection in liver transplant recipients . Aim : This study aimed to investigate the effect of and mechanism involved in the @GeneTgt$ IL-17 @/GeneTgt$ SNP on @ChemicalSrc$ cyclosporine @/ChemicalSrc$ metabolism and outcomes of liver transplantation ( LT ) . Materials & methods : The @GeneTgt$ IL-17 @/GeneTgt$ genotype , @GeneTgt$ IL-17 @/GeneTgt$ expression , postoperative outcome and @ChemicalSrc$ cyclosporine @/ChemicalSrc$ concentration were reviewed in 106 LT recipients . The functional relevance of rs2275913 was evaluated by luciferase assay . Furthermore , L02 cells were treated with @GeneTgt$ IL-17 @/GeneTgt$ recombinant protein or/and pregnane X receptor ( PXR ) knockdown lentiviruses , then the expression of PXR , CYP3A4 , CYP3A5 and IL-17R were detected by PCR and western blotting . Result : The significant distribution difference at @GeneTgt$ IL-17 @/GeneTgt$ locus G-197A was confirmed between patients with and without rejection ( p = 0.035 ) . Patients with acute rejection showed higher @GeneTgt$ IL-17 @/GeneTgt$ level than those without rejection . @ChemicalSrc$ Cyclosporine @/ChemicalSrc$ concentration was associated with the different @GeneTgt$ IL-17 @/GeneTgt$ genotype ( p < 0.05 ) . Luciferase assay revealed that 197 G genotype had higher luciferase activity than that in 197A genotype ( p = 0.009 ) . Furthermore , @GeneTgt$ IL-17 @/GeneTgt$ recombinant protein remarkably promoted the expressions of PXR , CYP3A4 and CYP3A5 ( p < 0.01 ) , but not IL-17R . PXR knockdown significantly inhibited the mRNA levels of CYP3A4 and CYP3A5 but not IL-17R ( p < 0.01 ) , while @GeneTgt$ IL-17 @/GeneTgt$ recombinant protein had no influence on the expressions of CYP3A4 and CYP3A5 when PXR was downregulated . Conclusion : This study revealed the possible association of @GeneTgt$ IL-17 @/GeneTgt$ G-197A with @ChemicalSrc$ cyclosporine @/ChemicalSrc$ metabolism and transplant rejection after LT , which might be partly related to the upregulations of CYP3A4/5 dependent on PXR .	4 4 4 6 6 6 10 10|7 10 10|7 6 10 13 10 17 17 17 10 6 23 23 23 23 23 26 24 28 26 28 28 28 31 37 37 37|34 37 37|34 32 41 37|41 41 37|41 32 41 41 46 46 43 48 46 48 23 73 53 53 53 60 60|57 60 60|57 53 60 60|64 64 60|64 60 60 67 60 67 71|66 71 71|66 67 73 73 77 77 77 73 73 84 84 88 86 84 88 88 91 91 88 88 98 98 96 98 98 98 103 103|99 103 103|99 103 98 98 107 107 112 109 107 109 112 104 126 126 116 126 118 116 118 118 118 118 118 118 126 98 128 126 128 131 128 126 134 134 139 139 139 146 144 144|140 144 144|140 144 139 146 134 148 146 152 149 149 148 155 155 152 155 155 134 164 163 163 160 164 168 168|165 168 168|165 164 170 168 172 170 164 174|177 177 174|177 179 179 179 185 185 185 185|181 185 185|181 179 188 188 185 188 188 179 195 196 196 201 200 200 201 196 204 204 201 206 204 209 209 206 212 212 209 212 212 196 223 223 217|221 221 217|221 221 223 223 223 225 223 227 225 227 227 227 227 235 235 235 227 235 227 239 227 227 223 244 246 246 246 249 249 246 251 249 251 251 255 251 251 260 260 260 251 260 246 268 267|263 267 267|263 267 268 246 270 268 273 273 270 275 273 275 275 281 281 281 268 246 284 288 287 288 284 291 291 288 295 292|295 295 292|295 291 299 299|295 299 299|295 291 299 302 299 304 299 304 310 310 310 310 291 313 313 310 315 313 315 318 316 284	Association
31250727	Chemical	Gene	C578009	10599	True	0	What is [PHARMGKB] between @ChemicalSrc$ grazoprevir @/ChemicalSrc$ and @GeneTgt$ SLCO1B1 @/GeneTgt$ ? [SEP] The pharmacogenetics of @GeneTgt$ OATP1B1 @/GeneTgt$ variants and their impact on the pharmacokinetics and efficacy of @ChemicalSrc$ elbasvir/grazoprevir @/ChemicalSrc$ . Aim : To evaluate the effect of @GeneTgt$ SLCO1B1 @/GeneTgt$ genetic variants on @ChemicalSrc$ grazoprevir @/ChemicalSrc$ pharmacokinetics and efficacy . Methods : A retrospective analysis of 1578 hepatitis C virus-infected participants from ten Phase II/III clinical trials . Results : Relative to noncarriers of the risk allele , geometric mean ratios ( 95 % CI ) of grazoprevir area under curve (AUC)0 - 24 were : rs4149056 ( risk allele C ) , one copy , 1.13 ( 1.06 - 1.21 ) , two copies , 1.43 ( 1.16 - 1.77 ) ; and rs11045819 ( risk allele A ) , one copy , 0.93 ( 0.87 - 1.00 ) ; two copies , 0.78 ( 0.61 - 1.00 ) . The rs2306283 variant was not associated with @ChemicalSrc$ grazoprevir @/ChemicalSrc$ exposure . None of the @GeneTgt$ SLCO1B1 @/GeneTgt$ variants were associated with sustained virologic response . Conclusion : Genetic variants in @GeneTgt$ SLCO1B1 @/GeneTgt$ were associated with modest changes in @ChemicalSrc$ grazoprevir @/ChemicalSrc$ pharmacokinetics , but not with meaningful differences in efficacy .	2 2 6 3|6 6 3|6 2 2 9 2 12 12 9 12 12 16 12|14 12 12|14 2 21 24 24 21 26 24 31 31|27 31 31|27 31 26 35 31|35 35 31|35 26 35 35 21 41 41 45 45 41 51 51 50 50 51 45 57 57 57 57 57 51 41 59 59 59 63 61 67 67 67 63 61 70 71 59 75 74 75 71 75 79 79 71 82 82 71 84 82 71 87 85 91 91 91 87 91 87 95 87 95 101 101 101 101 95 95 87 105 87 105 111 111 111 111 105 105 87 87 87 119 119 119 115 119 115 123 115 129 129 129 129 129 115 129 115 133 71 133 133 139 139 139 135 139 59 144 144 147 147 147 147 151 151|148 151 151|148 147 147 161 159 159 156|159 159 156|159 154 161 161 165 165 165 161 161 168 168 171 176 173 171|172 171 171|172 176 168 179 179 176 183 183|179 183 183|179 179 183 183 189 189 189 179 191 189 168	Association
31462767	Chemical	Gene	D008694	56899	True	0	What is [PHARMGKB] between @ChemicalSrc$ methamphetamine @/ChemicalSrc$ and @GeneTgt$ ANKS1B @/GeneTgt$ ? [SEP] Identification of novel risk loci with shared effects on alcoholism , heroin , and @ChemicalSrc$ methamphetamine @/ChemicalSrc$ dependence . Different substance dependences have common effects on reward pathway and molecular adaptations , however little is known regarding their shared genetic factors . We aimed to identify the risk genetic variants that are shared for substance dependence ( SD ) . First , promising genome-wide significant loci were identified from 3296 patients ( 521 alcoholic/1026 heroin/1749 @ChemicalSrc$ methamphetamine @/ChemicalSrc$ ) vs 2859 healthy controls and independently replicated using 1954 patients vs 1904 controls . Second , the functional effects of promising variants on gene expression , addiction characteristics , brain structure ( gray and white matter ) , and addiction behaviors in addiction animal models ( chronic administration and self-administration ) were assessed . In addition , we assessed the genetic correlation among the three SDs using LD score regression . We identified and replicated three novel loci that were associated with the common risk of heroin , @ChemicalSrc$ methamphetamine @/ChemicalSrc$ addiction , and alcoholism : @GeneTgt$ ANKS1B @/GeneTgt$ rs2133896 ( Pmeta = 3.60 x 10 - 9 ) , AGBL4 rs147247472 ( Pmeta = 3.40 x 10 - 12 ) , and CTNNA2 rs10196867 ( Pmeta = 4.73 x 10 - 9 ) . Rs2133896 in @GeneTgt$ ANKS1B @/GeneTgt$ was associated with @GeneTgt$ ANKS1B @/GeneTgt$ gene expression and had effects on gray matter of the left calcarine and white matter of the right superior longitudinal fasciculus in heroin dependence . Overexpression of anks1b gene in the ventral tegmental area decreased addiction vulnerability for heroin and @ChemicalSrc$ methamphetamine @/ChemicalSrc$ in self-administration rat models . Our findings could shed light on the root cause for substance dependence and will be helpful for the development of cost-effective prevention strategies for general addiction disorders .	1 5 5 5 1 8 8 1 10 8 10 10 12 10 17|14 17 17|14 10 1 22 22 23 23 25 23 28 28 25 28 31 28 23 36 36 36 23 41 41 41 41 36 23 44 44 46 44 50 50 50 46 53 53 50 56 56 53 58 56 58 44 68 68 66 66 66 68 68 68 71 71 68 76 76 75 76 71|75 71 71|75 76 71 82 82 71 68 85 68 85 88 86 88 91 88 68 132 132 98 98 132 101 101 98 104 104 101 104 107 104 107 110 107 112 110 112 112 112 112 107 104 120 104 124 124 124 104 127 127 124 127 127 127 132 132 132 135 138 138 138 138 141 141 138 145 145 145 141 141 149 149 146 138 152 152 152 152 157 157 154 160 160 157 164 164 164 160 166 164 166 167|170 170 167|170 166 166 166 166 166 177|173 177 177|173 164 179 177 179 180 181 185 185 181 185 179 179 188 191 179 191 192 193 197 197 193 192 191 191 202 191 204 191 204 210 206 206 210 205 204 152 220 217 215|216 215 215|216 220 220 225 225|220 225 225|220 225 220 220 220 227 231 231 228 235 235 235 231 235 238 235 244 244 242 244 244 235 247 247 227 220 260 254 254 251 259 259 259 259 251 260 262 260 264 262 264 264|265 264 264|265 271 271 271 262 260 275 277 277 277 277 282 282 282 277 285 285 282 277 289 289 277 292 292 289 296 296 296 292 300 300 300 292 277	Association
31462767	Chemical	Gene	D003932	56899	True	0	What is [PHARMGKB] between @ChemicalSrc$ heroin @/ChemicalSrc$ and @GeneTgt$ ANKS1B @/GeneTgt$ ? [SEP] Identification of novel risk loci with shared effects on alcoholism , @ChemicalSrc$ heroin @/ChemicalSrc$ , and methamphetamine dependence . Different substance dependences have common effects on reward pathway and molecular adaptations , however little is known regarding their shared genetic factors . We aimed to identify the risk genetic variants that are shared for substance dependence ( SD ) . First , promising genome-wide significant loci were identified from 3296 patients ( 521 alcoholic/1026 heroin/1749 methamphetamine ) vs 2859 healthy controls and independently replicated using 1954 patients vs 1904 controls . Second , the functional effects of promising variants on gene expression , addiction characteristics , brain structure ( gray and white matter ) , and addiction behaviors in addiction animal models ( chronic administration and self-administration ) were assessed . In addition , we assessed the genetic correlation among the three SDs using LD score regression . We identified and replicated three novel loci that were associated with the common risk of @ChemicalSrc$ heroin @/ChemicalSrc$ , methamphetamine addiction , and alcoholism : @GeneTgt$ ANKS1B @/GeneTgt$ rs2133896 ( Pmeta = 3.60 x 10 - 9 ) , AGBL4 rs147247472 ( Pmeta = 3.40 x 10 - 12 ) , and CTNNA2 rs10196867 ( Pmeta = 4.73 x 10 - 9 ) . Rs2133896 in @GeneTgt$ ANKS1B @/GeneTgt$ was associated with @GeneTgt$ ANKS1B @/GeneTgt$ gene expression and had effects on gray matter of the left calcarine and white matter of the right superior longitudinal fasciculus in heroin dependence . Overexpression of anks1b gene in the ventral tegmental area decreased addiction vulnerability for @ChemicalSrc$ heroin @/ChemicalSrc$ and methamphetamine in self-administration rat models . Our findings could shed light on the root cause for substance dependence and will be helpful for the development of cost-effective prevention strategies for general addiction disorders .	1 5 5 5 1 8 8 1 10 8 10 10|11 10 10|11 12 10 17 10 1 22 22 23 23 25 23 28 28 25 28 31 28 23 36 36 36 23 41 41 41 41 36 23 44 44 46 44 50 50 50 46 53 53 50 56 56 53 58 56 58 44 68 68 66 66 66 68 68 68 71 71 68 76 76 75 76 71 76 71 81 81 71 68 84 68 84 87 85 87 90 87 68 130 130 96 96 130 99 99 96 102 102 99 102 105 102 105 108 105 110 108 110 110 110 110 105 102 118 102 122 122 122 102 125 125 122 125 125 125 130 130 130 133 136 136 136 136 139 139 136 143 143 143 139 139 147 147 144 136 150 150 150 150 155 155 152 158 158 155 162 162 162 158 164 162|163 162 162|163 164 168 164 164 164 164 164 175|171 175 175|171 162 177 175 177 178 179 183 183 179 183 177 177 186 189 177 189 190 191 195 195 191 190 189 189 200 189 202 189 202 208 204 204 208 203 202 150 218 215 213|214 213 213|214 218 218 223 223|218 223 223|218 223 218 218 218 225 229 229 226 233 233 233 229 233 236 233 242 242 240 242 242 233 245 245 225 218 258 252 252 249 257 257 257 257 249 258 260 258 262 260|261 260 260|261 262 262 269 269 269 260 258 273 275 275 275 275 280 280 280 275 283 283 280 275 287 287 275 290 290 287 294 294 294 290 298 298 298 290 275	Association
31634677	Chemical	Gene	D000431	775	False	3	What is [PHARMGKB] between @ChemicalSrc$ alcohol @/ChemicalSrc$ and @GeneTgt$ CACNA1C @/GeneTgt$ ? [SEP] Association between CANCA1C gene rs1034936 polymorphism and alcohol dependence in bipolar disorder . INTRODUCTION : Bipolar disorder ( BD ) is a highly heritable and disabling mental illness , commonly associated with substance abuse , being @ChemicalSrc$ alcohol @/ChemicalSrc$ abuse the most frequent . Comorbid BD and substance abuse disorders are often associated with high levels of health service utilization and destabilization of the course of illness resulting in poor treatment outcomes . Although recent genome-wide association studies have detected a number of risk genes for BD , the data is still sparse and inconclusive for those genes that may contribute to the increased risk of comorbid @ChemicalSrc$ alcohol @/ChemicalSrc$ abuse ( AA ) in BD . The primary aim of the present study was to investigate the effects of 46 single-nucleotide polymorphisms ( SNPs ) within eight genes on different phenotypes of BD patients , such as comorbid @ChemicalSrc$ alcohol @/ChemicalSrc$ abuse . We further assessed clinical variables associated with AA . METHODS : One-hundred fifty-eight BD I and II patients were enrolled in a naturalistic cohort study . Genomic DNA of 92 patients was extracted from whole blood using standard procedures and 46 tag SNPs in eight genes of interest ( ANK , @GeneTgt$ CACNA1C @/GeneTgt$ , CACNB2 , FKBP5 , GRM7 , ITIH3 , SYNE1 and TCF4 ) were genotyped . RESULTS : Seventy-one patients out of 158 ( 45 % ) satisfied diagnostic criteria for comorbid AA . Among 46 SNPs analyzed , the only SNP associated with comorbid AA was rs1034936 polymorphism in the CANCA1C gene . This polymorphism was also associated with lifetime cocaine abuse , manic switch and current atypical antipsychotics . CONCLUSIONS : Our findings suggest a role of rs1034936 @GeneTgt$ CACNA1C @/GeneTgt$ gene variant in BD-AA group . Despite their preliminary nature , the present results may provide new insight on mechanisms underlying AA in BD .	1 6 6 6 6 1 6 6 6 12 12 9 1 14 24 17 24 19 17 19 24 24 24 14 24 24 28 26 24 31 24 34 34 31 24 42 39|36 39 39|36 36 42 42 24 14 46 53 46 46 50 53 53 53 53 56 56 53 60 59 60 56 56 56 65 65 62 67 65 65 72 72 72 68 53 80 78 78 78 80 80 93 82 80 85 85 82 87 85 93 90 93 93 93 93 93 93 98 98 95 101 101 98 105 105 105 101 110 110 107|110 110 107|110 105 112 110 112 115 110 93 120 120 125 124 124 124 120 125 127 125 129 127 133 133 133 129 135 133 135 139 139 129 142 142 139 145 145 142 145 152 147 152 149|152 152 149|152 145 125 157 157 157 159 157 159 162 160 157 174 174 167 168 172 168 169 169 174 174 174 179 179 179 179 174 174 182 187 185 185 182 187 187 190 190 187 187 193 191 193 197 197 193 200 200 191 202 200 204 202 204 204|205 204 204|205 206 204 204 204 204 204 213 213 213 213 213 213 204 222 187 187 225 225 228 225 228 231 229 234 234 228 234 238 238 228 241 241 238 225 245 245 257 245 257 250 250 257 250 254 254 251 257 257 257 261 261 261 257 257 264 267 267 267 267 271 271 271 267 271 274 271 274 278 278 274 267 280 280 283 284 280 286 284 292 292 288|292 292 288|292 292 286 295 295 286 280 301 301 301 307 307 305 305 307 307 307 309 307 311 309 311 312 315 313 307	Association
32787509	Chemical	Gene	C089740	4904	True	0	What is [PHARMGKB] between @ChemicalSrc$ abiraterone @/ChemicalSrc$ and @GeneTgt$ YB-1 @/GeneTgt$ ? [SEP] YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients . Aim : To evaluate the influence of @GeneTgt$ YB-1 @/GeneTgt$ rs10493112 variant as a genetic marker for response to second-generation androgen receptor axis-target agents . Methods : A hospital-based cohort study of 78 patients with metastatic castration-resistant prostate cancer was conducted . Genotyping was performed by TaqMan allelic discrimination technology . Main results : In @ChemicalSrc$ abiraterone-treated @/ChemicalSrc$ and high-risk patients , @GeneTgt$ YB-1 @/GeneTgt$ rs10493112 AA genotype carriers showed lower progression-free survival than C allele genotype patients ( 4 vs 17 months ; p = 0.009 ) . For carriers of AA genotype , multivariate Cox regression analysis revealed a fivefold increased risk of progression ( p = 0.035 ) . Conclusion : The study findings suggest that , for metastatic and castration-resistant prostate cancer patients , this polymorphism might be a putative marker for the clinical outcome .	2 2 2 6 6 7 2 13 13 13 13 13 7 2 15 18 18 15 20 18 25 24|21 24 24|21 25 20 29 29 29 20 31 29 37 37 37 37 37 31 15 55 40 45 45 45 55 48 48 45 53 53 53 53 48 55 55 55 59 59 59 64 64 63 64 59 59 67 67 67 74 74|69 74 74|69 70 70 82 82 81|74 81 81|74 81 81 81 82 67 85 85 82 90 90 90 90 85 95 95 92 92 90 98 98 82 98 98 82 105 114 108 108 105 114 113 113 113 114 114 118 117 118 114 120 118 123 123 118 123 123 114 132 132 131 131 132 132 149 149 136 149 136 136 141 141 136 149 144 149 149 149 149 149 132 153 153 153 149 132	Association
12893983	Chemical	Gene	C058254	2784	True	0	What is [PHARMGKB] between @ChemicalSrc$ sibutramine @/ChemicalSrc$ and @GeneTgt$ GNB3 @/GeneTgt$ ? [SEP] Prediction of successful weight reduction under @ChemicalSrc$ sibutramine @/ChemicalSrc$ therapy through genotyping of the @GeneTgt$ G-protein beta3 @/GeneTgt$ subunit gene ( @GeneTgt$ GNB3 @/GeneTgt$ ) C825 T polymorphism . BACKGROUND : @ChemicalSrc$ Sibutramine @/ChemicalSrc$ , a centrally acting noradrenaline and serotonin re-uptake inhibitor , enhances satiety and is frequently used to support weight loss . However , a significant variability exists among individuals concerning the response to @ChemicalSrc$ sibutramine @/ChemicalSrc$ . METHODS : We genotyped 111 participants of a randomized placebo-controlled clinical trial for the @GeneTgt$ GNB3 @/GeneTgt$ C825 T polymorphism and analysed associations of genotypes with treatment outcome . Patients undergoing a structured weight loss programme were treated with either placebo or 15 mg @ChemicalSrc$ sibutramine @/ChemicalSrc$ daily for 54 weeks . RESULTS : In the placebo group , the non-pharmacological programme alone resulted in a significantly greater weight loss in individuals with the @GeneTgt$ GNB3 @/GeneTgt$ TT/TC genotypes as compared to individuals with the CC genotype ( -7.1 + /- 1.2 vs. -2.7 + /- 1.5 kg , P = 0.031 ) . Administration of 15 mg @ChemicalSrc$ sibutramine @/ChemicalSrc$ was more effective in individuals with the CC genotype than in the subjects with the TT/TC genotypes ( weight loss : 7.2 + /- 2.2 vs. 4.1 + /- 2.1 kg , P = 0.0013 , @ChemicalSrc$ sibutramine @/ChemicalSrc$ vs. placebo ) . In the CC genotype carriers , the odds ratio ( OR ) for a weight loss greater than 5 % ( @ChemicalSrc$ sibutramine @/ChemicalSrc$ vs. placebo ) was 6.6 ( 95 % CI 1.8 - 25.6 ; P = 0.004 ) and for a weight loss greater than 10 % was 9.6 ( 95 % CI 1.7 - 53.8 ; P = 0.010 ) . CONCLUSION : Genotyping for the @GeneTgt$ GNB3 @/GeneTgt$ C825 T polymorphism is highly predictive for the identification of obese individuals who will benefit from @ChemicalSrc$ sibutramine @/ChemicalSrc$ treatment .	1 5 5 5 1 9 9|6 9 9|6 5 11 1 18 18 18|12 18|12 18 18|12 18 25 20 16|25 25 16|25 25 25 25 11 1 30 30 31|44 44 31|44 32 38 37 38 32 38 38 42 38 32 30 44 44 49 49 44 51 49 53 51 30 61 61 60 60 61 61 63 61 66 66 63 68 66|67 66 66|67 61 75 75 75 75 77 75 83 83 83 83 83 77 90 90 90|85 90 90|85 90 90 83 75 75 92 95 93 98 98 93 75 109 101 107 107 107 107 102 109 109 112 112 109 112 115 116 118|115 118 118|115 112 121 121 109 109 135 124 129 129 129 135 135 133 133 135 133 135 141 141 139 141 141 135 143 141 149 149 149|145 149 149|145 149 143 151 135 153 151 157 157 157 153 159 157 159 159 159 162 162 159 168 168 159 171 171 159 171 171 135 184 180 179 180 176|179 176 176|179 184 184 184 186 184 190 190 190 186 194 194 194 184 198 198 198 194 201 201 215 203 212 203 203 203 206 206 203 212 212 215 215 215 184 215 216 215|216 215 215|216 218 218 184 184 230 230 230 230 257 257 234 234 257 236 234 236 241 241 241 234 245 244 245 234 247 245|246 245 245|246 247 247 247 257 257 256 256 257 257 260 260 257 263 263 257 263 263 257 270 270 270 257 274 273 274 270 276 280 279 279 280 270 283 283 280 286 286 280 286 286 257 291 291 303 300 300 300|295 300 300|295 300 300 293 303 303 291 306 306 303 309 309 306 312 312 309 316 316|312 316 316|312 312 303	Association
17261659	Chemical	Gene	C044946	183	True	0	What is [PHARMGKB] between @ChemicalSrc$ benazepril @/ChemicalSrc$ and @GeneTgt$ AGT @/GeneTgt$ ? [SEP] Association between @GeneTgt$ angiotensinogen @/GeneTgt$ , angiotensin II receptor genes , and blood pressure response to an angiotensin-converting enzyme inhibitor . BACKGROUND : To identify the genetic contribution to the variation in blood pressure ( BP ) response to angiotensin-converting enzyme inhibitors ( ACEIs ) , single-nucleotide polymorphisms ( SNPs ) in the @GeneTgt$ angiotensinogen @/GeneTgt$ ( @GeneTgt$ AGT @/GeneTgt$ ) , angiotensin receptor 1 ( AGTR1 ) , and angiotensin receptor 2 ( AGTR2 ) genes were evaluated for their association with BP response to ACEI in Chinese patients with hypertension in a 2-stage design . METHODS AND RESULTS : We selected 1447 hypertensive patients from a 3-year benazepril postmarket surveillance trial and genotyped them for 14 SNPs in the @GeneTgt$ AGT @/GeneTgt$ , AGTR1 , and AGTR2 genes . The @GeneTgt$ AGT @/GeneTgt$ rs7079 ( C/T ) SNP ( 3'-untranslated region ) was significantly associated with the response of diastolic BP to @ChemicalSrc$ benazepril @/ChemicalSrc$ ( diastolic BP response : -7.4 mm Hg for subjects with the CC genotype , -8.9 mm Hg for CA , and -10.1 mm Hg for AA ; P=0.001 ) . Although there was no association of individual SNPs in the AGTR1 gene , there was a graded response between common haplotypes and systolic BP reduction in the order of haplotype 2 (H2)/lack of haplotype 3 ( non-H3 ) ( -13.6 mm Hg ) & gt ; non-H2/non-H3 ( -10.9 mm Hg ) & gt ; H3/non-H2 ( -6.6 mm Hg ) ( P=0.004 ) . The total variations in response to ACEI therapy that were explained by the @GeneTgt$ AGT @/GeneTgt$ SNP and AGTR1 haplotype groups were 13 % for systolic and 9 % to 9.6 % for diastolic BP , respectively . CONCLUSIONS : @GeneTgt$ AGT @/GeneTgt$ SNP rs7079 and AGTR1 haplotypes were associated with BP reduction in response to ACEI therapy in hypertensive Chinese patients . This will be useful in future studies , providing genetic markers to predict the hypertensive response to ACEI therapy .	1 3 1|2 1 1|2 3 9 9 9 3 3 3 14 14 3 19 19 19 19 14 1 77 25 25 22 28 28 25 31 31 28 38 34 38 36 34 38 31 42 42 42 38 44 42 44 42 48 42 50 48 50 54 54 53|48 48 53|48 57 54|55 54 54|55 57 54 62 54 62 65 62 65 62 54 70 75 70 73 75 75 77 77 77 80 80 77 83 83 80 85 83 88 88 85 90 88 94 94 94 80 77 98 98 98 103 103 98 106 106 103 113 113 113 113 113 113 106 103 103 115 119 119 115 122 122 121|119 119 121|119 122 122 122 122 122 122 103 139 132|135 135 132|135 139 137 139 139 146 142 142 139 142 146 146 146 149 149 146 152 152 149 159 159|152 159 159|152 159 159 159 149 146 163 163 146 165 163 169 169 169 165 165 173 173 165 175 173 175 173 180 180 163 182 180 180 180 163 146 191 191 203 193 191 196 196 193 200 200 200 193 203 203 203 206 206 203 209 209 206 209 212 213 209 216 216 206 218 216 220 216 222 220 222 225 222 225 230 229 230 220 230 220 220 220 220 239 239 239 235 239 235 235 235 220 247 247 248 244 251 251 248 244 203 256 256 276 258 256 261 261 258 264 264 261 269 269 269|266 269 269|266 264 269 272 273 269 276 276 276 278 276 278 281 283 283 284 278 287 287 278 276 276 276 292 292 293|297 297 293|297 297 302 297 300 297 302 292 305 305 302 307 305 310 310 307 314 314 314 310 292 320 320 320 320 323 323 320 320 320 327 325 329 325 332 332 329 335 335 332 320	Association
17344938	Chemical	Gene	D009543	8170	True	0	What is [PHARMGKB] between @ChemicalSrc$ nifedipine @/ChemicalSrc$ and @GeneTgt$ SLC14A2 @/GeneTgt$ ? [SEP] Genetic polymorphisms of the urea transporter gene are associated with antihypertensive response to @ChemicalSrc$ nifedipine @/ChemicalSrc$ GITS . @ChemicalSrc$ Nifedipine @/ChemicalSrc$ GITS has diuretic and natriuretic properties , which may enhance its antihypertensive efficacy . We assessed contributions of polymorphisms in the urea transporter-A gene ( @GeneTgt$ SLC14A2 @/GeneTgt$ ) to interindividual variations in blood pressure ( BP ) response to @ChemicalSrc$ nifedipine @/ChemicalSrc$ treatment . 405 subjects from a single Chinese county received a single oral dose of 30 mg @ChemicalSrc$ nifedipine @/ChemicalSrc$ GITS ( gastrointestinal therapeutic system ) daily for 16 days . We genotyped two SNPs in @GeneTgt$ SLC14A2 @/GeneTgt$ and found significant associations for the Val227Ile ( rs1123617 ) and Ala357Thr ( rs3745009 ) polymorphisms with BP response to @ChemicalSrc$ nifedipine @/ChemicalSrc$ treatment . After treatment , subjects with either Ala357/Thr357 or Thr357/Thr357 genotypes had significantly smaller mean changes in systolic BP ( SBP ) ( beta + /- SE = -2.87 + /- 1.24 mmHg , p = 0.020 ) and diastolic BP ( DBP ) ( beta + /- SE = -1.69 + /- 0.62 mmHg , p = 0.006 ) compared to those with the Ala357/Ala357 genotype . Subjects with either Val227/Ile227 or Ile227/Ile227 genotypes had significantly larger mean changes in SBP ( beta + /- SE = 3.13 + /- 1.19 , p = 0.009 ) and DBP ( beta + /- SE = 1.50 + /- 0.60 mmHg , p = 0.013 ) compared with those with the Val227/Val227 genotype after treatment . Subjects carrying both the Ala357/Ala357 genotype in the Ala357Thr polymorphism and either Val227/Ile227 or Ile227/Ile227 genotypes in the Val227Ile polymorphism had the highest mean change in SBP and DBP . Our study supports the conclusion that polymorphisms in the @GeneTgt$ SLC14A2 @/GeneTgt$ gene can predict the antihypertensive efficacy of @ChemicalSrc$ nifedipine @/ChemicalSrc$ GITS .	2 9 7 7 7 7 2 9 9 12 12 9 16 16|13 16 16|13 12 9 18|21 21 18|21 22 22 22 23 23 23 22 30 30 22 33 33 30 22 37 37 37 40 38 45 45 45 45 38 47 45|46 45 45|46 47 52 52 38 59 55 59 57 55 59 52 63 59|63 63 59|63 59 37 68 74 73 73 73 73 68 74 78 78 78 74 84 81 84 84|81 84 84|81 78 88 88 86 84 88 74 93 93 74 74 97 97 99 97 101 99|100 99 99|100 97 97 106 104 109 109 106 111 109 111 109 109 116 114 116 109 121 121 118 125 121|125 125 121|125 121 97 130 139 130 131 135 135 132 135 135 135 139 141 143 143 139 146 146 151 148 151 148 151 143 151 139 155 139 155 155 155 160 155 163 163 155 163 163 155 168 155 170 168 170 173 168 173 173 177 155 177 155 155 182 155 185 185 155 185 185 190 190 155 194 194 194 190 139 205 199 199 196 199 199 199 205 205 205 207 205 209 207 211 209 211 211 211 214 215 215 215 211 222 222 211 222 222 211 228 228 211 228 211 211 231 232 232 232 237 240 240 240 205 240 240 205 245 243 249 249 249 245 251 245 205 273 253 258 258 258 254 262 262 262 254 262 265 262 265 265 265 272 272 272 262 273 277 276 277 273 279 277 279 279 273 284 285 285 287 285 296 296 294 294 291|294 294 291|294 289 296 287 299 299 296 303 299|303 303 299|303 299 285	Association
17541557	Chemical	Gene	D002395	153	True	0	What is [PHARMGKB] between @ChemicalSrc$ catecholamine @/ChemicalSrc$ and @GeneTgt$ beta(1)AR @/GeneTgt$ ? [SEP] In patients chronically treated with metoprolol , the demand of inotropic @ChemicalSrc$ catecholamine @/ChemicalSrc$ support after coronary artery bypass grafting is determined by the @GeneTgt$ Arg389Gly-beta 1-adrenoceptor @/GeneTgt$ polymorphism . In vitro , the Arg389Gly-beta(1)-adrenoceptor ( AR ) polymorphism exhibits decreased receptor signaling . In vivo , dobutamine infusion evoked smaller heart rate and/or contractility increases in subjects carrying @GeneTgt$ Gly389Gly-beta(1)AR @/GeneTgt$ vs subjects carrying @GeneTgt$ Arg389Arg-beta(1)AR @/GeneTgt$ . The aim of this study was to find out whether the @GeneTgt$ Arg389Gly-beta(1)AR @/GeneTgt$ polymorphism might also determine demand of @ChemicalSrc$ catecholamine-induced @/ChemicalSrc$ inotropic support in patients with low cardiac index ( CI ) after coronary artery bypass grafting ( CABG ) surgery with cardiopulmonary bypass ( CPB ) . For this purpose , we assessed in 82 patients , who were preoperatively chronically treated with metoprolol , after CABG surgery with CPB , the dose and duration of adrenaline-induced inotropic support in relation to the @GeneTgt$ Arg389Gly-beta(1)AR @/GeneTgt$ genotype . Patients homozygous for the @GeneTgt$ Arg389-beta(1)AR @/GeneTgt$ variant ( n = 45 ) required , in comparison to patients homozygous for the @GeneTgt$ Gly389-beta(1)AR @/GeneTgt$ variant ( n = 9 ) , lower adrenaline doses ( 53 + /- 24 vs 164 + /- 39 ng/kg body weight/min , p & lt ; 0.05 ) to reach a stable and comparable hemodynamic status and a CI & gt;or= 3.0 l/min/m(2 ) . Moreover , the time necessary for inotropic support tended to be shorter in patients homozygous for the @GeneTgt$ Arg389-beta(1)AR @/GeneTgt$ than in patients homozygous for the @GeneTgt$ Gly389-beta(1)AR @/GeneTgt$ ( 10.5 + /- 6 vs 20.5 + /- 12 h ) . Values for patients heterozygous for the @GeneTgt$ Arg389Gly-beta(1)AR @/GeneTgt$ ( n = 28 ) were in between . We conclude that the @GeneTgt$ Arg389Gly-beta(1)AR @/GeneTgt$ polymorphism appears to be a determinant of cardiac responses to @ChemicalSrc$ catecholamine @/ChemicalSrc$ stimulation . Thus , by assessment of the @GeneTgt$ Arg389Gly-beta(1)AR @/GeneTgt$ polymorphism , it might be possible to predict demand of and therapeutic responses to beta AR agonist treatment .	2 21 4 2 6 4 21 9 21 14 14 11|14 14 11|14 9 19 19 18 19 14 21 21 27 27 27|22 27|22 27 27|22 21 21 32 40 40 39 39 39 39 39 40 41 41 43 41 41 46 50 50 49 50 50 53 53 50 53 53 50 58 56 58 59 59 59 60 60 58 63|64 64 63|64 50 71 75 74 74 71 75 77 75 77 86 83 80|83 83 80|83 86 86 86 77 86 92 87|92 92 87|92 92 87 94 92 98 98 98 94 100 98 100 106 106 106 106 110 108 106 108 94 113 113 110 115 113 115 75 122 122 125 125 125 125 128 128 125 128 134 134 134 134 128 136 134 128 140 140 128 142 140 142 145 142 145 145 151 151 151 145 153 145 158 158 155|158 158 155|158 153 125 161 161 167 167 164|167 167 164|167 162 173 173 169 170 170 161 173 176 173 178 176 178 184 184 184|180 184 184|180 179 186 193 186 187 187 193 193 193 178 195 193 195 195 195 198 198 195 195 205 205 195 205 195 195 208 208 195 195 195 215 173 221 221 217 217 221 215 221 224 221 224 224 228 173 173 161 241 241 236 241 236 240 240 237 241 244 244 241 246 244 246 250 250 249|247 247 249|247 254 254 244 254 258 258 256|255 255 256|255 261 254 261 264 261 264 264 261 270 270 261 270 241 289 277 275 277 281 281 278|280 278 278|280 284 281 284 285 284 289 289 289 289 294 294 300 299 296|299 299 296|299 300 294 304 304 304 300 307 307 304 311 311|307 311 311|307 304 294 328 328 318 328 323 323 323|320 323 323|320 318 328 328 328 328 328 330 328 330 335 332 332 331 340 340 340 340 331 328	Association
19204081	Chemical	Gene	D003630	873	True	0	What is [PHARMGKB] between @ChemicalSrc$ DAUN @/ChemicalSrc$ and @GeneTgt$ CBR1 @/GeneTgt$ ? [SEP] Two nonsynonymous single nucleotide polymorphisms of human @GeneTgt$ carbonyl reductase 1 @/GeneTgt$ demonstrate reduced in vitro metabolism of @ChemicalSrc$ daunorubicin @/ChemicalSrc$ and doxorubicin . Carbonyl reductases ( CBRs ) are a group of metabolic enzymes belonging to the short-chain dehydrogenase family with NADPH-dependent oxidoreductase activity . These enzymes are known to metabolize the anthracyclines doxorubicin ( DOX ) and @ChemicalSrc$ daunorubicin @/ChemicalSrc$ ( @ChemicalSrc$ DAUN @/ChemicalSrc$ ) . Both DOX and @ChemicalSrc$ DAUN @/ChemicalSrc$ are highly effective in cancer therapy ; however , there is considerable interpatient variability in adverse effects seen in patients undergoing treatment with these drugs . This may be attributed to altered metabolism associated with nonsynonymous single nucleotide polymorphisms ( ns-SNPs ) in the genes encoding for CBRs . In this study , we examine the effect of the V88I and P131S mutations in the human @GeneTgt$ CBR1 @/GeneTgt$ gene on the metabolism of anthracyclines to their respective major metabolites , doxorubicinol and daunorubicinol . Kinetic studies using purified , histidine-tagged , recombinant enzymes in a high-performance liquid chromatography-fluorescence assay demonstrated that the V88I mutation leads to a significantly reduced maximal rate of activity ( V(max ) ) ( 2090 + /- 112 and 257 + /- 11 nmol/min x mg of purified protein for @ChemicalSrc$ DAUN @/ChemicalSrc$ and DOX , respectively ) compared with that for the wild-type ( 3430 + /- 241 and 364 + /- 37 nmol/min x mg of purified protein for @ChemicalSrc$ DAUN @/ChemicalSrc$ and DOX , respectively ) . In the case of the P131S mutation , a significant increase in substrate affinity ( K(m ) ) was observed for @ChemicalSrc$ DAUN @/ChemicalSrc$ only ( 89 + /- 13 microM ) compared with that for the wild-type ( 51 + /- 13 microM ) . In the presence of either anthracycline , both variants exhibited a 20 to 40 % decrease in catalytic efficiency ( k(cat)/K(m ) ) compared with that for the wild-type enzyme . Therefore , the ns-SNPs generating both these mutations may alter bioavailability of these anthracyclines in cancer patients and should be examined in clinical studies as potential biomarkers for @ChemicalSrc$ DAUN- @/ChemicalSrc$ and DOX-induced adverse effects .	5 5 5 5 12 8 8 8|5|7 8|5|7 8|5|7 8|5 8|5|7 12 12 16 14 13 18 16|14 16 16|14 18 18 12 26 32 28 26 28 32 32 32 35 35 32 35 41 41 41 41 36 45 45 45 36 32 48 50 50 50 52 50 55 55 52 57 55 57 55 55|59 55 55|59 63 60|61 60 60|61 63 50 70 76 70 70|71 70 70|71 76 76 76 79 79 76 76 84 84 84 76 87 87 84 90 90 87 90 93 91 93 94 98 98 95 76 104 104 104 104 107 107 104 107 113 113 113 113 108 115 113 115 119 119 113 119 122 120 104 126 126 129 129 129 129 131 129 137 137 133 134 134 131 143 143 143 140|143 143 140|143 131 146 146 131 148 146 153 153 153 153 131 153 153 155 155 129 161 175 161 168 163 163 168 168 162 174 174 174 174 174 168 175 180 179 179 180 175 186 186 184 186 186 180 188 186 190 188 190 190 194 190 194 194 194 197 197 190 190 203 190 205 190 208 208 205 210 208|209 208 208|209 210 210 190 190 190 186 219 217 222 222 219 224 222 224 224 224 227 227 222 175 233 175 233 233 238 238 233 240 238 238 238 240 240 233 233 233 175 252 252 269 256 256 256 252 269 260 260 269 263 263 260 265 263 265 265 269 269 271 269|270 269 269|270 275 275 269 275 279 279 275 279 275 283 281 286 286 283 288 286 288 292 292 288 292 269 298 298 305 301 301 298 305 304 305 305 311 309 309 310 311 305 314 314 311 316 314 316 314 305 321 319 325 325 325 321 305 336 336 330 336 330 334 334 331 336 336 336 340 340 337 343 343 337 336 347 347 336 350 350 347 353 353 350 355 360|354 360 360|354 355 355 360 353 336	Association
19204081	Chemical	Gene	D004317	873	True	0	What is [PHARMGKB] between @ChemicalSrc$ DOX @/ChemicalSrc$ and @GeneTgt$ CBR1 @/GeneTgt$ ? [SEP] Two nonsynonymous single nucleotide polymorphisms of human @GeneTgt$ carbonyl reductase 1 @/GeneTgt$ demonstrate reduced in vitro metabolism of daunorubicin and @ChemicalSrc$ doxorubicin @/ChemicalSrc$ . Carbonyl reductases ( CBRs ) are a group of metabolic enzymes belonging to the short-chain dehydrogenase family with NADPH-dependent oxidoreductase activity . These enzymes are known to metabolize the anthracyclines @ChemicalSrc$ doxorubicin @/ChemicalSrc$ ( @ChemicalSrc$ DOX @/ChemicalSrc$ ) and daunorubicin ( DAUN ) . Both @ChemicalSrc$ DOX @/ChemicalSrc$ and DAUN are highly effective in cancer therapy ; however , there is considerable interpatient variability in adverse effects seen in patients undergoing treatment with these drugs . This may be attributed to altered metabolism associated with nonsynonymous single nucleotide polymorphisms ( ns-SNPs ) in the genes encoding for CBRs . In this study , we examine the effect of the V88I and P131S mutations in the human @GeneTgt$ CBR1 @/GeneTgt$ gene on the metabolism of anthracyclines to their respective major metabolites , doxorubicinol and daunorubicinol . Kinetic studies using purified , histidine-tagged , recombinant enzymes in a high-performance liquid chromatography-fluorescence assay demonstrated that the V88I mutation leads to a significantly reduced maximal rate of activity ( V(max ) ) ( 2090 + /- 112 and 257 + /- 11 nmol/min x mg of purified protein for DAUN and @ChemicalSrc$ DOX @/ChemicalSrc$ , respectively ) compared with that for the wild-type ( 3430 + /- 241 and 364 + /- 37 nmol/min x mg of purified protein for DAUN and @ChemicalSrc$ DOX @/ChemicalSrc$ , respectively ) . In the case of the P131S mutation , a significant increase in substrate affinity ( K(m ) ) was observed for DAUN only ( 89 + /- 13 microM ) compared with that for the wild-type ( 51 + /- 13 microM ) . In the presence of either anthracycline , both variants exhibited a 20 to 40 % decrease in catalytic efficiency ( k(cat)/K(m ) ) compared with that for the wild-type enzyme . Therefore , the ns-SNPs generating both these mutations may alter bioavailability of these anthracyclines in cancer patients and should be examined in clinical studies as potential biomarkers for DAUN- and @ChemicalSrc$ DOX-induced @/ChemicalSrc$ adverse effects .	5 5 5 5 12 8 8 8|5|7 8|5|7 8|5|7 8|5 8|5|7 12 12 16 14 13 18 16 18 16|18 18 16|18 12 26 32 28 26 28 32 32 32 35 35 32 35 41 41 41 41 36 45 45 45 36 32 48 50 50 50 52 50 55 55 54|52 52 54|52 58 55|56 55 55|56 58 55 55 64 62 64 50 70 76|69 76 76|69 70 70 76 76 76 79 79 76 76 84 84 84 76 87 87 84 90 90 87 90 93 91 93 94 98 98 95 76 104 104 104 104 107 107 104 107 113 113 113 113 108 115 113 115 119 119 113 119 122 120 104 126 126 129 129 129 129 131 129 137 137 133 134 134 131 143 143 143 140|143 143 140|143 131 146 146 131 148 146 153 153 153 153 131 153 153 155 155 129 161 175 161 168 163 163 168 168 162 174 174 174 174 174 168 175 180 179 179 180 175 186 186 184 186 186 180 188 186 190 188 190 190 194 190 194 194 194 197 197 190 190 203 190 205 190 208 208 205 210 208 210 210|211 210 210|211 190 190 190 186 219 217 222 222 219 224 222 224 224 224 227 227 222 175 233 175 233 233 238 238 233 240 238 240 240 240 240 233 233 233 175 252 252 269 256 256 256 252 269 260 260 269 263 263 260 265 263 265 265 269 269 271 269 274 274 269 274 278 278 274 278 274 282 280 285 285 282 287 285 287 291 291 287 291 269 296 296 303 299 299 296 303 302 303 303 309 307 307 308 309 303 312 312 309 314 312 314 312 303 319 317 323 323 323 319 303 334 334 328 334 328 332 332 329 334 334 334 338 338 335 341 341 335 334 345 345 334 348 348 345 351 351 348 353 358 353 353|354 353 353|354 358 351 334	Association
19386276	Chemical	Gene	D008694	2099	True	0	What is [PHARMGKB] between @ChemicalSrc$ methamphetamine @/ChemicalSrc$ and @GeneTgt$ ESR1 @/GeneTgt$ ? [SEP] A functional polymorphism in @GeneTgt$ estrogen receptor alpha @/GeneTgt$ gene is associated with Japanese @ChemicalSrc$ methamphetamine @/ChemicalSrc$ induced psychosis . BACKGROUND : A recent study reported an association between rs2234693 , which influences enhancer activity levels in @GeneTgt$ estrogen receptor alpha @/GeneTgt$ gene ( @GeneTgt$ ESR1 @/GeneTgt$ ) , and schizophrenia . This study reported that schizophrenic patients with the CC genotype have significantly lower @GeneTgt$ ESR1 @/GeneTgt$ mRNA levels in the prefrontal cortex than patients with other genotypes . The symptoms of @ChemicalSrc$ methamphetamine @/ChemicalSrc$ induced psychosis are similar to those of paranoid type schizophrenia . Therefore , we conducted an association analysis of rs2234693 with Japanese @ChemicalSrc$ methamphetamine @/ChemicalSrc$ induced psychosis patients . METHOD : Using rs2234693 , we conducted a genetic association analysis of case-control samples ( 197 @ChemicalSrc$ methamphetamine @/ChemicalSrc$ induced psychosis patients and 197 healthy controls ) . The age and sex of the control subjects did not differ from those of the @ChemicalSrc$ methamphetamine @/ChemicalSrc$ induced psychosis patients . RESULTS : We detected a significant association between @GeneTgt$ ESR1 @/GeneTgt$ and @ChemicalSrc$ methamphetamine @/ChemicalSrc$ induced psychosis patients in allele/genotype-wise analysis . For further interpretation of these associations , we performed single marker analysis of subjects divided by sex . Rs2234693 was associated with male @ChemicalSrc$ methamphetamine @/ChemicalSrc$ induced psychosis . DISCUSSION : Our results suggest that rs2234693 in @GeneTgt$ ESR1 @/GeneTgt$ may play a role in the pathophysiology of Japanese @ChemicalSrc$ methamphetamine @/ChemicalSrc$ induced psychosis patients .	3 3 11 9 9|4 9|4 9|4 9 9|4 3 11 11 14 14 16|10 16 16|10 11 16 11 21 21 25 25 26 21 28 26 30 28 30 33 30 35 36 33 42 37|42 37|42 37|42 42 37|42 36 44 40|42 42 40|42 44 42 42 42 21 54 55 55 65 58 65 62 62 62 58 65 65 55 69|65 69 69|65 69 65 73 73 73 65 75 73 78 78 75 55 82 86 84 82|83 82 82|83 87 89 89 89 91 89 95 95 95 91 89 101 101 101 101 104 104 101 106 104 109 109 108|104 104 108|104 101 113 111 101 116 116 116 118 122 122 116 126 126 126 122 129 129 126 134 132 131|134 134 131|134 116 136 134 136 140 140 136 134 116 145 154 145 145 151 151 151 145 154 154 154 156 154 159 159 156|158 156 156|158 154 163 161 154 179 166 169 166 172 172 169 174 173|172 172 173|172 174 174|175 174 174|175 179 181 179 184 184 179 179 190 190 196 193 193 190 196 196 196 199 199 196 201 199 201 204 202 196 208 208 208 211 211 213|210 213 213|210 208 213 208 221 221 220 221 221 228 228 225 224|223 223 224|223 228 221 230 228 233 233 228 236 236 233|234 233 233|234 228 240 238 221	Association
19919814	Chemical	Gene	D006221	6261	False	2	What is [PHARMGKB] between @ChemicalSrc$ halothane @/ChemicalSrc$ and @GeneTgt$ RyR1 @/GeneTgt$ ? [SEP] Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia @GeneTgt$ RyR1 @/GeneTgt$ mutation p. Thr2206Met . OBJECTIVE : Malignant hyperthermia ( MH ) is a classically unapparent pharmacogenetic disorder of the skeletal muscles triggered by inhalational anesthetics or depolarizing muscle relaxants . The disposition to MH is inherited in an autosomal-dominant manner and is primarily due to mutations in the gene for the @GeneTgt$ ryanodine receptor type 1 @/GeneTgt$ ( @GeneTgt$ RyR1 @/GeneTgt$ ) . The present study intended to analyze whether mild muscular symptoms ( elevation of the resting CK , cramps in the calves , slight calf hypertrophy ) may be associated with susceptibility to MH and/or with histopathological changes . METHODS : A muscle biopsy was taken from 12 out of 44 blood relatives ( three generations ) of a large family and was investigated with the @ChemicalSrc$ halothane/caffeine @/ChemicalSrc$ in vitro contracture test ( IVCT ) . Afterwards a histological , histochemical and immunhistological examination was performed . Altogether in 29 persons the DNA was analyzed for mutations in the @GeneTgt$ RyR1-gene @/GeneTgt$ . RESULTS : Eight persons were diagnosed as susceptible to MH ( MHS ) by the IVCT , 4 were MH negative . All MHS persons carried the MH causative c.6617C & gt ; T ( Thr2206Met ) mutation and showed slight clinical signs of a myopathy as well as mild biopsy changes with isolated hypotrophic fibers and disseminated small areas with reduction of oxidative staining ( multi-minicore like lesions ) . The Thr2206Met mutation was identified in another further 9 relatives who also experienced mild myopathological features . Clinical MH incidents were not reported in this large family . CONCLUSION : The @GeneTgt$ RyR1 @/GeneTgt$ Thr2206Met mutation is one of the most frequent mutations in the European MH population but carriers are normally healthy . In this study we could demonstrate that the MH causative Thr2206Met mutation may also be associated both with clinical symptoms of a mild myopathy and histopathological changes in the oxidative inter myofibrillar network .	2 2 2 2 2 7 2 9 7 11 20 11 11 20 20 20|15 20 20|15 20 20 9 2 23 23 26 35 28 26 28 35 35 33 35 35 23 39 39 39 35 39 43 43 40 43 47 47 43 23 50 54 52 50 54 54 58 58 58 54 54 64 64 64 62 54 67 67 64 70 70 67|69|70 67|69|70 67|69|70 67|69|70 67|70 67|69|70 76 70|71 70 70|71 76 54 84 84 85 85 87 85 110 91 91 110 93 91 97 97 97 93 97 93 102 102 99 99 106 106 99 99 110 110 87 112 110 114 112 114 118 118 114 85 126 126 124 124 126 126 126 128 126 133 131 133 133 126 136 136 133 136 141 141 141 133 126 144 126 147 147 152|146 152 152|146 152 149 152 144 154 152 154 126 167 165 165 160 160 160 160 167 167 167 167 176 172 172 176 174 176 176 176 178 176 181 181 178|180 178 178|180 176 205 185 188 190 190 185 192 190 194 192 196 194 196 200 200 192 205 205 205 205 205 205 209 209 210 210 214 213 214 210 214 214 222 220 220 222 222 210 210 210 227 227 224 230 230 227 230 231 231 236 236 227 240 240 240 236 240 244 244 240 246 244 249 249 246 251 249 253 251 251 210 258 258 260 260 260 265 265 265 265 260 268 268 265 271 271 268 260 275 275 278 278 278 278 282 282 282 278 278 284 292 290 286|290 290 286|290 290 292 292 284 297 297 296 297 292 302 302 302 302 297 292 307 307 307 292 284 312 312 315 315 315 315 325 321 319 321 321 325 325 325 325 315 329 329 329 325 333 333 333 329 333 333 333 342 342 342 342 342 329 315	Association
19952982	Chemical	Gene	D010672	2052	True	0	What is [PHARMGKB] between @ChemicalSrc$ phenytoin @/ChemicalSrc$ and @GeneTgt$ EPHX1 @/GeneTgt$ ? [SEP] Maternal @GeneTgt$ EPHX1 @/GeneTgt$ polymorphisms and risk of @ChemicalSrc$ phenytoin-induced @/ChemicalSrc$ congenital malformations . OBJECTIVES : The teratogenic effects of the anti-epileptic drug @ChemicalSrc$ phenytoin @/ChemicalSrc$ have been linked to genetic differences in @ChemicalSrc$ phenytoin @/ChemicalSrc$ disposition . The goal of this study was to assess the effect of maternal genotype of functional polymorphisms in two genes involved in @ChemicalSrc$ phenytoin @/ChemicalSrc$ metabolism , CYP2C9 ( R144C , I395L ) and @GeneTgt$ EPHX1 @/GeneTgt$ ( Y113H , H139R ) , on the presence of major craniofacial abnormalities ( CFAs ) in the child . METHODS : We used data from the Collaborative Perinatal Project ( 1959 - 1974 ) , a study involving 42 000 mothers and 55 000 children to assess the effect of maternal genotype . We studied 174 pregnancies in 155 women who used @ChemicalSrc$ phenytoin @/ChemicalSrc$ throughout their pregnancy , gave birth to a live child and had available stored blood specimens suitable for DNA extraction . RESULTS : Nineteen children had CFA . In a logistic regression model adjusted for history of @ChemicalSrc$ phenytoin @/ChemicalSrc$ use during the first trimester and maternal epilepsy ( N=157 pregnancies ) , the maternal @GeneTgt$ EPHX1 @/GeneTgt$ 113 H [ per rare allele odds ratio ( OR ): 2.43 , 95 % confidence interval ( CI ): 1.16 - 5.10 , P=0.02 ] and 139 R ( per rare allele OR : 2.33 , 95 % CI : 1.09 - 5.00 , P=0.03 ) alleles were associated with CFAs in the child . The maternal @GeneTgt$ EPHX1 @/GeneTgt$ Y113/H139 ( common ) haplotype showed a significant protective association with CFAs in the child ( OR : 0.29 , 95 % CI : 0.12 - 0.68 , P=0.004 ) , when compared to other haplotypes . CYP2C9 genotype was not related to fetal endpoints . CONCLUSION : Maternal @GeneTgt$ EPHX1 @/GeneTgt$ genotype may be associated with risk of fetal anomalies among pregnant women taking @ChemicalSrc$ phenytoin @/ChemicalSrc$ . Future study is required to confirm these results in larger , independent populations .	4 1|4 4 1|4 4 4 4 11 11|6 11 11|6 11 6 4 15 15 19 19 28 24 24 24 24 23|19 19 23|19 28 28 15 31 31 28 35 31|35 35 31|35 28 28 40 44 43 43 40 44 46 44 48 46 51 51 48 54 54 51 57 57 54 57 62 62|59 62 62|59 58 62 68 66 68 66 62 68 62 62|69 62 62|69 74 71 74 74 74 57 81 81 46 85 85 85 81 87 85 87 91 91 85 44 98 98 98 98 98 104 104 104 104 99 104 108 106 104 104 98 112 98 112 116 116 113 116 119 120 116 122 113 124 122 127 127 124 98 130 130 132 130 135 135 132 137 135 137 137 137 142 142 137 130 130 144 149 149 149 144 144 130 155 152 155 151 155 159 159 156 130 162 162 165 166 162 166 166 173 173 173 173 246 173 176 174 180 177|180 180 177|180 176 184 184 184 176 184 187 184 190 190 187 190 246 198 198 193|198 198 193|198 198 246 198 204 204 203 204 198 206 213 206 213 213 211 213 213 204 215 213 215 219 219 215 219 215 215 213 225 213 225 229 229 225 204 232 204 232 235 236 232 236 240 240 242 242 236 232 198 246 246 248 246 251 251 248 246 263 263 263|256 263 263|256 257 261 263 263 264 264 268 268 268 264 270 268 273 273 268 281 281 277 281 277 280 277 264 281 285 285 281 285 285 285 281 291 281 294 294 291 264 298 301 301 301 301 304 304 301 301 306 306 311 308|311 311 308|311 314 314 314 306 316 314 319 319 316 322 322 319 322 322|323 323 322|323 314 330 332 332 332 334 332 336 334 341 341 338 338 336 332	Association
20393862	Chemical	Gene	D001379	10257	False	1	What is [PHARMGKB] between @ChemicalSrc$ azathioprine @/ChemicalSrc$ and @GeneTgt$ MRP4 @/GeneTgt$ ? [SEP] The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease . BACKGROUND : @GeneTgt$ Multidrug resistance protein 4 @/GeneTgt$ ( @GeneTgt$ MRP4 @/GeneTgt$ ) functions as an efflux pump of nucleoside monophosphate analogs , such as 6-mercaptopurine ( 6-MP ) and 6-thioguanine nucleotide ( 6-TGN ) . A single-nucleotide polymorphism in human @GeneTgt$ MRP4 @/GeneTgt$ ( rs3765534 ) dramatically reduces @GeneTgt$ MRP4 @/GeneTgt$ function and results in the intracellular accumulation of 6-TGN . In this study , we investigated the association between @GeneTgt$ MRP4 @/GeneTgt$ G2269A polymorphism and thiopurine sensitivity in Japanese IBD patients . METHODS : Direct sequencing of the @GeneTgt$ MRP4 @/GeneTgt$ exon 18 was performed . The TPMT A719 G and ITPase C94A polymorphisms were determined by polymerase-chain reaction-restriction fragment length polymorphism analyses . RESULTS : Of the 279 samples analyzed ( 44 healthy volunteers and 235 IBD patients ) , 68 samples showed a heterozygote of @GeneTgt$ MRP4 @/GeneTgt$ G2269A and 7 carried a homozygote . The allelic frequency of @GeneTgt$ MRP4 @/GeneTgt$ G2269A was 14.7 % . In 130 IBD patients treated with @ChemicalSrc$ azathioprine/6-MP @/ChemicalSrc$ , the white blood cell count was significantly lower in patients with theMRP4 variant alone ( n = 26 ) than in patients with a wild allelotype ( n = 74 ) ( P = 0.014 ) or in patients with the ITPase variant alone ( n = 22 ) ( P = 0.0095 ) . The 6-TGN levels were significantly higher in patients with the @GeneTgt$ MRP4 @/GeneTgt$ variant alone than in patients with the wild allelotype(P = 0.049 ) . Of the 15 patients who experienced leucopenia ( & lt;3 x 109/l ) , 7 patients carried the @GeneTgt$ MRP4 @/GeneTgt$ variant . The odds ratio of carrying the @GeneTgt$ MRP4 @/GeneTgt$ variant alone and having leukopenia was 3.30 ( 95 % confidence interval 1.03 - 10.57 , P = 0.036 ) . CONCLUSIONS : These results suggest that @GeneTgt$ MRP4 @/GeneTgt$ G2269A might be a new factor accounting for thiopurine sensitivity in Japanese patients with IBD .	5 5 5 5 9 9 9 9 9 9 13 13 10 16 16 13 20 20 20 16 9 22 22 30|23|24|33 30|23|24|33 30|23|24|33 30|23|24|33 30|24|33 30|23|24|33 30 24|25 24 24|25 30 22 37 37 37 33 41 41 41 37 41 45 43 41 47 45 47 45 51 45 53 51 53 33 60 60 69 63 63 60|62 60 60|62 66 63 66 69 69 68|72 72 68|72 69 69 69 78 78 78 74 80 78 69 86 86 89 89 89 89 91 89 96 92|96 96 92|96 96 91 96 99 96 103 103 103 96 89 117 117 109 117 114 114 114|111 114 114|111 109 114 117 117 117 123 123 123 123 123 123 127 129 129 123 136 136 136 136 136 136 129 129 157 138 143 143 143 144 138 148 148 148 144 148 152 152 148 148 157 156 157 157 159 157 163 163|160 163 163|160 159 157 166 157 168 166 157 173 173 180 177 174|177 177 174|177 173 180 180 180 180 186 186 186 199 186 189 187|188 187 187|188 199 196 196 196 196 199 199 199 199 201 199 204 204 201 204 208 208 204 208 208 213 213 201 217 217 217 213 219 217 219 220 219 224 225 217 225 225 217 230 217 234 234 234 230 234 243 243 237 238 238 242 243 234 243 243 199 250 250 253 253 253 253 255 253 260 260 257|260 260 257|260 255 253 264 264 269 268 268 268 269 253 269 269 253 277 277 277 290 279 277 279 280 280 280 283 283 277 290 289 290 290 294 291|294 294 291|294 290 290 299 299 311 301 299 305 305|302 305 305|302 301 305 301 301 308 311 311 316 314 316 316 311 316 317 316 322 322 316 322 316 311 327 327 330 331 327 340 335|332 335 335|332 340 340 340 340 340 331 340 344 344 341 347 347 344 349 347 331	Association
20941486	Chemical	Gene	D011718	1557	False	1	What is [PHARMGKB] between @ChemicalSrc$ pyrazinamide @/ChemicalSrc$ and @GeneTgt$ CYP2C19 @/GeneTgt$ ? [SEP] NAT2 , CYP2C9 , @GeneTgt$ CYP2C19 @/GeneTgt$ , and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption . PURPOSE : It has been suggested that drug-metabolizing enzymes might play important roles in the development of anti-tuberculosis drug (ATD)-induced maculopapular eruption ( MPE ) , as in ATD-induced hepatitis . We investigated the associations between the genetic polymorphisms of drug-metabolizing enzymes and ATD-induced MPE . METHODS : We enrolled 62 patients with ATD-induced MPE ( mean age 47.2 + - 19.0 , male 59.7 % ) and 159 patients without any adverse reactions to ATD ( mean age 42.8 + - 17.6 , male 65.4 % ) , among patients with pulmonary tuberculosis ( TB ) and/or TB pleuritis and treated with first-line anti-TB medications , including isoniazid , rifampin , ethambutol , and @ChemicalSrc$ pyrazinamide @/ChemicalSrc$ . We compared the genotype distributions of single nucleotide polymorphisms and haplotypes in four drug-metabolizing enzymes ( N-acetyltransferase 2 ( NAT2 ) , cytochrome P450 ( CYP ) 2 C9 , @GeneTgt$ CYP2C19 @/GeneTgt$ , and CYP2E1 ) among patients with ATD-induced MPE and patients tolerant to ATD using a multivariate logistic regression analysis . These analyses were made without identification of the responsible ATD . RESULTS : -1565 C & gt ; T of CYP2C9 showed a significant association with ATD-induced MPE ( P = 0.022 , OR = 0.23 , 95 % CI 0.07 - 0.78 ) , with a lower frequency of genotypes carrying minor alleles ( CT or TT ) in the case group than in the controls . Additionally , W212X of @GeneTgt$ CYP2C19 @/GeneTgt$ was significantly associated with the risk of ATD-induced MPE ( P = 0.042 , OR = 0.27 , 95 % CI 0.09 - 0.82 ) . In an analysis of the @GeneTgt$ CYP2C19-CYP2C9 @/GeneTgt$ haplotypes ( -1418 C & gt ; T_W212X_-1565 C & gt ; T_-1188 C & gt ; T ) , ht3[T-A-T-C ] showed a significant association with the development of ATD-induced MPE ( P = 0.012 , OR = 0.13 , 95 % CI 0.03 - 0.57 ) . No significant associations between the other genetic polymorphisms and ATD-induced MPE were observed . CONCLUSIONS : @GeneTgt$ CYP2C19 @/GeneTgt$ and CYP2C9 genetic polymorphisms are significantly associated with the risk of developing ATD-induced MPE , and the genetic variants in NAT2 and CYP2E1 are not closely related to the development of this adverse reaction .	1 1 1 1 1|4 1 1|4 1 1 10 11 1 16 16 13 16 1 1 24 24 24 24 24 24 29 27 29 29 24 31 29 34 34 29 40 40 40 40 40 34 42 40 42 29 48 48 48 29 24 51 51 53 51 57 57 57 53 60 60 57 60 63 60 51 68 68 68 68 70 68 73 73 88 75 88 75 76 77 80 77 76 76 84 82 82 82 88 70 92 92 92 88 94 92 103 103 96 97 98 101 98 103 88 105 103 103 88 109 68 112 112 109 114 112 114 112 118 112 68 68 124 124 124 120 124 127 124 127 127 127 127 127 127 133|127 127 133|127 68 139 139 142 142 139 146 146 146 142 146 146 152 152 152 142 154 152 154 157 154 157 154 161 163 163 166 166 166 154 166 166|167 166 166|167 166 166 166 154 175 152 178 178 175 178 178 180 183 181 139 189 189 189 189 184 139 193 195 195 195 197 195 201 201 201 197 195 213 203 206 203 206 206 213 213 212 210 213 216 216 213 219 219 216 222 222 219 222 222 222 222 226 226 230 226 230 234 234 230 234 222 240 240 240 213 242 240 242 245 243 247 245 247 247 247 254 254 254 240 258 258 258 254 213 268 268 268 264 262|263 262 262|263 268 268 268 271 271 268 274 274 271 276 277 274 277 277 281 268 281 282 285 282 285 289 289 285 281 268 295 295 322 300 300 300|297 300 300|297 295 303 303 300 303 303 308 308 303 308 308 308 313 308 313 313 317 303 317 303 295 320 322 325 325 322 328 328 325 331 331 328 333 334 328 334 334 338 322 338 339 342 338 342 346 346 342 338 322 352 352 362 357 357 357 357 352 357 360 357 362 362 362 364 364 365|374 374 365|374 366 370 366 374 374 374 364 377 377 374 379 377 381 379 374 374 386 386 394 388 386 388 388 394 394 394 374 397 397 394 401 401 401 397 364	Association
20941486	Chemical	Gene	D007538	1557	False	1	What is [PHARMGKB] between @ChemicalSrc$ isoniazid @/ChemicalSrc$ and @GeneTgt$ CYP2C19 @/GeneTgt$ ? [SEP] NAT2 , CYP2C9 , @GeneTgt$ CYP2C19 @/GeneTgt$ , and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption . PURPOSE : It has been suggested that drug-metabolizing enzymes might play important roles in the development of anti-tuberculosis drug (ATD)-induced maculopapular eruption ( MPE ) , as in ATD-induced hepatitis . We investigated the associations between the genetic polymorphisms of drug-metabolizing enzymes and ATD-induced MPE . METHODS : We enrolled 62 patients with ATD-induced MPE ( mean age 47.2 + - 19.0 , male 59.7 % ) and 159 patients without any adverse reactions to ATD ( mean age 42.8 + - 17.6 , male 65.4 % ) , among patients with pulmonary tuberculosis ( TB ) and/or TB pleuritis and treated with first-line anti-TB medications , including @ChemicalSrc$ isoniazid @/ChemicalSrc$ , rifampin , ethambutol , and pyrazinamide . We compared the genotype distributions of single nucleotide polymorphisms and haplotypes in four drug-metabolizing enzymes ( N-acetyltransferase 2 ( NAT2 ) , cytochrome P450 ( CYP ) 2 C9 , @GeneTgt$ CYP2C19 @/GeneTgt$ , and CYP2E1 ) among patients with ATD-induced MPE and patients tolerant to ATD using a multivariate logistic regression analysis . These analyses were made without identification of the responsible ATD . RESULTS : -1565 C & gt ; T of CYP2C9 showed a significant association with ATD-induced MPE ( P = 0.022 , OR = 0.23 , 95 % CI 0.07 - 0.78 ) , with a lower frequency of genotypes carrying minor alleles ( CT or TT ) in the case group than in the controls . Additionally , W212X of @GeneTgt$ CYP2C19 @/GeneTgt$ was significantly associated with the risk of ATD-induced MPE ( P = 0.042 , OR = 0.27 , 95 % CI 0.09 - 0.82 ) . In an analysis of the @GeneTgt$ CYP2C19-CYP2C9 @/GeneTgt$ haplotypes ( -1418 C & gt ; T_W212X_-1565 C & gt ; T_-1188 C & gt ; T ) , ht3[T-A-T-C ] showed a significant association with the development of ATD-induced MPE ( P = 0.012 , OR = 0.13 , 95 % CI 0.03 - 0.57 ) . No significant associations between the other genetic polymorphisms and ATD-induced MPE were observed . CONCLUSIONS : @GeneTgt$ CYP2C19 @/GeneTgt$ and CYP2C9 genetic polymorphisms are significantly associated with the risk of developing ATD-induced MPE , and the genetic variants in NAT2 and CYP2E1 are not closely related to the development of this adverse reaction .	1 1 1 1 1|4 1 1|4 1 1 10 11 1 16 16 13 16 1 1 24 24 24 24 24 24 29 27 29 29 24 31 29 34 34 29 40 40 40 40 40 34 42 40 42 29 48 48 48 29 24 51 51 53 51 57 57 57 53 60 60 57 60 63 60 51 68 68 68 68 70 68 73 73 88 75 88 75 76 77 80 77 76 76 84 82 82 82 88 70 92 92 92 88 94 92 103 103 96 97 98 101 98 103 88 105 103 103 88 109 68 112 112 109 114 112 114 112 118 112 68 68 124 124 124 120 124 127 124|126 124 124|126 127 127 127 127 127 127 127 68 139 139 142 142 139 146 146 146 142 146 146 152 152 152 142 154 152 154 157 154 157 154 161 163 163 166 166 166 154 166 166|167 166 166|167 166 166 166 154 175 152 178 178 175 178 178 180 183 181 139 189 189 189 189 184 139 193 195 195 195 197 195 201 201 201 197 195 213 203 206 203 206 206 213 213 212 210 213 216 216 213 219 219 216 222 222 219 222 222 222 222 226 226 230 226 230 234 234 230 234 222 240 240 240 213 242 240 242 245 243 247 245 247 247 247 254 254 254 240 258 258 258 254 213 268 268 268 264 262|263 262 262|263 268 268 268 271 271 268 274 274 271 276 277 274 277 277 281 268 281 282 285 282 285 289 289 285 281 268 295 295 322 300 300 300|297 300 300|297 295 303 303 300 303 303 308 308 303 308 308 308 313 308 313 313 317 303 317 303 295 320 322 325 325 322 328 328 325 331 331 328 333 334 328 334 334 338 322 338 339 342 338 342 346 346 342 338 322 352 352 362 357 357 357 357 352 357 360 357 362 362 362 364 364 365|374 374 365|374 366 370 366 374 374 374 364 377 377 374 379 377 381 379 374 374 386 386 394 388 386 388 388 394 394 394 374 397 397 394 401 401 401 397 364	Association
20941486	Chemical	Gene	D004977	1557	False	1	What is [PHARMGKB] between @ChemicalSrc$ ethambutol @/ChemicalSrc$ and @GeneTgt$ CYP2C19 @/GeneTgt$ ? [SEP] NAT2 , CYP2C9 , @GeneTgt$ CYP2C19 @/GeneTgt$ , and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption . PURPOSE : It has been suggested that drug-metabolizing enzymes might play important roles in the development of anti-tuberculosis drug (ATD)-induced maculopapular eruption ( MPE ) , as in ATD-induced hepatitis . We investigated the associations between the genetic polymorphisms of drug-metabolizing enzymes and ATD-induced MPE . METHODS : We enrolled 62 patients with ATD-induced MPE ( mean age 47.2 + - 19.0 , male 59.7 % ) and 159 patients without any adverse reactions to ATD ( mean age 42.8 + - 17.6 , male 65.4 % ) , among patients with pulmonary tuberculosis ( TB ) and/or TB pleuritis and treated with first-line anti-TB medications , including isoniazid , rifampin , @ChemicalSrc$ ethambutol @/ChemicalSrc$ , and pyrazinamide . We compared the genotype distributions of single nucleotide polymorphisms and haplotypes in four drug-metabolizing enzymes ( N-acetyltransferase 2 ( NAT2 ) , cytochrome P450 ( CYP ) 2 C9 , @GeneTgt$ CYP2C19 @/GeneTgt$ , and CYP2E1 ) among patients with ATD-induced MPE and patients tolerant to ATD using a multivariate logistic regression analysis . These analyses were made without identification of the responsible ATD . RESULTS : -1565 C & gt ; T of CYP2C9 showed a significant association with ATD-induced MPE ( P = 0.022 , OR = 0.23 , 95 % CI 0.07 - 0.78 ) , with a lower frequency of genotypes carrying minor alleles ( CT or TT ) in the case group than in the controls . Additionally , W212X of @GeneTgt$ CYP2C19 @/GeneTgt$ was significantly associated with the risk of ATD-induced MPE ( P = 0.042 , OR = 0.27 , 95 % CI 0.09 - 0.82 ) . In an analysis of the @GeneTgt$ CYP2C19-CYP2C9 @/GeneTgt$ haplotypes ( -1418 C & gt ; T_W212X_-1565 C & gt ; T_-1188 C & gt ; T ) , ht3[T-A-T-C ] showed a significant association with the development of ATD-induced MPE ( P = 0.012 , OR = 0.13 , 95 % CI 0.03 - 0.57 ) . No significant associations between the other genetic polymorphisms and ATD-induced MPE were observed . CONCLUSIONS : @GeneTgt$ CYP2C19 @/GeneTgt$ and CYP2C9 genetic polymorphisms are significantly associated with the risk of developing ATD-induced MPE , and the genetic variants in NAT2 and CYP2E1 are not closely related to the development of this adverse reaction .	1 1 1 1 1|4 1 1|4 1 1 10 11 1 16 16 13 16 1 1 24 24 24 24 24 24 29 27 29 29 24 31 29 34 34 29 40 40 40 40 40 34 42 40 42 29 48 48 48 29 24 51 51 53 51 57 57 57 53 60 60 57 60 63 60 51 68 68 68 68 70 68 73 73 88 75 88 75 76 77 80 77 76 76 84 82 82 82 88 70 92 92 92 88 94 92 103 103 96 97 98 101 98 103 88 105 103 103 88 109 68 112 112 109 114 112 114 112 118 112 68 68 124 124 124 120 124 127 124 127 127 127 130|127 127 130|127 127 127 127 68 139 139 142 142 139 146 146 146 142 146 146 152 152 152 142 154 152 154 157 154 157 154 161 163 163 166 166 166 154 166 166|167 166 166|167 166 166 166 154 175 152 178 178 175 178 178 180 183 181 139 189 189 189 189 184 139 193 195 195 195 197 195 201 201 201 197 195 213 203 206 203 206 206 213 213 212 210 213 216 216 213 219 219 216 222 222 219 222 222 222 222 226 226 230 226 230 234 234 230 234 222 240 240 240 213 242 240 242 245 243 247 245 247 247 247 254 254 254 240 258 258 258 254 213 268 268 268 264 262|263 262 262|263 268 268 268 271 271 268 274 274 271 276 277 274 277 277 281 268 281 282 285 282 285 289 289 285 281 268 295 295 322 300 300 300|297 300 300|297 295 303 303 300 303 303 308 308 303 308 308 308 313 308 313 313 317 303 317 303 295 320 322 325 325 322 328 328 325 331 331 328 333 334 328 334 334 338 322 338 339 342 338 342 346 346 342 338 322 352 352 362 357 357 357 357 352 357 360 357 362 362 362 364 364 365|374 374 365|374 366 370 366 374 374 374 364 377 377 374 379 377 381 379 374 374 386 386 394 388 386 388 388 394 394 394 374 397 397 394 401 401 401 397 364	Association
21837673	Chemical	Gene	D000082	4988	False	1	What is [PHARMGKB] between @ChemicalSrc$ acetaminophen @/ChemicalSrc$ and @GeneTgt$ OPRM1 @/GeneTgt$ ? [SEP] Human mu-opioid receptor gene A118 G polymorphism predicts the efficacy of @ChemicalSrc$ tramadol/acetaminophen @/ChemicalSrc$ combination tablets ( ultracet ) in oxaliplatin-induced painful neuropathy . BACKGROUND : The A118 G polymorphism of the mu-opioid receptor gene ( @GeneTgt$ OPRM1 @/GeneTgt$ ) , resulting in the substitution of an amino acid , has been found to be associated with functional effects and response to opioid treatment . The purpose of this study was to assess whether this polymorphism contributes to the variability in response to @ChemicalSrc$ tramadol/acetaminophen @/ChemicalSrc$ combination tablets ( Ultracet ) for treating oxaliplatin-induced painful neuropathy . METHODS : A total of 96 patients with adenocarcinoma of the colon or rectum ( n = 84 ) , or stomach ( n = 12 ) who had developed oxaliplatin-induced painful neuropathy were enrolled . Ultracet was administered at 1 tablet every 6 hours , and pain was assessed and scored using a visual analog scale ( VAS ) . The @GeneTgt$ OPRM1 @/GeneTgt$ A118 G polymorphism was examined with a polymerase chain reaction-direct sequencing method . RESULTS : The allelic frequency of variant ( 118 G ) allele was 39.6 % , and the prevalence of @GeneTgt$ OPRM1 @/GeneTgt$ - 118 AA , AG , and GG genotypes was 31.3 % ( n = 30 ) , 58.3 % ( n = 56 ) , and 10.4 % ( n = 10 ) , respectively . For all patients , the mean pre-treatment and post-treatment VAS scores were 3.1 and 2.1 , respectively ( P & lt ; .001 ) . Patients with AA genotype had a better analgesic effect than those with G allele variants ( AG or GG genotypes ) . Pre-treatment and post-treatment VAS scores for patients with G allele variants were 3.1 and 2.6 , respectively ; however , for patients with AA genotype , pre-treatment and post-treatment VAS scores were 3.0 and 0.9 , respectively ( P & lt ; .001 ) . The requirement for rescue analgesia was also higher for patients with G allele variants ( P = .01 ) . CONCLUSIONS : These data suggest that Ultracet is effective in the management of oxaliplatin-induced painful neuropathy . A118 G polymorphism of @GeneTgt$ OPRM1 @/GeneTgt$ , by altered function of the mu-opioid receptor and consequential analgesic effect on opioid agents , could be a key determinant for decreased response to Ultracet .	7 7 7 7 7 7 8 8 10 8 15 11|15 15 11|15 15 10 17 15 17 22 22 22 10 8 25 25 30 30 30 52 35 35 35 35 30 37 35|36 35 35|36 37 30 30 44 44 41 48 48 48 44 30 52 52 25 55 55 52 58 58 55 58 58 63 63 60 52 67 71 70 70 67 71 73 71 77 76 77 73 80 80 77 82 80 87 83|87 87 83|87 87 82 89 87 89 92 80 95 95 92 71 132 132 101 132 104 104 101 106 104 109 109 106 109 109 114 114 104 114 114 104 104 104 121 119 121 122 121 127 127 119 130 130 127 132 132 132 136 136 136 139 139 136 142 142 136 136 136 147 147 136 147 147 149 154 154 154 150 156 154 156 147 164 159|164 164 159|164 164 164 166 166 166 173 173 173 173 173 173 166 166 176 176 180 180 190 182 180 187 185 187 187 180 190 190 176 190 190 194 209 196 195|206 206 195|206 196 200 196 200 200 202 200 206 194 209 209 176 211 209 211 212 211 209 217 209 219 220 217 220 220 209 209 226 209 228 226 228 229 228 209 209 209 238 238 248 248 246 246 246 242 242 246 248 248 248 248 248 248 248 254 248 254 254 254 254 254 248 265 264 264 261 265 269 269 269 265 271 269 275 275 275 271 277 280 277 277 275 265 265 287 283 283 287 295 289 287 293 293 293 289 295 295 295 295 295 295 295 295 295 304 309 307 307 304 307 295 309 309 313 315 315 295 315 315 315 315 321 315 321 321 321 321 321 295 329 335 332 332 329 335 335 335 337 335 341 341 341 337 343 337 343 344 343 335 348 348 351 352 348 356 356 356 352 359 359 356 363 363 363 359 348 367 367 391 369 367|368 367 367|368 367 374 374 367 378 378 378 374 378 382 382 378 385 385 374 391 391 391 391 391 391 394 394 391 396 394 391	Association
23324807	Chemical	Gene	D008874	5447	True	0	What is [PHARMGKB] between @ChemicalSrc$ midazolam @/ChemicalSrc$ and @GeneTgt$ POR @/GeneTgt$ ? [SEP] Impact of @GeneTgt$ POR*28 @/GeneTgt$ on the clinical pharmacokinetics of CYP3A phenotyping probes @ChemicalSrc$ midazolam @/ChemicalSrc$ and erythromycin . OBJECTIVE : @GeneTgt$ P450 oxidoreductase @/GeneTgt$ ( @GeneTgt$ POR @/GeneTgt$ ) is essential for cytochrome P450 ( CYP ) activity in humans . The @GeneTgt$ POR*28 @/GeneTgt$ allele ( A503V ) has been shown to impact on in-vitro CYP-mediated metabolism , including CYP3A isoenzymes . The aim of the present study was to determine the in vivo impact of the @GeneTgt$ POR*28 @/GeneTgt$ allele on the pharmacokinetics of the classic CYP3A phenotyping probes @ChemicalSrc$ midazolam @/ChemicalSrc$ and erythromycin . Whereas @ChemicalSrc$ midazolam @/ChemicalSrc$ is metabolized by both CYP3A4 and CYP3A5 , erythromycin is exclusively oxidized by CYP3A4 . MATERIALS AND METHODS : To assess CYP3A activity , 108 cancer patients received @ChemicalSrc$ midazolam @/ChemicalSrc$ and 45 others underwent the erythromycin breath test . Patients were genotyped for @GeneTgt$ POR*28 @/GeneTgt$ , CYP3A4 * 22 and CYP3A5 * 3 . RESULTS : In patients expressing CYP3A5 , @GeneTgt$ POR*28 @/GeneTgt$ carriers showed 45 % lower @ChemicalSrc$ midazolam @/ChemicalSrc$ metabolic ratios compared with POR*1/*1 patients ( P&lt;0.001 ) . This is in line with a lower CYP3A5 activity toward @ChemicalSrc$ midazolam @/ChemicalSrc$ for @GeneTgt$ POR*28 @/GeneTgt$ carriers . In CYP3A5 nonexpressers , @GeneTgt$ POR*28 @/GeneTgt$ had no influence on @ChemicalSrc$ midazolam @/ChemicalSrc$ pharmacokinetics . For erythromycin , @GeneTgt$ POR*28 @/GeneTgt$ carriership did not influence its metabolism . CONCLUSION : Our data show that the @GeneTgt$ POR*28 @/GeneTgt$ allele is associated with a lower in vivo CYP3A5 activity , but has no effects on CYP3A4-mediated erythromycin and @ChemicalSrc$ midazolam @/ChemicalSrc$ metabolism .	1 3 1|2 1 1|2 8 8 8 1 12 12 12 8 11|12 12 11|12 13 13 1 20 20 30|21|22 30|21|22 30|22 30|21|22 26 22|23 22 22|23 26 30 20 37 37 37 35 33 35 30 39 37 30 46 43|46 46 43|46 52 48 46 48 52 52 52 54 52 58 58 58 54 58 62 62 58 52 66 71 70 70 70 66 71 73 71 77 77 75 73 82 82 82|79 82 82|79 77 85 85 77 91 91 91 91 91 85 90|91 91 90|91 92 92 71 103 99|103 103 99|103 103 113 106 106 103 106 106 113 113 113 113 113 115 113 113 118 118 118 118 123 118 125 123 130 129 129 130 123 136|130 136 136|130 131 135 131 123 140 140 140 136 118 145 145 145 147 145|146 145 145|146 147 147 147 147 147 147 147 147 145 159 159 162 169 162 163 169 168|165 168 168|165 169 159 171 172 176 176|171 176 176|171 176 169 176 180 180 177 182 180 182 159 190 190 190 190 195 195 195 195 190 197 195|196 195 195|196 202 202|198 202 202|198 197 190 208 208 212 212 209|212 212 209|212 212 214 212 218 214|218 218 214|218 214 212 223 230 230 224|227 227 224|227 230 230 230 230 232 230 230 239 239 238 239 239 246 244 244|241 244 244|241 246 246 239 253 253 253 253 250 253 246 239 239 239 258 256 261 261 258 261 261|265 265 261|265 261 239	Association
24681963	Chemical	Gene	C093875	154	True	0	What is [PHARMGKB] between @ChemicalSrc$ montelukast @/ChemicalSrc$ and @GeneTgt$ ADRB2 @/GeneTgt$ ? [SEP] The effects of a Gly16Arg @GeneTgt$ ADRB2 @/GeneTgt$ polymorphism on responses to salmeterol or @ChemicalSrc$ montelukast @/ChemicalSrc$ in Japanese patients with mild persistent asthma . BACKGROUND : Long-acting beta2-agonists and leukotriene receptor antagonists are two principal agents that can be added to inhaled corticosteroids ( ICS ) for patients with asthma that is not adequately controlled by ICS alone . The Gly16Arg genotype of the @GeneTgt$ beta2-adrenergic receptor @/GeneTgt$ ( @GeneTgt$ ADRB2 @/GeneTgt$ ) gene may influence the bronchodilator effects of beta2-agonists . We hypothesized that differential responses to long-acting beta2-agonists or leukotriene receptor antagonists might be determined partly by the Gly16Arg polymorphism in Japanese asthma patients . MATERIALS AND METHODS : This randomized , genotype-stratified , two-period crossover study included 80 patients with mild-to-moderate asthma ( 35 Arg/Arg and 45 Gly/Gly individuals ) . The primary study outcome was the difference in peak expiratory flow ( DeltaPEF ) ( DeltaPEF , l/min ) by genotype after 16 weeks of treatment with salmeterol ( DeltaPEFsal ) or @ChemicalSrc$ montelukast @/ChemicalSrc$ ( DeltaPEFmon ) . In addition , multivariate analyses were used to identify independent factors that were predictive of responses to each treatment . RESULTS : The mean DeltaPEFsal-DeltaPEFmon was 19.3 + -46.6 among Arg/Arg individuals and 16.8 + -51.5 among Gly/Gly individuals , indicating that the Gly16Arg genotype did not influence the differential bronchodilator effect of the two agents . Multivariate analysis showed that higher peripheral eosinophil counts were associated with better response to salmeterol ( P&lt;0.05 ) . CONCLUSION : The Gly16Arg genotype did not influence the differential bronchodilator effect of salmeterol or @ChemicalSrc$ montelukast @/ChemicalSrc$ as an add-on therapy to ICS within 16 weeks of follow-up . Higher peripheral eosinophil counts may be associated with better responses to salmeterol in combination with ICS .	2 2 8 8 8 8|5 8 8|5 2 10 2 12 10 12 12 12 12 18 18 12 22 22 22 18 2 26 26 29 37 29 33 33 29 37 37 37 26 41 41 41 37 44 44 41 46 44 46 49 44 51 49 56 56 56 56 49 58 56 58 37 63 63 75 73 73 73|65 73|65 73 73|65 70 73|67 73 73|67 73 63 75 75 78 78 75 80 78 75 85 85 98 88 98 91 91 88 91 95 95 91 98 98 85 98 103 103 103 98 107 107 107 103 85 109 109 109 109 120 120 114 114 114 114 120 121 109 123 121 126 126 123 133 129 133 129 132 129 123 133 109 139 139 139 142 142 142 142 146 146 146 142 148 146 148 151 146 153 151 151 156 142 159 159 156 161 159 163 161 165 163 165 163 167|163 163 167|163 171 168 171 142 176 181 181 179 181 181 181 183 181 185 183 188 188 185 190 188 193 193 190 181 215 195 198 201 198 201 195 201 201 206 206 201 201 201 208 208 213 213 201 201 215 222 219 219 222 222 222 215 226 226 226 222 230 230 230 226 215 233 234 234 241 239 239 239 241 241 234 244 244 241 246 244 248 246 248 234 251 258 255 255 258 258 258 251 262 262 262 258 264 262 264 264|265 264 264|265 271 271 271 258 273 271 276 276 271 278 276 258 284 284 284 287 287 287 287 290 290 287 292 290 294 292 296 294 287	Association
25311995	Chemical	Gene	C545203	1080	True	0	What is [PHARMGKB] between @ChemicalSrc$ ivacaftor @/ChemicalSrc$ and @GeneTgt$ CFTR @/GeneTgt$ ? [SEP] Long-term safety and efficacy of @ChemicalSrc$ ivacaftor @/ChemicalSrc$ in patients with cystic fibrosis who have the @GeneTgt$ Gly551Asp-CFTR @/GeneTgt$ mutation : a phase 3 , open-label extension study ( PERSIST ) . BACKGROUND : @ChemicalSrc$ Ivacaftor @/ChemicalSrc$ , a @GeneTgt$ cystic fibrosis transmembrane conductance regulator @/GeneTgt$ ( @GeneTgt$ CFTR @/GeneTgt$ ) potentiator , is approved for the treatment of patients with cystic fibrosis aged 6 years or older with @GeneTgt$ Gly551Asp-CFTR @/GeneTgt$ . We assessed the safety and efficacy of @ChemicalSrc$ ivacaftor @/ChemicalSrc$ during 96 weeks of PERSIST in patients with cystic fibrosis who completed a previous 48-week , placebo-controlled trial of the drug ( STRIVE or ENVISION ) . METHODS : In this phase 3 , open-label extension study , patients received @ChemicalSrc$ ivacaftor @/ChemicalSrc$ 150 mg every 12 h in addition to their prescribed cystic fibrosis therapies . Patients who received placebo in their previous study initiated @ChemicalSrc$ ivacaftor @/ChemicalSrc$ in this extension study . Patients were eligible if they had a @GeneTgt$ Gly551Asp-CFTR @/GeneTgt$ mutation on at least one allele . The primary objective was to assess the long-term safety profile of @ChemicalSrc$ ivacaftor @/ChemicalSrc$ as assessed by adverse events , clinical laboratory assessments , electrocardiograms , vital signs , and physical examination ; secondary measures included change in forced expiratory volume in one second ( FEV1 ) , weight , and pulmonary exacerbations . This study is registered with ClinicalTrials.gov , number NCT01117012 and EudraCT , number 2009 - 012997 - 11 . FINDINGS : Between July 8 , 2010 , and April 8 , 2013 , 144 adolescents/adults ( & gt;=12 years ) from STRIVE and 48 children ( 6 - 11 years ) from ENVISION were enrolled . Across both trials , 38 ( 20 % ) patients had a serious adverse event during the first 48 weeks and 44 ( 23 % ) during the subsequent 48 weeks . Two adults ( 1 % ) and one child ( & lt;1 % ) discontinued because of adverse events . The most common adverse events were pulmonary exacerbation , cough , and upper respiratory tract infection . Patients previously treated with @ChemicalSrc$ ivacaftor @/ChemicalSrc$ had sustained improvements in FEV1 , weight , and rate of pulmonary exacerbations for up to 144 weeks of treatment . Among adolescents/adults and children who previously received @ChemicalSrc$ ivacaftor @/ChemicalSrc$ , absolute change in FEV1 at week 96 ( 144 weeks @ChemicalSrc$ ivacaftor @/ChemicalSrc$ ) was 9 4 and 10 3 % points and absolute increase in weight was 4 1 kg and 14 8 kg , respectively . For adolescents/adults only , the pulmonary exacerbation rate remained suppressed compared with that of patients who received placebo in the placebo-controlled study . INTERPRETATION : At 144 weeks of treatment , @ChemicalSrc$ ivacaftor @/ChemicalSrc$ was well tolerated , with no new safety concerns . @ChemicalSrc$ Ivacaftor @/ChemicalSrc$ also provided durable effects for 144 weeks in patients who had received active treatment in the placebo-controlled study . Those patients who previously received placebo had improvements comparable to those of patients treated with @ChemicalSrc$ ivacaftor @/ChemicalSrc$ in the placebo-controlled study . FUNDING : Vertex Pharmaceuticals Inc.	2 2 2 2 6 4|5 4 4|5 9 2 12 12 9 14 12 18 18|14 18 18|14 14 2 21 2 21 21 26 26 21 28 26 28 2 33 33 34|52 52 34|52 35 49 49|37|39 49|37|39 49|37|39 49|37|39 49|37|39 49|39 49|37|39 49 49|39 49 49|39 49 35 35 52 33 55 55 52 57 55 60 60 57 60 63 55 55 55 67 65|59 65 65|59 52 75 75 77 75 77 77 81 77|80 77 77|80 85 85 75 87 85 89 87 92 92 89 94 89 97 97 94 100 100 75 103 103 100 105 103 105 105 105 75 123 111 115 115 120 115 120 120 120 123 123 123 123 123 123 123 127 124 130 130 123 132 123 138 138 138 138 138 132 123 149 143 141 143 148 148 148 143 149 149 149 149 155 155 155 149 149 160 160 160 163 163 160 167 167|164 167 167|164 163 172 171 169 172 163 160 177 177 178 209 180 178 184 184 184 180 186 184|185 184 184|185 189 180 192 192 189 192 196 196 192 196 196 198 201 198 201 198 205 198 209 208 209 209 209 214 214 214 210 217 217 209 219 217 219 219 219 222 222 226 222 209 230 232 232 232 234 232 234 237 234 237 237 234 246 241 241 241 246 234 232 283 283 251 283 251 251 251 251 251 251 257 257 257 257 263 267 263 263 263 257 267 270 257 270 270 270 278 278 277 275 273 278 281 270 283 283 283 287 287 295 295 294 292 292 289 292 295 295 299 299 299 295 304 304 304 304 295 304 304 309 309 306 309 315 315 315 315 295 295 318 331 321 321 318 321 318 325 318 325 325 329 325 325 331 335 332 335 331 331 341 339 341 341 344 344 344 344 344 344 346 346 352 352 352 346 344 360 356 354 358 356|357 356 356|357 360 362 360 364 362 364 364 364 364 364 372 372 369 377 376 376 377 360 379 377 360 383 421 383 383 388 388 385 388 388 388 412 393 412 395 393 397 393 397 402 401 402 397|400 397 397|400 402 412 412 406 407 410 406 412 383 412 415 412 417 415 421 421 421 421 421 425 425 421 425 425 421 432 439 431 439 438 438 438 439 439 439 440 443 441 445 443 447 445 447 452 452 452 447 439 454 454 458 458 466 460 458 466 461|466 466 461|466 466 466 454 466 472 472 472 472 466 466 474|478 478 474|478 478 478 480 478 483 483 480 485 480 488 488 485 490 488 494 494 494 488 478 498 503 501 501 498 501 503 503 504 507 505 509 507 509 512 510|511 510 510|511 517 517 517 510 503 520 520 524 524 520	Association
25583994	Chemical	Gene	C411602	115	True	0	What is [PHARMGKB] between @ChemicalSrc$ dalcetrapib @/ChemicalSrc$ and @GeneTgt$ ADCY9 @/GeneTgt$ ? [SEP] Pharmacogenomic determinants of the cardiovascular effects of @ChemicalSrc$ dalcetrapib @/ChemicalSrc$ . BACKGROUND : @ChemicalSrc$ Dalcetrapib @/ChemicalSrc$ did not improve clinical outcomes , despite increasing high-density lipoprotein cholesterol by 30 % . These results differ from other evidence supporting high-density lipoprotein as a therapeutic target . Responses to @ChemicalSrc$ dalcetrapib @/ChemicalSrc$ may vary according to patients ' genetic profile . METHODS AND RESULTS : We conducted a pharmacogenomic evaluation using a genome-wide approach in the dal-OUTCOMES study ( discovery cohort , n=5749 ) and a targeted genotyping panel in the dal-PLAQUE-2 imaging trial ( support cohort , n=386 ) . The primary endpoint for the discovery cohort was a composite of cardiovascular events . The change from baseline in carotid intima-media thickness on ultrasonography at 6 and 12 months was evaluated as supporting evidence . A single-nucleotide polymorphism was found to be associated with cardiovascular events in the dalcetrapib arm , identifying the @GeneTgt$ ADCY9 @/GeneTgt$ gene on chromosome 16 ( rs1967309 ; P=2.41x10(-8 ) ) , with 8 polymorphisms providing P&lt;10(-6 ) in this gene . Considering patients with genotype AA at rs1967309 , there was a 39 % reduction in the composite cardiovascular endpoint with @ChemicalSrc$ dalcetrapib @/ChemicalSrc$ compared with placebo ( hazard ratio , 0.61 ; 95 % confidence interval , 0.41 - 0.92 ) . In patients with genotype GG , there was a 27 % increase in events with @ChemicalSrc$ dalcetrapib @/ChemicalSrc$ versus placebo . Ten single-nucleotide polymorphism in the @GeneTgt$ ADCY9 @/GeneTgt$ gene , the majority in linkage disequilibrium with rs1967309 , were associated with the effect of @ChemicalSrc$ dalcetrapib @/ChemicalSrc$ on intima-media thickness ( P&lt;0.05 ) . Marker rs2238448 in @GeneTgt$ ADCY9 @/GeneTgt$ , in linkage disequilibrium with rs1967309 ( r(2)=0.8 ) , was associated with both the effects of @ChemicalSrc$ dalcetrapib @/ChemicalSrc$ on intima-media thickness in dal-PLAQUE-2 ( P=0.009 ) and events in dal-OUTCOMES ( P=8.88x10(-8 ) ; hazard ratio , 0.67 ; 95 % confidence interval , 0.58 - 0.78 ) . CONCLUSIONS : The effects of @ChemicalSrc$ dalcetrapib @/ChemicalSrc$ on atherosclerotic outcomes are determined by correlated polymorphisms in the @GeneTgt$ ADCY9 @/GeneTgt$ gene . CLINICAL TRIAL INFORMATION : URL : http://www.clinicaltrials.gov . Unique identifiers : NCT00658515 and NCT01059682 .	2 2 6 6 6 2 8 6|7 6 6|7 2 18 12 13|18 18 13|18 18 18 18 20 18 18 23 18 26 26 23 29 29 23 18 33 34 34 37 37 34 37 40 38 44 44 44 38 34 51 48 46|47 46 46|47 51 51 57 52 57 54 57 51 51 65 60 60 65 65 65 68 68 65 68 72 72 69 76 76 76 72 79 79 65 79 79 81 79 87 87 87 79 92 92 92 92 87 95 95 92 95 95 95 65 102 102 109 106 106 106 102 109 109 109 112 112 109 109 115 130 117 115 121 121 121 115 123 115 125 128 125 125 115 130 130 133 133 130 130 137 137 139 139 139 142 142 139 145 145 142 149 149 149 145 139 139 155 152|155 155 152|155 151 157 155 157 160 157 160 160 160 160 157 168 168 155 168 169 170 174 174 169 139 178 186 181 181 178 183 178 186 186 186 190 189 190 186 195 195 195 195 190 197 195|196 195 195|196 186 201 199 204 204 201 204 204 206 211 211 211 206 211 215 215 211 204 186 220 226 223 223 220 226 226 226 230 229 230 226 232 230 234 232|233 232 232|233 234 234 226 242 242 258 247 247 247|244 247 247|244 242 247 250 247 253 253 250 255 253 242 258 258 261 261 258 263 261 261 261 267 267 261 269 267 269 258 275 290 277 275|276 275 275|276 277 282 282 275 284 282 286 284 286 275 290 290 294 294 294 290 296 294 294 294 300 300 294 302 294 304 302 304 302 294 309 307 311 309 311 290 315 290 315 315 317 322 322 322 317 322 326 326 322 315 290 331 331 334 342 336 334|335 334 334|335 340 340 334 342 331 345 345 342 350 350 346|350 350 346|350 345 331 355 356 356 356 356 358 358 356 363 363 363 363 365 365 363	Association
25816720	Chemical	Gene	D000077157	3791	True	0	What is [PHARMGKB] between @ChemicalSrc$ sorafenib @/ChemicalSrc$ and @GeneTgt$ VEGFR2 @/GeneTgt$ ? [SEP] Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus @ChemicalSrc$ Sorafenib @/ChemicalSrc$ in Metastatic Renal Cell Carcinoma . BACKGROUND : In the phase III axitinib second-line ( AXIS ) trial , axitinib significantly prolonged progression-free survival ( PFS ) versus @ChemicalSrc$ sorafenib @/ChemicalSrc$ in patients with previously treated metastatic renal cell carcinoma ( mRCC ) . Analyses of associations between germline single-nucleotide polymorphisms ( SNPs ) and outcomes are reported . PATIENTS AND METHODS : DNA samples from blood were genotyped using TaqMan allelic discrimination . Logistic/Cox regression analyses were used to evaluate association of 15 SNPs in vascular endothelial growth factor (VEGF)-A , VEGF receptor (VEGFR)1 , @GeneTgt$ VEGFR2 @/GeneTgt$ , or hypoxia-inducible factor (HIF)-1alpha with outcomes for blood pressure ( BP ; Grade & gt;= 3 hypertension , diastolic BP & gt ; 90 mm Hg , and increase & gt;= 15 mm Hg from baseline ) and efficacy ( independent review committee-assessed objective response rate and PFS , and overall survival [ OS ] ) . Multivariate analyses assessed SNPs and baseline characteristics as potential predictors of PFS and OS . RESULTS : Genotype data were available for 305 ( 42.7 % ) of 714 patients ; 159 received axitinib and 146 @ChemicalSrc$ sorafenib @/ChemicalSrc$ . After Bonferroni adjustment , no SNP was associated with BP outcomes . In axitinib-treated patients , VEGF-A rs699947 ( A/A vs. C/C ) and rs833061 ( C/C vs. T/T ) were associated with longer OS ( 27.0 vs. 13.4 months ; hazard ratio [ HR ] , 0.39 ; Padjusted = .015 ) . In @ChemicalSrc$ sorafenib-treated @/ChemicalSrc$ patients , @GeneTgt$ VEGFR2 @/GeneTgt$ rs2071559 ( G/G vs. A/A ) was associated with longer OS ( 26.8 vs. 13.8 months ; HR , 0.41 ; Padjusted = .030 ) . In multivariate analyses , no SNP predicted axitinib efficacy ; @GeneTgt$ VEGFR2 @/GeneTgt$ rs2071559 predicted PFS ( P = .0053 ) and OS ( P = .0027 ) for @ChemicalSrc$ sorafenib @/ChemicalSrc$ . Sensitivity/specificity of @GeneTgt$ VEGFR2 @/GeneTgt$ rs2071559 for OS was & lt ; 80 % . CONCLUSION : No SNP predicted axitinib outcomes . Although @GeneTgt$ VEGFR2 @/GeneTgt$ rs2071559 predicted @ChemicalSrc$ sorafenib @/ChemicalSrc$ efficacy in patients with mRCC , sensitivity/specificity limitations preclude its use for selecting individual patients for @ChemicalSrc$ sorafenib @/ChemicalSrc$ treatment .	2 2 5 5 2 5 5 13 13 13 13 13 2 16 16 13 18 17|13 13 17|13 24 24 24 24 13 2 27 42 38 38 38 38 38 38 38 38 38 42 42 42 42 27 44 42 46 44 46 49 44|48 44 44|48 52 44 59 55 59 59 59 59 52 61 59 61 27 78 67 65 71 71 71 67 73 71 73 71 71 78 78 78 80 80 80 80 85 89 87 85 89 80 89 93 93 90 80 97 97 99 99 99 101 99 101 105 105 102 110 110 110 110 111 102 115 114 115 99 115 115|116 115 115|116 117 115 122 115 122 125 122 128 128 125 130 128 130 130 132 132 136 132 136 139 136 139 139 130 144 145 130 130 115 115 148 148 152 153 150 155 148 155 115 115 160 161 165 165 165 165 115 165 165 115 115 171 115 173 171 173 115 99 179 180 180 180 181 184 181 187 187 180 189 187 189 189 180 193 193 196 198 198 193 200 198 203 203 200 203 207 207 200 198 210 198 210 211 214 211|213 211 211|213 198 220 220 225 225 223 225 225 225 228 228 225 225 232 232 249 249 235 249 237 235 237 237 237 235 235 244 242 244 244 244 249 249 252 252 249 257 257 254 254 252 257 260 252 262 260 262 260 268 265 268 252 268 268 249 275 272|275 275 272|275 286 286 279|275 279 279|275 286 281 279 281 281 281 286 286 289 289 286 294 294 291 291 289 286 286 296 296 296 301 296 301 296 286 309 309 313 313 312 313 313 315 313 320 316|319 319 316|319 320 313 320 324 324 321 324 324 321 321 330 328 330 331 330 335 333|321 321 333|321 320 349 344 341|344 344 341|344 340 346 340 349 347 349 352 352 349 352 355 359 358 359 355 361 359 355 367 363|366 366 363|366 367 378 370|366 370 370|366 367 372 370 374 372 378 377 378 378 380 378 382 380 384 382 388 388|383 388 388|383 384 378	Association
26367500	Chemical	Gene	C063287	10599	True	0	What is [PHARMGKB] between @ChemicalSrc$ simvastatin acid @/ChemicalSrc$ and @GeneTgt$ SLCO1B1 @/GeneTgt$ ? [SEP] Impact of CYP2D6 , CYP3A5 , CYP2C19 , CYP2A6 , @GeneTgt$ SLCO1B1 @/GeneTgt$ , ABCB1 , and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and @ChemicalSrc$ simvastatin acid @/ChemicalSrc$ . OBJECTIVE : The effects of various polymorphisms in cytochrome P450 ( CYP ) enzyme and transporter genes on the pharmacokinetics ( PK ) of simvastatin were evaluated in healthy Korean men . METHODS : Plasma concentration data for simvastatin and @ChemicalSrc$ simvastatin acid @/ChemicalSrc$ were pooled from four phase I studies comprising 133 participants . The polymorphisms CYP2D6 * 4 , CYP2D6 * 5 , CYP2D6 * 14 , CYP2D6 * 41 , CYP3A5 * 3 , CYP2C19 * 2 , CYP2C19 * 3 , CYP2A6 * 7 , and CYP2A6 * 9 ; @GeneTgt$ SLCO1B1 @/GeneTgt$ rs4149056 , rs2306283 , and rs4149015 ; ABCB1 rs1128503 , rs2032582 , and rs1045642 ; and ABCG2 rs2231142 were evaluated in each participant . Noncompartmental PK results were compared by genotype . RESULTS : CYP2D6 * 5 and CYP2D6 * 14 were found to be associated with a higher area under the curve ( AUC ) for simvastatin , whereas the AUC of @ChemicalSrc$ simvastatin acid @/ChemicalSrc$ was significantly increased in patients with the @GeneTgt$ SLCO1B1 @/GeneTgt$ rs4149056 , ABCG2 rs2231142 , and CYP2D6 * 41 allele variants . Patients with the CYP2D6 * 41 variant showed a higher peak serum concentration ( Cmax ) of both simvastatin and @ChemicalSrc$ simvastatin acid @/ChemicalSrc$ . The @GeneTgt$ SLCO1B1 @/GeneTgt$ rs4149056 and rs4149015 polymorphisms were associated with an increased AUC ratio ( i.e. ratio of @ChemicalSrc$ simvastatin acid @/ChemicalSrc$ to simvastatin ) , whereas the @GeneTgt$ SLCO1B1 @/GeneTgt$ rs4149056 and CYP2D6 * 5 variants were related to a higher Cmax ratio . CONCLUSION : The CYP2D6 * 5 , CYP2D6 * 14 , CYP2D6 * 41 , CYP3A5 * 3 , @GeneTgt$ SLCO1B1 @/GeneTgt$ rs4149056 and rs4149015 , and ABCG2 rs2231142 genetic polymorphisms are associated with the PK of both simvastatin and @ChemicalSrc$ simvastatin acid @/ChemicalSrc$ . This could potentially be used as a basis for individualized simvastatin therapy by predicting the clinical outcomes of this treatment .	1 3 1 3 3 3 3 3 3 9 9|10 9 9|10 3 3 3 3 3 19 3 22 22 1 24 22 24 24 24 24 24 1 32 32 35 58 38 38 35 45 41 45 43 41 43 35 45 48 45 51 51 35 53 51 53 56 51 58 32 62 61 62 58 58 76 76 68 68 76 70 68 70 71|70 71|70 70 71|70 76 76 79 79 81 81 76 81 84 82 76 89 89 147 89 89 91 91 93 93 91 89 97 101 101 97 101 105 105 101 105 97 97 97 109 109 97 97 113 113 97 97 117 117 119 97 97 122 122 97 97|125 97 97|125 126 128 128 128 128 128 89 136 89 136 136 136 136 136 136 89 145 89 147 147 150 150 147 147 154 155 157 157 157 159 157 157 161 161 171 163 163 165 163 163 163 171 161 174 174 171 178 178 178 174 181 181 178 183 181 183 186 178 171 171 190 197 192 192|190|191 192|190|191 192|190 192|190|191 197 197 171 199 197 202 202 214|199 214 214|199 202 204 207 204 204 204 204 214 214 214 199 161 225 221 221 218 224 224 218 225 230 230 230 230 225 232 230 232 236 236 230 236 236|237 236|237 236 236|237 225 244 243|251 251 243|251 244 246 246 251 251 251 256 256 256 256 251 259 259 251 261 259|261 259|261 259|261 259|261 265 259 259 251 251 270 266|279 279 266|279 270 272 272 277 277 272 279 251 284 284 284 284 279 251 289 289 292 320 292 296 296 292 296 296 296 296 300 304 304 300 304 304 300 307|292 292 307|292 308 310 310 292 292 317 317 318 320 320 289 323 323 320 326 326 323 326 323|326 323|326 323|326 323|326 320 338 338 338 338 338 341 341 338 345 345 345 341 347 338 350 350 347 353 353 350 338	Association
26652611	Chemical	Gene	D008727	2356	True	0	What is [PHARMGKB] between @ChemicalSrc$ MTX @/ChemicalSrc$ and @GeneTgt$ FPGS @/GeneTgt$ ? [SEP] @ChemicalSrc$ Methotrexate @/ChemicalSrc$ pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients . BACKGROUND : @ChemicalSrc$ Methotrexate @/ChemicalSrc$ ( @ChemicalSrc$ MTX @/ChemicalSrc$ ) is the most used drug for the treatment of rheumatoid arthritis ( RA ) although outcome differs among patients . AIM : To evaluate whether polymorphisms in pharmacokinetic genes are associated with outcome in RA patients receiving @ChemicalSrc$ MTX @/ChemicalSrc$ . PATIENTS & amp ; METHODS : We analyzed 28 SNPs in SLC19A1/RFC1 , ABCB1 , @GeneTgt$ FPGS @/GeneTgt$ and GGH genes . RESULTS : We studied 194 RA patients receiving @ChemicalSrc$ MTX @/ChemicalSrc$ monotherapy . Two @GeneTgt$ FPGS @/GeneTgt$ SNPs , rs10987742 and rs10106 , were associated with response ( p = 0.033 and p = 0.041 , respectively ) . The @GeneTgt$ FPGS @/GeneTgt$ rs10106 variant was also associated with @ChemicalSrc$ MTX @/ChemicalSrc$ survival ( p = 0.005 ) and toxicity ( p = 0.021 ) . Three ABCB1 SNPs , rs868755 , rs10280623 and rs1858923 , were associated with toxicity ( p = 0.025 , p = 0.048 and p = 0.031 , respectively ) . CONCLUSION : @GeneTgt$ FPGS @/GeneTgt$ and ABCB1 genetic variants can influence the outcome in RA patients receiving @ChemicalSrc$ MTX @/ChemicalSrc$ monotherapy .	0|5 5 0|5 5 5 7 7 7 9 7 13 13 13 9 7 16 16 17|28 28 17|28 21 18|19 18 18|19 21 28 28 27 28 16 31 31 28 34 34 31 36 34 36 40 40 28 42 40 16 49 49 49 49 56 56 54 54 51 56 49 58 56 61 61 58 61 62 62 62 49 67 67 67 67 67 74 74 67 76 74 78 76 78 78 78 78|81 78 78|81 78 78 78 74 89 89 92 89 95 95 92 95 96|99 99 96|99 96 89 105 102|105 105 102|105 112 105 105 107 107 105 112 112 114 112 117 117 114 117 117 121 117 121 121 117 117 112 132 128|131 131 128|131 132 135 135 135 135 139 135|139 139 135|139 135 142 142 139 142 142 139 139 149 149 146 149 149 135 157 157 166 157 157 159 159 161 161 157 166 166 168 166 171 171 168 171 171 175 171 175 175 179 175 179 179 171 171 166 185 185 186|194 194 186|194 187 187 192 187 194 185 196 194 199 199 196 199 203|199 203 203|199 200 185	Association
26652611	Chemical	Gene	D008727	5243	True	0	What is [PHARMGKB] between @ChemicalSrc$ MTX @/ChemicalSrc$ and @GeneTgt$ ABCB1 @/GeneTgt$ ? [SEP] @ChemicalSrc$ Methotrexate @/ChemicalSrc$ pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients . BACKGROUND : @ChemicalSrc$ Methotrexate @/ChemicalSrc$ ( @ChemicalSrc$ MTX @/ChemicalSrc$ ) is the most used drug for the treatment of rheumatoid arthritis ( RA ) although outcome differs among patients . AIM : To evaluate whether polymorphisms in pharmacokinetic genes are associated with outcome in RA patients receiving @ChemicalSrc$ MTX @/ChemicalSrc$ . PATIENTS & amp ; METHODS : We analyzed 28 SNPs in SLC19A1/RFC1 , @GeneTgt$ ABCB1 @/GeneTgt$ , FPGS and GGH genes . RESULTS : We studied 194 RA patients receiving @ChemicalSrc$ MTX @/ChemicalSrc$ monotherapy . Two FPGS SNPs , rs10987742 and rs10106 , were associated with response ( p = 0.033 and p = 0.041 , respectively ) . The FPGS rs10106 variant was also associated with @ChemicalSrc$ MTX @/ChemicalSrc$ survival ( p = 0.005 ) and toxicity ( p = 0.021 ) . Three @GeneTgt$ ABCB1 @/GeneTgt$ SNPs , rs868755 , rs10280623 and rs1858923 , were associated with toxicity ( p = 0.025 , p = 0.048 and p = 0.031 , respectively ) . CONCLUSION : FPGS and @GeneTgt$ ABCB1 @/GeneTgt$ genetic variants can influence the outcome in RA patients receiving @ChemicalSrc$ MTX @/ChemicalSrc$ monotherapy .	0|5 5 0|5 5 5 7 7 7 9 7 13 13 13 9 7 16 16 17|28 28 17|28 21 18|19 18 18|19 21 28 28 27 28 16 31 31 28 34 34 31 36 34 36 40 40 28 42 40 16 49 49 49 49 56 56 54 54 51 56 49 58 56 61 61 58 61 62 62 62 49 67 67 67 67 67 74 74 67 76 74 78 76 78 78|79 78 78|79 78 78 78 78 78 74 89 89 92 89 95 95 92 95 96|99 99 96|99 96 89 104 104 111 104 104 106 106 104 111 111 113 111 116 116 113 116 116 120 116 120 120 116 116 111 129 128 129 132 132 132 132 136 133|136 136 133|136 132 139 139 136 139 139 136 136 146 146 143 146 146 132 154 151|154 154 151|154 163 154 154 156 156 158 158 154 163 163 165 163 168 168 165 168 168 172 168 172 172 176 172 176 176 168 168 163 183 183 192 185 185|186 185 185|186 190 185 192 183 194 192 197 197 194 197 201|197 201 201|197 198 183	Association
28627804	Chemical	Gene	D000068718	11309	True	0	What is [PHARMGKB] between @ChemicalSrc$ rosuvastatin @/ChemicalSrc$ and @GeneTgt$ SLCO2B1 @/GeneTgt$ ? [SEP] The Effect of Genetic Polymorphisms in @GeneTgt$ SLCO2B1 @/GeneTgt$ on the Lipid-Lowering Efficacy of @ChemicalSrc$ Rosuvastatin @/ChemicalSrc$ in Healthy Adults with Elevated Low-Density Lipoprotein . @ChemicalSrc$ Rosuvastatin @/ChemicalSrc$ is an HMG-CoA reductase inhibitor widely used for treating hypercholesterolaemia . We investigated whether genetic polymorphisms in @GeneTgt$ solute carrier organic anion transporter 2B1 @/GeneTgt$ ( @GeneTgt$ SLCO2B1 @/GeneTgt$ ) affect the lipid-lowering effect of @ChemicalSrc$ rosuvastatin @/ChemicalSrc$ in healthy adults with elevated low-density lipoprotein ( LDL ) . This study included 18 volunteers with LDL levels above 130 mg/dL. @ChemicalSrc$ Rosuvastatin @/ChemicalSrc$ ( 20 mg ) was administered once a day for 8 weeks . Blood samples were drawn before and after the 8-week treatment to measure changes in lipid levels . The presence of single nucleotide polymorphisms ( SNPs ) of @GeneTgt$ SLCO2B1 @/GeneTgt$ ( c.935G&gt;A and c.1457C&gt;T ) , SLCO1B1 ( c.521C&gt;T , c.388A&gt;G and c.-11187G&gt;A ) and ABCG2 ( c.421C&gt;A ) was determined by genotyping . Responses to @ChemicalSrc$ rosuvastatin @/ChemicalSrc$ were compared between wild-type and variant genotypes using permutation test on each polymorphism . In volunteers with @GeneTgt$ SLCO2B1 @/GeneTgt$ c.935G&gt;A ( rs12422149 ) variant , @ChemicalSrc$ rosuvastatin @/ChemicalSrc$ was less effective at lowering LDL ( mean % decrease : GG 62.8 % GA 50.6 % AA 49.3 % , p = 0.012 ) and apoprotein B ( mean % decrease : GG 52.1 % GA 42.8 % AA 42.8 % , p = 0.036 ) . Regarding @GeneTgt$ SLCO2B1 @/GeneTgt$ c.1457C&gt;T ( rs2306168 ) SNP , there was no significant difference between wild-type and variant genotypes . This study demonstrated that @GeneTgt$ SLCO2B1 @/GeneTgt$ c.935G&gt;A ( rs12422149 ) polymorphism influenced the lipid-lowering effects of @ChemicalSrc$ rosuvastatin @/ChemicalSrc$ in volunteers with hypercholesterolaemia .	2 2 5 5 2 7 2|6 2 2|6 12 12 12 2 14 12 12 12 18 18 12 22 22 22 2 2 25|32 32 25|32 32 32 32 32 32 34 32 36 34 36 32 41 41 57 44 57 54 45|54 45|54 45|54 45|54 45|54 45|54 54 45|54 54 47|44 44 47|44 54 41 60 60 57 62 60|54 60 60|54 66 66 60 70 70 70 60 72 70 72 41 79 80 80 82 80 85 85 82 89 89 89 85|88 85 85|88 93 93 89 93 96 80 96 99 97 102 102 96 80 106 108 108 108 114 109 114 114 114 108 116 108 116 120 120 117 108 123 154 127 127 127 123 129 127 129 132 131|127 127 131|127 135 132 135 135 135 132 132 142 140 142 142 144 144 142 132 132 151 127 151 154 154 156 154 154 164 161 159|160 159 159|160 164 164 166 169 166 166 164 164 172 170 175 175 172 164 179 193 181 187|180 187 187|180 181 185 187 185 179 193 193|187 193 193|187 193 193 193 196 196 193 200 200 200 193 200 204 204 208 204 207 208 213 210 208 213 213 200 213 213 200 218 200 222 222 222 200 222 232 226 232 229 229 232 232 232 235 235 235 222 235 222 193 248 248|241 248 248|241 242 246 248 248 251 251 251 251 254 254 251 256 254 256 256 256 251 263 264 264 273 272|265 272 272|265 266 270 272 270 273 264 276 276 273 278 276 276 276 281 276 283 281 264	Association
29341237	Chemical	Gene	D000493	9429	True	0	What is [PHARMGKB] between @ChemicalSrc$ Allopurinol @/ChemicalSrc$ and @GeneTgt$ ABCG2 @/GeneTgt$ ? [SEP] The impact of diuretic use and @GeneTgt$ ABCG2 @/GeneTgt$ genotype on the predictive performance of a published @ChemicalSrc$ allopurinol @/ChemicalSrc$ dosing tool . AIM : This research aims to evaluate the predictive performance of a published @ChemicalSrc$ allopurinol @/ChemicalSrc$ dosing tool . METHODS : @ChemicalSrc$ Allopurinol @/ChemicalSrc$ dose predictions were compared to the actual dose required to achieve serum urate ( SU ) & lt;0.36 mmol l-1 using mean prediction error . The influence of patient factors on dose predictions was explored using multilinear regression . RESULTS : @ChemicalSrc$ Allopurinol @/ChemicalSrc$ doses were overpredicted by the dosing tool ; however , this was minimal in patients without diuretic therapy ( MPE 63 mg day-1 , 95 % CI 40 - 87 ) compared to those receiving diuretics ( MPE 295 mg day-1 , 95 % CI 260 - 330 , P & lt ; 0.0001 ) . @GeneTgt$ ABCG2 @/GeneTgt$ genotype ( rs2231142 , G&gt;T ) had an important impact on the dose predictions ( MPE 201 , 107 , 15 mg day-1 for GG , GT and TT , respectively , P & lt ; 0.0001 ) . Diuretic use and @GeneTgt$ ABCG2 @/GeneTgt$ genotype explained 53 % of the variability in prediction error ( R2 = 0.53 , P = 0.0004 ) . CONCLUSIONS : The dosing tool produced acceptable maintenance dose predictions for patients not taking diuretics . Inclusion of @GeneTgt$ ABCG2 @/GeneTgt$ genotype and a revised adjustment for diuretics would further improve the performance of the dosing tool .	2 2 5 5 2 5 9|6 9 9|6 5 13 13 13 2 20 20 20 20|15 20 20|15 20 13 2 28 28 27 28 28 30 28 33 33 30 40 40 40 40|36 40 40|36 40 33 28 50 50 44|48 48 44|48 48 50 50 50 54 54 54 50 54 57 55 59 57 61 59 61 59 65 59 65 57 70 70 67 50 74 82 77 77 74 80 80 74 82 82 82 85 83 82 87 87 88|91 91 88|91 93 93 87 97 97 97 93 93 103 103 103 103 93 105 103 108 108 105 113 113 113 113 108 113 116 117 113 120 120 117 117 131 124 122 124 125 131 131 131 131 103 131 134 135 103 135 138 136 135 135 140 140 144 103 144 87 147|150 150 147|150 156 152 150 152 152 152 156 159 159 156 163 163 163 159 165 172 165 165 165 172 171 172 156 174 172 174 174 174 174 172 172 172 172 182 182 186 156 186 156 191 196 191 192|195 195 192|195 191 196 198 196 201 201 198 204 204 201 206 204 206 207 211 211 206 211 206 196 216 216 220 220 221 216 225 225 225 221 227 225 229 227 229 216 245 236 233|236 236 233|236 232 232 240 240 232 242 240 245 245 245 247 245 251 251 251 247 245	Association
29723928	Chemical	Gene	D020280	5243	False	1	What is [PHARMGKB] between @ChemicalSrc$ sertraline @/ChemicalSrc$ and @GeneTgt$ ABCB1 @/GeneTgt$ ? [SEP] Effect of @GeneTgt$ ABCB1 @/GeneTgt$ C3435 T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants . @GeneTgt$ P-glycoprotein @/GeneTgt$ , encoded by @GeneTgt$ ABCB1 @/GeneTgt$ , is an ATP-dependent drug efflux pump which exports substances outside the cell . Some studies described connections between C3435 T polymorphism T allele and lower @GeneTgt$ P-glycoprotein @/GeneTgt$ expression ; therefore , homozygous T/T could show higher plasma levels . Our aim was to evaluate the effect of C3435 T on pharmacokinetics of 4 antipsychotics ( olanzapine , quetiapine , risperidone and aripiprazole ) and 4 antidepressants ( trazodone , @ChemicalSrc$ sertraline @/ChemicalSrc$ , agomelatine and citalopram ) . The study included 473 healthy volunteers receiving a single oral dose of one of these drugs , genotyped by real-time PCR . Multivariate analysis was performed to adjust the effect of sex and genotype of the main cytochrome P450 enzymes . C3435 T polymorphism had an effect on olanzapine pharmacokinetics , as T/T individuals showed lower clearance and volume of distribution . T/T individuals showed lower T1/2 of 9-OH-risperidone , but this difference disappeared after multivariate correction . T/T homozygous individuals showed lower dehydro-aripiprazole and trazodone area under the concentration-time curve , along with lower half-life and higher clearance of trazodone . C/T genotype was associated to higher citalopram maximum concentration . C3435 T had no effect on quetiapine , @ChemicalSrc$ sertraline @/ChemicalSrc$ or agomelatine pharmacokinetics . C3435 T can affect the elimination of some drugs in different ways . Regarding risperidone , trazodone and dehydro-aripiprazole , we observed enhanced elimination while it was reduced in olanzapine and citalopram . However , in quetiapine , aripiprazole , @ChemicalSrc$ sertraline @/ChemicalSrc$ and agomelatine , no changes were detected . These results suggest that @GeneTgt$ P-glycoprotein @/GeneTgt$ polymorphisms could affect CNS drugs disposition , but the genetic factor that alters its activity is still unknown . This fact leads to consider the analysis of @GeneTgt$ ABCB1 @/GeneTgt$ haplotypes instead of individual variants .	1 7 2|7 7 2|7 7 7 1 9 1 11 9 11 11 1 15|29 29 15|29 16 16 21 19 19 19 16 29 29 29 29 29 29 31 29 31 35 35 31 29 40 41 41 41 48 48 48 48 48 42 48 53 50|53 53 50|53 48 41 60 60 58 60 60 41 63 63 60 60 67 70 70 70 70 72 70 75 75 72 77 72 80 80 77 82 80 82 82 82 82 82 82 82 80 92 77 94 92 94 94|95 94 94|95 94 94 94 94 94 70 106 107 107 110 110 107 110 115 115 115 111 117 115 120 120 117 117 117 125 125 122 107 128 130 130 130 132 130 134 132 136 134 136 136 144 144 144 144 144 136 130 148 148 149 149 151 149 154 154 151 149 159 158 159 149 161 159 161 161 165 163 149 168 169 169 171 169 173 171 169 169 177 178 169 181 181 178 169 184 185 186 186 188 186 188 188 188 195 195 195 186 186 200 200 200 186 200 203 200 205 203 186 208 210 210 210 215 215 215 215 210 210 218 219 219 221 219 223 221 223 224|223 223 224|223 223 229 223 219 233 235 235 235 237 235 240 240 237 243 243 237 235 246 253 246 246 248 248 253 253 253 255 253 259 259 259 253 261 259 261 261 253 280 280 268 280 268 268 270 270|271 270 270|271 272 272 280 278 280 280 280 280 284 285 285 291 286|289 289 286|289 291 291 285 294 294 291 291 291 299 299 306 301 299 303 301 306 306 291 285 310 311 311 313 311 315 313 319 316|319 319 316|319 315 323 323 323 315 311	Association
29723928	Chemical	Gene	D000069348	5243	False	1	What is [PHARMGKB] between @ChemicalSrc$ quetiapine @/ChemicalSrc$ and @GeneTgt$ ABCB1 @/GeneTgt$ ? [SEP] Effect of @GeneTgt$ ABCB1 @/GeneTgt$ C3435 T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants . @GeneTgt$ P-glycoprotein @/GeneTgt$ , encoded by @GeneTgt$ ABCB1 @/GeneTgt$ , is an ATP-dependent drug efflux pump which exports substances outside the cell . Some studies described connections between C3435 T polymorphism T allele and lower @GeneTgt$ P-glycoprotein @/GeneTgt$ expression ; therefore , homozygous T/T could show higher plasma levels . Our aim was to evaluate the effect of C3435 T on pharmacokinetics of 4 antipsychotics ( olanzapine , @ChemicalSrc$ quetiapine @/ChemicalSrc$ , risperidone and aripiprazole ) and 4 antidepressants ( trazodone , sertraline , agomelatine and citalopram ) . The study included 473 healthy volunteers receiving a single oral dose of one of these drugs , genotyped by real-time PCR . Multivariate analysis was performed to adjust the effect of sex and genotype of the main cytochrome P450 enzymes . C3435 T polymorphism had an effect on olanzapine pharmacokinetics , as T/T individuals showed lower clearance and volume of distribution . T/T individuals showed lower T1/2 of 9-OH-risperidone , but this difference disappeared after multivariate correction . T/T homozygous individuals showed lower dehydro-aripiprazole and trazodone area under the concentration-time curve , along with lower half-life and higher clearance of trazodone . C/T genotype was associated to higher citalopram maximum concentration . C3435 T had no effect on @ChemicalSrc$ quetiapine @/ChemicalSrc$ , sertraline or agomelatine pharmacokinetics . C3435 T can affect the elimination of some drugs in different ways . Regarding risperidone , trazodone and dehydro-aripiprazole , we observed enhanced elimination while it was reduced in olanzapine and citalopram . However , in @ChemicalSrc$ quetiapine @/ChemicalSrc$ , aripiprazole , sertraline and agomelatine , no changes were detected . These results suggest that @GeneTgt$ P-glycoprotein @/GeneTgt$ polymorphisms could affect CNS drugs disposition , but the genetic factor that alters its activity is still unknown . This fact leads to consider the analysis of @GeneTgt$ ABCB1 @/GeneTgt$ haplotypes instead of individual variants .	1 7 2|7 7 2|7 7 7 1 9 1 11 9 11 11 1 15|29 29 15|29 16 16 21 19 19 19 16 29 29 29 29 29 29 31 29 31 35 35 31 29 40 41 41 41 48 48 48 48 48 42 48 53 50|53 53 50|53 48 41 60 60 58 60 60 41 63 63 60 60 67 70 70 70 70 72 70 75 75 72 77 72 80 80 77 82 80 82 82|83 82 82|83 82 82 82 82 82 80 93 77 95 93 95 95 95 95 95 95 95 70 106 107 107 110 110 107 110 115 115 115 111 117 115 120 120 117 117 117 125 125 122 107 128 130 130 130 132 130 134 132 136 134 136 136 144 144 144 144 144 136 130 148 148 149 149 151 149 154 154 151 149 159 158 159 149 161 159 161 161 165 163 149 168 169 169 171 169 173 171 169 169 177 178 169 181 181 178 169 184 185 186 186 188 186 188 188 188 195 195 195 186 186 200 200 200 186 200 203 200 205 203 186 208 210 210 210 215 215 215 215 210 210 218 219 219 221 219 223 221|222 221 221|222 223 223 223 229 223 219 233 235 235 235 237 235 240 240 237 243 243 237 235 246 253 246 246 248 248 253 253 253 255 253 259 259 259 253 261 259 261 261 253 280 280 268 280|267 280 280|267 268 268 271 271 273 273 280 278 280 280 280 280 284 285 285 291 286|289 289 286|289 291 291 285 294 294 291 291 291 299 299 306 301 299 303 301 306 306 291 285 310 311 311 313 311 315 313 319 316|319 319 316|319 315 323 323 323 315 311	Association
29723928	Chemical	Gene	D015283	5243	False	1	What is [PHARMGKB] between @ChemicalSrc$ citalopram @/ChemicalSrc$ and @GeneTgt$ ABCB1 @/GeneTgt$ ? [SEP] Effect of @GeneTgt$ ABCB1 @/GeneTgt$ C3435 T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants . @GeneTgt$ P-glycoprotein @/GeneTgt$ , encoded by @GeneTgt$ ABCB1 @/GeneTgt$ , is an ATP-dependent drug efflux pump which exports substances outside the cell . Some studies described connections between C3435 T polymorphism T allele and lower @GeneTgt$ P-glycoprotein @/GeneTgt$ expression ; therefore , homozygous T/T could show higher plasma levels . Our aim was to evaluate the effect of C3435 T on pharmacokinetics of 4 antipsychotics ( olanzapine , quetiapine , risperidone and aripiprazole ) and 4 antidepressants ( trazodone , sertraline , agomelatine and @ChemicalSrc$ citalopram @/ChemicalSrc$ ) . The study included 473 healthy volunteers receiving a single oral dose of one of these drugs , genotyped by real-time PCR . Multivariate analysis was performed to adjust the effect of sex and genotype of the main cytochrome P450 enzymes . C3435 T polymorphism had an effect on olanzapine pharmacokinetics , as T/T individuals showed lower clearance and volume of distribution . T/T individuals showed lower T1/2 of 9-OH-risperidone , but this difference disappeared after multivariate correction . T/T homozygous individuals showed lower dehydro-aripiprazole and trazodone area under the concentration-time curve , along with lower half-life and higher clearance of trazodone . C/T genotype was associated to higher @ChemicalSrc$ citalopram @/ChemicalSrc$ maximum concentration . C3435 T had no effect on quetiapine , sertraline or agomelatine pharmacokinetics . C3435 T can affect the elimination of some drugs in different ways . Regarding risperidone , trazodone and dehydro-aripiprazole , we observed enhanced elimination while it was reduced in olanzapine and @ChemicalSrc$ citalopram @/ChemicalSrc$ . However , in quetiapine , aripiprazole , sertraline and agomelatine , no changes were detected . These results suggest that @GeneTgt$ P-glycoprotein @/GeneTgt$ polymorphisms could affect CNS drugs disposition , but the genetic factor that alters its activity is still unknown . This fact leads to consider the analysis of @GeneTgt$ ABCB1 @/GeneTgt$ haplotypes instead of individual variants .	1 7 2|7 7 2|7 7 7 1 9 1 11 9 11 11 1 15|29 29 15|29 16 16 21 19 19 19 16 29 29 29 29 29 29 31 29 31 35 35 31 29 40 41 41 41 48 48 48 48 48 42 48 53 50|53 53 50|53 48 41 60 60 58 60 60 41 63 63 60 60 67 70 70 70 70 72 70 75 75 72 77 72 80 80 77 82 80 82 82 82 82 82 82 82 80 92 77 94 92 94 94 94 94 94 99|94 94 99|94 94 70 106 107 107 110 110 107 110 115 115 115 111 117 115 120 120 117 117 117 125 125 122 107 128 130 130 130 132 130 134 132 136 134 136 136 144 144 144 144 144 136 130 148 148 149 149 151 149 154 154 151 149 159 158 159 149 161 159 161 161 165 163 149 168 169 169 171 169 173 171 169 169 177 178 169 181 181 178 169 184 185 186 186 188 186 188 188 188 195 195 195 186 186 200 200 200 186 200 203 200 205 203 186 208 210 210 210 216 216 216|212 216 216|212 216 210 210 220 221 221 223 221 225 223 225 225 225 230 225 221 233 235 235 235 237 235 240 240 237 243 243 237 235 246 253 246 246 248 248 253 253 253 255 253 259 259 259 253 261 259 261 261|262 261 261|262 253 281 281 270 281 270 270 272 272 274 274 281 279 281 281 281 281 284 285 285 291 286|289 289 286|289 291 291 285 294 294 291 291 291 299 299 306 301 299 303 301 306 306 291 285 310 311 311 313 311 315 313 319 316|319 319 316|319 315 323 323 323 315 311	Association
30024814	Chemical	Gene	D019821	1244	True	0	What is [PHARMGKB] between @ChemicalSrc$ simvastatin @/ChemicalSrc$ and @GeneTgt$ ABCC2 @/GeneTgt$ ? [SEP] Association of @GeneTgt$ ABCC2 @/GeneTgt$ polymorphism and gender with high-density lipoprotein cholesterol response to @ChemicalSrc$ simvastatin @/ChemicalSrc$ . AIM : The clinical benefits of lipid-lowering therapy with statins are widely recognized . However , the lipid-lowering efficacy of statins shows significant differences between individuals . @GeneTgt$ ABCC2 @/GeneTgt$ has been demonstrated to contribute to the transmembrane transport of the substrate compounds . The @GeneTgt$ ABCC2 @/GeneTgt$ SNPs may be important factors that affect individual differences in clinical drug response . The aim of this study was to evaluate the association of rs717620 of @GeneTgt$ ABCC2 @/GeneTgt$ with treatment response to @ChemicalSrc$ simvastatin @/ChemicalSrc$ in a Chinese Han population . METHODS : A total of 318 subjects were medicated with @ChemicalSrc$ simvastatin @/ChemicalSrc$ 20 mg/day for 12 weeks after enrollment . Venous blood was obtained before and after @ChemicalSrc$ simvastatin @/ChemicalSrc$ treatment for measurement of blood lipid profile . Subjects were classified into high-response and low-response groups depending on whether their lipid profile change was higher or lower than median change values . The @GeneTgt$ ABCC2 @/GeneTgt$ SNP rs717620 was genotyped from blood samples with a snapshot assay . RESULTS : A total of 12 weeks of treatment with @ChemicalSrc$ simvastatin @/ChemicalSrc$ significantly decreased low-density lipoprotein cholesterol ( LDL-C ) , total cholesterol ( TC ) , triglycerides ( TGs ) and significantly increased high-density lipoprotein cholesterol ( HDL-C ; p & lt ; 0.05 ) . In multivariate analysis , there were no significant genetic effects of SNP rs717620 on the incidence of high- or low-response patients among TC , TG and LDL-C groups . However , rs717620 A-allele and female gender are significantly associated with the risk of low-response of HDL-C elevation after @ChemicalSrc$ simvastatin @/ChemicalSrc$ treatment . CONCLUSION : @GeneTgt$ ABCC2 @/GeneTgt$ rs717620 and female gender may be related to the low-effect of @ChemicalSrc$ simvastatin @/ChemicalSrc$ treatment on the HDL-C level in the Chinese Han population . Female Chinese patients with hyperlipidemia carrying rs717620 GA/AA genotypes might have reduced benefit from @ChemicalSrc$ simvastatin @/ChemicalSrc$ treatment .	1 5 2|5 5 2|5 1 5 5 12 12 12 12 1 14 12 12 12 1 19 19 23 23 31 26 26 23 28 26 31 31 19 31 40 40 37 37 40 39 37 40 42 40 44 42 40 45|50 50 45|50 50 50 50 52 50 56 56 56 52 60 60 60 56 50 66 63|66 66 63|66 70 70 70 70 70 72 70 74 72 78 78 78 74 70 82 86 85 85 82 86 88 86 90 88 92 90 94 92|93 92 92|93 98 98 90 100 98 98 98 106 106 106 106 100 86 118 118 113 118 116 116 113 118 118 120 118|119 118 118|119 123 120 126 126 118 128 126 118 132 134 134 134 140 135 140 140|137 140 140|137 134 142 140 146 146 146 142 134 151 151 151 156 156 153 153 151 165 165 165 163 162 163 165 165 151 165 165 171 171 171 167 151 177 173|177 177 173|177 177 179 179 179 182 182 179 186 186 186 179 179 189 189 192 202 195 195 192 197 195 199 197|198 197 197|198 202 189 205 205 202 207 205 207 205 211 205 213 211 213 211 211 218 216 218 202 222 202 225 225 222 227 225 227 227 229 229 227 227 227 189 239 239 242 242 242 242 246 246 246 242 249 249 246 252 252 246 257 257 254 254 252 259 257 259 259 259 259 259 242 275 275 272 268 269 269 275 275 275 275 278 278 275 280 278 283 283 280 287 284|287 287 284|287 283 275 290 290 291|294 294 291|294 300 294 294 294 300 300 290 303 303 300 307 307|303 307 307|303 303 311 311 311 307 316 316 316 316 311 290 322 322 331 324 322 324 328 328 325 331 331 331 331 336 336|333 336 336|333 332 331	Association
30304062	Chemical	Gene	D000068718	221458	True	0	What is [PHARMGKB] between @ChemicalSrc$ rosuvastatin @/ChemicalSrc$ and @GeneTgt$ KIF6 @/GeneTgt$ ? [SEP] @GeneTgt$ KIF6 @/GeneTgt$ gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment . INTRODUCTION : The therapeutic response to statins has a high interindividual variability with respect to reductions in plasma LDL-cholesterol ( c-LDL ) and increases in HDL cholesterol ( c-HDL ) . Many studies suggest that there is a relationship between the rs20455 @GeneTgt$ KIF6 @/GeneTgt$ gene variant ( c.2155T&gt ; C , Trp719Arg ) and a lower risk of cardiovascular disease in patients being treated with statins . AIM : The aim of this study was to investigate whether or not the c.2155T&gt ; C @GeneTgt$ KIF6 @/GeneTgt$ gene variant modulates the hypercholesteremic effects of treatment with simvastatin , atorvastatin , or @ChemicalSrc$ rosuvastatin @/ChemicalSrc$ . MATERIALS AND METHODS : This was a prospective , observational and multicenter study . Three hundred and forty-four patients who had not undergone prior lipid-lowering treatment were recruited . Simvastatin , atorvastatin or @ChemicalSrc$ rosuvastatin @/ChemicalSrc$ were administered . Lipid profiles and multiple clinical and biochemical variables were assessed before and after treatment . RESULTS : The c.2155T&gt ; C variant of the @GeneTgt$ KIF6 @/GeneTgt$ gene was shown to influence physiological responses to treatment with simvastatin and atorvastatin . Patients who were homozygous for the c.2155T&gt ; C variant ( CC genotype , ArgArg ) had a 7.0 % smaller reduction of LDL cholesterol levels ( p = 0.015 ) in response to hypolipidemic treatment compared to patients with the TT ( TrpTrp ) or CT ( TrpArg ) genotype . After pharmacological treatment with @ChemicalSrc$ rosuvastatin @/ChemicalSrc$ , patients carrying the genetic variant had an increase in c-HDL that was 21.9 % lower compared to patients who did not carry the variant ( p = 0.008 ) . CONCLUSION : Being a carrier of the c.2155T&gt ; C variant of the @GeneTgt$ KIF6 @/GeneTgt$ gene negatively impacts patient responses to simvastatin , atorvastatin or @ChemicalSrc$ rosuvastatin @/ChemicalSrc$ in terms of lipid lowering effect . Increasing the intensity of hypolipidemic therapy may be advisable for patients who are positive for the c.2155T&gt ; C variant .	0|3 3 0|3 3 7 7 7 3 10 10 7 13 13 10 3 23 16 20 20 23 22 20 23 27 27 27 23 29 27 31 29 34 34 31 36 34 36 23 23 42 42 39 44 42 44 23 48 49 49 52 52 49 54 52 61 61 61 57|61 61 57|61 61 54 72 62 63 63 67 65 67 63 72 72 61 75 75 72 77 72 79 77 81 79 49 91 84 87 91 90 90 87 91 93 91 105 94 98 98 94 105 104 100|104 104 100|104 104 105 93 108 108 105 110 108 112 110 112 112 112 112 115|112 112 115|112 91 122 122 122 122 134 134 134 134 129 129 131 131 122 122 137 140 137 137 149 144 144 144 140 147 147 144 149 149 149 158 151 151 151 151|154 151 151|154 158 158 158 162 170 162 165 162 165 165 170 170 170 174 171 174 170 170 176 176 179 182 179 182 189 187 187 184|187 187 184|187 182 189 176 191 189 193 191 195 191 197 195 197 197 176 218 205 205 202 208 208 205 218 211 218 214 214 211 214 214 214 218 223 221 222 223 218 227 227 227 223 230 230 223 230 230 234 237 237 237 218 237 240 238 243 243 240 245 243 245 243 252 250 252 252 243 218 256 256 266 258 256|257 256 256|257 258 258 261 265 265 262 266 268 266 270 268 275 275 274 275 268 266 278 276 282 282 282 278 284 282 287 287 284 287 287 266 309 296 296 296 292 299 299 296 296 302 309 307 307 307|304 307 307|304 302 309 309 311 309 313 311 313 313 313 315|313 313 315|313 320 309 324 324 324 320 309 336 330 328 333 333 330 336 336 336 338 336 341 341 338 347 347 347 347 347 341 336	Association
30304062	Chemical	Gene	D000069059	221458	True	0	What is [PHARMGKB] between @ChemicalSrc$ atorvastatin @/ChemicalSrc$ and @GeneTgt$ KIF6 @/GeneTgt$ ? [SEP] @GeneTgt$ KIF6 @/GeneTgt$ gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment . INTRODUCTION : The therapeutic response to statins has a high interindividual variability with respect to reductions in plasma LDL-cholesterol ( c-LDL ) and increases in HDL cholesterol ( c-HDL ) . Many studies suggest that there is a relationship between the rs20455 @GeneTgt$ KIF6 @/GeneTgt$ gene variant ( c.2155T&gt ; C , Trp719Arg ) and a lower risk of cardiovascular disease in patients being treated with statins . AIM : The aim of this study was to investigate whether or not the c.2155T&gt ; C @GeneTgt$ KIF6 @/GeneTgt$ gene variant modulates the hypercholesteremic effects of treatment with simvastatin , @ChemicalSrc$ atorvastatin @/ChemicalSrc$ , or rosuvastatin . MATERIALS AND METHODS : This was a prospective , observational and multicenter study . Three hundred and forty-four patients who had not undergone prior lipid-lowering treatment were recruited . Simvastatin , @ChemicalSrc$ atorvastatin @/ChemicalSrc$ or rosuvastatin were administered . Lipid profiles and multiple clinical and biochemical variables were assessed before and after treatment . RESULTS : The c.2155T&gt ; C variant of the @GeneTgt$ KIF6 @/GeneTgt$ gene was shown to influence physiological responses to treatment with simvastatin and @ChemicalSrc$ atorvastatin @/ChemicalSrc$ . Patients who were homozygous for the c.2155T&gt ; C variant ( CC genotype , ArgArg ) had a 7.0 % smaller reduction of LDL cholesterol levels ( p = 0.015 ) in response to hypolipidemic treatment compared to patients with the TT ( TrpTrp ) or CT ( TrpArg ) genotype . After pharmacological treatment with rosuvastatin , patients carrying the genetic variant had an increase in c-HDL that was 21.9 % lower compared to patients who did not carry the variant ( p = 0.008 ) . CONCLUSION : Being a carrier of the c.2155T&gt ; C variant of the @GeneTgt$ KIF6 @/GeneTgt$ gene negatively impacts patient responses to simvastatin , @ChemicalSrc$ atorvastatin @/ChemicalSrc$ or rosuvastatin in terms of lipid lowering effect . Increasing the intensity of hypolipidemic therapy may be advisable for patients who are positive for the c.2155T&gt ; C variant .	0|3 3 0|3 3 7 7 7 3 10 10 7 13 13 10 3 23 16 20 20 23 22 20 23 27 27 27 23 29 27 31 29 34 34 31 36 34 36 23 23 42 42 39 44 42 44 23 48 49 49 52 52 49 54 52 61 61 61 57|61 61 57|61 61 54 72 62 63 63 67 65 67 63 72 72 61 75 75 72 77 72 79 77 81 79 49 91 84 87 91 90 90 87 91 93 91 105 94 98 98 94 105 104 100|104 104 100|104 104 105 93 108 108 105 110 108 112 110 112 112 112 112 112 112 112 91 122 122 122 122 134 134 134 134 129 129 131 131 122 122 137 140 137 137 149 144 144 144 140 147 147 144 149 149 149 158 151 151|152 151 151|152 151 151 158 158 158 162 170 162 165 162 165 165 170 170 170 174 171 174 170 170 176 176 179 182 179 182 189 187 187 184|187 187 184|187 182 189 176 191 189 193 191 195 191 197 195 197 197 197 197 176 220 207 207 204 210 210 207 220 213 220 216 216 213 216 216 216 220 225 223 224 225 220 229 229 229 225 232 232 225 232 232 236 239 239 239 220 239 242 240 245 245 242 247 245 247 245 254 252 254 254 245 220 258 258 267 260 258 260 260 262 266 266 263 267 269 267 271 269 276 276 275 276 269 267 279 277 283 283 283 279 285 283 288 288 285 288 288 267 309 296 296 296 292 299 299 296 296 302 309 307 307 307|304 307 307|304 302 309 309 311 309 313 311 313 313 313 313 313 313 320 309 324 324 324 320 309 336 330 328 333 333 330 336 336 336 338 336 341 341 338 347 347 347 347 347 341 336	Association
